
<html lang="en"     class="pb-page"  data-request-id="650adb3c-0e95-491c-8c34-30e68079b961"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-14;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/jm3003203;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks" /></meta><meta name="dc.Creator" content="Tjeerd  Barf" /></meta><meta name="dc.Creator" content="Allard  Kaptein" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 8, 2012" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm3003203" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm3003203" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm3003203" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm3003203" /></link>
        
    
    

<title>Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm3003203" /></meta><meta property="og:title" content="Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm3003203"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm3003203">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm3003203&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm3003203&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm3003203&amp;href=/doi/10.1021/jm3003203" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6243-6262</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm300455c" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tjeerd++Barf">Tjeerd Barf</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Allard++Kaptein">Allard Kaptein</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands</span></div><div class="corresp-info"><strong>*</strong>Phone: +31 618 193139. E-mail, <a href="/cdn-cgi/l/email-protection#bfcbd5dadacddb91dddecdd9ffdcd0c9ded3cacbd6d0d191dcd0d2"><span class="__cf_email__" data-cfemail="7c081619190e18521e1d0e1a3c1f130a1d100908151312521f1311">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm3003203&amp;href=/doi/10.1021%2Fjm3003203" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6243–6262</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 23, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 March 2012</li><li><span class="item_label"><b>Published</b> online</span>8 June 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 July 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm3003203" title="DOI URL">https://doi.org/10.1021/jm3003203</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6243%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTjeerd%2BBarf%252C%2BAllard%2BKaptein%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D14%26contentID%3Djm3003203%26title%3DIrreversible%2BProtein%2BKinase%2BInhibitors%253A%2BBalancing%2Bthe%2BBenefits%2Band%2BRisks%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6262%26publicationDate%3DJuly%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm3003203"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">12262</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">226</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm3003203" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tjeerd&quot;,&quot;last_name&quot;:&quot;Barf&quot;},{&quot;first_name&quot;:&quot;Allard&quot;,&quot;last_name&quot;:&quot;Kaptein&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;6243-6262&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm3003203&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm3003203&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3003203" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm3003203&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3003203" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm3003203&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3003203" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm3003203&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3003203&amp;href=/doi/10.1021/jm3003203" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm3003203" /></input><a href="/doi/pdf/10.1021/jm3003203" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26pmid%3D22621397%26genre%3Darticle%26aulast%3DBarf%26date%3D2012%26atitle%3DIrreversible%2BProtein%2BKinase%2BInhibitors%253A%2BBalancing%2Bthe%2BBenefits%2Band%2BRisks%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291264" title="Kinase inhibitors">Kinase inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jmcmar.2012.55.issue-14/production/jmcmar.2012.55.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the relatively young but expanding field of irreversible kinase inhibitor drug discovery, there are two main developments that are of central importance. First, the patients have watched the first wave of low molecular weight protein kinase inhibitors becoming available to them over the past decade. These kinase inhibitors have been approved by the U.S. Food and Drug Administration (FDA) for therapeutic use in oncology indications and constitute an important addition to the arsenal of drugs to combat cancer (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Without exception, these marketed protein kinase inhibitors have been identified and developed using conventional approaches, i.e., reversible inhibitors that (partly) occlude the ATP pocket in the catalytic domain of the kinase. Although protein kinases are regarded as an attractive drug target family, it took (and still takes) huge efforts to master the human kinome, which comprises more than 500 protein kinases. The search for clinically applicable kinase inhibitors that target the highly conserved ATP pocket has been thwarted by a couple of well-known hurdles. Selectivity, cellular potency, and an increasingly crowded intellectual property arena are major points of attention.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. FDA Approved Protein Kinase Inhibitors (as of March 2012)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">generic (brand) name</th><th class="colsep0 rowsep0" align="center">year of approval</th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">target kinase</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imatinib (Gleevec)</td><td class="colsep0 rowsep0" align="left">2001</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">chronic myeloid leukemia (CML)</td><td class="colsep0 rowsep0" align="left">Abl, c-Kit,PDGFRα/β</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib (Iressa)</td><td class="colsep0 rowsep0" align="left">2003</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">non-small-cell lung carcinoma (NSCLC)</td><td class="colsep0 rowsep0" align="left">EGFR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib (Tarceva)</td><td class="colsep0 rowsep0" align="left">2004</td><td class="colsep0 rowsep0" align="left">Genetech, OSI</td><td class="colsep0 rowsep0" align="left">NSCLC, pancreatic cancer</td><td class="colsep0 rowsep0" align="left">EGFR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sorafenib (Nexavar)</td><td class="colsep0 rowsep0" align="left">2005</td><td class="colsep0 rowsep0" align="left">Bayer, Onyx</td><td class="colsep0 rowsep0" align="left">hepatocellular carcinoma, renal cell carcinoma (RCC)</td><td class="colsep0 rowsep0" align="left">Raf, VEGFR2/3,c-Kit, PDGFRβ</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib (Sutent)</td><td class="colsep0 rowsep0" align="left">2006</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">gastrointestinal stromal tumor (GIST), RCC</td><td class="colsep0 rowsep0" align="left">c-Kit, VEGFR, PDGFR, FLT3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dasatinib (Sprycel)</td><td class="colsep0 rowsep0" align="left">2006</td><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb</td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">Abl, c-Kit, PDGFR, Src</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nilotinib (Tasigna)</td><td class="colsep0 rowsep0" align="left">2007</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">Abl, c-Kit, PDGFR, Src, ephrin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lapatinib (Tykerb)</td><td class="colsep0 rowsep0" align="left">2007</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">EGFR, ErbB2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pazopanib (Votrient)</td><td class="colsep0 rowsep0" align="left">2009</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td><td class="colsep0 rowsep0" align="left">RCC</td><td class="colsep0 rowsep0" align="left">VEGFR, PDGFRα/β,c-Kit</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vandetanib (Caprelsa)</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">thyroid cancer</td><td class="colsep0 rowsep0" align="left">VEGFR, EGFR, RET</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vemurafinib (Zelboraf)</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">Roche, Plexxicon</td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">Abl, c-Kit, PDGFR, Src, ephrin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib (Xalkori)</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">NSCLC (ALK +ve)</td><td class="colsep0 rowsep0" align="left">ALK, MET</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ruxolitinib (Jakafi)</td><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">Incyte</td><td class="colsep0 rowsep0" align="left">myelofibrosis</td><td class="colsep0 rowsep0" align="left">JAK1/2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">axitinib (Inlyta)</td><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">RCC</td><td class="colsep0 rowsep0" align="left">VEGFR, PDGFRβ, c-Kit</td></tr></tbody></table></div></div><div class="NLM_p">The second important development is the renewed interest in covalent binding drugs (reviewed by Potashman and Duggan and by Singh et al).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> This recent revival results from a better understanding of the benefits of the covalent binding principle and the approval of effective and safe covalent drugs. Historically, drug discoverers have been taught to stay away from small molecular entities that harbor reactive electrophilic groups because these used to be equivalent to promiscuity.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Promiscuous hits that relied on reactive groups were traditionally hard to optimize toward leads, since these were more than often interfering with the biochemical assay rather than truly modifying the activity of the target of interest.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Even if the target modulation was real, indiscriminant reactivity was believed to trigger insurmountable toxic events that may surface in late stage clinical trials when larger patient populations are involved. As a consequence, “suicide inhibitors”, “warheads”, and covalent irreversible inhibitors developed a negative flavor over time and became almost synonymous with toxicity in some organizations. The skepticism toward irreversible drugs may evaporate as more examples of irreversible drugs progress clinically that demonstrate good efficacy and safety margins.</div><div class="NLM_p">In a nutshell, the therapeutic applicability or the success of irreversible binding kinase inhibitors is dependent on whether or not the covalent bond can be confined solely to the protein kinase of interest. So this approach is in essence a story about two T’s: treatment and toxicity. When relying on the covalent binding principle, it is important to discern adduct-based toxicity and adduct-based treatment, since the adducting molecular entities in question obey overlapping fundamental rules in terms of reactivity. The only key difference is the nature and the function of the proteins that are covalently modified. Covalent kinase inhibitors with well-balanced recognition and reactivity should provide efficacy, selectivity, and ultimately the safety margins that are required for regulatory approval. If we strike the right balance, a third “T” will give enough comfort: therapeutic window.</div><div class="NLM_p last">This Perspective aims to give a comprehensive account from a medicinal chemist's point of view on the progress of irreversible kinase inhibitor drug discovery. The “state of the art” is reviewed by means of reported irreversible kinase inhibitors profiles and their chemical structures. The potential upsides and pitfalls that are associated with this concept are highlighted to provide a general understanding of the differences with respect to conventional drug discovery, as well as the future potential of this approach.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Effect of Residence Time on the Therapeutic Window</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Residence Time and Efficacy</h3><div class="NLM_p">A kinase inhibitor will only be efficacious when it is modulating the action of the physiological kinase and can only do so when the inhibitor is bound. This general paradigm was effectively captured by Copeland and co-workers, who described the potential advantages of long residence time in terms of duration of action and target selectivity.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The equilibrium dissociation constant (<i>K</i><sub>d</sub>) for the drug–target binary complex as determined in a closed (in vitro) system is a more accurate measure than the IC<sub>50</sub> or <i>K</i><sub>i</sub>. Yet the equilibrium setting is different in vivo, since the drug concentrations are no longer constant, and the efficacy is dependent on the on-rate (<i>k</i><sub>on</sub>) and even more importantly the off-rate constant (<i>k</i><sub>off</sub>). The importance of the related occupancy time or half-life for the protein–drug complex was corroborated in the context of pharmacological agents for whom longer residence times seemed to be beneficial in terms of biological or clinical efficacy.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> In this respect, kinase inhibitors that exert covalent and irreversible binding can achieve the ultimate physiological goal: Efficacy is maintained until the target kinase is physically restored by the body to physiologically relevant levels (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In other words, the pharmacodynamics will be a function of the de novo synthesis rate of the target protein rather than the trough level of the compound.</div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0017.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. For conventional drugs, the pharmacodynamic effect is driven by the pharmacokinetics of the drug (left). For irreversible covalent drugs, the pharmacodynamic effect is driven by the turnover rate (de novo synthesis) of the protein target (right). The red hatched area is drug exposure not required for efficacy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Unlike for kinase inhibitors with a reversible binding mode, we anticipate that not all ADME parameters need to be as efficiently optimized for covalent inhibitors. The general requirements for absorption and distribution characteristics remain relatively unchanged with respect to the conventional approach. It is still advantageous to have good oral availability and rapid distribution, but in the case of an irreversible kinase inhibitor it would be favorable to clear the drug from the body once the target kinase is maximally occupied. Thus, the in vitro and in vivo criteria for optimization cycles with respect to metabolism and excretion are very much different and should accentuate a swift clearance of the drug.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Residence Time and Toxicity</h3><div class="NLM_p">Drug-safety-related issues pose a serious problem to the pharmaceutical industry and have been a major contributing factor to attrition rates in the drug development trajectories.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> As discussed above, since no excessive circulating levels are required to maintain efficacy with irreversible binding drugs, rapid clearance should lead to a lower propensity for off-target related adverse effects. But this can only be achieved when off-target protein–drug interactions are short-lived because of the noncovalent nature of binding.</div><div class="NLM_p">On the other hand, toxic events can also be associated with covalent binding, and this can be either on-target or off-target related. If the toxicity is a direct consequence of on-target modulation, then irreversible inhibition might exacerbate the adverse effect potential. In this case, the clinical benefit should outweigh the adverse event. Alternatively, prolonged residence times can occur if collateral targets are being adducted by the potential drug. In that case, a high degree of in vivo selectivity can only be accomplished when the off-target turnover rate is (much) faster than the on-target resynthesis rate.</div><div class="NLM_p">For irreversible kinase inhibitors, the target selectivity thus should not only be discussed in terms of reversible binding to closely related kinases with respect to primary sequence homology. Especially kinases that (also) share the site of covalent modification are highly relevant to include in the selectivity panel. A good level of selectivity for those off-target kinases is suggestive of a high degree of overall selectivity within the human kinome, as well as for other protein classes. Also, potential adverse effects due to covalent inhibition of specific off-target kinases can be designed out early in the optimization cycles to yield a better therapeutic window.</div><div class="NLM_p">Much of the aversion to irreversible binders is predominantly the result of the negative experiences with reactive metabolites that could bind covalently to a variety of proteins.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> In such a case, the parent drugs are metabolically bioactivated to reactive species that potentially can bind covalently to all sorts of macromolecules. Next to the predictable intrinsic toxicity, this may lead to unpredictable idiosyncratic toxicity (IDT) in late stage clinical testing and beyond. In order to exclude or minimize the propensity of reactive metabolite formation, potential drugs are usually evaluated preclinically for (i) gluthathione (GSH) adduct formation and depletion when incubated with recombinant enzymes or human liver tissue preparations and (ii) magnitude of covalent protein binding in liver microsomal fractions and in rodents. It is obvious that these models are highly relevant for the optimization of irreversible kinase inhibitors as well. The advantage with irreversible kinase inhibitors in this respect is that the parent molecules are the reactive species, which should have a better predictive power for the reactivity assays and body retention models involved.</div><div class="NLM_p">Recently, the occurrence of IDT or hypersensitivity reaction has been linked by Nakayama et al. to the magnitude of covalent and irreversible binding to off-targets and the daily dose required in patients.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> A classification system to assess the risk of IDT was proposed based on covalent binding to human hepatocytes as the best predictor, in combination with the daily dose.</div><div class="NLM_p last">Another potential event that has to be considered for covalent and irreversible kinase inhibitors is hapten formation, i.e., triggering an immune response to the adducted protein.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Experiences with reactive compounds and reactive metabolites indicate that additional danger signals (e.g., mitochondrial damage) are required next to the hapten mechanism to induce an immune response (for a review, see Zhang et al).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Except for the β-lactam antibiotics, absence of reports of immune responses for recently marketed irreversible binding drugs does not support this concern as a general problem for covalent drugs.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Reactive Metabolite Considerations</h3><div class="NLM_p">Considerations that have been used historically within the pharmaceutical industry to assess the fate of conventional drugs with suspected reactive metabolites can provide guidance for irreversible binding kinase inhibitors as well.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> It is obvious that the “avoidance strategy”, i.e., complete elimination of reactive groups, cannot be applied on warhead-containing drugs, since the pharmacological effect is largely dependent on the reactive group. Perhaps it would be better to develop a reversible therapy for less severe disorders, especially if one can rationalize that reversible drugs should work equally well. Also, the anticipated human dose (for any drug) has to be considered, as the body burden has to be kept to a minimum (vide infra). In addition, a disease that needs acute dosing rather than chronic treatment might be more appropriate to engage with irreversible binding drugs. These and other questions need to be addressed before a covalent (kinase) inhibitor program can be progressed toward clinical development. Obviously, the key issue here is the benefit/risk ratio, and serious life threatening diseases may be particularly justified in this scenario.</div><div class="NLM_p last">One has to keep in mind though that most reactive metabolites are by no means tuned, and they can be uncontrollable like “unguided missiles”. In contrast, deliberately designed irreversible kinase inhibitors can be subjected to safety assays during optimization cycles to ensure selection of compounds that meet stringent safety prediction criteria. In some other instances, bioactivation is even required to generate the active drug, such as in the case of proton pump inhibitors like omeprazole and P2Y<sub>12</sub> receptor antagonist clopidogrel.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> No matter the type of covalent approach involved, a decision tree that incorporates several safety assessment parameters will be required to mitigate the risks. In addition, the level of acceptance that has been set for the magnitude of covalent binding of reactive metabolites in vitro and in vivo also applies for covalent binding parent drugs.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">The Concept Applied to Kinases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The question is whether the members belonging to the superfamily of protein kinases are suitable targets at all for irreversible inhibition. First of all, the replenishment of the target kinase has to be sluggish enough to allow drug dosing once or twice a day. This has to be checked on a kinase-by-kinase basis. Second, unlike for instance the enzyme families of (cysteine) proteases or phosphatases, kinases lack a catalytically active amino acid residue that is key to the function of a particular enzyme by virtue of its overt nucleophilicity. The relatively unreactive cysteines, serines, threonines, and lysines in kinases may have to be exposed to excessive reactivity to ensure covalent bond formation. There are plenty of examples of overly reactive electrophiles that despite the best of intentions, in retrospect never had a chance to make it into a safe drug. Nevertheless, these prototypical molecules definitely marked the beginning of this emerging platform.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Non-ATP Competitiveness</h3><div class="NLM_p">There is one major upside that can specifically be exploited in the kinase field. Non-ATP competitive inhibitors offer distinct advantages to conventional ATP competitive binders, especially in terms of efficacy and selectivity.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> The highly conserved nature of the ATP binding pocket poses a challenge in the identification of selective kinase inhibitors, but more important is that high intracellular ATP concentrations affect the cellular potency of ATP competitive kinase inhibitors under physiological conditions.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Besides allosteric binders of protein kinases, blockade of the ATP pocket with an irreversible inhibitor has emerged as an attractive and alternative strategy to achieve non-ATP competitive inhibition of kinase-mediated signaling.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> As a consequence, caution should be taken with the interpretation and/or comparison of the biochemical and functional IC<sub>50</sub> values, since irreversible inhibitors usually become more potent over time. The selection of the length of preincubation time will thus influence the observed value, unless maximal inhibition is achieved instantly. The inactivation of the kinase involves two steps: formation of a reversible complex based on affinity (<i>K</i><sub>i</sub>) followed by the covalent bond formation between the inhibitor and the kinase (<i>k</i><sub>inact</sub>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The first step depends on the ATP level used in the various assays reported. The second step is primarily influenced by the inherent reactivity of the electrophilic group, as well as the distance to the nucleophilic trap. The better the juxtaposition of the reacting partners, the better the inactivation step. As the kinase is effectively removed from the equilibrium with ATP and substrate, a shift in IC<sub>50</sub> is expected and, as demonstrated in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, the inhibitor shows an increasingly non-ATP competitive character as time progresses. Consequently, this would be beneficial for protein kinases with a low <i>K</i><sub>m,ATP</sub> in particular.</div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0016.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. IC<sub>50</sub> determination depends on the ATP concentration and preincubation time for an irreversible kinase inhibitor (left), whereas an ATP competitive kinase inhibitor is only affected by ATP concentration (right). Data are from an unpublished kinase inhibitor study included for illustration purposes only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Many research groups have already embarked intentionally, or unintentionally, on the search for irreversible kinase inhibitors (partly reviewed by Garuti et al).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In some instances, these inhibitors have become invaluable assets in the target validation stage. Others were deliberately designed to be the drugs of the future. The selection of examples that is reviewed in this Perspective covers both and in addition is primarily based on the diversity of cysteine locations within the known druggable binding regions of kinases. The electrophilic portions of these inhibitors (highlighted in blue in this Perspective) are either being trapped by the highly conserved lysine or cysteines at various positions of the kinases. To our knowledge, there are no reports to date that describe covalent kinase inhibitors that adduct other amino acid residues, such as serine or threonine.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Lysine-Trapping Covalent Kinase Inhibitors</h3><div class="NLM_p">Because of the well-conserved nature and its abundant presence, the lysine involved in the phosphate transfer machinery is not the most ideal candidate amino acid for trapping electrophilic inhibitors.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This particular lysine resides in virtually every ATP-binding pocket of the known human kinases. Nevertheless, a couple of lysine trapping covalent inhibitors have appeared in literature. One of the first reported is ATP analogue 5′-fluorosulfonylbenzoyl adenosine (FSBA, <b>1</b>), a tool frequently used as an affinity label for kinases like EGFR,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> p38γ,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and brain PI4K (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> As per example, Fox and co-workers used <b>1</b> for analysis of kinetic mechanisms and ATP-binding site reactivity toward p38γ and found it to bind irreversibly to the unphosphorylated and active form.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Digest maps showed that Lys56 of p38γ was selectively and covalently modified by <b>1</b>. The use of <b>1</b> has been reported in more than 200 publications, underscoring the usefulness of this particular chemical probe.</div><div class="NLM_p">Bell and co-workers discovered a pyrrole-5-carboxaldehyde class of type 1 insulin-like growth factor receptor (IGF-1R) inhibitors with modest activity but good selectivity over a small panel of other kinases.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> These aldehyde-based inhibitors were shown to bind in the ATP-binding pocket of IGF-1R in a covalent but reversible manner via imine formation between Lys1003 and the aldehyde functionality. Reduction of the imine adduct with sodium borohydride irreversibly inactivated the kinase, enabling a tryptic digest and X-ray crystallography examination. A representative example is inhibitor <b>2</b>, which demonstrated an IC<sub>50</sub> of 0.49 μM for IGF-1R.</div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0018.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of lysine trapping kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A frequently studied lipid kinase inhibitor is represented by antiproliferative agent wortmannin (<b>3</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This PI3K inhibitor modifies the ATP pocket covalently and irreversibly via trapping of conserved Lys802 (p110α numbering).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Analogues of <b>3</b> inhibit PI3K (reported IC<sub>50</sub> values in the low nanomolar range) by virtue of an activated furan ring as a fairly unusual electrophile, which opens upon nucleophilic attack of the side chain of Lys802.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> SAR studies on analogues of <b>3</b> demonstrated that omission (or modification) of this furan ring results in significant reduction in inhibitory activity. An X-ray crystallographic structure revealed the exact nature of the binding mode of <b>3</b>, and clear density was observed for the primary amine linking to the opened furane ring.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Later on, <b>3</b> was also shown to inhibit the protein kinase Plk1 (IC<sub>50</sub> = 24 nM), shedding some doubt on the pharmacology that was previously attributed to PI3K inhibition.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Subsequently, it was established that <b>3</b> also inhibits Plk3 by covalent modification of the conserved lysine in the ATP binding pocket.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In general, deliberately designed covalent drugs that target the invariant lysine in kinases are not to be expected. However, uniquely positioned lysines elsewhere in or near the ATP binding pocket may well be suitable for a covalent inhibitor approach.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Cysteine-Trapping Covalent Kinase Inhibitors</h3><div class="NLM_p">Unlike cysteines in kinases, cysteines involved in the catalytic machinery in, for instance, protein tyrosine phosphatases<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and cysteine proteases<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> are part of very specific environments made up of neighboring amino acids and ternary architecture of these particular proteins. Part of the active site architecture is the position of these cysteines, residing frequently at the “bottom” of one or more α-helixes. Backbone NH groups point downward generating a net positive charge that stabilizes the sulfhydryl anion and augments nucleophilicity.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The p<i>K</i><sub>a</sub> of a thiol in a typical cysteine residue is ∼8.5, whereas the presence of a polar or positively charged environment can decrease the p<i>K</i><sub>a</sub> up to 5 log units. In many protein families, cysteines contribute to maintaining ternary protein structures via disulfide bond formation. In the ATP-binding pocket of kinases, reduced cysteines generally do not seem overly nucleophilic and the side chain functionality may have a rudimentary role at most. There are, however, several recent reports that suggest that reaction of a cysteine thiol can regulate and control even protein kinase function, for instance, by means of redox signaling<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> or S-alkylation with endogenous electrophiles.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> For this very same reason, reducing agents such as dithiothreitol (DTT) or dithioerythritol (DTE) are indispensable ingredients in biochemical assays for kinases, in order to keep the enzyme in an active and sensitive state. This also supports the notion that these cysteines are sensitive enough for electrophilic modification by designer drugs.</div><figure id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0019.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic representation of available cysteines in or near the ATP binding pocket of kinases in the active conformation (based on the crystal structure of interleukin 2 tyrosine kinase, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SM2">1SM2</a>). The spheres indicate the locations of cysteines that are in principle accessible for covalent modification: group 1, glycine-rich- or P-loop (dark blue); group 2, the roof of the ATP binding pocket (pink); group 3, hinge region and front pocket (yellow); group 4, DFG-motif neighboring cysteine (light blue). Group 5 (in dark red) denotes the cluster of cysteines that resides on the activation loop. The gatekeeper group is shown in orange. Adapted by permission from Macmillan Publishers Ltd.: <i>Nature Reviews Cancer</i> (<a href="http://www.nature.com/nrc/index.html" class="extLink">http://www.nature.com/nrc/index.html</a>), Copyright 2009.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Recently, Zhang et al. have suggested a very useful classification system that originally binned the cysteines into four groups according to the relative positions in the ATP binding pocket (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> It is justified to add at least two additional groups to this initial classification, involving the cysteines located at the gatekeeper position and a fifth group. Group 5 covers cysteines residing at various locations in the activation loop. Some cysteines are more unique than others, and there are at least 200 kinases that seem tractable for a covalent approach. Given the known conformational flexibility of kinases, this number may be even higher. Structural analyses of the different conformations, including the active kinase state and inactive “DFG-out” and “C-helix-out” conformations, unveil additional cysteines that could be targeted.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> These cumulative analyses generate a fingerprint of the kinome active site toward cysteines, and the resulting “cysteinome” is of great value for the design of covalent kinase inhibitors. There are now several examples of covalent kinase inhibitors that target this region, and in the following sections the several groups are reviewed. The order of appearance is dictated by the group numbering as indicated in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Group 1 Cysteines</h3><div class="NLM_p">So far, there is only one report that describes the identification of covalent kinase inhibitors targeting a cysteine on the lip of the glycine-rich loop (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). An irreversible group 1B inhibitor is represented by fibroblast growth factor receptor (FGFR) inhibitor <b>4</b> (FIIN-1, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), which was identified via a structure-based approach using available reversible FGFR inhibitors.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The FGFR family consists of four members, FGFR1–4 and plays an important role in tumor formation and progression as well as wound healing.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Compound <b>4</b> is a biochemically potent acrylamide-based inhibitor of FGFR1, FGFR2, and FGFR3 (IC<sub>50</sub> values of 9.2, 6.2, and 11.9 nM, respectively) and is somewhat less potent on FGFR4 (IC<sub>50</sub> = 189 nM), with decent selectivity over the other group 1B cysteine kinases, such as Src, YES, and TNK1 (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The reversible propionyl analogue of <b>4</b> was 24- to 100-fold less potent in FGFR1 and FGFR3 harboring cells, respectively. With the aid of a biotinylated version of <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>), specific covalent wild type (WT) FGFR1 labeling was demonstrated in transfected HEK293 cells whereas the C486S mutant was barely modified. This is in line with the binding model that strongly suggests that <b>4</b> forms a covalent bond with FGFR1 via Cys486.</div><figure id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (Top) Chemical structure of FGFR inhibitor <b>4</b>. (Bottom) The human kinome and the group 1B cysteines. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Group 2 Cysteines</h3><div class="NLM_p">Within this cluster, subgroup 2B comprises only 11 kinase members and has been the sole subject of proven covalent kinase targeting within the group 2 cysteines. Cohen et al. were the first to exploit this particular cysteine as a selectivity filter in addition to the threonine gatekeeper residue in p90 ribosomal protein S6 kinase (RSK).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The four closely related RSKs (RSK1–4) all have the P-loop cysteine, whereas RSK3 has the sterically demanding methionine as a gatekeeper as opposed to threonine in the other three RSK kinase members. This was sufficient to develop a fluoromethylketone (FMK) derivative <b>5</b> as a highly potent and selective RSK1 and RSK2 inhibitor, with an IC<sub>50</sub> value against RSK2 of 15 nM (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">06</a>). Selective covalent labeling of WT (but not the C436V mutant) RSK2 was demonstrated by FMK-biotin in transfected HEK293 cells. Also, Michael acceptors such as an acrylate or acrylonitrile were appended from the same pyrrolopyrimidine scaffold, yielding irreversible RSK2 inhibitors with modest biochemical IC<sub>50</sub> values.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> By contrast, the doubly activated electrophiles, as in cyanoacrylamide <b>6</b>, were 200-fold more potent (IC<sub>50</sub> = 4 nM) in enzymatic assays than the monoactivated vinyl groups, yet in a fully reversible covalent binding mode. Owing to its greater reactivity, <b>6</b> demonstrated faster kinetics than <b>5</b> in cellular settings, but the duration of occupancy seemed to rely on protein resynthesis and was indistinguishable between the two inhibitors. Intriguingly, all RSK kinases also accommodate another cysteine which is located in the back of the ATP binding pocket, equivalent to Cys560 in RSK2 (group 4).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Potential trapping of derivatives of <b>5</b> by this cysteine was not investigated.</div><div class="NLM_p">NEK2 is a centrosomal kinase that interferes with the spindle assembly checkpoint, affecting mitosis. It harbors a cysteine (Cys22) in an identical position as the RSK family of kinases.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Henise and Taunton developed a reasonably potent (IC<sub>50</sub> = 770 nM) and cell permeable irreversible NEK2 inhibitor (<b>7</b>) based on an oxindole scaffold using a propynamide as the warhead. Selective covalent NEK2 inhibitors, such as <b>7</b>, are important validation assets to investigate the consequences of intracellular inactivation of NEK2 on regulating the proliferation of tumor cells overexpressing this kinase.</div><div class="NLM_p">The same specific cysteine on the P-loop of MEKK1 was previously identified as a glutathionylation site following oxidative stress.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Bioactive nutrients harbor electrophilic isothiocyanates that intervene with stress-signaling kinase pathways. Reported activities include cell cycle effects and protection of experimental carcinogenesis in animal models. The SAPK/JNK signaling pathway was investigated by means of phenylethyl isothiocyanate (PEITC) <b>8</b>, which was shown to inhibit WT MEKK1 (group 2B) but failed to intervene with the C1238V mutant in both biochemical and cellular assays.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> It was the second covalent kinase inhibitor reported for this subgroup, and although far from being druglike, it demonstrates the potential for covalent kinase inhibitors as research tools in the exploratory biology of kinase signaling pathways.</div><div class="NLM_p">One group 2C suspect has been reported, which is a p38α inhibitor with moderate biochemical potency (IC<sub>50</sub> = 200 nM). Dialkynylimidazole derivative <b>9</b> did covalently modify p38α following prolonged incubation and as determined by ESI-MS.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The authors propose trapping via an intricate cyclization and rearrangement mechanism involving both ethynyl groups of <b>9</b>, but the exact mode of action and site of covalent binding were not confirmed. Cys39 could be adducted given its position in the roof of the ATP pocket of p38α and the known binding mode of the imidazole class of p38 inhibitors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> However, the cysteine sulfhydryl group is directed away from the pocket itself, and as a consequence, this cysteine is unlikely to be involved in adduct formation.</div><figure id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (Left) Human kinome and the group 2B cysteines. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (Right) Chemical structures of group 2B inhibitor <b>5</b>–<b>8</b> and group 2C kinase inhibitor <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Group 3 Cysteines</h3><div class="NLM_p">The 3F cluster of the group 3 cysteine-containing kinases has received by far the most attention because of the clinical potential of kinase inhibitors belonging to this subgroup.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In addition, the relatively high nucleophilicity with respect to the other cysteines facilitates the reaction with all sorts of electrophilic agents. The p<i>K</i><sub>a</sub> of the sulfhydryl group of this particular cysteine is most likely lower than average because of the position at the end of a C-lobe α-helix (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The net positive charge through the backbone NH groups stabilizes the thiolate anion, thus making it more amenable for electrophile trapping. Depending on the sequence alignment used, there are 10 kinases with a cysteine on this position (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">07</a>). The TEC family (Bmx, Btk, Itk, TEC, and Txk) and ErbB family (EGFR, ErbB2, and ErbB4) constitute the majority of this subgroup and in addition comprise Blk and JAK3.</div><figure id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Human kinome and the group 3F kinases. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ErbB family kinases were the first ones to be deliberately scrutinized via a targeted irreversible covalent approach. Reversible small molecule kinase inhibitors gefitinib (<b>10</b>) and erlotinib (<b>11</b>) have shown excellent clinical benefit, particularly in the treatment of non-small-cell lung carcinomas (NSCLC). The chemical structures of these reversible kinase inhibitors are presented in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">08</a>. Unfortunately, the ability of these ATP competitive EGFR inhibitors to treat NSCLC patients effectively is short-lived partly because of acquired drug resistant mutations in EGFR which concerns roughly 50% of the treated population.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(51, 52)</a> One of these mutations involves the threonine gatekeeper, which is converted to a methionine (T790M). This prevents reversible inhibitors from binding at higher ATP concentrations.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> An additional postulated explanation is the increased internalization of EGFR as observed in drug resistant tumor cell lines.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(54)</a> Both resistance mechanisms may efficiently be circumvented by irreversible kinase inhibitors and have spurred the search for irreversible (pan) ErbB inhibiting drug candidates.</div><figure id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Reversible ATP competitive EGFR inhibitors gefitinib and erlotinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 1997, it was demonstrated by Singh and colleagues of the Parke-Davis group that EGFR and ErbB2 could be covalently modified by an adenosine thiol analogue (<b>12</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> Inactivation of EGFR was shown to be time-dependent, a hallmark for covalent binding, and the binding model suggested the proximity of the 2′-thiol group of <b>12</b> to Cys797 in EGFR and to Cys805 in ErbB2. Around the same time, the highly potent and selective <b>13</b> (PD-168393) was shown to inactivate EGFR and ErbB2 in an irreversible manner by means of an acrylamide (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(56)</a> While the subnanomolar potency of <b>13</b> for EGFR (IC<sub>50</sub> = 0.7 nM) was indistinguishable from the reversible propionyl counterpart, a range of data (MS, site-directed mutagenesis, <sup>14</sup>C-labeling) demonstrated unequivocally the alkylation of Cys797. This translated into a significant advantage in a xenograft mouse model, since the duration of action had become a function of the protein turnover rate (de novo synthesis) rather than the pharmacokinetic profile of the inhibitor. Although <b>13</b> should be regarded as the prototype 4-anilinoquinazoline-based irreversible EGFR inhibitor, this particular compound did not make it into the clinic. A plethora of newer ErbB inhibitors have been identified that may display advantageous properties. One line of research focused on replacement of the acrylamide function by alternative and less reactive electrophiles, since this warhead was initially considered as too aggressive.</div><figure id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Group 3F irreversible ErbB family kinase inhibitors <b>12</b>–<b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A nearly identical and highly potent analogue discovered by Wyeth researchers is <b>14</b> (CL-387,785, IC<sub>50</sub> = 0.37 nM), which harbors a 2-butynamide as the Michael acceptor (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(57)</a> It showed potent inhibition of EGF-induced EGFR autophosphorylation in A431 cells (IC<sub>50</sub> ≈ 5 nM) and blocked tumor growth in a xenograft mouse model when given orally (80 mg kg<sup>–1</sup> day<sup>–1</sup>, q.d.). This compound, also known as EKI-785, was the first irreversible EGFR inhibitor considered for further clinical development but was abandoned later because of poor bioavailability.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(58)</a> A major improvement was observed when introducing a dialkylamino group as in compound <b>15</b>. This electrophile serves both as an internal base to accelerate the reaction with the cysteine and as a water-solubilizing group.</div><div class="NLM_p">Carmi et al. explored a variety of warheads characterized by different reaction mechanisms with respect to nucleophiles.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(59)</a> The electrophiles studied included epoxides, phenoxymethylamides, carbamates, nitriles, and (benz)isothiazolinones. Epoxide derivative <b>16</b> was the EGFR inhibitor that stood out in terms of biochemical potency (IC<sub>50</sub> = 1.2 nM) and inhibition of EGFR autophosphorylation in cells with IC<sub>50</sub> values of 7 nM (immediately following 1 h of incubation with EGF) and 44 nM (8 h after removal of inhibitor from culture medium, following 1 h of incubation with inhibitor), respectively. The hysteresis in efficacy observed is in line with covalent binding, resulting in prolonged inhibition only reversed following de novo synthesis of EGFR.</div><div class="NLM_p">A less obvious and less reactive electrophile is the acetylene moiety on an electron-deficient thienopyrimidine scaffold as in <b>17</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(60)</a> Covalent adduct formation of this type of pan-ErbB kinase inhibitors was demonstrated by means of X-ray crystallography and mass spectrometry. Covalent modification of EGFR with <b>17</b> was much slower compared to <b>22</b> (CI-1033, Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>),<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(61)</a> while the enzymatic IC<sub>50</sub> values for EGFR, ErbB2, and ErbB4 ranged from 7 to 66 nM. At doses of 10, 30, and 100 mg/kg (b.i.d.), <b>17</b> displayed a dose-dependent inhibition of tumor regression in a BT474 xenograft mouse model.</div><div class="NLM_p">Although not extremely potent, boron-conjugated 4-anilinoquinazolines were also shown to inhibit EGFR with submicromolar IC<sub>50</sub> values.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(62)</a> Unlike the other boronic acid derivatives reported in this paper, compound <b>18</b> demonstrated irreversible inhibition, which was attributed to a covalent bond to Asp800 instead of Cys797. Unfortunately, no empirical proof was provided to strengthen this hypothesis. Additional warheads that have been employed in the search for ErbB family kinase inhibitors have recently been extensively reviewed.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(63)</a></div><figure id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Group 3F irreversible ErbB family kinase inhibitors <b>19</b>–<b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another line of focus is optimization of the nature and size of the linker between the 4-anilinoquinazoline scaffold and the warhead, with the aim to fine-tune warhead orientation. Cha et al. partially locked the orientation of the acrylamide with a conformationally rigid <span class="smallcaps smallerCapital">l</span>-proline, arriving at <b>19</b> as a potent and selective dual inhibitor of EGFR and ErbB2 with IC<sub>50</sub> values of 13 and 42 nM, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(64)</a> Its favorable cellular potency (IC<sub>50</sub> = 8 nM) and pharmacokinetic profile translated to robust reductions of tumor size in the A431 xenograft mouse model at 3 mg kg<sup>–1</sup> day<sup>–1</sup> (po).</div><div class="NLM_p">The use of completely new scaffolds also has led to the discovery of irreversible ErbB family kinase inhibitors, as was demonstrated by Coumar et al., who identified furanopyrimidine derivative <b>20</b>.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(65)</a> Docking studies of its des-acrylamido hit (IC<sub>50</sub> = 223 nM on EGFR) suggested the optimal position of the warhead. This led to a 30-fold improvement of the biochemical potency to 7 nM for <b>20</b>, along with potent antiproliferative activity in the HCC827 lung cancer cell line. The same group took a hybrid approach with another micromolar tetrahydrobenzothienopyrimidine hit, eventually resulting in <b>21</b>.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(66)</a> This EGFR inhibitor showed an IC<sub>50</sub> of 8 nM biochemically, 3 nM toward inhibition of EGFR autophosphorylation in the HCC827 cell line, and again regression of tumor size in vivo in mice following 5–15 mg kg<sup>–1</sup> day<sup>–1</sup> iv dosing.</div><div class="NLM_p">Since the first reports of covalent irreversible ErbB family kinase inhibitors in the late 1990s, a number of these inhibitors have progressed to late stage clinical development.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(67)</a> The irreversible inhibitors fall into two related structural categories: 4-anilinoquinazolines and the reminiscent 4-anilino-3-cyanoquinolines. The chemical structures of the most prominent compounds are depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>, and data associated with these compounds are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. So far, these candidates seem to live up to the potential upsides, as prolonged inhibition of both the WT enzymes and primary resistance mutants has been demonstrated preclinically. However, it remains to be established whether the effectiveness observed for all of these agents in vitro against, for instance, the EGFR T790M mutants persists at concentrations realistic for successful clinical use.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(68)</a> Dose-limiting toxicity for neratinib (<b>23</b>, HKI-272) may have prevented progression toward NSCLC as a primary indication<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(69)</a> but is currently in phase 3 clinical trials for ErbB2-positive breast cancer.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(70)</a> The most advanced clinical trials for afatinib (<b>24</b>, BIBW-2992) concern several cancer indications, as a single agent or in combination therapy.<a onclick="showRef(event, 'ref68 ref72'); return false;" href="javascript:void(0);" class="ref ref68 ref72">(67, 71)</a> A phase 3 clinical trial of dacomitinib (<b>25</b>, PF-00299804) is ongoing for NSCLC, and the study is expected to be completed in 2013.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(72, 73)</a> Interestingly, all research groups independently of each other selected candidates that are decorated with a dialkylamino substituted crotonamide warhead. Although ω-alkyl substitution of the acrylamide normally is detrimental to reactivity, introduction of the amine function offsets this loss by deprotonation of the sulfhydryl group (vide infra). In addition, solubility is favorably impacted, and the volume of distribution is high because of the lower intracellular pH, presumably stimulating uptake in the target tissues.</div><figure id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Irreversible pan-ErbB kinase inhibitors in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Late Stage Clinical Development Irreversible ErbB Kinase Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">enzyme IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">originator</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EGFR</th><th class="colsep0 rowsep0" align="center">ErbB2</th><th class="colsep0 rowsep0" align="center">ErbB4</th><th class="colsep0 rowsep0" align="center">stage of development<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ParkeDavis<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>22</b>, canertinib</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">Ph 2, discontinued</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">61</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Wyeth<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>23</b>, neratinib</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Ph 3 (breast cancer)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">74</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Boehringer Ingelheim</td><td class="colsep0 rowsep0" align="left"><b>24</b>, afatinib</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Ph 3 (NSCLC, breast neoplasms, squamous cell carcinoma head and neck)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">71</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left"><b>25</b>, dacomitinib</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">74</td><td class="colsep0 rowsep0" align="left">Ph 3 (NSCLC)</td><td class="colsep0 rowsep0" align="left"><a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">72</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Source: Thomson Reuters and ref <a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">67</a>.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Now Pfizer.</p></div></div></div><div class="NLM_p">With the observed on-target related adverse effects (skin rash and diarrhea) for EGFR inhibitors, development of EGFR mutant selective inhibitors for relapsed NSCLC due to mutated EGFR could show great promise. These mutant-selective agents may be as efficacious but would be better tolerated when WT EGFR is not affected. As many of the irreversible ErbB family kinase inhibitors reported herein have dual activity toward both the EGFR wild-type and T790M or T790M/L858R mutants, truly effective inhibition of the latter two are usually hampered by a large back-pocket substituent that clashes with the sterically demanding gatekeeper methionine. The first mutant selective EGFR inhibitors that are based on entirely new chemical scaffolds have recently appeared in the literature.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(75)</a> To this end, covalent pyrimidine inhibitors were identified by screening, and <b>26</b> (WZ-4002) was extracted as the best inhibitor in terms of affinity with a <i>K</i><sub>d</sub> of 0.13 μM for EGFR L858R/T90M and about 100-fold less for WT EGFR (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>). The overall selectivity provides a good starting point for further optimization, but there is clearly room for improvement.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(76)</a> Nevertheless, <b>26</b> is less potent in vitro and in vivo against WT EGFR than irreversible quin(az)oline-based inhibitors and 30- to 100-fold more potent against EGFR T790M. <b>26</b> is efficacious in murine models of T790M-containing cancers, as was shown by reduced tumor volumes following a daily oral dose of 25 mg/kg.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(75)</a> Next to the binding mode, covalent binding to the Cys797 of EGFR T790M was confirmed via X-ray crystallography. Elucidation of the structure also revealed that <b>26</b> binds the active conformation of the kinase, as opposed to <b>23</b>, which binds the inactive form. One other mutant-selective inhibitor (<b>27</b>, CO-1686) has been described in a joint effort by Avila Therapeutics and Clovis Oncology, but this structure has not been disclosed.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(77)</a><b>27</b> inhibits cell proliferation of cell lines expressing mutant EGFR T790M and EGFR signaling in, for instance, L858R/T790M expressing H1975 cells with an IC<sub>50</sub> of 62 nM while sparing WT EGFR. Dose-dependent tumor regression in the H1975 and HCC827 xenograft models was achieved with complete inhibition at the highest dose (100 mg kg<sup>–1</sup> day<sup>–1</sup>, po), and <b>27</b> has recently been progressed to the clinic for the NSCLC indication. These mutant-selective irreversible inhibitors can be considered the third generation EGFR inhibitors, after the first (reversible, ATP competitive) and second (irreversible) generation WT EGFR inhibitors.</div><figure id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Crystal structure of EGFR T790M covalently bound to <b>26</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>.pdb; P-loop omitted for clearity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second kinase of the subgroup 3F that received considerable interest is Bruton’s tyrosine kinase (Btk). Btk is a key kinase in the signaling pathway activated via the B-cell receptor (BCR), regulating B-cell proliferation and activation. Inhibition of Btk shows great potential in the treatment of B-cell malignancies and autoimmune diseases. Celera researchers were the first to report on irreversible (Btk) inhibitors, including ibrutinib (<b>28</b>, PCI-32765, Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) that was subsequently taken to clinical development by Pharmacyclics.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(78)</a> Compound <b>28</b> is a potent and fairly selective Btk inhibitor with an IC<sub>50</sub> of 0.5 nM by virtue of covalent binding to Cys481. It was efficacious in collagen-induced arthritis (CIA) and lupus models in mice and in spontaneous canine B-cell lymphomas.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(79)</a> Phase 2 clinical studies in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) have been concluded successfully for this Btk inhibitor, showing an excellent response rate in CLL patients and in subtypes of NHL.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(80)</a> The reminiscent covalent Btk inhibitor <b>29</b> was disclosed recently, displaying an IC<sub>50</sub> of 2 nM for Btk.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(81)</a></div><figure id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of group 3F irreversible Btk inhibitors <b>28</b>–<b>32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CNX-774 (<b>30</b>) from Avila Therapeutics also targets Cys481 and is a potent Btk inhibitor (IC<sub>50</sub> < 1 nM) of yet another chemotype.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(82)</a> Btk activity in Ramos cells was strongly inhibited with an IC<sub>50</sub> of 1–10 nM, and <b>30</b> has demonstrated efficacy in a CIA mouse model at 60 mg kg<sup>–1</sup> day<sup>–1</sup>. However, the in vivo target occupancy reached only ∼70% as determined via a chemical probe method. Avila Therapeutics continued activities on a covalent Btk inhibitor, resulting in the development of the more potent compound <b>31</b> (AVL-292, structure not disclosed).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(83)</a><b>31</b> potently inhibits Btk in biochemical (IC<sub>50</sub> < 0.5 nM) and cellular assays (EC<sub>50</sub> = 1–10 nM), including α-IgM stimulation of B-cell proliferation and B-cell activation. The overall favorable efficacy and selectivity profile warranted clinical development, and early observations from a phase 1b clinical study suggest that <b>31</b> is safe and well tolerated in NHL and CLL patients.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(84)</a></div><div class="NLM_p last">Pfizer has reported on imidazoquinoxaline <b>32</b> and derivatives acting as irreversible Btk inhibitors, emphasizing its interest in this area.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(85)</a> Compound <b>32</b> combined good biochemical Btk potency (IC<sub>50</sub> = 1.93 nM; no preincubation) with selectivity over the Src family kinase members albeit not over ErbB family member EGFR. The nanomolar inhibition of B-cell proliferation (IC<sub>50</sub> = 3.41 nM) in combination with favorable pharmacokinetic properties led to dose-dependent efficacy in the mouse CIA model following 0.3–10 mg/kg via oral route dosing.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Group 4 Cysteines</h3><div class="NLM_p">Although this cluster is confined to a single cysteine adjacent to the DFG-motif and near the bottom of the ATP binding pocket, nearly 10% of all known kinases (48) have this particular cysteine at this very position (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>). Intuitively one would guess that in this case selectivity is a major issue to resolve. However, the fact that the kinases involved are clustered in eight or nine evolutionary families may clearly present options for additional selectivity filters.</div><div class="NLM_p">After the success of bringing the irreversible EGFR/ERbB2 inhibitors to the clinic, Wissner et al. also explored the 4-anilinoquinazoline scaffold for covalent binding with Cys1045 in KDR (VEGFR-2).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(86)</a> In their binding model, the aniline portion was located near the cysteine, and for this reason it was replaced by a reactive quinone group. Inhibitors were screened for KDR inhibition with and without GSH to ascertain a sulfhydryl reaction confined to the kinase of interest and at high and low ATP concentrations to confirm the non-ATP competitive nature. Compound <b>33</b> emerged as an attractive irreversible inhibitor with an IC<sub>50</sub> of 5 nM along with good selectivity and in vivo efficacy in a mouse xenograft model (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>). Although only a small panel of deselection kinases was used, other group 4 member kinases, such as GSK and MEK1, were reportedly not inhibited. Even though caution should be taken (many more group 4 kinases were not included), this suggests that it is feasible to induce selectivity even within this large cluster of kinases, as long as the chemical scaffold is appropriately chosen.</div><div class="NLM_p">Resorcylic acid lactones (RAL) that contain a <i>cis</i>-enone Michael acceptor were shown to be irreversible inhibitors of most of the group 4 kinases. Hypothemycin (<b>34</b>) turned out to be rather unselective within this cluster, inhibiting 18 out of 19 tested kinases containing this conserved cysteine.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(87)</a> A tryptic digest confirmed covalent binding to Erk2 but did not yet dismiss the other electrophilic functionality, the epoxide, as the reacting warhead. To this end, the crystal structure of the Erk2–hypothemycin complex provided proof that a covalent bond with Cys166 of Erk2 was formed with the <i>cis</i>-enone moiety.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(88)</a> Around the same time, another group reported on a small set of hypothemycin analogues, exemplified by <b>35</b> (FR-148083).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(89)</a> In analogy with <b>34</b>, X-ray crystallography showed the covalent interaction of <b>35</b> with Erk2 (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>). Next to Erk2 (IC<sub>50</sub> = 80 nM), the MAP2K kinases MEK1 (IC<sub>50</sub> = 6 nM) and MKK7 (MEK7; IC<sub>50</sub> = 300 nM) were substantially inhibited, whereas MKK4 (MEK4) showed IC<sub>50</sub> > 3 μM. No other kinases of this cluster were included in the selectivity profiling. The related analogue <b>36</b> (E6201) was evaluated for its anti-inflammatory and antihyperproliferative potential, reportedly owing to the inhibition of MEK1 (IC<sub>50</sub> = 5.2 nM) as well as several other MAP2K kinases and the upstream group 2B kinase MEKK1 (IC<sub>50</sub> = 31 nM).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(90)</a> Reduction of the <i>cis</i>-enone double bond was detrimental to cellular activity, and introduction of the γ-methyl was necessary to enhance metabolic stability. In animal models of dermatitis, compound <b>36</b> was active following topical administration<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(91)</a> and is currently in clinical trials as a topical formulation for psoriasis.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(67)</a><i>cis</i>-Enone harboring RAL derivatives remain an intriguing class of irreversible kinase inhibitors that in some instances have shown very potent in vivo effects in preclinical oncology models,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(92)</a> but highly selective inhibitors are usually not obtained. Other very similar RAL analogues appeared almost a decade earlier as fairly potent pan-MEK or TAK-1 inhibitors, which is not surprising given their incorporated α,β-unsaturated ketone moiety and the fact that the kinase involved belongs to group 4.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(93)</a> Nevertheless, the potential for irreversible binding was not interrogated at the time.</div><div class="NLM_p">The latest addition of irreversible kinase inhibitors in this cluster of kinases are thienyl halomethyl ketones.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(94)</a> Thiophene derivative <b>37</b> displayed a biochemical IC<sub>50</sub> of 0.5 μM for GSK3β, representing the first reported irreversible inhibitors for this kinase to date. Although moderately potent and far from being druglike, these agents can be considered as fragments that can be optimized for affinity toward GSK3α and/or GSK3β.</div><figure id="fig14" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0010.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (Top-Left) Human kinome and the group 4 kinases. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (Top-Right) Chemical structures of selected irreversible group 4 kinase inhibitors <b>33</b>–<b>37</b>. (Bottom) Compound <b>35</b> bound in the active site of Erk2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E14">2E14</a>.pdb).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Group 5 Cysteines</h3><div class="NLM_p">The location of this cluster is outside the ATP binding pocket and on the activation loop (regulatory or T-loop) of various kinases (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). It is not within the scope of this Perspective to present a thorough analysis of all potential cysteines via alignment of the kinase sequences. The flexible nature of the activation loops with respect to its length, but also the potential position of the cysteines, hampers a proper analysis. Therefore, it is practical to put all these cysteines in one group. In addition, because of flexibility of the activation loop, it is difficult to target these cysteines deliberately via a structure-based drug design approach, since 3D information for this region is scarce. Density with sufficient resolution is sometimes observed for activation loops but often not visible in crystal structures of kinases. On the other hand, it will probably be only a matter of time before the research community will identify and disclose meaningful ways of visualizing this structural “blind spot” for the majority of the kinases.</div><div class="NLM_p">Group 5 is an interesting cluster because Mother Nature already seems to incorporate activation loop cysteines in her kinase signaling pathways. For instance, some of the effects of naturally occurring ligands have been tied to allosteric covalent modification of activation loop cysteines. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IKKα/β, and they do so by covalent binding through a cysteine at position 179 within the activation loop.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(95)</a> Several lines of evidence were generated. First, the inhibitory effect was completely insensitive to high concentrations (1 mM) of ATP in a biochemical setting, which emphasized the non-ATP competitiveness, albeit not the site of covalent binding per se. Interestingly, both IKKs also have a cysteine located in the ATP binding pocket belonging to group 3B.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Second, comparing inhibitory responses of both PGA1 (<b>38</b>) and 15dPGJ2 (<b>39</b>) on WT IKKβ and the C179A mutant in vitro confirmed the probable site of binding (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">015</a>). The WT kinase was fully inhibited, whereas the mutant was not, yet both isoforms were equally responsive to the same stimuli. In line with these findings, the saturated analogous compounds cyclopentanone and cyclopentene derivatives failed to intervene with NF-κB activity.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(96)</a> The micromolar concentrations of cyclopentenone derivatives needed for inhibition of IKKβ have been detected at the site of inflammation, and so it can be inferred that inhibition of the NF-κB transcriptional activity is at least partly attributable to this covalent binding mechanism. Another endogenous degradation product, 4-hydroxy-2-nonenal (4-HNE, <b>40</b>), was also shown to block the NF-κB pathway.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(97)</a> In yet another study, artemisolide (<b>41</b>) was presented as an inhibitor of IKKβ by means of Cys179 targeting.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(98)</a> The common denominator in all these agents is the α,β-unsaturated ketone functionality, which can act as a Michael acceptor. Interestingly, the kinase LKB1 is a kinase with a nucleophilic Cys210 on the activation loop that aligns nicely with Cys179 in IKKα/β and is also prone to inhibition by some of these reactive lipids, such as <b>38</b> and <b>40</b>.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(99)</a></div><div class="NLM_p">The kinase Akt1 accommodates two cysteines on the activation loop (Cys296 and Cys310) and is sensitive to inhibition by pyranonaphthoquinone derivatives, such as lactoquinomycin (<b>42</b>, IC<sub>50</sub> = 149 nM) and frenolicin B (<b>43</b>, IC<sub>50</sub> = 313 nM).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(100)</a> Because of the redox sensitive nature of the cysteines involved, the authors speculated righteously that the cysteines could be covalently adducted by these pyranonaphthoquinone-containing inhibitors. First, preincubation with cysteine led to ∼60-fold loss of potency for the inhibitors, and second, both the C296A and C310A mutants were less sensitive to pyranonaphthoquinone derivatives. In contrast, staurosporine inhibited the WT and mutant kinases equally well.</div><div class="NLM_p">Although the activation loop has not yet been thoroughly addressed, from these collective data it can be inferred that covalent trapping in this region shows potential for the future. Especially when the ATP binding pocket is highly conserved within a kinase family, inactivation via covalent targeting specific activation loop cysteines may be an attractive alternative.</div><figure id="fig15" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Irreversible group 5 kinase inhibitors <b>38</b>–<b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Miscellaneous Cysteines</h3><div class="NLM_p">Beyond the kinase regions discussed so far, a first example of trapping a cysteine located on the catalytic loop has also been reported. While analyzing additional cysteines that are in the vicinity of the ATP binding pocket, taking into account the inactive “DFG-out” and “C-helix-out” conformations of protein kinases, the Winssinger group came across a cysteine located at the beginning of the catalytic loop of c-KIT and PDGFR.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> BCR-Abl inhibitor imatinib (<b>44</b>), which also blocks c-KIT and PDGFR via a type II allosteric binding conformation, served as the chemical starting point (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>). The cysteine involved (Cys788 and Cys814 in c-KIT and PDGFRα, respectively) was targeted by exchanging the <i>N</i>-methylpiperazine moiety for electrophilic groups. The resulting chloroacetamide derivative <b>45</b> was subsequently shown to adduct c-KIT and PDGFR covalently on the envisaged cysteine as shown in MS/MS experiments. The biochemical activity for the two kinases did not improve compared to <b>44</b>, but some advantage in terms of biochemical selectivity was achieved. Also, <b>45</b> lost some affinity for BCR-Abl, the prime target for <b>44</b>, which has a phenylalanine in the corresponding cysteine position. A serendipitous finding by Gray and co-workers with near identical compounds yielded potent and selective covalent inhibitors of JNK1, JNK2, and JNK3.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(101)</a> While working on covalent inhibitors for c-KIT, they observed significant inhibition of JNK. In particular, incorporation of 1,4-dianilino and 1,3-benzamide motifs, such as in <b>46</b>, yielded efficient and specific electrophilic inhibitors. The phenylaminopyrimidine analogues trapped Cys116 in JNK1 and JNK2, and equivalent Cys154 in JNK3, via a type I binding conformation, as was demonstrated via cocrystal structures with JNK3. The fairly unique cysteine in JNK1, JNK2, and JNK3 resides just outside the ATP pocket on the C-terminal domain α-helix near the group 3F position (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). With enzymatic low nanomolar IC<sub>50</sub> values for JNK1 (4.7 nM), JNK2 (18.7 nM), and JNK3 (0.98 nM) and selective cellular inhibition of c-Jun phosphorylation, <b>46</b> is among the JNK inhibitors that are well suited to further study of JNK-mediated intracellular signaling.</div><figure id="fig16" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0012.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Transformation of imatinib into an irreversible c-KIT/PDGFR inhibitor <b>45</b> and JNK inhibitor <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Chemical Reporter Probes for Protein Kinases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Highly efficacious and selective kinase inhibitors are extremely useful in in vitro or in vivo validation settings, especially when the kinase involved is blocked irreversibly. First, the inhibition observed is very often time-dependent, which is one of the hallmarks of covalent and irreversible binding. This helps to delineate the pathway involved, and the markers investigated are easier to tie to the kinase under scrutiny. Second and perhaps more importantly, appropriate decoration of a selective inhibitor with a linker-substituted label renders a very powerful chemical probe (also termed activity-based probe) to study intracellular phenomena (comparative application).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(102)</a> Also, such a selective chemical probe can aid in the determination of target occupancy of the (pre)clinical candidate irreversible inhibitors (competitive application).</div><div class="NLM_p">Several compelling examples have been reported for kinases underlining the strength of this platform, and many irreversible kinase inhibitors reviewed herein have been successfully transformed into such useful chemical probes. The irreversible inhibitors can be biotinylated to study in vitro or in vivo selectivity via (strept)avidin enrichment or (once the functional selectivity has been established) appended with a fluorescent tag to support visualization of intracellular processes (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>, see insert).</div><div class="NLM_p">One of the challenges for designing appropriate probes is the site of attachment of the linker on the core scaffold. Ideally, this position does not interfere with the potency that was obtained with the original parent inhibitor. To this end, Blair and co-workers decided to functionalize the quinazoline C7 position of <b>13</b> while searching for a selective EGFR affinity probe.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(103)</a> Both the PEG linker and the NBD fluorophore are solvent exposed, and the chance of disrupting the potency is minimal. The resulting fluorescent probe (<b>47</b>) was used in this case used to quantitate the relationship between EGFR stimulation and downstream kinases in living cells.</div><div class="NLM_p">For some of the validation work with respect to covalent FGFR inhibition, FIIN-1-biotin (<b>48</b>) was utilized (vide infra).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In the design, the authors were allowed to elongate the acrylamide of parent <b>4</b> with a dialkylaminomethylene moiety, since the resulting reactivity is normally in the range of the unsubstituted warhead (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>). Also in this case, the cellular EC<sub>50</sub> was comparable to that of parent inhibitor <b>4</b>.</div><div class="NLM_p">In some instances, the derived chemical probes fail to present the necessary properties like permeability. For this reason, a biotinylated FMK derivative was inappropriate for targeting RSK1 and RSK2 in intact cells, and also FMK-BODIPY (<b>49</b>) showed modest cellular activity (Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> This was very elegantly solved by Cohen et al., who incorporated the clickable propargyl linker allowing for postlabeling intracellular conjugation with an azide-labeled biotin or reporter molecule (biotin-azide or TAMRA-azide).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(104)</a> On this improved propargyl amine version of FMK (FMK-PA, <b>50</b>), the vector of the tethered reporter tag is extending from pyrrolopyridine portion into the ribose pocket and toward the solvent. The application of this highly versatile in situ click conjugation concept contributes significantly to the power of irreversible kinase inhibition with respect to validation of specific target kinases in signaling pathways.</div><div class="NLM_p">To specifically profile members of the PI3-kinase family, several activity-based probes have been developed based on wortmannin as a scaffold.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(105)</a> As per example, a wortmannin-BODIPY probe (structure not shown) turned out to be cell permeable allowing for labeling of proteins in intact living cells.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(106)</a> The additional finding by Liu et al. that <b>3</b> also targets the conserved lysine of protein kinases Plk1 and Plk3 via covalent binding can in part be attributed to the application of TAMRA-based probe of <b>3</b> (<b>51</b>, AX-7503) as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a>.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a></div><div class="NLM_p">The same group reported the utility of a selective PKCα/β probe via a slightly unorthodox design angle.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(107)</a> It was different, because a cysteine located just outside the ATP pocket of PKCα (C619) and PKCβ (C622) was targeted for covalent trapping. On the well-known PKC inhibitor bisindolylmaleimide core, a chloroacetamide warhead was incorporated on the TAMRA-tagged linker reaching out to the cysteine mentioned. The resulting exo-affinity probe <b>52</b> (AX-4697) provided a sensitive and permeable tool for further examination of the consequences of pharmacological intervention in PKC-mediated biology.</div><figure id="fig17" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0013.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Examples of chemical probes bases on irreversible protein kinase inhibitors. TAMRA = tetramethylrhodamine. NBD = nitrobenzoxadiazole. BODIPY = boron dipyrromethene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The determination of target occupancy has been an integral part of the (pre)clinical development of irreversible Btk inhibitors <b>31</b> and <b>28</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>). Honigberg et al. created the cell-permeable, fluorescently labeled derivative PCI-33380 (<b>53</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a>) of their clinical candidate.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(79)</a> The level of Btk target occupancy by <b>28</b> was determined using <b>53</b>, and this occupancy was shown to tightly correlate with the inhibition of BCR signaling and in vivo efficacy in mice and dogs. In the clinic, the same fluorescent probe was used to correlate target occupancy and pharmacodynamics effects in cancer patients.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(80)</a> To this end, Avila Therapeutics assessed ex vivo Btk occupancy with a biotinylated covalent probe and quantitated by ELISA.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(84)</a></div><div class="NLM_p">These probes provide excellent biomarkers, allowing efficacy and target occupancy to be linked in with the analysis of pharmacodynamics. Another upside for the utilization of probes is that it aids the selection of the highest relevant dose in the patient. In oncology clinical trials, patients are treated with increasing doses of the drug until dose limiting toxicity is observed. For a covalent drug, a modest excess of exposure with respect to the dose where full target occupancy is observed should be more than sufficient.</div><figure id="fig18" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0014.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of the BODIPY-derived Btk chemical probe <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Clearly, one should be able to design and synthesize suitable probes for diagnosis and target occupancy purposes with modest efforts. Covalent kinase inhibitor probes should constitute an integral part of kinase research, especially when the identification and development of irreversible inhibitors come into play.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Chemical Genetic Engineering</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05283" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05283" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The physical evidence of irreversible inhibition, and the site of modification on the WT kinase, is frequently corroborated with genetically engineered kinase mutants. To be specific, the naturally occurring nucleophilic amino acid residue is replaced by a nonreactive isoster that is not interfering with the functional activity of the kinase. Hence, the relative contribution of covalent binding to the WT kinase inhibition can be studied. Some research groups have exploited this genetic technique by reversing this concept and introduced a nucleophilic anchor point for irreversible binding that was previously not in the active site. Mutation of strategically positioned key residues into a cysteine creates an engineered pocket that allows unparalleled specificity, especially in combination with additional selectivity filters (often a mutated gatekeeper residue). SAR that has previously been developed for WT kinases, bearing a cysteine in the same position, can now be efficiently exploited for the mutant kinase via selective irreversible inhibition. The groups of Shokat and Rauh have been at the forefront of this so-called chemical genetic engineering platform. In one case, c-Src was subjected to two point mutations in the ATP binding pocket, gatekeeper T338G and S345C at the group 3F position.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(103)</a> The latter position is homologous to Cys797 in EGFR, and c-Src-dm has become extremely sensitive to irreversible prototype EGFR inhibitor <b>13</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>) and analogues. The mutant IC<sub>50</sub> values ranged from 1 to 250 nM for these analogues, as opposed to >27 μM for WT c-Src.</div><div class="NLM_p">Similarly, two selectivity filters were applied on fission yeast aurora (Ark1) in order to tailor the kinase for covalent trapping by these quinazoline derivatives.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(108)</a> The first mutant filter at the gatekeeper position, L166A, allowed better accommodation of the aniline portion of analogues of <b>13</b>, and the second E173C mutation provided the anchor point for covalent modification. The electrophilic inhibitors efficiently inhibited the newly engineered mutant Ark1 in the low nanomolar range, and both selectivity filters were necessary because neither the WT kinase nor the mono E173C mutant was inhibited biochemically (IC<sub>50</sub> > 20 μM). Subsequently, “analogue-sensitive” Ark1-mediated signaling in recombinant cells was efficiently and irreversibly blocked by the propynamide derivative of <b>13</b> while no detectable toxicity was observed.</div><div class="NLM_p">This covalent complementarity approach was taken one step further by mutating the gatekeeper residue into a unique cysteine.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(109)</a> This cysteine has not been previously targeted for covalent binding. Only two human protein kinases (MOK and SgK494) have this endogenous cysteine gatekeeper residue which corresponds with the orange sphere in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. Thus, cysteine gatekeeper engineering in theory allows electrophilic inhibitor discovery for most kinases, as long as the mutant kinase activity is not impaired. Again, the concept was validated employing c-Src T338C in combination with warhead substituted 3-benzylpyrazolopyrimidines, such as <b>54</b>, and 4-anilinoquinazolines (Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a>). Compound <b>54</b> showed a time-dependent inhibition of T338C c-Src and displayed an IC<sub>50</sub> of 114 nM (versus >5 μM for WT c-Src). MOK inhibition was hardly impacted by <b>54</b>, and a few off-target effects were noted when screening against a panel of 307 kinases. A couple of TEC family kinases were hit more than 50% by <b>54</b> at 1 μM but not when the fluoromethyl ketone moiety was employed as the electrophile. A crystal structure of <b>54</b> in complex with T338C c-Src was solved, which nicely demonstrated the formation of a covalent bond between the vinylsulfonamide warhead and the gatekeeper cysteine residue.</div><figure id="fig19" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0015.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Pyrazolopyrimidine derivative <b>54</b> in covalent complex with c-Src T338C (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SVV">3SVV</a>.pdb; P-loop omitted for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">KINASE KINETICS AND STRUCTURE–<i>REACTIVITY</i> RELATIONSHIPS (SRR)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28263" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28263" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is easy to get enchanted with extraordinary potencies and superb selectivity. However, embarking on a project with the aim to identify covalent inhibitors that should serve patients warrants an adapted flowchart for selecting candidate compounds with the required druglike properties. It is of paramount importance to incorporate specific off-target assays that are central in the flowchart (vide infra). These can be both computational and empirical of nature. Many of those assays, such as homologue cross-screening and monitoring of glutathione depletion, are already part of the conventional drug discovery toolbox. More importantly, addressing the kinetics of irreversible kinase inhibition and generation of robust structure–reactivity relationships are the real keys to success in the discovery of safe irreversible drugs. The activity of the ultimate irreversible kinase inhibitor should be an optimal mix of reversible binding affinity (SAR) and warhead reactivity (SRR). If the efficacy of the inhibitor depends solely on reactivity, the overall selectivity and consequently the safety profile will undoubtedly be compromised. When the reactivity is too low, the inhibitor will behave like a conventional reversible inhibitor and become more dependent on the clearance of the compound from the circulation again.</div><div class="NLM_p last">A suitable and straightforward assay system for the rate of kinase silencing has been reported by Rauh and co-workers. The kinetics of kinase inhibition were determined by monitoring changes in the intrinsic fluorescence signal upon covalent bond formation between electrophilic inhibitors and the S345C c-Src and the clinically relevant EGFR mutants.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(110)</a> Also, electrophilicity calculations by means of enthalpy changes (Δ<i>H</i>) were employed in analogy with previously published procedures for nitrile warhead containing compounds.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(111)</a> The potencies of irreversible inhibitors were extrapolated from the initial reaction velocities found in the linear range of the curves. With this technique, the influence of the altered gatekeeper residue size on the initial reactivity rate of the irreversible inhibitors could be directly monitored. A pragmatic way of ranking irreversible kinase inhibitors based on the intrinsic electrophilic strength has been described by Wyeth researchers, who rank-ordered the explored warheads based on simple glutathione adduct formation in a THF–water–methanol solution.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(58)</a> Others have incubated irreversible kinase inhibitor leads with glutathione or whole blood and monitored the stability over time.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(82)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For many kinases, a crucial regulatory role has been associated with a variety of malignancies, making this protein family an attractive drug target family. The challenge for this target family has been the identification and development of potent inhibitors with sufficient selectivity to generate efficacious drugs with a good safety profile. For a number of reasons, the kinase field in particular seems well equipped for the covalent inhibitor concept with clear potential advantages versus reversible inhibitors. The compelling upsides have been reviewed in this Perspective. First, with high intracellular ATP levels, non-ATP competitiveness is a major upside. Therefore, irreversible protein kinase inhibitors could outperform reversible drugs based on superior efficacy and functional selectivity. Indeed, the loss in cellular potency for biochemically potent reversible inhibitors is in many cases not observed for an irreversible inhibitor. Second, a substantial part of the human kinome harbors a specific cysteine in or near the ATP binding pocket that may be used to achieve both potency and selectivity. Third, the rate of turnover for many kinases, required for return of function of the target that has been effectively knocked down via irreversible kinase inhibition, renders this protein family suitable for less frequent dosing regimens. In addition, lower overall exposure is to be expected, since the pharmacodynamics effects are dependent on de novo synthesis of the target protein, rather than higher dosing required to maintain certain circulating levels for the drug to retain efficacy over time. This lower body burden is beneficial in circumventing off-target related adverse effects. Fourth, protein kinase inhibitors introduced to the market to date have without exception been approved for oncology indications, and it is in this area that irreversible kinase drugs might gain easier acceptance. Drug-induced resistance in many cancers remains a serious problem, and also here, irreversible binding kinase inhibitors could make a difference. It has been proposed that this mutational pressure even might exist for cysteines, which may render the irreversible kinase inhibitors currently in clinical development for oncology indications increasingly ineffective over time.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(69)</a> Future follow-up in these patients is required to substantiate the occurrence and prevalence of these inactivating mutations.</div><div class="NLM_p">Last but not least, irreversible kinase inhibitors as such are invaluable compounds as research tools in the validation of kinase signaling pathways or can with relative ease be appended with reporter tags. This may significantly speed the overall drug discovery process, as the biological validation of the target can be tackled early on and the availability of biomarker target occupancy probes facilitates dose-finding in clinical development.</div><div class="NLM_p last">Monitoring SRR is key in order to progress the most suitable covalent inhibitor candidates through the pipeline, since off-target toxicity related to the electrophile remains a substantial threat. The future will tell whether irreversible binding kinase inhibitors will live up to the expectations that have been generated by the research community; however, the progress that has been made in the past 2 decades has been impressive. The most advanced irreversible kinase inhibitors are in phase 3 clinical trials. Recently, two major deals have been struck within the pharmaceutical industry. Johnson & Johnson purchased phase 2 irreversible Btk inhibitor <b>28</b> from Pharmacyclics. Avila Therapeutics, a biotechnology company relying on the covalent binding platform, was recently acquired by Celgene. These developments seem exemplary for the general growing confidence in irreversible kinase inhibitors as effective and safe treatments. If irreversible kinase inhibition is shown to be sufficiently safe in cancer indications, chronic treatment for other disorders may also become accepted. Covalent drugs are already widely applied in indications outside the oncology arena. It is our belief that the covalent binding principle will gain common ground as we get more accustomed to the upsides while still keeping a critical eye on the potential risks. Those covalent drugs that have the appropriate benefit/risk balance are “bound to succeed”.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm3003203" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tjeerd Barf</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery Unit, Covalution
Pharma
BV, Ravenstein, The Netherlands</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#493d232c2c3b2d672b283b2f092a263f28253c3d202627672a2624"><span class="__cf_email__" data-cfemail="becad4dbdbccda90dcdfccd8feddd1c8dfd2cbcad7d1d090ddd1d3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allard Kaptein</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery Unit, Covalution
Pharma
BV, Ravenstein, The Netherlands</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Tjeerd Barf</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tjeerd Barf</b> obtained his Ph.D. in Medicinal Chemistry from the University of Groningen, The Netherlands, under the supervision of Prof. Håkan Wikström in 1996. He joined Pharmacia & Upjohn in Uppsala, Sweden, in 1997 and continued his employment in the spin-off company Biovitrum (2000). He has led medicinal chemistry programs concerning metabolic diseases and assumed overall program leadership later on. In 2005, he moved to Legacy Organon (Oss, The Netherlands), and as a Group Leader, his responsibilities encompassed heading immunology lead finding projects. After the acquisition by Schering-Plough and the merger with Merck, he led a global cross-site lead optimization effort for an autoimmune disease. In 2011, he cofounded Covalution Pharma and presently holds the position of Head of Chemistry within that biotechnology company.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Allard Kaptein</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Allard Kaptein</b> received his Ph.D. in 1993 in Biopharmaceutical Sciences at Gaubius Institute TNO/University of Leiden, The Netherlands. After 2 years as a Postdoctoral Fellow at Glaxo in Les Ulis, France, he joined the GlaxoWellcome in Stevenage, U.K. In 2000 he joined Organon in Oss, The Netherlands. From 2004 to 2008 he was head of the immunology lead finding program activities, and after 2009 headed a lead optimization program at Schering-Plough and Merck following the takeover of Organon. In July 2011 he founded, together with Tjeerd Barf, the R&D startup Covalution Pharma focusing on covalent kinase inhibitors in oncology and autoimmune diseases. His main areas of expertise include small molecule drug discovery on different target families, translational sciences, and cross-disciplinary knowledge bridging biology and chemistry in research.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i24" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i24"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i25" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i25"> Abbreviations Used</h2><tr><td class="NLM_term">(Bcr)-Abl</td><td class="NLM_def"><p class="first last">(breakpoint cluster region)-Abelson kinase</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">Akt1 (PKB)</td><td class="NLM_def"><p class="first last">Ak mouse strain thymoma</p></td></tr><tr><td class="NLM_term">Ark1</td><td class="NLM_def"><p class="first last">Aurora kinase</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B-cell receptor</p></td></tr><tr><td class="NLM_term">Blk</td><td class="NLM_def"><p class="first last">B-lymphocyte kinase</p></td></tr><tr><td class="NLM_term">Bmx</td><td class="NLM_def"><p class="first last">bone marrow tyrosine kinase gene in chromosome X</p></td></tr><tr><td class="NLM_term">Btk</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">ErbB</td><td class="NLM_def"><p class="first last">erythroblastosis oncogene B</p></td></tr><tr><td class="NLM_term">EGFR (ErbB1)</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">Erk2</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase-2</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-like tyrosine kinase-3</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">glycogen synthase kinase</p></td></tr><tr><td class="NLM_term">IDT</td><td class="NLM_def"><p class="first last">idiosyncratic toxicity</p></td></tr><tr><td class="NLM_term">IGF-1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor receptor</p></td></tr><tr><td class="NLM_term">IKKα/β</td><td class="NLM_def"><p class="first last">inhibitor of kappa-B kinase subunit α/β</p></td></tr><tr><td class="NLM_term">Itk</td><td class="NLM_def"><p class="first last">IL2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">JNK (SAPK)</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">c-Kit</td><td class="NLM_def"><p class="first last">steel growth factor receptor</p></td></tr><tr><td class="NLM_term">LKB1</td><td class="NLM_def"><p class="first last">liver kinase B1</p></td></tr><tr><td class="NLM_term">MEK (or MKK or MAP2K)</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">MEKK1 (MAP3K)</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase kinase 1</p></td></tr><tr><td class="NLM_term">MET</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">MOK</td><td class="NLM_def"><p class="first last">MAPK/MAK/MRK overlapping kinase</p></td></tr><tr><td class="NLM_term">NEK2 (NIMA)</td><td class="NLM_def"><p class="first last">never in mitosis gene a related kinase 2</p></td></tr><tr><td class="NLM_term">NHL</td><td class="NLM_def"><p class="first last">non-Hodgkin's lymphoma</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung carcinoma</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">PI4K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 4-kinase</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">Plk</td><td class="NLM_def"><p class="first last">polo-like kinase</p></td></tr><tr><td class="NLM_term">Raf</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection</p></td></tr><tr><td class="NLM_term">RSK</td><td class="NLM_def"><p class="first last">p90 ribosomal protein S6 kinase</p></td></tr><tr><td class="NLM_term">SgK494</td><td class="NLM_def"><p class="first last">Sugen kinase 494</p></td></tr><tr><td class="NLM_term">c-Src</td><td class="NLM_def"><p class="first last">Rous sarcoma oncogene cellular homologue</p></td></tr><tr><td class="NLM_term">SRR</td><td class="NLM_def"><p class="first last">structure–reactivity relationship</p></td></tr><tr><td class="NLM_term">TAK</td><td class="NLM_def"><p class="first last">TGF-β activated kinase</p></td></tr><tr><td class="NLM_term">TEC</td><td class="NLM_def"><p class="first last">tyrosine kinase expressed in hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">TNK1</td><td class="NLM_def"><p class="first last">tyrosine kinase nonreceptor 1</p></td></tr><tr><td class="NLM_term">Txk</td><td class="NLM_def"><p class="first last">T and X cell expressed kinase</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr><tr><td class="NLM_term">YES</td><td class="NLM_def"><p class="first last">Yamaguchi sarcoma viral oncogene homologue</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 111 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0ljRSufidH1hgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljShVQU9024ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference componds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+componds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520componds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Huth, J .R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olejniczak, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cothron, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span> </span><span class="NLM_article-title">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja0455547" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=217-224&author=J+.R.+Huthauthor=R.+Mendozaauthor=E.+T.+Olejniczakauthor=R.+W.+Johnsonauthor=D.+A.+Cothronauthor=Y.+Liuauthor=C.+G.+Lernerauthor=J.+Chenauthor=P.+J.+Hajduk&title=ALARM+NMR%3A+a+rapid+and+robust+experimental+method+to+detect+reactive+false+positives+in+biochemical+screens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span></div><div class="casAuthors">Huth, Jeffrey R.; Mendoza, Renaldo; Olejniczak, Edward T.; Johnson, Robert W.; Cothron, Darlene A.; Liu, Yaya; Lerner, Claude G.; Chen, Jun; Hajduk, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput screening (HTS) of large compd. collections typically results in numerous small mol. hits that must be carefully evaluated to identify valid drug leads.  Although several filtering mechanisms and other tools exist that can assist the chemist in this process, it is often the case that costly synthetic resources are expended in pursuing false positives.  We report here a rapid and reliable NMR-based method for identifying reactive false positives including those that oxidize or alkylate a protein target.  Importantly, the reactive species need not be the parent compd., as both reactive impurities and breakdown products can be detected.  The assay is called ALARM NMR (a La assay to detect reactive mols. by NMR) and is based on monitoring DTT-dependent 13C chem. shift changes of the human La antigen in the presence of a test compd. or mixt.  Extensive validation has been performed to demonstrate the reliability and utility of using ALARM NMR to assess thiol reactivity.  This included comparing ALARM NMR to a glutathione-based fluorescence assay, as well as testing a collection of more than 3500 compds. contg. HTS hits from 23 drug targets.  The data show that current in silico filtering tools fail to identify more than half of the compds. that can act via reactive mechanisms.  Significantly, we show how ALARM NMR data has been crit. in identifying reactive compds. that would otherwise have been prioritized for lead optimization.  In addn., a new filtering tool has been developed on the basis of the ALARM NMR data that can augment current in silico programs for identifying nuisance compds. and improving the process of hit triage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolKou1lGZ8tbVg90H21EOLACvtfcHk0ljShVQU9024ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF&md5=466332d4bdcddf6bc8a630aacbbb32ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fja0455547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0455547%26sid%3Dliteratum%253Aachs%26aulast%3DHuth%26aufirst%3DJ%2B.R.%26aulast%3DMendoza%26aufirst%3DR.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DJohnson%26aufirst%3DR.%2BW.%26aulast%3DCothron%26aufirst%3DD.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLerner%26aufirst%3DC.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DALARM%2520NMR%253A%2520a%2520rapid%2520and%2520robust%2520experimental%2520method%2520to%2520detect%2520reactive%2520false%2520positives%2520in%2520biochemical%2520screens%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D217%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug–target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug%E2%80%93target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug%25E2%2580%2593target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Residence time of receptor–ligand complexes and its effect on biological function</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5481</span><span class="NLM_x">–</span> <span class="NLM_lpage">5492</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi8002023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5481-5492&author=P.+J.+Tumminoauthor=R.+A.+Copeland&title=Residence+time+of+receptor%E2%80%93ligand+complexes+and+its+effect+on+biological+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fbi8002023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi8002023%26sid%3Dliteratum%253Aachs%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DResidence%2520time%2520of%2520receptor%25E2%2580%2593ligand%2520complexes%2520and%2520its%2520effect%2520on%2520biological%2520function%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D5481%26epage%3D5492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Smith, A. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, K. N.</span><span> </span><span class="NLM_article-title">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800498e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=225-233&author=A.+J.+T.+Smithauthor=X.+Zhangauthor=A.+G.+Leachauthor=K.+N.+Houk&title=Beyond+picomolar+affinities%3A+quantitative+aspects+of+noncovalent+and+covalent+binding+of+drugs+to+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span></div><div class="casAuthors">Smith, Adam J. T.; Zhang, Xiyun; Leach, Andrew G.; Houk, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review of 104 refs. summarized quant. aspects of noncovalent and covalent binding of drugs to proteins with subtopics including (1) introduction; (2) factors involved in ligand-recepto binding; (3) distribution of exptl. binding consts.; (3) covalent interactions with transition states as the origins of enzyme proficiency; (4) potential quant. advantages of covalent enzyme inhibitors and colent drugs; (5) selected examples of covalent inhibitors and drugs; (6) prospects for the design of covalent drugs; (7) conclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhUbRxt1fu7Vg90H21EOLACvtfcHk0lhfrWX05ixTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D&md5=529d4181046100b5e3c37a8fef571218</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm800498e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800498e%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DBeyond%2520picomolar%2520affinities%253A%2520quantitative%2520aspects%2520of%2520noncovalent%2520and%2520covalent%2520binding%2520of%2520drugs%2520to%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D225%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lewandowicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furneaux, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, V. L.</span><span> </span><span class="NLM_article-title">Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31465</span><span class="NLM_x">–</span> <span class="NLM_lpage">31468</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31465-31468&author=A.+Lewandowiczauthor=P.+C.+Tylerauthor=G.+B.+Evansauthor=R.+H.+Furneauxauthor=V.+L.+Schramm&title=Achieving+the+ultimate+physiological+goal+in+transition+state+analogue+inhibitors+for+purine+nucleoside+phosphorylase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewandowicz%26aufirst%3DA.%26aulast%3DTyler%26aufirst%3DP.%2BC.%26aulast%3DEvans%26aufirst%3DG.%2BB.%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26aulast%3DSchramm%26aufirst%3DV.%2BL.%26atitle%3DAchieving%2520the%2520ultimate%2520physiological%2520goal%2520in%2520transition%2520state%2520analogue%2520inhibitors%2520for%2520purine%2520nucleoside%2520phosphorylase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31465%26epage%3D31468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Park, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boobis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldring, C. E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenna, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laverty, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naisbitt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Managing the challenge of chemically reactive metabolites in drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+P.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+challenge+of+chemically+reactive+metabolites+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0lhfrWX05ixTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520challenge%2520of%2520chemically%2520reactive%2520metabolites%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D292%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, J. S.</span><span> </span><span class="NLM_article-title">Applying mechanisms of chemical toxicity to predict drug safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx600260a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslahsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=344-369&author=F.+P.+Guengerichauthor=J.+S.+MacDonald&title=Applying+mechanisms+of+chemical+toxicity+to+predict+drug+safety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Applying Mechanisms of Chemical Toxicity to Predict Drug Safety</span></div><div class="casAuthors">Guengerich, F. Peter; MacDonald, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-369</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Toxicol. can no longer be used only as a science that reacts to problems but must be more proactive in predicting potential human safety issues with new drug candidates.  Success in this area must be based on an understanding of the mechanisms of toxicity.  This review summarizes and extends some of the concepts of an American Chem. Society ProSpectives meeting on the title subject held in June 2006.  One important area is the discernment of the exact nature of the most common problems in drug toxicity.  Knowledge of chem. structure alerts and relevant biol. pathways are important.  Biol. activation to reactive products and off-target pharmacol. are considered to be major contexts of drug toxicity, although defining exactly what the contributions are is not trivial.  Some newer approaches to screening for both have been developed.  A goal in predictive toxicol. is the use of in vitro methods and database development to make predictions concerning potential modes of toxicity and to stratify drug candidates for further development.  Such predictions are desirable for several economic and other reasons but are certainly not routine yet.  However, progress has been made using several approaches.  Some examples of the application of studies of wide-scale biol. responses are now available, with incorporation into development paradigms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxyWz1mKS0h7Vg90H21EOLACvtfcHk0lhfrWX05ixTlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslahsrk%253D&md5=d1ef7299d11c39d0ff3b031779915e54</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Ftx600260a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx600260a%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26aulast%3DMacDonald%26aufirst%3DJ.%2BS.%26atitle%3DApplying%2520mechanisms%2520of%2520chemical%2520toxicity%2520to%2520predict%2520drug%2520safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D344%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Nakayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takakusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span> <span class="citation_source-journal">Drug. Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1970</span><span class="NLM_x">–</span> <span class="NLM_lpage">1977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0lh0IW-gZVu-lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug.%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Erve, J. C. L.</span><span> </span><span class="NLM_article-title">Chemical toxicology: reactive intermediate and their role in pharmacology and toxicology</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1517%2F17425255.2.6.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17125409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=923-946&author=J.+C.+L.+Erve&title=Chemical+toxicology%3A+reactive+intermediate+and+their+role+in+pharmacology+and+toxicology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology</span></div><div class="casAuthors">Erve, John C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">923-946</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Reactive intermediates formed during the metab. of drugs have been investigated extensively over the past decades.  Today, interest in reactive intermediates in drug discovery is focused on minimizing bioactivation in hopes of reducing the risk of causing so-called idiosyncratic toxicity.  These efforts are justified based on the hapten hypothesis', namely, that on binding to protein, reactive intermediates may elicit an immune response to the modified protein, leading to a cascade of events that ultimately manifests as a toxic outcome.  However, the pharmacol. action of certain drugs depends on reactive intermediates that modify crit. amino acid residues of proteins, typically enzymes, thereby altering their activity.  Thus, the notion that reactive intermediates are inherently dangerous is unjustified.  When a reactive intermediate is necessary for the desired pharmacol. effect of a drug, the selectivity it displays towards the target protein is crucial, as off-target binding may produce unwanted toxicities.  On the other hand, reactive intermediates may play no role in toxicity.  This review provides a balanced perspective, primarily focusing on the proposed role of reactive intermediates in drug toxicity, while also highlighting examples in which they are involved in causing the desired pharmacol.  It is hoped that this knowledge can help scientists involved in drug discovery and development in their challenging task of producing safe and effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBIFLSUGUWN7Vg90H21EOLACvtfcHk0lh0IW-gZVu-lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK&md5=320b9ade5e38e5d21b92a4e2781e9e62</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.6.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.6.923%26sid%3Dliteratum%253Aachs%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26atitle%3DChemical%2520toxicology%253A%2520reactive%2520intermediate%2520and%2520their%2520role%2520in%2520pharmacology%2520and%2520toxicology%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26spage%3D923%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uetrecht, J.</span><span> </span><span class="NLM_article-title">Involvement of the immune system in idiosyncratic drug reactions</span> <span class="citation_source-journal">Drug. Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2133%2Fdmpk.DMPK-10-RV-085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21084762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ortb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=47-59&author=X.+Zhangauthor=F.+Liuauthor=X.+Chenauthor=X.+Zhuauthor=J.+Uetrecht&title=Involvement+of+the+immune+system+in+idiosyncratic+drug+reactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the immune system in idiosyncratic drug reactions</span></div><div class="casAuthors">Zhang, Xiaochu; Liu, Feng; Chen, Xin; Zhu, Xu; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-59</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A review.  There is strong evidence that most idiosyncratic drug reactions (IDRs) are immune-mediated and are caused by reactive metabolites of a drug rather than by the drug itself.  Several hypotheses have been proposed by which a drug could induce an immune response.  The major hypotheses are the hapten hypothesis and the danger hypothesis; however, the characteristics and spectrum of IDRs are different with different drugs, and this likely reflects mechanistic differences; therefore, no one hypothesis is likely to explain all IDRs.  Some IDRs appear to involve epigenetic effects, direct activation of antigen-presenting cells, or disturbing the normal balance of the immune system.  It has been suggested that many cases of idiosyncratic liver injury are not immune-mediated, and other mechanisms such as mitochondrial injury may be involved.  It is essential that any hypothesis be consistent with the clin. characteristics of the IDR.  Although the characteristics of most idiosyncratic liver injury do not suggest that mitochondria are the major target, it is quite possible that milder mitochondrial injury could stimulate an immune-mediated reaction.  The observation that IDRs can vary widely among different drugs and different patients is most easily explained by an immune mechanism in which the target of the immune response is different.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXisRIJF7wu7Vg90H21EOLACvtfcHk0lh0IW-gZVu-lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ortb4%253D&md5=9e5e4d5ec4ad38b14d58e10e8e739835</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.DMPK-10-RV-085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.DMPK-10-RV-085%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DInvolvement%2520of%2520the%2520immune%2520system%2520in%2520idiosyncratic%2520drug%2520reactions%26jtitle%3DDrug.%2520Metab.%2520Pharmacokinet.%26date%3D2011%26volume%3D26%26spage%3D47%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Garuti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Non-ATP competitive protein kinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2804</span><span class="NLM_x">–</span> <span class="NLM_lpage">2821</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F092986710791859333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20586715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2804-2821&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Non-ATP+competitive+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Non-ATP competitive protein kinase inhibitors</span></div><div class="casAuthors">Garuti, L.; Roberti, M.; Bottegoni, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2804-2821</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Protein kinases represent an attractive target in oncol. drug discovery.  Most of kinase inhibitors are ATP-competitive and are called type I inhibitors.  The ATP-binding pocket is highly conserved among members of the kinase family and it is difficult to find selective agents.  Moreover, the ATP-competitive inhibitors must compete with high intracellular ATP levels leading to a discrepancy between IC50s measured by biochem. vs. cellular assays.  The non-ATP competitive inhibitors, called type II and type III inhibitors, offer the possibility to overcome these problems.  These inhibitors act by inducing a conformational shift in the target enzyme such that the kinase is no longer able to function.  In the DFG-out form, the phenylalanine side chain moves to a new position.  This movement creates a hydrophobic pocket available for occupation by the inhibitor.  Some common features are present in these inhibitors.  They contain a heterocyclic system that forms one or two hydrogen bonds with the kinase hinge residue.  They also contain a hydrophobic moiety that occupies the pocket formed by the shift of phenylalanine from the DFG motif.  Moreover, all the inhibitors bear a hydrogen bond donor-acceptor pair, usually urea or amide, that links the hinge-binding portion to the hydrophobic moiety and interacts with the allosteric site.  Examples of non ATP-competitive inhibitors are available for various kinases.  In this review small mols. capable of inducing the DFG-out conformation are reported, esp. focusing on structural feature, SAR and biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXB1pXUfqNQLVg90H21EOLACvtfcHk0lh0IW-gZVu-lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bF&md5=6211d4dba33e8863d5781dfbaaa0fbfc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F092986710791859333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791859333%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DNon-ATP%2520competitive%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2804%26epage%3D2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Qin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhondi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palani, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent dihydrooxadiazole series of non-ATP competitive MK2 (MAPKAPK2) inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200238g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=100-105&author=J.+Qinauthor=P.+Dhondiauthor=X.+Huangauthor=R.+Aslanianauthor=J.+Fossettaauthor=F.+Tianauthor=D.+Lundellauthor=A.+Palani&title=Discovery+of+a+potent+dihydrooxadiazole+series+of+non-ATP+competitive+MK2+%28MAPKAPK2%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml200238g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200238g%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DDhondi%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DAslanian%26aufirst%3DR.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DF.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DPalani%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520dihydrooxadiazole%2520series%2520of%2520non-ATP%2520competitive%2520MK2%2520%2528MAPKAPK2%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D100%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0ljUw-9HtdqZgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluge, A. F.</span><span> </span><span class="NLM_article-title">Targeted covalent drugs of the kinase family</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&author=J.+Singhauthor=R.+D.+Petterauthor=A.+F.+Kluge&title=Targeted+covalent+drugs+of+the+kinase+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0ljUw-9HtdqZgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BD.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520covalent%2520drugs%2520of%2520the%2520kinase%2520family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D475%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Krippendorf, B.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisinga, W.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition: deriving <i>K</i><sub>i</sub> and <i>k</i><sub>inact</sub> directly from time-dependent IC<sub>50</sub> values</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19675314" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-923&author=B.-F.+Krippendorfauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+Huisinga&title=Mechanism-based+inhibition%3A+deriving+Ki+and+kinact+directly+from+time-dependent+IC50+values"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorf%26aufirst%3DB.-F.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%26atitle%3DMechanism-based%2520inhibition%253A%2520deriving%2520Ki%2520and%2520kinact%2520directly%2520from%2520time-dependent%2520IC50%2520values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Garuti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2981</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F092986711796391705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21651479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2981-2994&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Irreversible+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible protein kinase inhibitors</span></div><div class="casAuthors">Garuti, L.; Roberti, M.; Bottegoni, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2981-2994</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting cancer with small mol. irreversible inhibitors of kinases represents an emerging challenge in drug discovery.  Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket.  The most common mechanism is the Michael reaction, that refers to the addn. of a nucleophile, such as cysteine, to an α,β-unsatd. carbonyl.  The nucleophile reacts at the electrophilic β-position to form an adduct; as a result the inhibitor irreversibly blocks binding of ATP to the kinase, rendering the kinase inactive.  Different cysteine-reactive groups have been evaluated, an acrylamide or a substituted acrylamide moiety are the Michael acceptors of choice.  There are some advantages for the irreversible kinase inhibition.  These compds. are highly selective because they target a specific cysteine and only a limited no. of kinases has a cysteine at the corresponding position.  Another advantage is that covalent bond formation can overcome competition with the high endogenous concn. of ATP.  A further motivation for designing irreversible inhibitors is their longer duration of action respect to conventional inhibitors.  In fact, once bound to enzyme, these compds. do not readily dissoc. and the inhibition continues even after the inhibitor leaves the circulation.  Moreover, these inhibitors have the potential to overcome and prevent the emergence of acquired resistance conferred by mutations.  In this review examples of irreversible inhibitors are reported, focusing on chem. structures, SAR and biol. activities.  The great potential of these compds. could open new and promising perspectives for a broader application of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkLFECsvPg2LVg90H21EOLACvtfcHk0liJxYRMQAoxdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D&md5=8c732cb9de810f9fac6484c245e41867</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F092986711796391705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391705%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2981%26epage%3D2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Carrera, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrov, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span> </span><span class="NLM_article-title">The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">442</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.90.2.442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=8421674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADyaK3sXns1Srsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=442-446&author=A.+C.+Carreraauthor=K.+Alexandrovauthor=T.+M.+Roberts&title=The+conserved+lysine+of+the+catalytic+domain+of+protein+kinases+is+actively+involved+in+the+phosphotransfer+reaction+and+not+required+for+anchoring+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP</span></div><div class="casAuthors">Carrera, Ana C.; Alexandrov, Kirill; Roberts, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">442-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The study of the various protein kinases reveals that, despite their considerably diversity, they have evolved from a common origin.  Eleven conserved subdomains have been described that encompass the catalytic core of these enzymes.  One of these conserved regions, subdomain II, contains an invariant lysine residue present in all known protein kinase catalytic domains.  Two facts have suggested that this conserved lysine of subdomain II is essential for binding ATP: (i) several investigators have demonstrated that this residue is phys. proximal to the ATP mol., and (ii) conservative substitutions at this site render the kinase inactive.  However, these results are also consistent with a functional role of the conserved lysine of subdomain II in orienting or facilitating the transfer of phosphpate.  To study in more detail the role of subdomain II, mutants of the protein-tyrosine kinase pp56lck were generated that have single amino acid substitutions within the area surrounding the conserved residue Lys-273 in subdomain II.  When compared with wild-type pp56lck, these mutants displayed profound redns. in their phosphotransfer efficiencies and small differences in their affinities for ATP.  Further, the substitution of arginine for Lys-273 resulted in a mutant protein unable to transfer the γ-phosphate of ATP but able to bind 8-azido-ATP with an efficiency similar to that of wild-type pp56lck.  These results suggest that the region including Lys-273 of subdomain II is involved in the enzymic process of phosphate transfer, rather than in anchoring ATP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobhyjaBAT6A7Vg90H21EOLACvtfcHk0liJxYRMQAoxdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXns1Srsg%253D%253D&md5=ce9443a738a784493a3258d13210968a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.2.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.2.442%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DA.%2BC.%26aulast%3DAlexandrov%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26atitle%3DThe%2520conserved%2520lysine%2520of%2520the%2520catalytic%2520domain%2520of%2520protein%2520kinases%2520is%2520actively%2520involved%2520in%2520the%2520phosphotransfer%2520reaction%2520and%2520not%2520required%2520for%2520anchoring%2520ATP%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D442%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Buhrow, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staros, J. V.</span><span> </span><span class="NLM_article-title">Affinity labeling of the protein kinase associated with the epidermal growth factor receptor in membrane vesicles from A431 cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">4019</span><span class="NLM_x">–</span> <span class="NLM_lpage">4020</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=4019-4020&author=S.+A.+Buhrowauthor=S.+Cohenauthor=J.+V.+Staros&title=Affinity+labeling+of+the+protein+kinase+associated+with+the+epidermal+growth+factor+receptor+in+membrane+vesicles+from+A431+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuhrow%26aufirst%3DS.%2BA.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DStaros%26aufirst%3DJ.%2BV.%26atitle%3DAffinity%2520labeling%2520of%2520the%2520protein%2520kinase%2520associated%2520with%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520membrane%2520vesicles%2520from%2520A431%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D4019%26epage%3D4020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Scoggins, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerfield, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staros, J. V.</span><span> </span><span class="NLM_article-title">5′-(<i>p</i>-Fluorosulfonylbenzoyl)-2′(or 3′)-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: Interaction with the kinase active site of the receptor for epidermal growth factor</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">9197</span><span class="NLM_x">–</span> <span class="NLM_lpage">9203</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi952909d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=9197-9203&author=R.+M.+Scogginsauthor=A.+E.+Summerfieldauthor=R.+A.+Steinauthor=C.+A.+Guyerauthor=J.+V.+Staros&title=5%E2%80%B2-%28p-Fluorosulfonylbenzoyl%29-2%E2%80%B2%28or+3%E2%80%B2%29-%28methylanthraniloyl%29adenosine%2C+fluorescent+affinity+labels+for+adenine+nucleotide+binding+sites%3A+Interaction+with+the+kinase+active+site+of+the+receptor+for+epidermal+growth+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1021%2Fbi952909d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi952909d%26sid%3Dliteratum%253Aachs%26aulast%3DScoggins%26aufirst%3DR.%2BM.%26aulast%3DSummerfield%26aufirst%3DA.%2BE.%26aulast%3DStein%26aufirst%3DR.%2BA.%26aulast%3DGuyer%26aufirst%3DC.%2BA.%26aulast%3DStaros%26aufirst%3DJ.%2BV.%26atitle%3D5%25E2%2580%25B2-%2528p-Fluorosulfonylbenzoyl%2529-2%25E2%2580%25B2%2528or%25203%25E2%2580%25B2%2529-%2528methylanthraniloyl%2529adenosine%252C%2520fluorescent%2520affinity%2520labels%2520for%2520adenine%2520nucleotide%2520binding%2520sites%253A%2520Interaction%2520with%2520the%2520kinase%2520active%2520site%2520of%2520the%2520receptor%2520for%2520epidermal%2520growth%2520factor%26jtitle%3DBiochemistry%26date%3D1996%26volume%3D35%26spage%3D9197%26epage%3D9203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Fox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgibbon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brummel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M. S.-S.</span><span> </span><span class="NLM_article-title">Kinetic mechanism and ATP-binding site reactivity of p38γ MAP kinase</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">461</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=1999&pages=323-328&author=T.+Foxauthor=M.+J.+Fitzgibbonauthor=M.+A.+Flemingauthor=H.-M.+Hsiaoauthor=C.+L.+Brummelauthor=M.+S.-S.+Su&title=Kinetic+mechanism+and+ATP-binding+site+reactivity+of+p38%CE%B3+MAP+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DT.%26aulast%3DFitzgibbon%26aufirst%3DM.%2BJ.%26aulast%3DFleming%26aufirst%3DM.%2BA.%26aulast%3DHsiao%26aufirst%3DH.-M.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DSu%26aufirst%3DM.%2BS.-S.%26atitle%3DKinetic%2520mechanism%2520and%2520ATP-binding%2520site%2520reactivity%2520of%2520p38%25CE%25B3%2520MAP%2520kinase%26jtitle%3DFEBS%2520Lett.%26date%3D1999%26volume%3D461%26spage%3D323%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Vereb, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gergely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulkan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heilmeyer, L. M. G.</span><span> </span><span class="NLM_article-title">The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5′-<i>p</i>-fluorosulfonylbenzoyladenosine</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2FS1357-2725%2801%2900006-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=11311856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislGgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=249-259&author=G.+Verebauthor=A.+Ballaauthor=P.+Gergelyauthor=M.+P.+Wymannauthor=H.+Gulkanauthor=S.+Suerauthor=L.+M.+G.+Heilmeyer&title=The+ATP-binding+site+of+brain+phosphatidylinositol+4-kinase+PI4K230+as+revealed+by+5%E2%80%B2-p-fluorosulfonylbenzoyladenosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5'-p-fluorosulfonylbenzoyladenosine</span></div><div class="casAuthors">Vereb, G.; Balla, A.; Gergely, P.; Wymann, M. P.; Gulkan, H.; Suer, S.; Heilmeyer, L. M. G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The ATP-binding site of purified bovine brain phosphatidylinositol 4-kinase 230 (PI4K230) was studied by its reaction with 5'-p-fluorosulfonylbenzoyladenosine (FSBA), an ATP-like alkylating reagent.  Four hundred to eight hundred micromolar FSBA inactivated PI4K230 specifically with apparently first-order kinetics and resulted in 50% loss of enzyme activity in 36-130 min.  The specificity of the reaction with FSBA was demonstrated by the lack of inactivation with 5'-p-fluorosulfonylbenzoyl chloride and by protection with ATP and ATP analogs against inactivation.  Most ATP analogs competed with FSBA inactivation in order of their increasing hydrophobicity, parallel to their inhibitory potency in activity measurements.  The specific binding of FSBA to PI4K230 was demonstrated also by Western-blot expts.  These results suggest that FSBA-reactive group(s) involved in the enzyme activity are located near to the ATP-binding site in a hydrophobic region of native PI4K230.  Expts. with site-directed mutagenesis indicate that the conserved Lys-1792 plays an essential role in the enzyme activity and serves as one target of affinity labeling by FSBA.  Prevention of both Lys-1792-directed and Lys-1792-independent binding of FSBA by Cibacron Blue 3GA suggest that these sites are located spatially close to each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjba_qOmUngbVg90H21EOLACvtfcHk0lh_-2HCoT4W8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislGgsbo%253D&md5=3de0c6c1ab29228d9a6d25a9f4bd8a2d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2801%2900006-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252801%252900006-1%26sid%3Dliteratum%253Aachs%26aulast%3DVereb%26aufirst%3DG.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DGulkan%26aufirst%3DH.%26aulast%3DSuer%26aufirst%3DS.%26aulast%3DHeilmeyer%26aufirst%3DL.%2BM.%2BG.%26atitle%3DThe%2520ATP-binding%2520site%2520of%2520brain%2520phosphatidylinositol%25204-kinase%2520PI4K230%2520as%2520revealed%2520by%25205%25E2%2580%25B2-p-fluorosulfonylbenzoyladenosine%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2001%26volume%3D33%26spage%3D249%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culberson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallicchio, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kett, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quigley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waxmann, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zartman, C. B.</span><span> </span><span class="NLM_article-title">Biochemical and structural characterization of a novel class of inhibitors of the type 1 insuline-like growth factor and insulin receptor kinases</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">9430</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0500628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=9430-9440&author=I.+M.+Bellauthor=S.+M.+Stirdivantauthor=J.+Ahernauthor=C.+Culbersonauthor=P.+L.+Darkeauthor=C.+J.+Dinsmoreauthor=R.+A.+Drakasauthor=S.+N.+Gallicchioauthor=S.+L.+Grahamauthor=D.+C.+Heimbrookauthor=D.+L.+Hallauthor=J.+Huaauthor=N.+R.+Kettauthor=A.+S.+Kimauthor=M.+Kornienkoauthor=L.+C.+Kuoauthor=S.+K.+Munshiauthor=A.+G.+Quigleyauthor=J.+C.+Reidauthor=B.+W.+Trotterauthor=L.+H.+Waxmannauthor=T.+M.+Williamsauthor=C.+B.+Zartman&title=Biochemical+and+structural+characterization+of+a+novel+class+of+inhibitors+of+the+type+1+insuline-like+growth+factor+and+insulin+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi0500628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0500628%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DAhern%26aufirst%3DJ.%26aulast%3DCulberson%26aufirst%3DC.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DKett%26aufirst%3DN.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DKuo%26aufirst%3DL.%2BC.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26aulast%3DWaxmann%26aufirst%3DL.%2BH.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DZartman%26aufirst%3DC.%2BB.%26atitle%3DBiochemical%2520and%2520structural%2520characterization%2520of%2520a%2520novel%2520class%2520of%2520inhibitors%2520of%2520the%2520type%25201%2520insuline-like%2520growth%2520factor%2520and%2520insulin%2520receptor%2520kinases%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D9430%26epage%3D9440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Powis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonjouklian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berggren, M. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallegos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashendel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalkow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grindey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlahos, C. J.</span><span> </span><span class="NLM_article-title">Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2419</span><span class="NLM_x">–</span> <span class="NLM_lpage">2423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=2419-2423&author=G.+Powisauthor=R.+Bonjouklianauthor=M.+M+Berggrenauthor=A.+Gallegosauthor=R.+Abrahamauthor=C.+Ashendelauthor=L.+Zalkowauthor=W.+F.+Matterauthor=J.+Dodgeauthor=G.+Grindeyauthor=C.+J.+Vlahos&title=Wortmannin%2C+a+potent+and+selective+inhibitor+of+phosphatidylinositol-3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPowis%26aufirst%3DG.%26aulast%3DBonjouklian%26aufirst%3DR.%26aulast%3DBerggren%26aufirst%3DM.%2BM%26aulast%3DGallegos%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DR.%26aulast%3DAshendel%26aufirst%3DC.%26aulast%3DZalkow%26aufirst%3DL.%26aulast%3DMatter%26aufirst%3DW.%2BF.%26aulast%3DDodge%26aufirst%3DJ.%26aulast%3DGrindey%26aufirst%3DG.%26aulast%3DVlahos%26aufirst%3DC.%2BJ.%26atitle%3DWortmannin%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520phosphatidylinositol-3-kinase%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D2419%26epage%3D2423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulgarelli-Leva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van-haesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span> </span><span class="NLM_article-title">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">–</span> <span class="NLM_lpage">1733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1128%2FMCB.16.4.1722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=8657148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=1722-1733&author=M.+P.+Wymannauthor=G.+Bulgarelli-Levaauthor=M.+J.+Zvelebilauthor=M.+L.+Pirolaauthor=B.+Van-haesebroeckauthor=M.+D.+Waterfieldauthor=G.+Panayotou&title=Wortmannin+inactivates+phosphoinositide+3-kinase+by+covalent+modification+of+Lys-802%2C+a+residue+involved+in+the+phosphate+transfer+reaction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span></div><div class="casAuthors">Wymann, Matthias P.; Bulgarelli-Leva, Ginette; Zvelebil, Marketa J.; Pirola, Luciano; Vanhaesebroeck, Bart; Waterfield, Michael D.; Panayotou, George</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1722-33</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Wortmannin at nanomolar concns. is a potent and specific inhibitor of phosphoinositide (PI) 3-kinase and has been used extensively to demonstrate the role of this enzyme in diverse signal transduction processes.  At higher concns., wortmannin inhibits the ataxia telangiectasia gene (ATM)-related DNA dependent protein kinase (DNA-PKcs).  The authors report here the identification of the site of interaction of wortmannin in the catalytic subunit of PI3-kinase, p110α.  At physiol. pH (6.5 to 8) wortmannin reacted specifically with p110α.  Phosphatidylinositol-4,5-diphosphate, ATP, and ATP analogs [adenine and 5'-(4-fluorosulfonylbenzoyl)adenine] competed effectively with wortmannin, while substances contg. nucleophilic amino acid side chain functions had no effect at the same concns.  This suggests that the wortmannin target site is localized in proximity to the substrate-binding site and that residues involved in wortmannin binding have an increased nucleophilicity because of their protein environment.  Proteolytic fragments of wortmannin-treated, recombinant P110α were mapped with anti-wortmannin and anti-p110α peptide antibodies, thus limiting the target site within a 10-kDa fragment, colocalizing with the ATP-binding site.  Site-directed mutagenesis of all candidate residues within this region showed that only the conservative Lys-802-59-Arg mutation abolished wortmannin binding.  Inhibition of PI 3-kinase occurs, therefore, by the formation of an enamine following the attack of Lys-802 on the furan ring (at C-20) of wortmannin.  The Lys-802-t9-Arg mutant was also unable to bind FSBA and was catalytically inactive in lipid and protein kinase assays, indicating a crucial role for Lys-802 in the phosphotransfer reaction.  In contrast, an Arg-916-to-Pro mutation abolished the catalytic activity whereas covalent wortmannin binding remained intact.  The results provide the basis for the design of novel and specific inhibitors of an enzyme family, including PI kinases and ATM-related genes, that play a central role in many physiol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoobMQ6HMdUcbVg90H21EOLACvtfcHk0ljbZWAjcjSSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D&md5=54ebe365b4ad8260555c8b962e03d28b</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.4.1722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.4.1722%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DBulgarelli-Leva%26aufirst%3DG.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DPirola%26aufirst%3DM.%2BL.%26aulast%3DVan-haesebroeck%26aufirst%3DB.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DPanayotou%26aufirst%3DG.%26atitle%3DWortmannin%2520inactivates%2520phosphoinositide%25203-kinase%2520by%2520covalent%2520modification%2520of%2520Lys-802%252C%2520a%2520residue%2520involved%2520in%2520the%2520phosphate%2520transfer%2520reaction%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D1722%26epage%3D1733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Norman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worzalla, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlahos, C. J.</span><span> </span><span class="NLM_article-title">Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1106</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm950619p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADyaK28XpsFKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1106-1111&author=B.+H.+Normanauthor=C.+Shihauthor=J.+E.+Tothauthor=J.+E.+Rayauthor=J.+A.+Dodgeauthor=D.+W.+Johnsonauthor=P.+G.+Rutherfordauthor=R.+M.+Schultzauthor=J.+F.+Worzallaauthor=C.+J.+Vlahos&title=Studies+on+the+mechanism+of+phosphatidylinositol+3-kinase+inhibition+by+wortmannin+and+related+analogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the Mechanism of Phosphatidylinositol 3-Kinase Inhibition by Wortmannin and Related Analogs</span></div><div class="casAuthors">Norman, Bryan H.; Shih, Chuan; Toth, John E.; Ray, James E.; Dodge, Jeffrey A.; Johnson, Doug W.; Rutherford, Pamela G.; Schultz, Richard M.; Worzalla, John F.; Vlahos, Chris J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1106-11</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Wortmannin, a fungal metabolite, was identified as a potent inhibitor (IC50 = 4.2 nM) of phosphatidylinositol 3-kinase (PI 3-kinase).  Due to the importance of PI 3-kinase in several intracellular signaling pathways, structure-activity studies on wortmannin analogs were performed in an effort to understand the structural requirements necessary for PI 3-kinase inhibition.  Since wortmannin is an irreversible inhibitor of PI 3-kinase, it was postulated that covalent attachment at the electrophilic C-21 site was a possible mode of action for PI 3-kinase inhibition.  The authors have prepd. various wortmannin analogs which address the possibility of this mechanism.  Of particular interest are compds. which affect the C-21 position of wortmannin either sterically or electronically.  Our results support the conclusion that nucleophilic addn. by the kinase onto the C-21 position of wortmannin is required for inhibition of PI 3-kinase by wortmannin analogs.  Addnl., we have prepd. several D-ring analogs of wortmannin, and their activities are reported herein.  The authors conclude that the wortmannin D ring is an important recognition site since modifications have such a dramatic effect on inhibitor potency.  Finally, the identification of 17β-hydroxywortmannin represents the first reported subnanomolar inhibitor of PI 3-kinase.  These studies, along with in vivo antitumor expts., suggest that the mechanism of PI 3-kinase inhibition correlates to the assocd. toxicity obsd. with wortmannin-based inhibitors of PI 3-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiKiIYaSVQJrVg90H21EOLACvtfcHk0ljbZWAjcjSSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XpsFKhsQ%253D%253D&md5=62f71b396d36de4fe03a63ee624753c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm950619p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950619p%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DB.%2BH.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DJ.%2BE.%26aulast%3DRay%26aufirst%3DJ.%2BE.%26aulast%3DDodge%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DD.%2BW.%26aulast%3DRutherford%26aufirst%3DP.%2BG.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DWorzalla%26aufirst%3DJ.%2BF.%26aulast%3DVlahos%26aufirst%3DC.%2BJ.%26atitle%3DStudies%2520on%2520the%2520mechanism%2520of%2520phosphatidylinositol%25203-kinase%2520inhibition%2520by%2520wortmannin%2520and%2520related%2520analogs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D1106%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Walker, E. H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporin</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporin%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreder, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferris, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, J. S.</span><span> </span><span class="NLM_article-title">Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian Polo-like kinase</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2004.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15664519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=99-107&author=Y.+Liuauthor=K.+R.+Shrederauthor=W.+Gaiauthor=S.+Corralauthor=D.+K.+Ferrisauthor=J.+S.+Rosenblum&title=Wortmannin%2C+a+widely+used+phosphoinositide+3-kinase+inhibitor%2C+also+potently+inhibits+mammalian+Polo-like+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin, a Widely Used Phosphoinositide 3-Kinase Inhibitor, also Potently Inhibits Mammalian Polo-like Kinase</span></div><div class="casAuthors">Liu, Yongsheng; Shreder, Kevin R.; Gai, Wenzhi; Corral, Sergio; Ferris, Douglas K.; Rosenblum, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polo-like kinases (PLKs) play crit. roles throughout mitosis.  Here, we report that wortmannin, which was previously thought to be a highly selective inhibitor of phosphoinositide (PI) 3-kinases, is a potent inhibitor of mammalian PLK1.  Observation of the wortmannin-PLK1 interaction was enabled by a tetramethylrhodamine-wortmannin conjugate (AX7503) that permits rapid detection of PLK1 activity and expression in complex proteomes.  Importantly, we show that wortmannin inhibits PLK1 activity in an in vitro kinase assay with an IC50 of 24 nM and when incubated with intact cells.  Taken together, our results indicate that, at the concns. of wortmannin commonly used to inhibit PI 3-kinases, PLK1 is also significantly inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo0cYBstR6BbVg90H21EOLACvtfcHk0ljbZWAjcjSSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlKmuw%253D%253D&md5=8aaad2a6d961730e547db70be1dc0c32</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26aulast%3DGai%26aufirst%3DW.%26aulast%3DCorral%26aufirst%3DS.%26aulast%3DFerris%26aufirst%3DD.%2BK.%26aulast%3DRosenblum%26aufirst%3DJ.%2BS.%26atitle%3DWortmannin%252C%2520a%2520widely%2520used%2520phosphoinositide%25203-kinase%2520inhibitor%252C%2520also%2520potently%2520inhibits%2520mammalian%2520Polo-like%2520kinase%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D99%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, J. S.</span><span> </span><span class="NLM_article-title">Polo-like kinases inhibited by wortmannin</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">2505</span><span class="NLM_x">–</span> <span class="NLM_lpage">2511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=2505-2511&author=Y.+Liuauthor=N.+Jiangauthor=J.+Wuauthor=W.+Daiauthor=J.+S.+Rosenblum&title=Polo-like+kinases+inhibited+by+wortmannin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DRosenblum%26aufirst%3DJ.%2BS.%26atitle%3DPolo-like%2520kinases%2520inhibited%2520by%2520wortmannin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D2505%26epage%3D2511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Barr, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugochukwu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, O. N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfano, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savitsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess-Brown, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.cell.2008.11.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19167335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=352-363&author=A.+J.+Barrauthor=E.+Ugochukwuauthor=W.+H.+Leeauthor=O.+N.+F.+Kingauthor=P.+Filippakopoulosauthor=I.+Alfanoauthor=P.+Savitskyauthor=N.+A.+Burgess-Brownauthor=S.+M%C3%BCllerauthor=S.+Knapp&title=Large-scale+structural+analysis+of+the+classical+human+protein+tyrosine+phosphatome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span></div><div class="casAuthors">Barr, Alastair J.; Ugochukwu, Emilie; Lee, Wen Hwa; King, Oliver N. F.; Filippakopoulos, Panagis; Alfano, Ivan; Savitsky, Pavel; Burgess-Brown, Nicola A.; Muller, Susanne; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">352-363</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) play a crit. role in regulating cellular functions by selectively dephosphorylating their substrates.  Here we present 22 human PTP crystal structures that, together with prior structural knowledge, enable a comprehensive anal. of the classical PTP family.  Despite their largely conserved fold, surface properties of PTPs are strikingly diverse.  A potential secondary substrate-binding pocket is frequently found in phosphatases, and this has implications for both substrate recognition and development of selective inhibitors.  Structural comparison identified four diverse catalytic loop (WPD) conformations and suggested a mechanism for loop closure.  Enzymic assays revealed vast differences in PTP catalytic activity and identified PTPD1, PTPD2, and HDPTP as catalytically inert protein phosphatases.  We propose a "head-to-toe" dimerization model for RPTPγ/ζ that is distinct from the "inhibitory wedge" model and that provides a mol. basis for inhibitory regulation.  This phosphatome resource gives an expanded insight into intrafamily PTP diversity, catalytic activity, substrate recognition, and autoregulatory self-assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0kaabM4U0LLVg90H21EOLACvtfcHk0liUmmY63CetXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D&md5=f47994736342cc0490609596d66fd03e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26aulast%3DUgochukwu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DKing%26aufirst%3DO.%2BN.%2BF.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DAlfano%26aufirst%3DI.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DBurgess-Brown%26aufirst%3DN.%2BA.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DLarge-scale%2520structural%2520analysis%2520of%2520the%2520classical%2520human%2520protein%2520tyrosine%2520phosphatome%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D352%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Roberts, R.</span><span> </span><span class="NLM_article-title">Lysosomal cysteine proteases: structure, function and inhibition of cathepsins</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1358%2Fdnp.2005.18.10.949485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=16491162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1KrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=605-614&author=R.+Roberts&title=Lysosomal+cysteine+proteases%3A+structure%2C+function+and+inhibition+of+cathepsins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal cysteine proteases: Structure, function and inhibition of cathepsins</span></div><div class="casAuthors">Roberts, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">605-614</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Lysosomal cysteine proteases, a subgroup of the cathepsin family, are crit. for normal cellular functions such as general protein turnover, antigen processing, and bone remodeling.  In the past decade, the no. of identified human cathepsins has more than doubled and their known role in several pathologies has expanded rapidly.  An increased understanding of the structure and mechanism of this class of enzymes has brought on new fervor in the design of small-mol. inhibitors with the hope of producing specific, therapeutic drugs for diseases such as arthritis, allergy, multiple sclerosis, atherosclerosis, Alzheimer's disease, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMyLfopyr_tLVg90H21EOLACvtfcHk0liUmmY63CetXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1KrtrY%253D&md5=bb28891faef6af18373b82ad41407e2a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2005.18.10.949485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2005.18.10.949485%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DR.%26atitle%3DLysosomal%2520cysteine%2520proteases%253A%2520structure%252C%2520function%2520and%2520inhibition%2520of%2520cathepsins%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2005%26volume%3D18%26spage%3D605%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kortemme, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, T. E.</span><span> </span><span class="NLM_article-title">Ionisation of cysteine residues at the termini of model alpha-helical peptides. Relevance to unusual thiol p<i>K</i><sub>a</sub> values in proteins of the thioredoxin family</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">253</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">812</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1995&pages=799-812&author=T.+Kortemmeauthor=T.+E.+Creighton&title=Ionisation+of+cysteine+residues+at+the+termini+of+model+alpha-helical+peptides.+Relevance+to+unusual+thiol+pKa+values+in+proteins+of+the+thioredoxin+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DCreighton%26aufirst%3DT.%2BE.%26atitle%3DIonisation%2520of%2520cysteine%2520residues%2520at%2520the%2520termini%2520of%2520model%2520alpha-helical%2520peptides.%2520Relevance%2520to%2520unusual%2520thiol%2520pKa%2520values%2520in%2520proteins%2520of%2520the%2520thioredoxin%2520family%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D253%26spage%3D799%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Paulsen, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K. S.</span><span> </span><span class="NLM_article-title">Orchestrating redox signaling networks through regulatory cysteine switches</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=47-62&author=C.+E.+Paulsenauthor=K.+S.+Carroll&title=Orchestrating+redox+signaling+networks+through+regulatory+cysteine+switches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DC.%2BE.%26aulast%3DCarroll%26aufirst%3DK.%2BS.%26atitle%3DOrchestrating%2520redox%2520signaling%2520networks%2520through%2520regulatory%2520cysteine%2520switches%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D47%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Paulsen, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K. S.</span><span> </span><span class="NLM_article-title">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio.736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=57-64&author=C.+E.+Paulsenauthor=T.+H.+Truongauthor=F.+J.+Garciaauthor=A.+Homannauthor=V.+Guptaauthor=S.+E.+Leonardauthor=K.+S.+Carroll&title=Peroxide-dependent+sulfenylation+of+the+EGFR+catalytic+site+enhances+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span></div><div class="casAuthors">Paulsen, Candice E.; Truong, Thu H.; Garcia, Francisco J.; Homann, Arne; Gupta, Vinayak; Leonard, Stephen E.; Carroll, Kate S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein sulfenylation is a post-translational modification of emerging importance in higher eukaryotes.  However, investigation of its diverse roles remains challenging, particularly within a native cellular environment.  Herein we report the development and application of DYn-2, a new chemoselective probe for detecting sulfenylated proteins in human cells.  These studies show that epidermal growth factor receptor (EGFR)-mediated signaling results in H2O2 prodn. and oxidn. of downstream proteins.  In addn., we demonstrate that DYn-2 has the ability to detect differences in sulfenylation rates within the cell, which are assocd. with differences in target protein localization.  We also show that the direct modification of epidermal growth factor receptor by H2O2 at a crit. active site cysteine (Cys797) enhances its tyrosine kinase activity.  Collectively, our findings reveal sulfenylation as a global signaling mechanism that is akin to phosphorylation and has regulatory implications for other receptor tyrosine kinases and irreversible inhibitors that target oxidant-sensitive cysteines in proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp30snMrGIfzLVg90H21EOLACvtfcHk0lgmM5WNXCOwuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E&md5=44011c82266cf6a47922b1ba1038cc30</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.736%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DC.%2BE.%26aulast%3DTruong%26aufirst%3DT.%2BH.%26aulast%3DGarcia%26aufirst%3DF.%2BJ.%26aulast%3DHomann%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLeonard%26aufirst%3DS.%2BE.%26aulast%3DCarroll%26aufirst%3DK.%2BS.%26atitle%3DPeroxide-dependent%2520sulfenylation%2520of%2520the%2520EGFR%2520catalytic%2520site%2520enhances%2520kinase%2520activity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D57%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Leonberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, Y.-C.</span><span> </span><span class="NLM_article-title">The functional role of cysteine residues for c-Abl kinase activity</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2007&pages=207-212&author=A.+K.+Leonbergauthor=Y.-C.+Chai&title=The+functional+role+of+cysteine+residues+for+c-Abl+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeonberg%26aufirst%3DA.%2BK.%26aulast%3DChai%26aufirst%3DY.-C.%26atitle%3DThe%2520functional%2520role%2520of%2520cysteine%2520residues%2520for%2520c-Abl%2520kinase%2520activity%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2007%26volume%3D304%26spage%3D207%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Satoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipton, S. A.</span><span> </span><span class="NLM_article-title">Redox regulation of neuronal survival mediated by electrophilic compounds</span> <span class="citation_source-journal">Trends Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=37-45&author=T.+Satohauthor=S.+A.+Lipton&title=Redox+regulation+of+neuronal+survival+mediated+by+electrophilic+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DLipton%26aufirst%3DS.%2BA.%26atitle%3DRedox%2520regulation%2520of%2520neuronal%2520survival%2520mediated%2520by%2520electrophilic%2520compounds%26jtitle%3DTrends%2520Neurosci.%26date%3D2006%26volume%3D30%26spage%3D37%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lgmM5WNXCOwuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformatinally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformatinally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformatinally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. A.</span><span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+A.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lgmM5WNXCOwuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BA.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Powers, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeskey, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellstein, A.</span><span> </span><span class="NLM_article-title">Fibroblast growth factors, their receptors and signaling</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=165-197&author=C.+J.+Powersauthor=S.+W.+McLeskeyauthor=A.+Wellstein&title=Fibroblast+growth+factors%2C+their+receptors+and+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DC.%2BJ.%26aulast%3DMcLeskey%26aufirst%3DS.%2BW.%26aulast%3DWellstein%26aufirst%3DA.%26atitle%3DFibroblast%2520growth%2520factors%252C%2520their%2520receptors%2520and%2520signaling%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2000%26volume%3D7%26spage%3D165%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0liaub-UYNpEQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0liaub-UYNpEQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frödin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Fr%C3%B6dinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0liaub-UYNpEQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFr%25C3%25B6din%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Malakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tereshko, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z.</span><span> </span><span class="NLM_article-title">Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnsmb1347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18084304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=112-113&author=M.+Malakhovaauthor=V.+Tereshkoauthor=S.-Y.+Leeauthor=K.+Yaoauthor=Y.-Y.+Choauthor=A.+Bodeauthor=Z.+Dong&title=Structural+basis+for+activation+of+the+autoinhibitory+C-terminal+kinase+domain+of+p90+RSK2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2</span></div><div class="casAuthors">Malakhova, Margarita; Tereshko, Valentina; Lee, Sung-Young; Yao, Ke; Cho, Yong-Yeon; Bode, Ann; Dong, Zigang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-113</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The x-ray structure at 2.0-Å resoln. of the p90 ribosomal S6 kinase 2 C-terminal kinase domain revealed a C-terminal autoinhibitory αL-helix that was embedded in the kinase scaffold and dets. the inactive kinase conformation.  We suggest a mechanism of activation through displacement of the αL-helix and rearrangement of the conserved residue Glu500, as well as the reorganization of the T-loop into the active conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOwN4HkRh6CbVg90H21EOLACvtfcHk0lh68U8sDrx-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWgtA%253D%253D&md5=cf16ccfd40d8e3f605ddb0f740fa9578</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1347%26sid%3Dliteratum%253Aachs%26aulast%3DMalakhova%26aufirst%3DM.%26aulast%3DTereshko%26aufirst%3DV.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DYao%26aufirst%3DK.%26aulast%3DCho%26aufirst%3DY.-Y.%26aulast%3DBode%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DStructural%2520basis%2520for%2520activation%2520of%2520the%2520autoinhibitory%2520C-terminal%2520kinase%2520domain%2520of%2520p90%2520RSK2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D112%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Henise, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4133</span><span class="NLM_x">–</span> <span class="NLM_lpage">4146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0lh68U8sDrx-xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Cross, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Templeton, D. J.</span><span> </span><span class="NLM_article-title">Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2004&pages=675-683&author=J.+V.+Crossauthor=D.+J.+Templeton&title=Oxidative+stress+inhibits+MEKK1+by+site-specific+glutathionylation+in+the+ATP-binding+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DJ.%2BV.%26aulast%3DTempleton%26aufirst%3DD.%2BJ.%26atitle%3DOxidative%2520stress%2520inhibits%2520MEKK1%2520by%2520site-specific%2520glutathionylation%2520in%2520the%2520ATP-binding%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2004%26volume%3D381%26spage%3D675%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Cross, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foss, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rady, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Templeton, D. J.</span><span> </span><span class="NLM_article-title">The isothiocyanate class of bioactive nutrients covalently inhibit the MEKK1 protein kinase</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=183&author=J.+V.+Crossauthor=F.+W.+Fossauthor=J.+M.+Radyauthor=T.+L.+Macdonaldauthor=D.+J.+Templeton&title=The+isothiocyanate+class+of+bioactive+nutrients+covalently+inhibit+the+MEKK1+protein+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DJ.%2BV.%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DRady%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DTempleton%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520isothiocyanate%2520class%2520of%2520bioactive%2520nutrients%2520covalently%2520inhibit%2520the%2520MEKK1%2520protein%2520kinase%26jtitle%3DBMC%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaoud, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laroche, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalby, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, S. M.</span><span> </span><span class="NLM_article-title">Synthesis and biological evalution of p38α kinase-targeting dialkynylimidazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6293</span><span class="NLM_x">–</span> <span class="NLM_lpage">6297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6293-6297&author=J.+Liauthor=T.+S.+Kaoudauthor=C.+Larocheauthor=K.+N.+Dalbyauthor=S.+M.+Kerwin&title=Synthesis+and+biological+evalution+of+p38%CE%B1+kinase-targeting+dialkynylimidazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKaoud%26aufirst%3DT.%2BS.%26aulast%3DLaroche%26aufirst%3DC.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DKerwin%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520biological%2520evalution%2520of%2520p38%25CE%25B1%2520kinase-targeting%2520dialkynylimidazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6293%26epage%3D6297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Fitzgerald, C. E.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=764-769&author=C.+E.+Fitzgerald&title=Structural+basis+for+p38alpha+MAP+kinase+quinazolinone+and+pyridol-pyrimidine+inhibitor+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DC.%2BE.%26atitle%3DStructural%2520basis%2520for%2520p38alpha%2520MAP%2520kinase%2520quinazolinone%2520and%2520pyridol-pyrimidine%2520inhibitor%2520specificity%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D764%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris., M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=1-11&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+Kris.author=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris.%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance on non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+on+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljX6I7oXbo3-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520on%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljX6I7oXbo3-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haske, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span> </span><span class="NLM_article-title">Structure-based design of a potent, selective and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1130</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960380s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1130-1135&author=J.+Singhauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=T.+Haskeauthor=A.+Whittyauthor=D.+J.+McNamara&title=Structure-based+design+of+a+potent%2C+selective+and+irreversible+inhibitor+of+the+catalytic+domain+of+the+erbB+receptor+subfamily+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm960380s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960380s%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DHaske%26aufirst%3DT.%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26atitle%3DStructure-based%2520design%2520of%2520a%2520potent%252C%2520selective%2520and%2520irreversible%2520inhibitor%2520of%2520the%2520catalytic%2520domain%2520of%2520the%2520erbB%2520receptor%2520subfamily%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1130%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosin kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+T.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosin+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%2BT.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosin%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnick, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by <i>N</i>-[4-[3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,875)</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1999&pages=917-925&author=C.+M.+Discafaniauthor=M.+L.+Carrollauthor=M.+B.+Floydauthor=I%2C+J.+Hollanderauthor=Z.+Husainauthor=B.+D.+Johnsonauthor=D.+Kitchenauthor=M.+K.+Mayauthor=M.+S.+Maloauthor=A.+A.+Minnickauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=A.+Wissnerauthor=L.+M.+Greenberger&title=Irreversible+inhibition+of+epidermal+growth+factor+receptor+tyrosine+kinase+with+in+vivo+activity+by+N-%5B4-%5B3-bromophenyl%29amino%5D-6-quinazolinyl%5D-2-butynamide+%28CL-387%2C875%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DCarroll%26aufirst%3DM.%2BL.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DHollander%26aufirst%3DI%252C%2BJ.%26aulast%3DHusain%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DKitchen%26aufirst%3DD.%26aulast%3DMay%26aufirst%3DM.%2BK.%26aulast%3DMalo%26aufirst%3DM.%2BS.%26aulast%3DMinnick%26aufirst%3DA.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DIrreversible%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520activity%2520by%2520N-%255B4-%255B3-bromophenyl%2529amino%255D-6-quinazolinyl%255D-2-butynamide%2520%2528CL-387%252C875%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1999%26volume%3D57%26spage%3D917%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">The development of HKI-272 and related compounds for the treatment of cancer</span> <span class="citation_source-journal">Arch. Pharm. Chem. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1002%2Fardp.200800009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18493974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=465-477&author=A.+Wissnerauthor=T.+S.+Mansour&title=The+development+of+HKI-272+and+related+compounds+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The development of HKI-272 and related compounds for the treatment of cancer</span></div><div class="casAuthors">Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-477</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of HKI-272 and EKB-569 for the treatment of cancer is described.  These compds. function as irreversible inhibitors of some members of the ErbB family of receptor tyrosine kinases.  In particular, they target epidermal growth factor receptor (EGFR, also known as ErbB-1) and human epidermal growth factor receptor-2 (HER2, also known as ErbB-2).  Both, HKI-272 and EKB-569 are 4-anilino-3-cyano quinoline derivs. that contain a 4-(dimethylamino)crotonamide Michael-acceptor group at the 6-position.  These compds. inhibit the function of the target enzymes by forming a covalent interaction with a conserved cysteine residue located in the kinase domains of these proteins.  The potential advantages of using irreversible inhibitors for this purpose are discussed.  We summarize the recent findings concerning some somatic mutations in EGFR and their relevance with respect to the irreversible inhibitors.  In particular, we highlight the findings that these irreversible inhibitors retain activity against tumors that have acquired a resistance to the reversible binding inhibitors gefitinib and erlotinib.  The promising interim clin. trial results for HKI-272 and EKB-569 in treating colon, lung, and breast cancers are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSokM42ZhprVg90H21EOLACvtfcHk0liHYKxNTOQoyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E&md5=2e46d99ca74e297e6a7e860634bf096d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800009%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DThe%2520development%2520of%2520HKI-272%2520and%2520related%2520compounds%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DArch.%2520Pharm.%2520Chem.%2520Life%2520Sci.%26date%3D2008%26volume%3D341%26spage%3D465%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Monica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronin, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2038</span><span class="NLM_x">–</span> <span class="NLM_lpage">2050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901558p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2038-2050&author=C.+Carmiauthor=A.+Cavazzoniauthor=S.+Vezzosiauthor=F.+Bordiauthor=F.+Vacondioauthor=C.+Silvaauthor=S.+Rivaraauthor=A.+Lodolaauthor=R.+R.+Alfieriauthor=S.+La+Monicaauthor=M.+Galettiauthor=A.+Ardizzoniauthor=P.+G.+Petroninauthor=M.+Mor&title=Novel+irreversible+epidermal+growth+factor+receptor+inhibitors+by+chemical+modulation+of+the+cysteine-trap+portion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901558p%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DVezzosi%26aufirst%3DS.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronin%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DNovel%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520chemical%2520modulation%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2038%26epage%3D2050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brignola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasheard, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caferro, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reno, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">6-Ethynylthieno[3,2-<i>d</i>]- and 6-ethynylthieno[2,3-<i>d</i>]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2772</span><span class="NLM_x">–</span> <span class="NLM_lpage">2778</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2772-2778&author=E.+R.+Woodauthor=L.+M.+Shewchukauthor=B.+Byron+Ellisauthor=P.+Brignolaauthor=R.+L.+Brasheardauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=H.+D.+Dicksonauthor=K.+H.+Donaldsonauthor=M.+Gaulauthor=R.+J.+Griffinauthor=A.+M.+Hassellauthor=B.+Keithauthor=R.+Mullinauthor=K.+G.+Petrovauthor=M.+J.+Renoauthor=D.+W.+Rusnakauthor=S.+M.+Tadepalliauthor=J.+C.+Ulrichauthor=C.+D.+Wagnerauthor=D.+E.+Vanderwallauthor=A.+G.+Watersonauthor=J.+D.+Williamsauthor=W.+L.+Whiteauthor=D.+E.+Uehling&title=6-Ethynylthieno%5B3%2C2-d%5D-+and+6-ethynylthieno%5B2%2C3-d%5Dpyrimidin-4-anilines+as+tunable+covalent+modifiers+of+ErbB+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DByron%2BEllis%26aufirst%3DB.%26aulast%3DBrignola%26aufirst%3DP.%26aulast%3DBrasheard%26aufirst%3DR.%2BL.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DMullin%26aufirst%3DR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DReno%26aufirst%3DM.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTadepalli%26aufirst%3DS.%2BM.%26aulast%3DUlrich%26aufirst%3DJ.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BD.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BL.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3D6-Ethynylthieno%255B3%252C2-d%255D-%2520and%25206-ethynylthieno%255B2%252C3-d%255Dpyrimidin-4-anilines%2520as%2520tunable%2520covalent%2520modifiers%2520of%2520ErbB%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2772%26epage%3D2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Brigdes, A. J.</span><span> </span><span class="NLM_article-title">Chemical inhibitors of protein kinases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2541</span><span class="NLM_x">–</span> <span class="NLM_lpage">2571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2000&pages=2541-2571&author=A.+J.+Brigdes&title=Chemical+inhibitors+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrigdes%26aufirst%3DA.%2BJ.%26atitle%3DChemical%2520inhibitors%2520of%2520protein%2520kinases%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D101%26spage%3D2541%26epage%3D2571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Ban, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabeyama, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span> </span><span class="NLM_article-title">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4415</span><span class="NLM_x">–</span> <span class="NLM_lpage">4427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1039%2Fb909504g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19830290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4415-4427&author=H.+S.+Banauthor=T.+Usuiauthor=W.+Nabeyamaauthor=H.+Moritaauthor=K.+Fukuzawaauthor=H.+Nakamura&title=Discovery+of+boron-conjugated+4-anilinoquinazoline+as+a+prolonged+inhibitor+of+EGFR+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span></div><div class="casAuthors">Ban, Hyun Seung; Usui, Taikou; Nabeyama, Wataru; Morita, Hidetoshi; Fukuzawa, Kaori; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4415-4427</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Boron-conjugated 4-anilinoquinazolines were designed and synthesized as inhibitors of EGFR tyrosine kinase with possible covalent bond interactions between the boron atom and the nucleophilic groups of the EGFR kinase domain.  Among the compds. synthesized, compds. I and II (X = CH:CH, 1,4-phenylene) reduced the EGF-mediated phosphorylation of EGFR tyrosine kinase and its downstream kinases including ERK and Akt in A431 cells.  The cell growth was inhibited by these compds. through arrest of G1 cell cycle, which induced apoptosis.  A time-dependent in vitro preincubation assay demonstrated the irreversible inhibition of compd. II [X = 1,4-phenylene; (III)] against EGFR tyrosine kinase.  Quantum mech. docking simulation revealed that the boronic acid moiety of compd. III formed a covalent B-O bond with Asp800 in addn. to hydrogen bonds with Asp800 and Cys797, which may cause the prolonged inhibition of compd. III toward EGFR tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_ARjWKN7LLVg90H21EOLACvtfcHk0lgYlERDQDBTbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN&md5=b61ee61865bdff8e4706485b1f030554</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2Fb909504g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb909504g%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DH.%2BS.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DNabeyama%26aufirst%3DW.%26aulast%3DMorita%26aufirst%3DH.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520boron-conjugated%25204-anilinoquinazoline%2520as%2520a%2520prolonged%2520inhibitor%2520of%2520EGFR%2520tyrosine%2520kinase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D4415%26epage%3D4427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1019</span><span class="NLM_x">–</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F138955711797247725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21861809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1019-1030&author=C.+Carmiauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Cavazzoniauthor=R.+R.+Alfieriauthor=A.+Ardizzoniauthor=P.+G.+Petroniniauthor=M.+Mor&title=Epidermal+growth+factor+receptor+irreversible+inhibitors%3A+chemical+exploration+of+the+cysteine-trap+portion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span></div><div class="casAuthors">Carmi, C.; Lodola, A.; Rivara, S.; Vacondio, F.; Cavazzoni, A.; Alfieri, R. R.; Ardizzoni, A.; Petronini, P. G.; Mor, M.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1019-1030</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent EGFR irreversible inhibitors showed promising potential for the treatment of gefitinib-resistant tumors and for imaging purposes.  They contain a cysteine-reactive portion forming a covalent bond with the protein.  Irreversible kinase inhibitors have been advanced to clin. studies, mostly characterized by an acrylamide or butynamide warhead.  However, the clin. usefulness of these compds. has been hampered by resistances, toxicity and pharmacokinetic problems.  Investigation on the structure-activity and structure-reactivity relationships may provide useful information for compds. with improved selectivity and pharmacokinetic properties.  This review focuses on the exploration of the cysteine-trap portions able to irreversibly inhibit EGFR and other erbB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupbZjLNpfFrVg90H21EOLACvtfcHk0lgYlERDQDBTbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O&md5=d531960c09e4676366b3611c3187533d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2174%2F138955711797247725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955711797247725%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520irreversible%2520inhibitors%253A%2520chemical%2520exploration%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1019%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.’</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.%E2%80%99+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+a+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%25E2%2580%2599%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D52%26spage%3D6880%26epage%3D6888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=J.-S.+Pengauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.+K.+Chittimallaauthor=J.-S.+Songauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+Aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0lhRMDpDSIybcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520Aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Wu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno[2,3-<i>d</i>]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.-H.+Wuauthor=M.+S.+Coumarauthor=C.-Y.+Chuauthor=W.-H.+Linauthor=Y.-R.+Chenauthor=C.-T.+Chenauthor=H.-Y.+Shiaoauthor=S.+Rafiauthor=S.-Y.+Wangauthor=H.+Hsuauthor=C.-H.+Chenauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=T.-W.+Lienauthor=M.-Y.+Fangauthor=K.-C.+Yehauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=S.-H.+Hsiehauthor=J.+T.-A.+Hsuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+the+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DY.-R.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DYeh%26aufirst%3DK.-C.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHsieh%26aufirst%3DS.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520the%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit68"><span>Clinical Trials. <a href="http://clinicaltrials.gov/" class="extLink">http://clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials.+http%3A%2F%2Fclinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simar, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simarauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.-H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0liVw8GdX8Odrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimar%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.-H.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%9Cgatekeeper%E2%80%9D+mutation+in+EGFR+mediates+resistance+to+low+concentrations+of+an+irreversible+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0liVw8GdX8Odrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutation%2520in%2520EGFR%2520mediates%2520resistance%2520to%2520low%2520concentrations%2520of%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Ocana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amir, E.</span><span> </span><span class="NLM_article-title">Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.ctrv.2009.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19733440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=685-691&author=A.+Ocanaauthor=E.+Amir&title=Irreversible+pan-ErbB+tyrosine+kinase+inhibitors+and+breast+cancer%3A+current+status+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions</span></div><div class="casAuthors">Ocana, Alberto; Amir, Eitan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers.  Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients.  Despite overexpressing HER2, some patients do not respond to these targeted treatments or progress after a short period of time.  Irreversible tyrosine kinase inhibitors have been developed to bypass several pathways that could be involved in this resistance.  In vitro, these agents have been shown to be more potent and to prolong target inhibition.  Clin. development of these agents is ongoing and early results are promising.  This review will describe the biol. rationale that justifies the development of these agents in breast cancer focusing on the current status and future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4KYTpGeBILVg90H21EOLACvtfcHk0liVw8GdX8Odrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3E&md5=d7b5b04a11ec7dd6f187eb77e2df046f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2009.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2009.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DOcana%26aufirst%3DA.%26aulast%3DAmir%26aufirst%3DE.%26atitle%3DIrreversible%2520pan-ErbB%2520tyrosine%2520kinase%2520inhibitors%2520and%2520breast%2520cancer%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D685%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doorn, L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van.; Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G. E.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+L.+M.+Eskensauthor=C.+H.+Momauthor=A.+S.+T.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L+Doornauthor=H.+van.%3B+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+E.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0lhyCKLqj5DRBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%2BT.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3DDoorn%26aufirst%3DL%26aulast%3Dvan.%253B%2BBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.-M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0lhyCKLqj5DRBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Want, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wantauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWant%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nat. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Lacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DLacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNat.%2520Lett.%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lid508jRCT63A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Walter, A. O.; Tjin, R.; Haringsma, H.; Lin, K. K.; Dubrovskiy, A.; Lee, K.; St. Martin, T.; Karp, R.; Zhu, Z.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W. F.; Singh, J.; Raponi, M.; Allen, A.</span><span> </span><span class="NLM_article-title">CO-1886, an Orally Available, Mutant-Selective Inhibitor of the Epidermal Growth Factor Receptor (EGFR), Causes Tumor Skrinkage in Non-Small Cell Lung Cancer (NSCLC) with T790M Resistance Mutations</span>. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, November 12–16,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+O.+Walter&author=R.+Tjin&author=H.+Haringsma&author=K.+K.+Lin&author=A.+Dubrovskiy&author=K.+Lee&author=T.+St.+Martin&author=R.+Karp&author=Z.+Zhu&author=D.+Niu&author=M.+Nacht&author=R.+C.+Petter&author=W.+F.+Westlin&author=J.+Singh&author=M.+Raponi&author=A.+Allen&title=CO-1886%2C+an+Orally+Available%2C+Mutant-Selective+Inhibitor+of+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29%2C+Causes+Tumor+Skrinkage+in+Non-Small+Cell+Lung+Cancer+%28NSCLC%29+with+T790M+Resistance+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26atitle%3DCO-1886%252C%2520an%2520Orally%2520Available%252C%2520Mutant-Selective%2520Inhibitor%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%252C%2520Causes%2520Tumor%2520Skrinkage%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520with%2520T790M%2520Resistance%2520Mutations%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0liKSiCy-X8FbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.</span><span> </span><span class="NLM_article-title">The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study</span>. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Advani&author=J.+Sharman&author=S.+Smith&author=T.+Boyd&author=B.+Grant&author=K.+Kolibaba&author=R.+Furman&author=J.+Buggy&author=D.+Loury&author=E.+Hedrick&author=R.+Izumi&author=A.+Hamdy&author=N.+Fowler&title=The+Btk+Inhibitor+PCI-32765+Is+Highly+Active+and+Well+Tolerated+in+Patients+with+Relapsed%2FRefractory+B+Cell+Malignancies%3A+Final+Results+from+a+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%26atitle%3DThe%2520Btk%2520Inhibitor%2520PCI-32765%2520Is%2520Highly%2520Active%2520and%2520Well%2520Tolerated%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B%2520Cell%2520Malignancies%253A%2520Final%2520Results%2520from%2520a%2520Phase%2520I%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Moriarty, K. J.; Konteatis, Z.; Moffett, K.; Lee, Y.; Chao, W.</span> Int. Pat. Appl. WO 2010/126960 A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Moriarty%2C+K.+J.%3B+Konteatis%2C+Z.%3B+Moffett%2C+K.%3B+Lee%2C+Y.%3B+Chao%2C+W.+Int.+Pat.+Appl.+WO+2010%2F126960+A1%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DK.%2BJ.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Labenski, M.; Chaturvendi, P.; Evans, E.; Mazdiyasni, H.; Sheets, M.; Aslanian, S.; Niu, D.; Nacht, M.; Singh, J.; Westlin, W.</span><span> </span><span class="NLM_article-title">In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton’s Tyrosine Kinase</span>. Presented at the 17th North America Regional Meeting of International Society for the Study of Xenobiotics, Atlanta, GA, October 16–20,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster P211.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Labenski&author=P.+Chaturvendi&author=E.+Evans&author=H.+Mazdiyasni&author=M.+Sheets&author=S.+Aslanian&author=D.+Niu&author=M.+Nacht&author=J.+Singh&author=W.+Westlin&title=In+Vitro+Reactivity+Assessment+of+Covalent+Drugs+Targeting+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLabenski%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Reactivity%2520Assessment%2520of%2520Covalent%2520Drugs%2520Targeting%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Petter, R.</span><span> </span><span class="NLM_article-title">Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk</span>. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Petter%2C+R.+Targeted+Covalent+Kinase+Inhibitors%3A+AVL+292+as+a+Potent%2C+Irreversible+and+Selective+Inhibitor+of+Btk.+Presented+at+the+5th+Anglo-Swedish+Medicinal+Chemistry+Symposium+%28ASMC%29%2C+%C3%85re%2C+Sweden%2C+March+20%E2%80%9323%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPetter%26aufirst%3DR.%26atitle%3DTargeted%2520Covalent%2520Kinase%2520Inhibitors%253A%2520AVL%2520292%2520as%2520a%2520Potent%252C%2520Irreversible%2520and%2520Selective%2520Inhibitor%2520of%2520Btk%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Evans, E.; Tester, R.; Aslanian, S.; Mazdiyasni, H.; Ponader, S.; Tesar, B.; Chaturvedi, P.; Nacht, M.; Stiede, K.; Witowski, S.; Lounsbury, H.; Silver, B.; Burger, J.; Brown, J. R.; Mahadevan, D.; Sharman, J.; Harb, W.; Petter, R.; Singh, J.; Westlin, W.</span><span> </span><span class="NLM_article-title">Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies</span>. Presented at the ASH Annual Meeting, San Diego, CA, December 10–13,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=E.+Evans&author=R.+Tester&author=S.+Aslanian&author=H.+Mazdiyasni&author=S.+Ponader&author=B.+Tesar&author=P.+Chaturvedi&author=M.+Nacht&author=K.+Stiede&author=S.+Witowski&author=H.+Lounsbury&author=B.+Silver&author=J.+Burger&author=J.+R.+Brown&author=D.+Mahadevan&author=J.+Sharman&author=W.+Harb&author=R.+Petter&author=J.+Singh&author=W.+Westlin&title=Clinical+Development+of+AVL-292%3A+A+Potent%2C+Selective+Covalent+Btk+Inhibitor+for+the+Treatment+of+B+Cell+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DClinical%2520Development%2520of%2520AVL-292%253A%2520A%2520Potent%252C%2520Selective%2520Covalent%2520Btk%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520B%2520Cell%2520Malignancies%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Kim, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.-H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+Soutterauthor=N.+Caspersauthor=S.+Hanauthor=R.+Kurumbailauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalls, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nittoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annable, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loganzo, F.</span><span> </span><span class="NLM_article-title">2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7560</span><span class="NLM_x">–</span> <span class="NLM_lpage">7581</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050559f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7560-7581&author=A.+Wissnerauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=H.+Fraserauthor=C.+Ingallsauthor=T.+Nittoliauthor=R.+G.+Dushinauthor=C.+Discafaniauthor=R.+Nilakantanauthor=J.+Mariniauthor=M.+Raviauthor=K.+Cheungauthor=X.+Tanauthor=S.+Mustoauthor=T.+Annableauthor=M.+M.+Siegelauthor=F.+Loganzo&title=2-%28Quinazolin-4-ylamino%29-%5B1%2C4%5Dbenzoquinones+as+covalent-binding%2C+irreversible+inhibitors+of+the+kinase+domain+of+vascular+endothelial+growth+factor+receptor-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm050559f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050559f%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DFraser%26aufirst%3DH.%26aulast%3DIngalls%26aufirst%3DC.%26aulast%3DNittoli%26aufirst%3DT.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DMarini%26aufirst%3DJ.%26aulast%3DRavi%26aufirst%3DM.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DMusto%26aufirst%3DS.%26aulast%3DAnnable%26aufirst%3DT.%26aulast%3DSiegel%26aufirst%3DM.%2BM.%26aulast%3DLoganzo%26aufirst%3DF.%26atitle%3D2-%2528Quinazolin-4-ylamino%2529-%255B1%252C4%255Dbenzoquinones%2520as%2520covalent-binding%252C%2520irreversible%2520inhibitors%2520of%2520the%2520kinase%2520domain%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7560%26epage%3D7581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Schirmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">4234</span><span class="NLM_x">–</span> <span class="NLM_lpage">4239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.0600445103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=16537514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=4234-4239&author=A.+Schirmerauthor=J.+Kennedyauthor=S.+Murliauthor=R.+Reidauthor=D.+V.+Santi&title=Targeted+covalent+inactivation+of+protein+kinases+by+resorcylic+acid+lactone+polyketides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span></div><div class="casAuthors">Schirmer, Andreas; Kennedy, Jonathan; Murli, Sumati; Reid, Ralph; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4234-4239</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Resorcylic acid lactones contg. a cis-enone are susceptible to Michael addn. reactions and are potent inhibitors of several protein kinases.  A structural-bioinformatics anal. identified a conserved Cys residue in the ATP-binding site of the kinases reported to be inhibited by cis-enone resorcylic acid lactones but absent in those that are not.  Mining of the kinome database revealed that a subset of some 46 kinases contained this Cys residue.  Screening a panel of 124 kinases with the resorcylic acid lactone hypothemycin showed that 18 of 19 targets contg. the conserved Cys were inhibited.  Kinetic analyses showed time-dependent inhibition, a hallmark of covalent inactivation, and biochem. studies of the interaction of extracellular signal-regulated kinase (ERK)2 with hypothemycin confirmed covalent adduct formation.  Resorcylic acid lactones are unique among kinase inhibitors in that they target mitogen-activated protein (MAP) kinase pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downstream ERK substrates.  Cell lines dependent on the activation of Tyr kinase mitogen receptor targets of the resorcylic acid lactones were unusually sensitive toward hypothemycin and showed the expected inhibition of kinase phosphorylation due to inhibition of the mitogen receptors and/or MEK1/2 and ERK1/2.  Among cells without mitogen receptor targets, those harboring an ERK pathway-activating B-RAF V600E mutation were selectively and potently inhibited by hypothemycin.  Hypothemycin also prevented stimulated activation of the p38 cascade through inhibition of the Cys-contg. targets MEK3/6 and TGF-β-activated kinase 1 and of the JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase) cascade through inhibition of MEK4/7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraww22qbwEYLVg90H21EOLACvtfcHk0lig1vz_lgJ8hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D&md5=6a4be819f2c2a5a601e5c9cb75faf433</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0600445103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0600445103%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmer%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DJ.%26aulast%3DMurli%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DTargeted%2520covalent%2520inactivation%2520of%2520protein%2520kinases%2520by%2520resorcylic%2520acid%2520lactone%2520polyketides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D4234%26epage%3D4239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Molecular modeling and crystal structure of ERK2-hypothemycin complexes</span> <span class="citation_source-journal">J. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2008&pages=18-23&author=G.+Rastelliauthor=R.+Rosenfeldauthor=R.+Reidauthor=D.+V.+Santi&title=Molecular+modeling+and+crystal+structure+of+ERK2-hypothemycin+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DRosenfeld%26aufirst%3DR.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DMolecular%2520modeling%2520and%2520crystal%2520structure%2520of%2520ERK2-hypothemycin%2520complexes%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2008%26volume%3D164%26spage%3D18%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Ohori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kioshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span> </span><span class="NLM_article-title">Role of a cysteine residue in the active site of ERK and the MAPKK family</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">633</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2007&pages=633-637&author=M.+Ohoriauthor=T.+Kioshitaauthor=S.+Yoshimuraauthor=M.+Warizayaauthor=H.+Nakajimaauthor=H.+Miyake&title=Role+of+a+cysteine+residue+in+the+active+site+of+ERK+and+the+MAPKK+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhori%26aufirst%3DM.%26aulast%3DKioshita%26aufirst%3DT.%26aulast%3DYoshimura%26aufirst%3DS.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DMiyake%26aufirst%3DH.%26atitle%3DRole%2520of%2520a%2520cysteine%2520residue%2520in%2520the%2520active%2520site%2520of%2520ERK%2520and%2520the%2520MAPKK%2520family%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D353%26spage%3D633%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Goto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obaishi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirota, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusovsky, F.</span><span> </span><span class="NLM_article-title">E6201 [(3<i>S</i>,4<i>R</i>,5<i>Z</i>,8<i>S</i>,9<i>S</i>,11<i>E</i>)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1<i>H</i>-2-benzoxacyclotetradecine-1,7(8<i>H</i>)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1124%2Fjpet.109.156554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19684251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=485-495&author=M.+Gotoauthor=J.+Chowauthor=K.+Muramotoauthor=K.-I.+Chibaauthor=S.+Yamamotoauthor=M.+Fujitaauthor=H.+Obaishiauthor=K.+Taiauthor=Y.+Mizuiauthor=I.+Tanakaauthor=D.+Youngauthor=H.+Yangauthor=Y.+J.+Wangauthor=H.+Shirotaauthor=F.+Gusovsky&title=E6201+%5B%283S%2C4R%2C5Z%2C8S%2C9S%2C11E%29-14-%28ethylamino%29-8%2C9%2C16-trihydroxy-3%2C4-dimethyl-3%2C4%2C9%2C19-tetrahydro-1H-2-benzoxacyclotetradecine-1%2C7%288H%29-dione%5D%2C+a+novel+kinase+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase+%28MEK%29-1+and+MEK+kinase-1%3A+in+vitro+characterization+of+its+anti-inflammatory+and+antihyperproliferative+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities</span></div><div class="casAuthors">Goto, Masaki; Chow, Jesse; Muramoto, Kenzo; Chiba, Ken-ichi; Yamamoto, Satoshi; Fujita, Masanori; Obaishi, Hiroshi; Tai, Kenji; Mizui, Yoshiharu; Tanaka, Isao; Young, Donna; Yang, Hua; Wang, Yuan J.; Shirota, Hiroshi; Gusovsky, Fabian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-495</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The goal of this study is to identify a novel inhibitor with anti-inflammatory and antiproliferative properties for the treatment of psoriasis.  Compd. f152A1 [(3S,5Z,8S,11E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro- 1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione] was identified as the main active metabolite with strong inhibitory activity against tumor necrosis factor-α (TNFα) transcription in a fraction originated from the fermn. broth of the fungus Curvularia verruculosa.  Although active in cell-based assays, f152A1 was unstable in plasma and liver microsome prepns., thus limiting its pharmaceutical utilization.  To improve the metabolic properties of f152A1, a medicinal chem. program was undertaken, resulting in the generation of over 400 analogs of f152A1.  Eventually, E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione] was identified as a promising analog in this series.  In the present study, we characterized the in vitro activities of E6201 and discovered that the compd. inhibits lipopolysaccharide-activated TNFα reporter activity in THP-1-33 cells with an IC50 value of 50 nM and selectively inhibits mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1 in cell-free biochem. assays.  In addn., E6201 showed inhibitory activity in several other cell-based systems:(1) phosphorylation of c-jun N-terminal kinase and p38 MAPKs; (2) nuclear factor-κB and activated protein-1 activation in various cell types; (3) interleukin (IL)-2 prodn. from human lymphocytes; (4) hyperproliferation of human keratinocytes; (5) IL-8 prodn. from human keratinocytes; and (6) proinflammatory cytokine prodn. from human peripheral blood mononuclear cells.  Based on the data presented here, E6201 may be beneficial for treatment of inflammatory and hyperproliferative diseases such as psoriasis through its anti-inflammatory activities on immune cells and antihyperproliferative activities on keratinocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxBdDTs96tNbVg90H21EOLACvtfcHk0lig1vz_lgJ8hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7zO&md5=6d7f61889a8d50c2a073f8921c441814</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.156554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.156554%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DChow%26aufirst%3DJ.%26aulast%3DMuramoto%26aufirst%3DK.%26aulast%3DChiba%26aufirst%3DK.-I.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DObaishi%26aufirst%3DH.%26aulast%3DTai%26aufirst%3DK.%26aulast%3DMizui%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DI.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DShirota%26aufirst%3DH.%26aulast%3DGusovsky%26aufirst%3DF.%26atitle%3DE6201%2520%255B%25283S%252C4R%252C5Z%252C8S%252C9S%252C11E%2529-14-%2528ethylamino%2529-8%252C9%252C16-trihydroxy-3%252C4-dimethyl-3%252C4%252C9%252C19-tetrahydro-1H-2-benzoxacyclotetradecine-1%252C7%25288H%2529-dione%255D%252C%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase%2520%2528MEK%2529-1%2520and%2520MEK%2520kinase-1%253A%2520in%2520vitro%2520characterization%2520of%2520its%2520anti-inflammatory%2520and%2520antihyperproliferative%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D485%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Muramoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuboi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusovsky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirota, H.</span><span> </span><span class="NLM_article-title">E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1124%2Fjpet.110.168583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20627998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=23-31&author=K.+Muramotoauthor=M.+Gotoauthor=Y.+Inoueauthor=N.+Ishiiauthor=K.-I.+Chibaauthor=Y.+Kuboiauthor=T.+Omaeauthor=Y.+J.+Wangauthor=F.+Gusovskyauthor=H.+Shirota&title=E6201%2C+a+novel+kinase+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase-1+and+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase+kinase-1%3A+in+vivo+effects+on+cutaneous+inflammatory+responses+by+topical+administration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration</span></div><div class="casAuthors">Muramoto, Kenzo; Goto, Masaki; Inoue, Yoko; Ishii, Naoto; Chiba, Ken-ichi; Kuboi, Yoshikazu; Omae, Takao; Wang, Yuan J.; Gusovsky, Fabian; Shirota, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-31</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,10-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione)] is a novel anti-inflammatory agent that has potent inhibitory effects on the prodn. of proinflammatory cytokines from leukocytes and antiproliferative activity on keratinocytes.  To characterize the in vivo pharmacol. activity of E6201, topically administered E6201 was evaluated in several different animal models of dermatitis.  E6201 formulated as an ointment or cream showed dose-dependent inhibition of croton oil-induced acute edema formation and neutrophil infiltration into mouse skin.  In addn., E6201 cream inhibited the 1-fluoro-2,4-dinitrobenzene-induced contact hypersensitivity reaction mediated by T cells in mice.  In this model, E6201 cream also suppressed the migration of neutrophils and lymphocytes into the inflammatory site.  Pretreatment with E6201 cream attenuated phorbol-12 myristate 13-acetate-induced ornithine decarboxylase activity, a marker of proliferation in epidermis.  Furthermore, E6201 ointment showed inhibitory effects on both mezerein-induced and interleukin (IL)-23-induced epidermal hyperplasia.  E6201 also suppressed T cell receptor-stimulated IL-17 prodn. from human T cells.  These results indicate that topically administered E6201 may be a useful agent for the prevention and treatment of cutaneous inflammatory and hyperproliferative diseases such as psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WAaqpkhIvrVg90H21EOLACvtfcHk0lhami248MUYOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3M&md5=f951a66efba352d172abdc333b650de5</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.168583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.168583%26sid%3Dliteratum%253Aachs%26aulast%3DMuramoto%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DChiba%26aufirst%3DK.-I.%26aulast%3DKuboi%26aufirst%3DY.%26aulast%3DOmae%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DGusovsky%26aufirst%3DF.%26aulast%3DShirota%26aufirst%3DH.%26atitle%3DE6201%252C%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase-1%2520and%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase%2520kinase-1%253A%2520in%2520vivo%2520effects%2520on%2520cutaneous%2520inflammatory%2520responses%2520by%2520topical%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D23%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jogireddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koripelly, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">In vivo efficacy of natural product-inspired irreversible kinase inhibitors</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1002%2Fcbic.201000205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20623569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1692-1699&author=S.+Barluengaauthor=R.+Jogireddyauthor=G.+K.+Koripellyauthor=N.+Winssinger&title=In+vivo+efficacy+of+natural+product-inspired+irreversible+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Efficacy of Natural Product-Inspired Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Barluenga, Sofia; Jogireddy, Rajamalleswaramma; Koripelly, Girish K.; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1692-1699</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hypothemycin and related resorcylic acid lactones (RAL) bearing a cis-enone moiety have emerged as an alternative pharmacophore to heterocyclic motifs for kinase inhibition, and are endowed with a unique selectivity filter based on the irreversible reaction with a subset of the kinome bearing a suitably positioned cysteine residue.  Two prototypical examples of "edited" RAL were evaluated for antitumoral, antimetastatic and antiangiogenic efficacy in an orthotopic murine renal cell carcinoma (RENCA) model.  Both compds. (3 and 5) are good inhibitors of VEGFRs in vitro, and inhibited tumor growth in vivo with comparable efficacy to sunitinib, an FDA-approved VEGFRs inhibitor.  Compd. 3 promoted lung metastasis to a similar extent as sunitinib, while compd. 5 strongly inhibited lung metastasis.  This study attests to the potential of irreversible kinase inhibitors and mol. editing of natural pharmacophores and provides encouraging results to a clin. significant problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNKnAGz2gxurVg90H21EOLACvtfcHk0liD_ETppLAUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqu7c%253D&md5=cbe2869e3c669a89f3d5ac7f7a2c5479</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000205%26sid%3Dliteratum%253Aachs%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DJogireddy%26aufirst%3DR.%26aulast%3DKoripelly%26aufirst%3DG.%2BK.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DIn%2520vivo%2520efficacy%2520of%2520natural%2520product-inspired%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D1692%26epage%3D1699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit94"><span><div class="note"><p class="first last">Reviewed in the following: </p></div><span class="NLM_contrib-group">Gaestel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bothe, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asadullah, K.</span><span> </span><span class="NLM_article-title">Protein kinases as small molecule inhibitor targets in inflammation</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2214</span><span class="NLM_x">–</span> <span class="NLM_lpage">2234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F092986707781696636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17896971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=2214-2234&author=M.+Gaestelauthor=A.+Mengelauthor=U.+Botheauthor=K.+Asadullah&title=Protein+kinases+as+small+molecule+inhibitor+targets+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases as small molecule inhibitor targets in inflammation</span></div><div class="casAuthors">Gaestel, M.; Mengel, A.; Bothe, U.; Asadullah, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2214-2234</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The human kinome describes a major group of intracellular signaling mols.  In the last few years, many mols. in the group have become targets for therapeutic interventions.  Due to the conserved reaction mechanism of catalysis, protein kinases seem well "drugable" by small mol. wt. inhibitors, thus opening the chance to novel oral bioavailable drug development.  A large no. of small mol. wt. inhibitors for protein kinases have already been introduced into research and these mols. are extensively analyzed in regard to their efficiency, potency and selectivity.  Here we summarize the use of small mol. protein kinase inhibitors relevant for acute and chronic inflammation based on their essential role in cellular signaling mechanisms in immune cells such as macrophages, lymphocytes and granulocytes.  We describe the progress made to develop inhibitors against Toll-like receptor assocd. kinases (IRAKs), against the MAPK kinase kinases Cot/Tpl-2 and TAK1, against Inhibitor-κB kinases (IKKs), against MAPK kinases (MEKs, MKKs), against MAPKs (ERK2, p38, JNKs) and against their downstream kinases MNK1 and MK2/3.  This overview should help to keep up with the fast developing field and the continuously growing no. of protein kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtC245E_OSPbVg90H21EOLACvtfcHk0liD_ETppLAUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrvK&md5=ef5cdd7f122e37d8bf8bf0f22db131a9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2174%2F092986707781696636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707781696636%26sid%3Dliteratum%253Aachs%26aulast%3DGaestel%26aufirst%3DM.%26aulast%3DMengel%26aufirst%3DA.%26aulast%3DBothe%26aufirst%3DU.%26aulast%3DAsadullah%26aufirst%3DK.%26atitle%3DProtein%2520kinases%2520as%2520small%2520molecule%2520inhibitor%2520targets%2520in%2520inflammation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D2214%26epage%3D2234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Perez, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wandosell, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelpi, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span> </span><span class="NLM_article-title">Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6914</span><span class="NLM_x">–</span> <span class="NLM_lpage">6925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=6914-6925&author=D.+I.+Perezauthor=S.+Condeauthor=C.+Perezauthor=C.+Gilauthor=D.+Simonauthor=F.+Wandosellauthor=F.+J.+Morenoauthor=J.+L.+Gelpiauthor=F.+J.+Luqueauthor=A.+Martinez&title=Thienylhalomethylketones%3A+irreversible+glycogen+synthase+kinase+3+inhibitors+as+useful+pharmacological+tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DConde%26aufirst%3DS.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DD.%26aulast%3DWandosell%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26aulast%3DGelpi%26aufirst%3DJ.%2BL.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DThienylhalomethylketones%253A%2520irreversible%2520glycogen%2520synthase%2520kinase%25203%2520inhibitors%2520as%2520useful%2520pharmacological%2520tools%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D6914%26epage%3D6925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M. G.</span><span> </span><span class="NLM_article-title">Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkB kinase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">403</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2000&pages=103-108&author=A.+Rossiauthor=P.+Kapahiauthor=G.+Natoliauthor=T.+Takahashiauthor=Y.+Chenauthor=M.+Karinauthor=M.+G.+Santoro&title=Anti-inflammatory+cyclopentenone+prostaglandins+are+direct+inhibitors+of+IkB+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DKapahi%26aufirst%3DP.%26aulast%3DNatoli%26aufirst%3DG.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%2BG.%26atitle%3DAnti-inflammatory%2520cyclopentenone%2520prostaglandins%2520are%2520direct%2520inhibitors%2520of%2520IkB%2520kinase%26jtitle%3DNature%26date%3D2000%26volume%3D403%26spage%3D103%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Straus, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengchanthalangsy, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, C. K.</span><span> </span><span class="NLM_article-title">15-Deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> inhibits multiple steps in the NF-κB signaling pathway</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">4844</span><span class="NLM_x">–</span> <span class="NLM_lpage">4849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=4844-4849&author=D.+S.+Strausauthor=G.+Pascualauthor=M.+Liauthor=J.+S.+Welchauthor=M.+Ricoteauthor=C.-H.+Hsiangauthor=L.+L.+Sengchanthalangsyauthor=G.+Ghoshauthor=C.+K.+Glass&title=15-Deoxy-%CE%9412%2C14-prostaglandin+J2+inhibits+multiple+steps+in+the+NF-%CE%BAB+signaling+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStraus%26aufirst%3DD.%2BS.%26aulast%3DPascual%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWelch%26aufirst%3DJ.%2BS.%26aulast%3DRicote%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DC.-H.%26aulast%3DSengchanthalangsy%26aufirst%3DL.%2BL.%26aulast%3DGhosh%26aufirst%3DG.%26aulast%3DGlass%26aufirst%3DC.%2BK.%26atitle%3D15-Deoxy-%25CE%259412%252C14-prostaglandin%2520J2%2520inhibits%2520multiple%2520steps%2520in%2520the%2520NF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D4844%26epage%3D4849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Ji, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozak, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span> </span><span class="NLM_article-title">IκB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">18223</span><span class="NLM_x">–</span> <span class="NLM_lpage">18228</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=18223-18228&author=C.+Jiauthor=K.+R.+Kozakauthor=L.+J.+Marnett&title=I%CE%BAB+kinase%2C+a+molecular+target+for+inhibition+by+4-hydroxy-2-nonenal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DC.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DI%25CE%25BAB%2520kinase%252C%2520a%2520molecular%2520target%2520for%2520inhibition%2520by%25204-hydroxy-2-nonenal%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D18223%26epage%3D18228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Kim, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span> </span><span class="NLM_article-title">Artemisolide is a typical inhibitor of IκB kinase β targeting cysteine-179 residue and down-regulates NF-κB-dependent TNF-α expression in LPS-activated macrophages</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2007&pages=593-598&author=B.+H.+Kimauthor=J.-Y.+Leeauthor=J.+H.+Seoauthor=H.+Y.+Leeauthor=S.+Y.+Ryuauthor=B.+W.+Ahnauthor=C.-K.+Leeauthor=B.+Y.+Hwangauthor=S.-B.+Hanauthor=Y.+Kim&title=Artemisolide+is+a+typical+inhibitor+of+I%CE%BAB+kinase+%CE%B2+targeting+cysteine-179+residue+and+down-regulates+NF-%CE%BAB-dependent+TNF-%CE%B1+expression+in+LPS-activated+macrophages"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DJ.-Y.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DRyu%26aufirst%3DS.%2BY.%26aulast%3DAhn%26aufirst%3DB.%2BW.%26aulast%3DLee%26aufirst%3DC.-K.%26aulast%3DHwang%26aufirst%3DB.%2BY.%26aulast%3DHan%26aufirst%3DS.-B.%26aulast%3DKim%26aufirst%3DY.%26atitle%3DArtemisolide%2520is%2520a%2520typical%2520inhibitor%2520of%2520I%25CE%25BAB%2520kinase%2520%25CE%25B2%2520targeting%2520cysteine-179%2520residue%2520and%2520down-regulates%2520NF-%25CE%25BAB-dependent%2520TNF-%25CE%25B1%2520expression%2520in%2520LPS-activated%2520macrophages%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D361%26spage%3D593%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Wagner, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullally, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, F. A.</span><span> </span><span class="NLM_article-title">Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">2598</span><span class="NLM_x">–</span> <span class="NLM_lpage">2604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=2598-2604&author=T.+M.+Wagnerauthor=J.+E.+Mullallyauthor=F.+A.+Fitzpatrick&title=Reactive+lipid+species+from+cyclooxygenase-2+inactivate+tumor+suppressor+LKB1%2FSTK11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DT.%2BM.%26aulast%3DMullally%26aufirst%3DJ.%2BE.%26aulast%3DFitzpatrick%26aufirst%3DF.%2BA.%26atitle%3DReactive%2520lipid%2520species%2520from%2520cyclooxygenase-2%2520inactivate%2520tumor%2520suppressor%2520LKB1%252FSTK11%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D2598%26epage%3D2604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salaski, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, W.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernan, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F1535-7163.MCT-07-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17989320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWkt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3028-3038&author=L.+Toral-Barzaauthor=W.-G.+Zhangauthor=X.+Huangauthor=L.+A.+McDonaldauthor=E.+J.+Salaskiauthor=L.+R.+Barbieriauthor=W.-D.+Dingauthor=G.+Krishnamurthyauthor=Y.+B.+Huauthor=J.+Lucasauthor=V.+S.+Bernanauthor=P.+Caiauthor=J.+I.+Levinauthor=T.+S.+Mansourauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=K.+Yu&title=Discovery+of+lactoquinomycin+and+related+pyranonaphthoquinones+as+potent+and+allosteric+inhibitors+of+AKT%2FPKB%3A+mechanistic+involvement+of+AKT+catalytic+activation+loop+cysteines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines</span></div><div class="casAuthors">Toral-Barza, Lourdes; Zhang, Wei-Guo; Huang, Xinyi; McDonald, Leonard A.; Salaski, Edward J.; Barbieri, Laurel R.; Ding, Wei-Dong; Krishnamurthy, Girija; Hu, Yong Bo; Lucas, Judy; Bernan, Valerie S.; Cai, Ping; Levin, Jeremy I.; Mansour, Tarek S.; Gibbons, James J.; Abraham, Robert T.; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine kinase AKT/PKB plays a crit. role in cancer and represents a rational target for therapy.  Although efforts in targeting AKT pathway have accelerated in recent years, relatively few small mol. inhibitors of AKT have been reported.  The development of selective AKT inhibitors is further challenged by the extensive conservation of the ATP-binding sites of the AGC kinase family.  In this report, we have conducted a high-throughput screen for inhibitors of activated AKT1.  We have identified lactoquinomycin as a potent inhibitor of AKT kinases (AKT1 IC50, 0.149±0.045 μmol/L).  Biochem. studies implicated a novel irreversible interaction of the inhibitor and AKT involving a crit. cysteine residue(s).  To examine the role of conserved cysteines in the activation loop (T-loop), we studied mutant AKT1 harboring C296A, C310A, and C296A/C310A.  Whereas the ATP-pocket inhibitor, staurosporine, indiscriminately targeted the wild-type and all three mutant-enzymes, the inhibition by lactoquinomycin was drastically diminished in the single mutants C296A and C310A, and completely abolished in the double mutant C296A/C310A.  These data strongly implicate the binding of lactoquinomycin to the T-loop cysteines as crit. for abrogation of catalysis, and define an unprecedented mechanism of AKT inhibition by a small mol.  Lactoquinomycin inhibited cellular AKT substrate phosphorylation induced by growth factor, loss of PTEN, and myristoylated AKT.  The inhibition was substantially attenuated by coexpression of C296A/C310A.  Moreover, lactoquinomycin reduced cellular mammalian target of rapamycin signaling and cap-dependent mRNA translation initiation.  Our results highlight T-loop targeting as a new strategy for the generation of selective AKT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55q72vlKjqrVg90H21EOLACvtfcHk0lj3eqggRG5s3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWkt7fI&md5=160c96c8a11ec01c0c919c4c8361c27a</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0211%26sid%3Dliteratum%253Aachs%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DMcDonald%26aufirst%3DL.%2BA.%26aulast%3DSalaski%26aufirst%3DE.%2BJ.%26aulast%3DBarbieri%26aufirst%3DL.%2BR.%26aulast%3DDing%26aufirst%3DW.-D.%26aulast%3DKrishnamurthy%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DY.%2BB.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DBernan%26aufirst%3DV.%2BS.%26aulast%3DCai%26aufirst%3DP.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520lactoquinomycin%2520and%2520related%2520pyranonaphthoquinones%2520as%2520potent%2520and%2520allosteric%2520inhibitors%2520of%2520AKT%252FPKB%253A%2520mechanistic%2520involvement%2520of%2520AKT%2520catalytic%2520activation%2520loop%2520cysteines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3028%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inesta-Vaquera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niepel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoGrasso, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorger, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective covalent inhibitors of JNK</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=22284361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=140-154&author=T.+Zhangauthor=F.+Inesta-Vaqueraauthor=M.+Niepelauthor=J.+Zhangauthor=S.+B.+Ficarroauthor=T.+Machleidtauthor=T.+Xieauthor=J.+A+Martoauthor=N.+Kimauthor=T.+Simauthor=J.+D.+Laughlinauthor=H.+Parkauthor=P.+V.+LoGrassoauthor=M.+Patricelliauthor=T.+K.+Nomanbhoyauthor=P.+K.+Sorgerauthor=D.+R.+Alessiauthor=N.+S.+Gray&title=Discovery+of+potent+and+selective+covalent+inhibitors+of+JNK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Covalent Inhibitors of JNK</span></div><div class="casAuthors">Zhang, Tinghu; Inesta-Vaquera, Francisco; Niepel, Mario; Zhang, Jianming; Ficarro, Scott B.; Machleidt, Thomas; Xie, Ting; Marto, Jarrod A.; Kim, Nam Doo; Sim, Taebo; Laughlin, John D.; Park, Hajeung; LoGrasso, Philip V.; Patricelli, Matt; Nomanbhoy, Tyzoon K.; Sorger, Peter K.; Alessi, Dario R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-154</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response.  Here, we report the discovery of irreversible inhibitors of JNK1/2/3.  We describe two JNK3 cocrystal structures at 2.60 and 2.97 Å resoln. that show the compds. form covalent bonds with a conserved cysteine residue.  JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue.  Extensive biochem., cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compd. will be broadly useful as a pharmacol. probe of JNK-dependent signal transduction.  Potential lead compds. have also been identified for kinases, including IRAK1, PIK3C3, PIP4K2C, and PIP5K3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXs0FY7FSmt7Vg90H21EOLACvtfcHk0lhfSJOfLWBFrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D&md5=f7d9647fb2be162c637b1d31a778ceb4</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DInesta-Vaquera%26aufirst%3DF.%26aulast%3DNiepel%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DLaughlin%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520covalent%2520inhibitors%2520of%2520JNK%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D140%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Cravatt, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">Activity-based protein profiling: from enzyme chemistry to proteomic chemistry</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1146%2Fannurev.biochem.75.101304.124125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18366325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1ekur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=383-414&author=B.+F.+Cravattauthor=A.+T.+Wrightauthor=J.+W.+Kozarich&title=Activity-based+protein+profiling%3A+from+enzyme+chemistry+to+proteomic+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-based protein profiling: From enzyme chemistry to proteomic chemistry</span></div><div class="casAuthors">Cravatt, Benjamin F.; Wright, Aaron T.; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">383-414</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Genome sequencing projects have provided researchers with a complete inventory of the predicted proteins produced by eukaryotic and prokaryotic organisms.  Assignment of functions to these proteins represents one of the principal challenges for the field of proteomics.  Activity-based protein profiling (ABPP) has emerged as a powerful chem. proteomic strategy to characterize enzyme function directly in native biol. systems on a global scale.  Here, the authors review the basic technol. of ABPP, the enzyme classes addressable by this method, and the biol. discoveries attributable to its application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFnUWDsqzOLVg90H21EOLACvtfcHk0lhfSJOfLWBFrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1ekur0%253D&md5=2f2c471169d2473f7024eeb41d4eaecd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.75.101304.124125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.75.101304.124125%26sid%3Dliteratum%253Aachs%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DWright%26aufirst%3DA.%2BT.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DActivity-based%2520protein%2520profiling%253A%2520from%2520enzyme%2520chemistry%2520to%2520proteomic%2520chemistry%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2008%26volume%3D77%26spage%3D383%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. V.</span><span> </span><span class="NLM_article-title">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17334377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=229-238&author=J.+A.+Blairauthor=D.+Rauhauthor=C.+Kungauthor=C.-H.+Yunauthor=Q.+W.+Fanauthor=H.+Rodeauthor=C.+Zhangauthor=M.+J.+Eckauthor=W.+A.+Weissauthor=K.+V.+Shokat&title=Structure-guided+development+of+affinity+probes+for+tyrosine+kinases+using+chemical+genetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span></div><div class="casAuthors">Blair, Jimmy A.; Rauh, Daniel; Kung, Charles; Yun, Cai-Hong; Fan, Qi-Wen; Rode, Haridas; Zhang, Chao; Eck, Michael J.; Weiss, William A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-mol. inhibitors.  The authors report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue.  Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Cocrystal structures of two irreversible quinazoline inhibitors (I, II) bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Based on these structures, the authors developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe (III) to report the fraction of kinase necessary for cellular signaling, and the authors used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0KmYAm-skrVg90H21EOLACvtfcHk0lhfSJOfLWBFrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D&md5=ce4d24a8d65d7080645bf382cd65dbca</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnchembio866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio866%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DFan%26aufirst%3DQ.%2BW.%26aulast%3DRode%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BV.%26atitle%3DStructure-guided%2520development%2520of%2520affinity%2520probes%2520for%2520tyrosine%2520kinases%2520using%2520chemical%2520genetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadjivassiliou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">A clickable inhibitor reveals context-dependent autoactivation of p90 RSK</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17259979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=156-160&author=M.+S.+Cohenauthor=H.+Hadjivassiliouauthor=J.+Taunton&title=A+clickable+inhibitor+reveals+context-dependent+autoactivation+of+p90+RSK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">A clickable inhibitor reveals context-dependent autoactivation of p90 RSK</span></div><div class="casAuthors">Cohen, Michael S.; Hadjivassiliou, Haralambos; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P90 ribosomal protein S6 kinases (RSKs) integrate upstream signals through two catalytic domains.  Autophosphorylation of Ser386 by the regulatory C-terminal kinase domain (CTD) is thought to be essential for activation of the N-terminal kinase domain (NTD), which phosphorylates multiple downstream targets.  We recently reported fmk, an irreversible inhibitor of the CTD of RSK1 and RSK2.  Here we describe fmk-pa, a propargylamine variant that has improved cellular potency and a 'clickable' tag for assessing the extent and selectivity of covalent RSK modification.  Copper-catalyzed conjugation of an azidoalkyl reporter (the click reaction) revealed that fmk-pa achieves selective and saturable modification of endogenous RSK1 and RSK2 in mammalian cells.  Satg. concns. of fmk-pa inhibited Ser386 phosphorylation and downstream signaling in response to phorbol ester stimulation, but had no effect on RSK activation by lipopolysaccharide.  RSK autoactivation by the CTD is therefore context dependent, which suggests that NTD and CTD inhibitors should have distinct physiol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVn6uut4m1lbVg90H21EOLACvtfcHk0lhfSJOfLWBFrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWgsL4%253D&md5=68f7da1c274678e884ea71d1078b092c</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fnchembio859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio859%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DHadjivassiliou%26aufirst%3DH.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DA%2520clickable%2520inhibitor%2520reveals%2520context-dependent%2520autoactivation%2520of%2520p90%2520RSK%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D156%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josephson, L.</span><span> </span><span class="NLM_article-title">Synthesis and activity of C11-modified wortmannin probes for PI3 kinase</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049714f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Kit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=669-675&author=H.+Yuanauthor=J.+Luoauthor=S.+Fieldauthor=R.+Weisslederauthor=L.+Cantleyauthor=L.+Josephson&title=Synthesis+and+activity+of+C11-modified+wortmannin+probes+for+PI3+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Activity of C11-Modified Wortmannin Probes for PI3 Kinase</span></div><div class="casAuthors">Yuan, Hushan; Luo, Ji; Field, Seth; Weissleder, Ralph; Cantley, Lewis; Josephson, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">669-675</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The key role played by PI3 kinase in cancer, hormone action, and a host of other biol. functions suggests that specific inhibitors whose disposition could be ascertained in vivo would be useful in biol. research or, potentially, for imaging PI3K in a clin. setting.  Wortmannin (Wm, 1) is an inhibitor of PI3 kinase with high specificity for this enzyme.  We synthesized three modified Wm probes, a biotinylated Wm (7a), a 4-hydroxy-3-iodophenylated Wm, which was obtained both unlabeled (7b) and labeled with 125I (8), and a fluoresceinated Wm (7c), through modification at C-11, and evaluated their inhibitive activity as inhibitors of PI3 kinase.  Biotinylated (7a) and 4-hydroxy-3-iodophenylated Wm's (7b) had IC50s for PI3K of 6.11 and 11.02 nM, resp., compared to an IC50 for Wm of 1.63 nM.  Fluoresceinated Wm (7c) lost considerably more activity than the other derivs., with an IC50 of 64.9 nM.  The 125I labeled 4-hydroxy-3-iodophenylated Wm (8) could be detected after reaction with an immunoppt. of PI3 kinase.  The activity of these reporter Wm's is discussed in relationship to earlier findings on the pharmacol. activity of Wm derivs. and the ability of inhibitors to fit into the ATP pocket of PI3 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXkEj722oMLVg90H21EOLACvtfcHk0lh53WljUaQ37A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Kit7o%253D&md5=faa35d07c25d7ea709f3557a15db49dc</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fbc049714f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049714f%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DField%26aufirst%3DS.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DCantley%26aufirst%3DL.%26aulast%3DJosephson%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520activity%2520of%2520C11-modified%2520wortmannin%2520probes%2520for%2520PI3%2520kinase%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D669%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Yee, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fas, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stohlmeyer, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wandless, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cimprich, K. A.</span><span> </span><span class="NLM_article-title">A cell-permeable, activity-based probe for protein and lipid kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">29053</span><span class="NLM_x">–</span> <span class="NLM_lpage">29059</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=29053-29059&author=M.-C.+Yeeauthor=S.+C.+Fasauthor=M.+M.+Stohlmeyerauthor=T.+J.+Wandlessauthor=K.+A.+Cimprich&title=A+cell-permeable%2C+activity-based+probe+for+protein+and+lipid+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DM.-C.%26aulast%3DFas%26aufirst%3DS.%2BC.%26aulast%3DStohlmeyer%26aufirst%3DM.%2BM.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26atitle%3DA%2520cell-permeable%252C%2520activity-based%2520probe%2520for%2520protein%2520and%2520lipid%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D29053%26epage%3D29059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betancort, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gai, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samii, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szardenings, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreder, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">Design and synthesis of AX4697, a bisindolylmaleimide exo-affinity probe that labels protein kinase C alpha and beta</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5955</span><span class="NLM_x">–</span> <span class="NLM_lpage">5958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5955-5958&author=Y.+Liuauthor=J.+Wuauthor=H.+Weissigauthor=J.+M.+Betancortauthor=W.+Z.+Gaiauthor=P.+S.+Leventhalauthor=M.+P.+Patricelliauthor=B.+Samiiauthor=A.+K.+Szardeningsauthor=K.+R.+Shrederauthor=J.+W.+Kozarich&title=Design+and+synthesis+of+AX4697%2C+a+bisindolylmaleimide+exo-affinity+probe+that+labels+protein+kinase+C+alpha+and+beta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DBetancort%26aufirst%3DJ.%2BM.%26aulast%3DGai%26aufirst%3DW.%2BZ.%26aulast%3DLeventhal%26aufirst%3DP.%2BS.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DSamii%26aufirst%3DB.%26aulast%3DSzardenings%26aufirst%3DA.%2BK.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520AX4697%252C%2520a%2520bisindolylmaleimide%2520exo-affinity%2520probe%2520that%2520labels%2520protein%2520kinase%2520C%2520alpha%2520and%2520beta%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5955%26epage%3D5958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Koch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauf, S.</span><span> </span><span class="NLM_article-title">A chemical genetic approach for covalent inhibition of analogue-sensitive aurora kinase</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb200465c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=723-731&author=A.+Kochauthor=H.+R.+Rodeauthor=A.+Richtersauthor=D.+Rauhauthor=S.+Hauf&title=A+chemical+genetic+approach+for+covalent+inhibition+of+analogue-sensitive+aurora+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fcb200465c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb200465c%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DRode%26aufirst%3DH.%2BR.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DHauf%26aufirst%3DS.%26atitle%3DA%2520chemical%2520genetic%2520approach%2520for%2520covalent%2520inhibition%2520of%2520analogue-sensitive%2520aurora%2520kinase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D723%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Garske, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortesi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Chemical genetic strategy for targeting protein kinases based on covalent complementarity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">15046</span><span class="NLM_x">–</span> <span class="NLM_lpage">15062</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=15046-15062&author=A.+L.+Garskeauthor=U.+Petersauthor=A.+T.+Cortesiauthor=J.+L.+Perezauthor=K.+M.+Shokat&title=Chemical+genetic+strategy+for+targeting+protein+kinases+based+on+covalent+complementarity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarske%26aufirst%3DA.%2BL.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DCortesi%26aufirst%3DA.%2BT.%26aulast%3DPerez%26aufirst%3DJ.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DChemical%2520genetic%2520strategy%2520for%2520targeting%2520protein%2520kinases%2520based%2520on%2520covalent%2520complementarity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D15046%26epage%3D15062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterlo, van, W. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">–</span> <span class="NLM_lpage">2566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2557-2566&author=S.+Kl%C3%BCterauthor=J.+R.+Simardauthor=H.+R.+Rodeauthor=C.+Gr%C3%BCtterauthor=V.+Pawarauthor=H.+A.+Raaijmakersauthor=T.+A.+Barfauthor=M.+Rabillerauthor=W.+A.+L.+Otterlo%2C+vanauthor=D.+Rauh&title=Characterization+of+irreversible+kinase+inhibitors+by+directly+detecting+covalent+bond+formation%3A+a+tool+for+dissecting+kinase+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRode%26aufirst%3DH.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DRaaijmakers%26aufirst%3DH.%2BA.%26aulast%3DBarf%26aufirst%3DT.%2BA.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DOtterlo%252C%2Bvan%26aufirst%3DW.%2BA.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520irreversible%2520kinase%2520inhibitors%2520by%2520directly%2520detecting%2520covalent%2520bond%2520formation%253A%2520a%2520tool%2520for%2520dissecting%2520kinase%2520drug%2520resistance%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D2557%26epage%3D2566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Oballa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truchon, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayly, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauret, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crane, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthelette, C.</span><span> </span><span class="NLM_article-title">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">998</span><span class="NLM_x">–</span> <span class="NLM_lpage">1002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.bmcl.2006.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17157022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=998-1002&author=R.+M.+Oballaauthor=J.+F.+Truchonauthor=C.+I.+Baylyauthor=N.+Chauretauthor=S.+Dayauthor=S.+Craneauthor=C.+Berthelette&title=A+generally+applicable+method+for+assessing+the+electrophilicity+and+reactivity+of+diverse+nitrile-containing+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span></div><div class="casAuthors">Oballa, Renata M.; Truchon, Jean-Francois; Bayly, Christopher I.; Chauret, Nathalie; Day, Stephen; Crane, Sheldon; Berthelette, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">998-1002</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nitrile-based inhibitors of cathepsin K have been known for some time and mechanism-of-action studies have demonstrated that cysteinyl proteases interact with nitriles in a reversible fashion.  Three main classes of nitrile-contg. inhibitors have been published in the cathepsin K field: (i) cyanamides, (ii) arom. nitriles, and (iii) aminoacetonitriles.  A computational approach was used to calc. the theor. reactivities of diverse nitriles and this was found to correlate with their extent of reactivity with free cysteine.  Moreover, there is a tentative link between high reactivity with cysteine and the potential to lead to irreversible covalent binding to proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFCCd4sSYvbVg90H21EOLACvtfcHk0li5jlY8OmyfFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D&md5=b8fff00bdd6a746753f8f244d25b0cc8</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DCrane%26aufirst%3DS.%26aulast%3DBerthelette%26aufirst%3DC.%26atitle%3DA%2520generally%2520applicable%2520method%2520for%2520assessing%2520the%2520electrophilicity%2520and%2520reactivity%2520of%2520diverse%2520nitrile-containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D998%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 226 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yi Zhang, Deqin Rong, Bingbing Li, <span class="NLM_string-name hlFld-ContribAuthor">Yuanxiang Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7900-7925. <a href="https://doi.org/10.1021/acs.jmedchem.0c02055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BEpigenetic%252BRegulators%252Bwith%252BCovalent%252BSmall-Molecule%252BInhibitors%26aulast%3DZhang%26aufirst%3DYi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26112020%26date%3D18022021%26volume%3D64%26issue%3D12%26spage%3D7900%26epage%3D7925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Genesis M. Bacani, Jianmei Wei, Leon Chang, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, JieJun Wu, Mark Seierstad, Scott D. Bembenek, Kristi A. Leonard, Alec D. Lebsack, Jennifer D. Venable, <span class="NLM_string-name hlFld-ContribAuthor">James P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 782-790. <a href="https://doi.org/10.1021/acsmedchemlett.1c00044" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BOral%252BAnti-Inflammatory%252BActivity%26aulast%3DTichenor%26aufirst%3DMark%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D28032021%26date%3D05042021%26volume%3D12%26issue%3D5%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria E. Cilento, Karen A. Kirby, <span class="NLM_string-name hlFld-ContribAuthor">Stefan G. Sarafianos</span>. </span><span class="cited-content_cbyCitation_article-title">Avoiding Drug Resistance in HIV Reverse Transcriptase. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3271-3296. <a href="https://doi.org/10.1021/acs.chemrev.0c00967" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00967%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DAvoiding%252BDrug%252BResistance%252Bin%252BHIV%252BReverse%252BTranscriptase%26aulast%3DCilento%26aufirst%3DMaria%2BE.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D06092020%26date%3D28012021%26volume%3D121%26issue%3D6%26spage%3D3271%26epage%3D3296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guoyi Yan, Xinxin Zhong, Chunlan Pu, Lin Yue, Huifang Shan, Suke Lan, Meng Zhou, Xueyan Hou, Jie Yang, Deyu Li, Shilong Fan, <span class="NLM_string-name hlFld-ContribAuthor">Rui Li</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1558-1569. <a href="https://doi.org/10.1021/acs.jmedchem.0c01707" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01707</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01707%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BCysteine%252BLocated%252BOutside%252Bthe%252BActive%252BSite%25253A%252BAn%252BEffective%252BStrategy%252Bfor%252BCovalent%252BALKi%252BDesign%26aulast%3DYan%26aufirst%3DGuoyi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29092020%26date%3D20012021%26volume%3D64%26issue%3D3%26spage%3D1558%26epage%3D1569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robin A. Fairhurst, Thomas Knoepfel, Nicole Buschmann, Catherine Leblanc, Robert Mah, Milen Todorov, Pierre Nimsgern, Sebastien Ripoche, Michel Niklaus, Nicolas Warin, Van Huy Luu, Mario Madoerin, Jasmin Wirth, Diana Graus-Porta, Andreas Weiss, Michael Kiffe, Markus Wartmann, Jacqueline Kinyamu-Akunda, Dario Sterker, Christelle Stamm, Flavia Adler, Alexandra Buhles, Heiko Schadt, Philippe Couttet, Jutta Blank, Inga Galuba, Jörg Trappe, Johannes Voshol, Nils Ostermann, Chao Zou, Jörg Berghausen, Alberto Del Rio Espinola, Wolfgang Jahnke, <span class="NLM_string-name hlFld-ContribAuthor">Pascal Furet</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12542-12573. <a href="https://doi.org/10.1021/acs.jmedchem.0c01019" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01019%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BRoblitinib%252B%252528FGF401%252529%252Bas%252Ba%252BReversible-Covalent%252BInhibitor%252Bof%252Bthe%252BKinase%252BActivity%252Bof%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B4%26aulast%3DFairhurst%26aufirst%3DRobin%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15062020%26date%3D01102020%26date%3D15092020%26volume%3D63%26issue%3D21%26spage%3D12542%26epage%3D12573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bo Li, Yongliang Li, Céline Tomkiewicz-Raulet, Pascal Dao, Daniel Lietha, Expédite Yen-Pon, Zhiyun Du, Xavier Coumoul, Christiane Garbay, Mélanie Etheve-Quelquejeu, <span class="NLM_string-name hlFld-ContribAuthor">Huixiong Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12707-12724. <a href="https://doi.org/10.1021/acs.jmedchem.0c01059" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01059%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BCovalent%252BInhibitors%252Bof%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Bagainst%252BHuman%252BMalignant%252BGlioblastoma%26aulast%3DLi%26aufirst%3DBo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19062020%26date%3D29102020%26volume%3D63%26issue%3D21%26spage%3D12707%26epage%3D12724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adam Birkholz, David J. Kopecky, Laurie P. Volak, Michael D. Bartberger, Yuping Chen, Christopher M. Tegley, Tara Arvedson, John D. McCarter, Christopher Fotsch, <span class="NLM_string-name hlFld-ContribAuthor">Victor J. Cee</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11602-11614. <a href="https://doi.org/10.1021/acs.jmedchem.0c00749" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00749%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BStudy%252Bof%252Bthe%252BGlutathione%252BReactivity%252Bof%252BN-Phenylacrylamides%25253A%252B2.%252BEffects%252Bof%252BAcrylamide%252BSubstitution%26aulast%3DBirkholz%26aufirst%3DAdam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04052020%26date%3D09102020%26date%3D23092020%26volume%3D63%26issue%3D20%26spage%3D11602%26epage%3D11614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fubao Huang, Hangchen Hu, Kai Wang, Chengyuan Peng, Wenwei Xu, Yu Zhang, Jing Gao, Yishen Liu, Hu Zhou, Ruimin Huang, Minjun Li, Jianhua Shen, <span class="NLM_string-name hlFld-ContribAuthor">Yechun Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7052-7065. <a href="https://doi.org/10.1021/acs.jmedchem.0c00372" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00372%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BHighly%252BSelective%252BLipoprotein-Associated%252BPhospholipase%252BA2%252B%252528Lp-PLA2%252529%252BInhibitors%252Bby%252Ba%252BCovalent%252BFragment-Based%252BApproach%26aulast%3DHuang%26aufirst%3DFubao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03032020%26date%3D10062020%26date%3D27052020%26volume%3D63%26issue%3D13%26spage%3D7052%26epage%3D7065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mami Sato, Hirokazu Fuchida, Naoya Shindo, Keiko Kuwata, Keisuke Tokunaga, Guo Xiao-Lin, Ryo Inamori, Keitaro Hosokawa, Kosuke Watari, Tomohiro Shibata, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Mayumi Ono, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1137-1144. <a href="https://doi.org/10.1021/acsmedchemlett.9b00574" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00574%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSelective%252BCovalent%252BTargeting%252Bof%252BMutated%252BEGFR%252528T790M%252529%252Bwith%252BChlorofluoroacetamide-Pyrimidines%26aulast%3DSato%26aufirst%3DMami%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D04122019%26date%3D08042020%26date%3D10042020%26date%3D08042020%26volume%3D11%26issue%3D6%26spage%3D1137%26epage%3D1144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kirsten McAulay, Emily A. Hoyt, Morgan Thomas, Marianne Schimpl, Michael S. Bodnarchuk, Hilary J. Lewis, Derek Barratt, Deepa Bhavsar, David M. Robinson, Michael J. Deery, Derek J. Ogg, Gonçalo J. L. Bernardes, Richard A. Ward, Michael J. Waring, <span class="NLM_string-name hlFld-ContribAuthor">Jason G. Kettle</span>. </span><span class="cited-content_cbyCitation_article-title">Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (23)
                                     , 10358-10372. <a href="https://doi.org/10.1021/jacs.9b13391" title="DOI URL">https://doi.org/10.1021/jacs.9b13391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b13391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b13391%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DAlkynyl%252BBenzoxazines%252Band%252BDihydroquinazolines%252Bas%252BCysteine%252BTargeting%252BCovalent%252BWarheads%252Band%252BTheir%252BApplication%252Bin%252BIdentification%252Bof%252BSelective%252BIrreversible%252BKinase%252BInhibitors%26aulast%3DMcAulay%26aufirst%3DKirsten%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D12122019%26date%3D02062020%26date%3D15052020%26volume%3D142%26issue%3D23%26spage%3D10358%26epage%3D10372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniela Angst, François Gessier, Philipp Janser, Anna Vulpetti, Rudolf Wälchli, Christian Beerli, Amanda Littlewood-Evans, Janet Dawson, Barbara Nuesslein-Hildesheim, Grazyna Wieczorek, Sascha Gutmann, Clemens Scheufler, Alexandra Hinniger, Alfred Zimmerlin, Enrico G. Funhoff, Robert Pulz, <span class="NLM_string-name hlFld-ContribAuthor">Bruno Cenni</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5102-5118. <a href="https://doi.org/10.1021/acs.jmedchem.9b01916" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BLOU064%252B%252528Remibrutinib%252529%25252C%252Ba%252BPotent%252Band%252BHighly%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DAngst%26aufirst%3DDaniela%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19112019%26date%3D04032020%26date%3D21022020%26volume%3D63%26issue%3D10%26spage%3D5102%26epage%3D5118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nobuaki Takahashi, Kensuke Kaneko, <span class="NLM_string-name hlFld-ContribAuthor">Hideaki Kakeya</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis and Antimicrobial Activity of Tumescenamide C and Its Derivatives. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (6)
                                     , 4530-4535. <a href="https://doi.org/10.1021/acs.joc.9b03516" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03516</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03516%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTotal%252BSynthesis%252Band%252BAntimicrobial%252BActivity%252Bof%252BTumescenamide%252BC%252Band%252BIts%252BDerivatives%26aulast%3DTakahashi%26aufirst%3DNobuaki%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D31122019%26date%3D26022020%26date%3D18022020%26volume%3D85%26issue%3D6%26spage%3D4530%26epage%3D4535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Julia Hardick, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 40-51. <a href="https://doi.org/10.1021/acs.jmedchem.9b00964" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BDefines%252BFunction%25253A%252BClinically%252BRelevant%252BMutations%252Bin%252BErbB%252BKinases%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D17062019%26date%3D28082019%26date%3D15082019%26volume%3D63%26issue%3D1%26spage%3D40%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaojing Lin, Yuliana Yosaatmadja, Maria Kalyukina, Martin J. Middleditch, Zhen Zhang, Xiaoyun Lu, Ke Ding, Adam V. Patterson, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. Squire</span>. </span><span class="cited-content_cbyCitation_article-title">Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1180-1186. <a href="https://doi.org/10.1021/acsmedchemlett.9b00196" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00196%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRotational%252BFreedom%25252C%252BSteric%252BHindrance%25252C%252Band%252BProtein%252BDynamics%252BExplain%252BBLU554%252BSelectivity%252Bfor%252Bthe%252BHinge%252BCysteine%252Bof%252BFGFR4%26aulast%3DLin%26aufirst%3DXiaojing%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30042019%26date%3D03072019%26date%3D09072019%26date%3D03072019%26volume%3D10%26issue%3D8%26spage%3D1180%26epage%3D1186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Weiyang Dai, Soma Samanta, Ding Xue, Elyse M. Petrunak, Jeanne A. Stuckey, Yanyan Han, Duxin Sun, Yong Wu, <span class="NLM_string-name hlFld-ContribAuthor">Nouri Neamati</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 3068-3087. <a href="https://doi.org/10.1021/acs.jmedchem.8b01960" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01960</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01960%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252BN-%2525285-Phenylthiazol-2-yl%252529acrylamides%252Bas%252BNovel%252Band%252BPotent%252BGlutathione%252BS-Transferase%252BOmega%252B1%252BInhibitors%26aulast%3DDai%26aufirst%3DWeiyang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D14122018%26date%3D22022019%26date%3D08022019%26volume%3D62%26issue%3D6%26spage%3D3068%26epage%3D3087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dennis Bensinger, Daniel Stubba, Anjali Cremer, Vanessa Kohl, Theresa Waßmer, Johanna Stuckert, Victoria Engemann, Kimberly Stegmaier, Katja Schmitz, <span class="NLM_string-name hlFld-ContribAuthor">Boris Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2428-2446. <a href="https://doi.org/10.1021/acs.jmedchem.8b01714" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01714%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DVirtual%252BScreening%252BIdentifies%252BIrreversible%252BFMS-like%252BTyrosine%252BKinase%252B3%252BInhibitors%252Bwith%252BActivity%252Btoward%252BResistance-Conferring%252BMutations%26aulast%3DBensinger%26aufirst%3DDennis%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D02112018%26date%3D25022019%26date%3D11022019%26volume%3D62%26issue%3D5%26spage%3D2428%26epage%3D2446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Patrik Wolle, Julia Hardick, Shane J. F. Cronin, Julian Engel, Matthias Baumann, Jonas Lategahn, Josef M. Penninger, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the MKK7–JNK (Mitogen-Activated Protein Kinase Kinase 7–c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2843-2848. <a href="https://doi.org/10.1021/acs.jmedchem.9b00102" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00102%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252BMKK7%2525E2%252580%252593JNK%252B%252528Mitogen-Activated%252BProtein%252BKinase%252BKinase%252B7%2525E2%252580%252593c-Jun%252BN-Terminal%252BKinase%252529%252BPathway%252Bwith%252BCovalent%252BInhibitors%26aulast%3DWolle%26aufirst%3DPatrik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16012019%26date%3D21022019%26date%3D15022019%26volume%3D62%26issue%3D5%26spage%3D2843%26epage%3D2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elma Mons, Ineke D. C. Jansen, Jure Loboda, Bjorn R. van Doodewaerd, Jill Hermans, Martijn Verdoes, Constant A. A. van Boeckel, Peter A. van Veelen, Boris Turk, Dusan Turk, <span class="NLM_string-name hlFld-ContribAuthor">Huib Ovaa</span>. </span><span class="cited-content_cbyCitation_article-title">The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (8)
                                     , 3507-3514. <a href="https://doi.org/10.1021/jacs.8b11027" title="DOI URL">https://doi.org/10.1021/jacs.8b11027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b11027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b11027%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DThe%252BAlkyne%252BMoiety%252Bas%252Ba%252BLatent%252BElectrophile%252Bin%252BIrreversible%252BCovalent%252BSmall%252BMolecule%252BInhibitors%252Bof%252BCathepsin%252BK%26aulast%3DMons%26aufirst%3DElma%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D17102018%26date%3D14022019%26date%3D28012019%26volume%3D141%26issue%3D8%26spage%3D3507%26epage%3D3514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kuen-Da Wu, Grace Shiahuy Chen, Jia-Rong Liu, Chen-En Hsieh, <span class="NLM_string-name hlFld-ContribAuthor">Ji-Wang Chern</span>. </span><span class="cited-content_cbyCitation_article-title">Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 22-26. <a href="https://doi.org/10.1021/acsmedchemlett.8b00270" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00270%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAcrylamide%252BFunctional%252BGroup%252BIncorporation%252BImproves%252BDrug-like%252BProperties%25253A%252BAn%252BExample%252Bwith%252BEGFR%252BInhibitors%26aulast%3DWu%26aufirst%3DKuen-Da%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15062018%26date%3D06122018%26date%3D10122018%26date%3D06122018%26volume%3D10%26issue%3D1%26spage%3D22%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wataru Kawahata, Tokiko Asami, Takao Kiyoi, Takayuki Irie, Haruka Taniguchi, Yuko Asamitsu, Tomoko Inoue, Takahiro Miyake, <span class="NLM_string-name hlFld-ContribAuthor">Masaaki Sawa</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (19)
                                     , 8917-8933. <a href="https://doi.org/10.1021/acs.jmedchem.8b01147" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01147%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BAmino-triazine%252BAnalogues%252Bas%252BSelective%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DKawahata%26aufirst%3DWataru%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22072018%26date%3D28092018%26date%3D14092018%26volume%3D61%26issue%3D19%26spage%3D8917%26epage%3D8933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ernest Awoonor-Williams, <span class="NLM_string-name hlFld-ContribAuthor">Christopher N. Rowley</span>. </span><span class="cited-content_cbyCitation_article-title">How Reactive are Druggable Cysteines in Protein Kinases?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (9)
                                     , 1935-1946. <a href="https://doi.org/10.1021/acs.jcim.8b00454" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00454%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DHow%252BReactive%252Bare%252BDruggable%252BCysteines%252Bin%252BProtein%252BKinases%25253F%26aulast%3DAwoonor-Williams%26aufirst%3DErnest%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09072018%26date%3D29082018%26date%3D17082018%26volume%3D58%26issue%3D9%26spage%3D1935%26epage%3D1946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Expédite Yen-Pon, Bo Li, Marta Acebrón-Garcia-de-Eulate, Céline Tomkiewicz-Raulet, John Dawson, Daniel Lietha, Margaret C. Frame, Xavier Coumoul, Christiane Garbay, Mélanie Etheve-Quelquejeu, <span class="NLM_string-name hlFld-ContribAuthor">Huixiong Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (8)
                                     , 2067-2073. <a href="https://doi.org/10.1021/acschembio.8b00250" title="DOI URL">https://doi.org/10.1021/acschembio.8b00250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.8b00250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.8b00250%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DStructure-Based%252BDesign%25252C%252BSynthesis%25252C%252Band%252BCharacterization%252Bof%252Bthe%252BFirst%252BIrreversible%252BInhibitor%252Bof%252BFocal%252BAdhesion%252BKinase%26aulast%3DYen-Pon%26aufirst%3DExp%25C3%25A9dite%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16032018%26date%3D13062018%26date%3D22062018%26date%3D13062018%26volume%3D13%26issue%3D8%26spage%3D2067%26epage%3D2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ye Ding, Dengfeng Li, Chunyong Ding, Pingyuan Wang, Zhiqing Liu, Eric A. Wold, Na Ye, Haiying Chen, Mark A. White, Qiang Shen, <span class="NLM_string-name hlFld-ContribAuthor">Jia Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2737-2752. <a href="https://doi.org/10.1021/acs.jmedchem.7b01514" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01514%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRegio-%252Band%252BStereospecific%252BSynthesis%252Bof%252BOridonin%252BD-Ring%252BAziridinated%252BAnalogues%252Bfor%252Bthe%252BTreatment%252Bof%252BTriple-Negative%252BBreast%252BCancer%252Bvia%252BMediated%252BIrreversible%252BCovalent%252BWarheads%26aulast%3DDing%26aufirst%3DYe%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D11102017%26date%3D20032018%26date%3D12032018%26volume%3D61%26issue%3D7%26spage%3D2737%26epage%3D2752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomoya  Sameshima</span>, <span class="hlFld-ContribAuthor ">Takeshi  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Osamu  Sano</span>, <span class="hlFld-ContribAuthor ">Satoshi  Sogabe</span>, <span class="hlFld-ContribAuthor ">Shigeru  Igaki</span>, <span class="hlFld-ContribAuthor ">Kotaro  Sakamoto</span>, <span class="hlFld-ContribAuthor ">Koh  Ida</span>, <span class="hlFld-ContribAuthor ">Mika  Gotou</span>, <span class="hlFld-ContribAuthor ">Yasuhiro  Imaeda</span>, <span class="hlFld-ContribAuthor ">Junichi  Sakamoto</span>, and <span class="hlFld-ContribAuthor ">Ikuo  Miyahisa</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein–Protein Interaction Interface. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2018,</strong> <em>57 </em>
                                    (8)
                                     , 1369-1379. <a href="https://doi.org/10.1021/acs.biochem.7b00732" title="DOI URL">https://doi.org/10.1021/acs.biochem.7b00732</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.7b00732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.7b00732%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DDiscovery%252Bof%252Ban%252BIrreversible%252Band%252BCell-Active%252BBCL6%252BInhibitor%252BSelectively%252BTargeting%252BCys53%252BLocated%252Bat%252Bthe%252BProtein%2525E2%252580%252593Protein%252BInteraction%252BInterface%26aulast%3DSameshima%26aufirst%3DTomoya%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D31072017%26date%3D20122017%26date%3D07022018%26date%3D27022018%26date%3D02012018%26volume%3D57%26issue%3D8%26spage%3D1369%26epage%3D1379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ken A.  Brameld</span>, <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>, <span class="hlFld-ContribAuthor ">Erik  Verner</span>, <span class="hlFld-ContribAuthor ">Eleni  Venetsanakos</span>, <span class="hlFld-ContribAuthor ">J. Michael  Bradshaw</span>, <span class="hlFld-ContribAuthor ">Vernon T.  Phan</span>, <span class="hlFld-ContribAuthor ">Danny  Tam</span>, <span class="hlFld-ContribAuthor ">Kwan  Leung</span>, <span class="hlFld-ContribAuthor ">Jin  Shu</span>, <span class="hlFld-ContribAuthor ">Jacob  LaStant</span>, <span class="hlFld-ContribAuthor ">David G.  Loughhead</span>, <span class="hlFld-ContribAuthor ">Tony  Ton</span>, <span class="hlFld-ContribAuthor ">Dane E.  Karr</span>, <span class="hlFld-ContribAuthor ">Mary E.  Gerritsen</span>, <span class="hlFld-ContribAuthor ">David M.  Goldstein</span>, and <span class="hlFld-ContribAuthor ">Jens Oliver  Funk</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (15)
                                     , 6516-6527. <a href="https://doi.org/10.1021/acs.jmedchem.7b00360" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BIrreversible%252BCovalent%252BFGFR%252BInhibitor%252B8-%2525283-%2525284-Acryloylpiperazin-1-yl%252529propyl%252529-6-%2525282%25252C6-dichloro-3%25252C5-dimethoxyphenyl%252529-2-%252528methylamino%252529pyrido%25255B2%25252C3-d%25255Dpyrimidin-7%2525288H%252529-one%252B%252528PRN1371%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumors%26aulast%3DBrameld%26aufirst%3DKen%2BA.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07032017%26date%3D25072017%26date%3D10082017%26date%3D30062017%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven  Smith</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Debjit  Basu</span>, <span class="hlFld-ContribAuthor ">Simone  Eppmann</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Characterization of Covalent-Reversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2017,</strong> <em>2 </em>
                                    (4)
                                     , 1563-1575. <a href="https://doi.org/10.1021/acsomega.7b00157" title="DOI URL">https://doi.org/10.1021/acsomega.7b00157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.7b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.7b00157%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DCharacterization%252Bof%252BCovalent-Reversible%252BEGFR%252BInhibitors%26aulast%3DSmith%26aufirst%3DSteven%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D10022017%26date%3D03042017%26date%3D30042017%26volume%3D2%26issue%3D4%26spage%3D1563%26epage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Spencer  Bliven</span>, <span class="hlFld-ContribAuthor ">Lei  Xie</span>, and <span class="hlFld-ContribAuthor ">Philip E.  Bourne</span>  . </span><span class="cited-content_cbyCitation_article-title">Determining Cysteines Available for Covalent Inhibition Across the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 2879-2889. <a href="https://doi.org/10.1021/acs.jmedchem.6b01815" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01815%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDetermining%252BCysteines%252BAvailable%252Bfor%252BCovalent%252BInhibition%252BAcross%252Bthe%252BHuman%252BKinome%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D13122016%26date%3D04042017%26date%3D13042017%26date%3D22032017%26volume%3D60%26issue%3D7%26spage%3D2879%26epage%3D2889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Behenna</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Theodore O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">T. Eric  Ballard</span>, <span class="hlFld-ContribAuthor ">Louise  Bernier</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle  Hemkens</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">James  Solowiej</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Paolo  Vicini</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Longqing  Liu</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Chengyi  Zhang</span>, and <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 3002-3019. <a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%252528%2525283R%25252C4R%252529-4-Fluoro-1-%2525286-%252528%2525283-methoxy-1-methyl-1H-pyrazol-4-yl%252529amino%252529-9-methyl-9H-purin-2-yl%252529pyrrolidine-3-yl%252529acrylamide%252B%252528PF-06747775%252529%252Bthrough%252BStructure-Based%252BDrug%252BDesign%25253A%252BA%252BHigh%252BAffinity%252BIrreversible%252BInhibitor%252BTargeting%252BOncogenic%252BEGFR%252BMutants%252Bwith%252BSelectivity%252Bover%252BWild-Type%252BEGFR%26aulast%3DPlanken%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11012017%26date%3D29032017%26date%3D13042017%26date%3D13032017%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Puminan  Punthasee</span>, <span class="hlFld-ContribAuthor ">Adrian R.  Laciak</span>, <span class="hlFld-ContribAuthor ">Andrea H.  Cummings</span>, <span class="hlFld-ContribAuthor ">Kasi Viswanatharaju  Ruddraraju</span>, <span class="hlFld-ContribAuthor ">Sarah M.  Lewis</span>, <span class="hlFld-ContribAuthor ">Roman  Hillebrand</span>, <span class="hlFld-ContribAuthor ">Harkewal  Singh</span>, <span class="hlFld-ContribAuthor ">John J.  Tanner</span>, and <span class="hlFld-ContribAuthor ">Kent S.  Gates</span>  . </span><span class="cited-content_cbyCitation_article-title">Covalent Allosteric Inactivation of Protein Tyrosine Phosphatase 1B (PTP1B) by an Inhibitor–Electrophile Conjugate. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2017,</strong> <em>56 </em>
                                    (14)
                                     , 2051-2060. <a href="https://doi.org/10.1021/acs.biochem.7b00151" title="DOI URL">https://doi.org/10.1021/acs.biochem.7b00151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.7b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.7b00151%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DCovalent%252BAllosteric%252BInactivation%252Bof%252BProtein%252BTyrosine%252BPhosphatase%252B1B%252B%252528PTP1B%252529%252Bby%252Ban%252BInhibitor%2525E2%252580%252593Electrophile%252BConjugate%26aulast%3DPunthasee%26aufirst%3DPuminan%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D19022017%26date%3D03042017%26date%3D11042017%26date%3D27032017%26volume%3D56%26issue%3D14%26spage%3D2051%26epage%3D2060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofei  Liang</span>, <span class="hlFld-ContribAuthor ">Fengchao  Lv</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Weili  Miao</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shanchuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zi  Ye</span>, <span class="hlFld-ContribAuthor ">Chu  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Yinsheng  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, and <span class="hlFld-ContribAuthor ">Jing  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (5)
                                     , 1793-1816. <a href="https://doi.org/10.1021/acs.jmedchem.6b01413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%252528%2525283-Acrylamido-4-methylphenyl%252529amino%252529-N-%2525282-methyl-5-%2525283%25252C4%25252C5-trimethoxybenzamido%252529phenyl%252529-4-%252528methylamino%252529pyrimidine-5-carboxamide%252B%252528CHMFL-BMX-078%252529%252Bas%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BType%252BII%252BIrreversible%252BBone%252BMarrow%252BKinase%252Bin%252Bthe%252BX%252BChromosome%252B%252528BMX%252529%252BKinase%252BInhibitor%26aulast%3DLiang%26aufirst%3DXiaofei%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D22092016%26date%3D14022017%26date%3D09032017%26date%3D31012017%26volume%3D60%26issue%3D5%26spage%3D1793%26epage%3D1816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul A.  Jackson</span>, <span class="hlFld-ContribAuthor ">John C.  Widen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Harki</span>, and <span class="hlFld-ContribAuthor ">Kay M.  Brummond</span>  . </span><span class="cited-content_cbyCitation_article-title">Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (3)
                                     , 839-885. <a href="https://doi.org/10.1021/acs.jmedchem.6b00788" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00788%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252BModifiers%25253A%252BA%252BChemical%252BPerspective%252Bon%252Bthe%252BReactivity%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BCarbonyls%252Bwith%252BThiols%252Bvia%252BHetero-Michael%252BAddition%252BReactions%26aulast%3DJackson%26aufirst%3DPaul%2BA.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D25052016%26date%3D20122016%26date%3D09022017%26volume%3D60%26issue%3D3%26spage%3D839%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aline Dantas  de Araujo</span>, <span class="hlFld-ContribAuthor ">Junxian  Lim</span>, <span class="hlFld-ContribAuthor ">Andrew C.  Good</span>, <span class="hlFld-ContribAuthor ">Renato T.  Skerlj</span>, and <span class="hlFld-ContribAuthor ">David P.  Fairlie</span>  . </span><span class="cited-content_cbyCitation_article-title">Electrophilic Helical Peptides That Bond Covalently, Irreversibly, and Selectively in a Protein–Protein Interaction Site. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (1)
                                     , 22-26. <a href="https://doi.org/10.1021/acsmedchemlett.6b00395" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00395%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DElectrophilic%252BHelical%252BPeptides%252BThat%252BBond%252BCovalently%25252C%252BIrreversibly%25252C%252Band%252BSelectively%252Bin%252Ba%252BProtein%2525E2%252580%252593Protein%252BInteraction%252BSite%26aulast%3Dde%2BAraujo%26aufirst%3DAline%2BDantas%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D07102016%26date%3D15112016%26date%3D17112016%26date%3D12012017%26date%3D15112016%26volume%3D8%26issue%3D1%26spage%3D22%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott B.  Ficarro</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Browne</span>, <span class="hlFld-ContribAuthor ">Joseph D.  Card</span>, <span class="hlFld-ContribAuthor ">William M.  Alexander</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Eunyoung  Park</span>, <span class="hlFld-ContribAuthor ">Randall  McNally</span>, <span class="hlFld-ContribAuthor ">Sirano  Dhe-Paganon</span>, <span class="hlFld-ContribAuthor ">Hyuk-Soo  Seo</span>, <span class="hlFld-ContribAuthor ">Ilaria  Lamberto</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>, <span class="hlFld-ContribAuthor ">Sara J.  Buhrlage</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, and <span class="hlFld-ContribAuthor ">Jarrod A.  Marto</span>  . </span><span class="cited-content_cbyCitation_article-title">Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2016,</strong> <em>88 </em>
                                    (24)
                                     , 12248-12254. <a href="https://doi.org/10.1021/acs.analchem.6b03394" title="DOI URL">https://doi.org/10.1021/acs.analchem.6b03394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.analchem.6b03394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.analchem.6b03394%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DLeveraging%252BGas-Phase%252BFragmentation%252BPathways%252Bfor%252BImproved%252BIdentification%252Band%252BSelective%252BDetection%252Bof%252BTargets%252BModified%252Bby%252BCovalent%252BProbes%26aulast%3DFicarro%26aufirst%3DScott%2BB.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D29082016%26date%3D07112016%26date%3D30112016%26date%3D20122016%26volume%3D88%26issue%3D24%26spage%3D12248%26epage%3D12254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Serge  Christmann-Franck</span>, <span class="hlFld-ContribAuthor ">Gerard J. P.  van Westen</span>, <span class="hlFld-ContribAuthor ">George  Papadatos</span>, <span class="hlFld-ContribAuthor ">Fanny  Beltran Escudie</span>, <span class="hlFld-ContribAuthor ">Alexander  Roberts</span>, <span class="hlFld-ContribAuthor ">John P.  Overington</span>, and <span class="hlFld-ContribAuthor ">Daniel  Domine</span>  . </span><span class="cited-content_cbyCitation_article-title">Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound–Kinase Activities: A Way toward Selective Promiscuity by Design?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (9)
                                     , 1654-1675. <a href="https://doi.org/10.1021/acs.jcim.6b00122" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00122%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DUnprecedently%252BLarge-Scale%252BKinase%252BInhibitor%252BSet%252BEnabling%252Bthe%252BAccurate%252BPrediction%252Bof%252BCompound%2525E2%252580%252593Kinase%252BActivities%25253A%252BA%252BWay%252Btoward%252BSelective%252BPromiscuity%252Bby%252BDesign%25253F%26aulast%3DChristmann-Franck%26aufirst%3DSerge%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03032016%26date%3D11082016%26date%3D26092016%26date%3D02082016%26volume%3D56%26issue%3D9%26spage%3D1654%26epage%3D1675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Danfeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Haozhong  Tian</span>, <span class="hlFld-ContribAuthor ">Yu  Jiao</span>, <span class="hlFld-ContribAuthor ">Zhihao  Shi</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Anyang  Xu</span>, <span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Lingfeng  Yin</span>, <span class="hlFld-ContribAuthor ">Weineng  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, and <span class="hlFld-ContribAuthor ">Yadong  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (9)
                                     , 3106-3118. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00302" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00302%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DIdentification%252Bof%252BCovalent%252BBinding%252BSites%252BTargeting%252BCysteines%252BBased%252Bon%252BComputational%252BApproaches%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05042016%26date%3D02082016%26date%3D07072016%26date%3D10082016%26date%3D06092016%26date%3D02082016%26volume%3D13%26issue%3D9%26spage%3D3106%26epage%3D3118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Sangita  Baxi</span>, <span class="hlFld-ContribAuthor ">Doug  Behenna</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Jun Li  Feng</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Hemkens</span>, <span class="hlFld-ContribAuthor ">Amy  Jackson-Fisher</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Ted O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Susan  Kephart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>, <span class="hlFld-ContribAuthor ">Beth  Lunney</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Liu</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Martha A.  Ornelas</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Shijian  Ren</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neal  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Jim  Solowiej</span>, <span class="hlFld-ContribAuthor ">Scott  Sutton</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">William  Vernier</span>, <span class="hlFld-ContribAuthor ">Marlena  Walls</span>, <span class="hlFld-ContribAuthor ">Shuiwang  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>, <span class="hlFld-ContribAuthor ">Min-Jean  Yin</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, and <span class="hlFld-ContribAuthor ">John C.  Kath</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 2005-2024. <a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25257B%2525283R%25252C4R%252529-3-%25255B%252528%25257B5-Chloro-2-%25255B%2525281-methyl-1H-pyrazol-4-yl%252529amino%25255D-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%25257Doxy%252529methyl%25255D-4-methoxypyrrolidin-1-yl%25257Dprop-2-en-1-one%252B%252528PF-06459988%252529%25252C%252Ba%252BPotent%25252C%252BWT%252BSparing%25252C%252BIrreversible%252BInhibitor%252Bof%252BT790M-Containing%252BEGFR%252BMutants%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17102015%26date%3D28012016%26date%3D10032016%26date%3D12012016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (1)
                                     , 2-5. <a href="https://doi.org/10.1021/acsmedchemlett.5b00475" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00475</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHope%252Band%252BDisappointment%25253A%252BCovalent%252BInhibitors%252Bto%252BOvercome%252BDrug%252BResistance%252Bin%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DEngel%26aufirst%3DJulian%26date%3D2016%26date%3D2015%26date%3D14122015%26date%3D18122015%26date%3D14012016%26volume%3D7%26issue%3D1%26spage%3D2%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor J.  Cee</span>, <span class="hlFld-ContribAuthor ">Laurie P.  Volak</span>, <span class="hlFld-ContribAuthor ">Yuping  Chen</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Chris  Tegley</span>, <span class="hlFld-ContribAuthor ">Tara  Arvedson</span>, <span class="hlFld-ContribAuthor ">John  McCarter</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>, and <span class="hlFld-ContribAuthor ">Christopher  Fotsch</span>  . </span><span class="cited-content_cbyCitation_article-title">Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (23)
                                     , 9171-9178. <a href="https://doi.org/10.1021/acs.jmedchem.5b01018" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01018%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BStudy%252Bof%252Bthe%252BGlutathione%252B%252528GSH%252529%252BReactivity%252Bof%252BN-Arylacrylamides%25253A%252B1.%252BEffects%252Bof%252BAryl%252BSubstitution%26aulast%3DCee%26aufirst%3DVictor%2BJ.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D29062015%26date%3D18112015%26date%3D10122015%26volume%3D58%26issue%3D23%26spage%3D9171%26epage%3D9178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">André  Richters</span>, <span class="hlFld-ContribAuthor ">Matthäus  Getlik</span>, <span class="hlFld-ContribAuthor ">Stefano  Tomassi</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Martin  Termathe</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Christian  Becker</span>, <span class="hlFld-ContribAuthor ">Svenja  Mayer-Wrangowski</span>, <span class="hlFld-ContribAuthor ">Christian  Grütter</span>, <span class="hlFld-ContribAuthor ">Niklas  Uhlenbrock</span>, <span class="hlFld-ContribAuthor ">Jasmin  Krüll</span>, <span class="hlFld-ContribAuthor ">Niklas  Schaumann</span>, <span class="hlFld-ContribAuthor ">Simone  Eppmann</span>, <span class="hlFld-ContribAuthor ">Patrick  Kibies</span>, <span class="hlFld-ContribAuthor ">Franziska  Hoffgaard</span>, <span class="hlFld-ContribAuthor ">Jochen  Heil</span>, <span class="hlFld-ContribAuthor ">Sascha  Menninger</span>, <span class="hlFld-ContribAuthor ">Sandra  Ortiz-Cuaran</span>, <span class="hlFld-ContribAuthor ">Johannes M.  Heuckmann</span>, <span class="hlFld-ContribAuthor ">Verena  Tinnefeld</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Martin L.  Sos</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Roman K.  Thomas</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Kast</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (17)
                                     , 6844-6863. <a href="https://doi.org/10.1021/acs.jmedchem.5b01082" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BDrug%252BResistance%252Bin%252BEGFR%252Bwith%252BCovalent%252BInhibitors%25253A%252BA%252BStructure-Based%252BDesign%252BApproach%26aulast%3DEngel%26aufirst%3DJulian%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D16042015%26date%3D31082015%26date%3D10092015%26date%3D14082015%26volume%3D58%26issue%3D17%26spage%3D6844%26epage%3D6863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Kate  Ashton</span>, <span class="hlFld-ContribAuthor ">James  Brown</span>, <span class="hlFld-ContribAuthor ">Jian Jeffrey  Chen</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Fang-Tsao  Hong</span>, <span class="hlFld-ContribAuthor ">Essa  Hu-Harrington</span>, <span class="hlFld-ContribAuthor ">Tom  Nguyen</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean, Jr.</span>, <span class="hlFld-ContribAuthor ">Seifu  Tadesse</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Michele  Kubryk</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhan</span>, <span class="hlFld-ContribAuthor ">Keegan  Cooke</span>, <span class="hlFld-ContribAuthor ">Petia  Mitchell</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Faye  Hsieh</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Nataraj  Kalyanaraman</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Edward K.  Lobenhofer</span>, <span class="hlFld-ContribAuthor ">Dina A.  Andrews</span>, <span class="hlFld-ContribAuthor ">Nancy  Everds</span>, <span class="hlFld-ContribAuthor ">Roberto  Guzman</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Parsons</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hedley</span>, <span class="hlFld-ContribAuthor ">Jason  Tedrow</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Thiel</span>, <span class="hlFld-ContribAuthor ">Matthew  Potter</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Pedro J.  Beltran</span>, and <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 987-992. <a href="https://doi.org/10.1021/acsmedchemlett.5b00193" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00193%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOxopyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08052015%26date%3D27072015%26date%3D31072015%26date%3D10092015%26date%3D27072015%26volume%3D6%26issue%3D9%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minsoo  Song</span>  . </span><span class="cited-content_cbyCitation_article-title">Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (9)
                                     , 3672-3681. <a href="https://doi.org/10.1021/jm501464c" title="DOI URL">https://doi.org/10.1021/jm501464c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501464c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501464c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Bin%252BDiscovery%252Bof%252BKIF5B-RET%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DMinsoo%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D24092014%26date%3D04022015%26date%3D14052015%26date%3D27012015%26volume%3D58%26issue%3D9%26spage%3D3672%26epage%3D3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicole C.  Goodwin</span>, <span class="hlFld-ContribAuthor ">Giovanni  Cianchetta</span>, <span class="hlFld-ContribAuthor ">Hugh A.  Burgoon</span>, <span class="hlFld-ContribAuthor ">Jason  Healy</span>, <span class="hlFld-ContribAuthor ">Ross  Mabon</span>, <span class="hlFld-ContribAuthor ">Eric D.  Strobel</span>, <span class="hlFld-ContribAuthor ">Jason  Allen</span>, <span class="hlFld-ContribAuthor ">Shuli  Wang</span>, <span class="hlFld-ContribAuthor ">Brian D.  Hamman</span>, and <span class="hlFld-ContribAuthor ">David B.  Rawlins</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (1)
                                     , 53-57. <a href="https://doi.org/10.1021/ml500242y" title="DOI URL">https://doi.org/10.1021/ml500242y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500242y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500242y%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BType%252BIII%252BInhibitor%252Bof%252BLIM%252BKinase%252B2%252BThat%252BBinds%252Bin%252Ba%252BDFG-Out%252BConformation%26aulast%3DGoodwin%26aufirst%3DNicole%2BC.%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D10062014%26date%3D07082014%26date%3D12082014%26date%3D08012015%26date%3D07082014%26volume%3D6%26issue%3D1%26spage%3D53%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Abramite</span>, <span class="hlFld-ContribAuthor ">Dennis P.  Anderson</span>, <span class="hlFld-ContribAuthor ">Ann  Aulabaugh</span>, <span class="hlFld-ContribAuthor ">Upendra P.  Dahal</span>, <span class="hlFld-ContribAuthor ">Adam M.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Chao  Li</span>, <span class="hlFld-ContribAuthor ">Justin  Montgomery</span>, <span class="hlFld-ContribAuthor ">Stacey R.  Oppenheimer</span>, <span class="hlFld-ContribAuthor ">Tim  Ryder</span>, <span class="hlFld-ContribAuthor ">Brandon P.  Schuff</span>, <span class="hlFld-ContribAuthor ">Daniel P.  Uccello</span>, <span class="hlFld-ContribAuthor ">Gregory S.  Walker</span>, <span class="hlFld-ContribAuthor ">Yan  Wu</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Jinshan M.  Chen</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Hayward</span>, <span class="hlFld-ContribAuthor ">Mark C.  Noe</span>, <span class="hlFld-ContribAuthor ">R. Scott  Obach</span>, <span class="hlFld-ContribAuthor ">Laurence  Philippe</span>, <span class="hlFld-ContribAuthor ">Veerabahu  Shanmugasundaram</span>, <span class="hlFld-ContribAuthor ">Michael J.  Shapiro</span>, <span class="hlFld-ContribAuthor ">Jeremy  Starr</span>, <span class="hlFld-ContribAuthor ">Justin  Stroh</span>, and <span class="hlFld-ContribAuthor ">Ye  Che</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (23)
                                     , 10072-10079. <a href="https://doi.org/10.1021/jm501412a" title="DOI URL">https://doi.org/10.1021/jm501412a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501412a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChemical%252Band%252BComputational%252BMethods%252Bfor%252Bthe%252BCharacterization%252Bof%252BCovalent%252BReactive%252BGroups%252Bfor%252Bthe%252BProspective%252BDesign%252Bof%252BIrreversible%252BInhibitors%26aulast%3DFlanagan%26aufirst%3DMark%2BE.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D17092014%26date%3D26112014%26date%3D11122014%26date%3D06112014%26volume%3D57%26issue%3D23%26spage%3D10072%26epage%3D10079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangxin  Xia</span>, <span class="hlFld-ContribAuthor ">Wenteng  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiaan  Shao</span>, <span class="hlFld-ContribAuthor ">Yong  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Leduo  Zhang</span>, <span class="hlFld-ContribAuthor ">Weixing  Qi</span>, <span class="hlFld-ContribAuthor ">Xing  Sun</span>, <span class="hlFld-ContribAuthor ">Bojun  Li</span>, <span class="hlFld-ContribAuthor ">Zhixiong  Xiang</span>, <span class="hlFld-ContribAuthor ">Chen  Ma</span>, <span class="hlFld-ContribAuthor ">Jia  Xu</span>, <span class="hlFld-ContribAuthor ">Hailin  Deng</span>, <span class="hlFld-ContribAuthor ">Yufeng  Li</span>, <span class="hlFld-ContribAuthor ">Ping  Li</span>, <span class="hlFld-ContribAuthor ">Hong  Miao</span>, <span class="hlFld-ContribAuthor ">Jiansheng  Han</span>, <span class="hlFld-ContribAuthor ">Yanjun  Liu</span>, <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>, and <span class="hlFld-ContribAuthor ">Yongping  Yu</span>  . </span><span class="cited-content_cbyCitation_article-title">A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (23)
                                     , 9889-9900. <a href="https://doi.org/10.1021/jm5014659" title="DOI URL">https://doi.org/10.1021/jm5014659</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5014659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5014659%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BChemical%252BTuned%252BStrategy%252Bto%252BDevelop%252BNovel%252BIrreversible%252BEGFR-TK%252BInhibitors%252Bwith%252BImproved%252BSafety%252Band%252BPharmacokinetic%252BProfiles%26aulast%3DXia%26aufirst%3DGuangxin%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D01072014%26date%3D01122014%26date%3D11122014%26date%3D19112014%26volume%3D57%26issue%3D23%26spage%3D9889%26epage%3D9900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dora  Toledo Warshaviak</span>, <span class="hlFld-ContribAuthor ">Gali  Golan</span>, <span class="hlFld-ContribAuthor ">Kenneth W.  Borrelli</span>, <span class="hlFld-ContribAuthor ">Kai  Zhu</span>, and <span class="hlFld-ContribAuthor ">Ori  Kalid</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2014,</strong> <em>54 </em>
                                    (7)
                                     , 1941-1950. <a href="https://doi.org/10.1021/ci500175r" title="DOI URL">https://doi.org/10.1021/ci500175r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500175r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500175r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DStructure-Based%252BVirtual%252BScreening%252BApproach%252Bfor%252BDiscovery%252Bof%252BCovalently%252BBound%252BLigands%26aulast%3DToledo%2BWarshaviak%26aufirst%3DDora%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18032014%26date%3D26062014%26date%3D28072014%26date%3D16062014%26volume%3D54%26issue%3D7%26spage%3D1941%26epage%3D1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xitao  Li</span>, <span class="hlFld-ContribAuthor ">Yingying  Zuo</span>, <span class="hlFld-ContribAuthor ">Guanghui  Tang</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Yiqing  Zhou</span>, <span class="hlFld-ContribAuthor ">Xueying  Wang</span>, <span class="hlFld-ContribAuthor ">Tianlin  Guo</span>, <span class="hlFld-ContribAuthor ">Mengying  Xia</span>, <span class="hlFld-ContribAuthor ">Ning  Ding</span>, and <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (12)
                                     , 5112-5128. <a href="https://doi.org/10.1021/jm4017762" title="DOI URL">https://doi.org/10.1021/jm4017762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4017762%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BSeries%252Bof%252B2%25252C5-Diaminopyrimidine%252BCovalent%252BIrreversible%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252Bin%252BVivo%252BAntitumor%252BActivity%26aulast%3DLi%26aufirst%3DXitao%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D16112013%26date%3D10062014%26date%3D26062014%26volume%3D57%26issue%3D12%26spage%3D5112%26epage%3D5128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Liu</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, and <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>  . </span><span class="cited-content_cbyCitation_article-title">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2014,</strong> <em>9 </em>
                                    (6)
                                     , 1230-1241. <a href="https://doi.org/10.1021/cb500129t" title="DOI URL">https://doi.org/10.1021/cb500129t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb500129t%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DExploration%252Bof%252BType%252BII%252BBinding%252BMode%25253A%252BA%252BPrivileged%252BApproach%252Bfor%252BKinase%252BInhibitor%252BFocused%252BDrug%252BDiscovery%25253F%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D19022014%26date%3D14042014%26date%3D29042014%26date%3D20062014%26date%3D14042014%26volume%3D9%26issue%3D6%26spage%3D1230%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thuy  Nguyen</span>, <span class="hlFld-ContribAuthor ">Robert A.  Coover</span>, <span class="hlFld-ContribAuthor ">Jenson  Verghese</span>, <span class="hlFld-ContribAuthor ">Richard G.  Moran</span>, and <span class="hlFld-ContribAuthor ">Keith C.  Ellis</span>  . </span><span class="cited-content_cbyCitation_article-title">Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (5)
                                     , 462-467. <a href="https://doi.org/10.1021/ml500088x" title="DOI URL">https://doi.org/10.1021/ml500088x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500088x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500088x%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPhenylalanine-Based%252BInactivator%252Bof%252BAKT%252BKinase%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%26aulast%3DNguyen%26aufirst%3DThuy%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D29082013%26date%3D07032014%26date%3D12032014%26date%3D08052014%26date%3D07032014%26volume%3D5%26issue%3D5%26spage%3D462%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tony  Taldone</span>, <span class="hlFld-ContribAuthor ">Yanlong  Kang</span>, <span class="hlFld-ContribAuthor ">Hardik J.  Patel</span>, <span class="hlFld-ContribAuthor ">Maulik R.  Patel</span>, <span class="hlFld-ContribAuthor ">Pallav D.  Patel</span>, <span class="hlFld-ContribAuthor ">Anna  Rodina</span>, <span class="hlFld-ContribAuthor ">Yogita  Patel</span>, <span class="hlFld-ContribAuthor ">Alexander  Gozman</span>, <span class="hlFld-ContribAuthor ">Ronnie  Maharaj</span>, <span class="hlFld-ContribAuthor ">Cristina C.  Clement</span>, <span class="hlFld-ContribAuthor ">Alvin  Lu</span>, <span class="hlFld-ContribAuthor ">Jason C.  Young</span>, and <span class="hlFld-ContribAuthor ">Gabriela  Chiosis</span>  . </span><span class="cited-content_cbyCitation_article-title">Heat Shock Protein 70 Inhibitors. 2. 2,5′-Thiodipyrimidines, 5-(Phenylthio)pyrimidines, 2-(Pyridin-3-ylthio)pyrimidines, and 3-(Phenylthio)pyridines as Reversible Binders to an Allosteric Site on Heat Shock Protein 70. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (4)
                                     , 1208-1224. <a href="https://doi.org/10.1021/jm401552y" title="DOI URL">https://doi.org/10.1021/jm401552y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401552y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401552y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeat%252BShock%252BProtein%252B70%252BInhibitors.%252B2.%252B2%25252C5%2525E2%252580%2525B2-Thiodipyrimidines%25252C%252B5-%252528Phenylthio%252529pyrimidines%25252C%252B2-%252528Pyridin-3-ylthio%252529pyrimidines%25252C%252Band%252B3-%252528Phenylthio%252529pyridines%252Bas%252BReversible%252BBinders%252Bto%252Ban%252BAllosteric%252BSite%252Bon%252BHeat%252BShock%252BProtein%252B70%26aulast%3DTaldone%26aufirst%3DTony%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D04102013%26date%3D18022014%26date%3D27022014%26volume%3D57%26issue%3D4%26spage%3D1208%26epage%3D1224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (21)
                                     , 8803-8813. <a href="https://doi.org/10.1021/jm4012388" title="DOI URL">https://doi.org/10.1021/jm4012388</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4012388%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252B2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidinyl%252BDerivatives%252Bas%252BNew%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252Bwith%252BImproved%252BPharmacokinetic%252BProperties%26aulast%3DXu%26aufirst%3DShilin%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D09082013%26date%3D31102013%26date%3D14112013%26date%3D14102013%26volume%3D56%26issue%3D21%26spage%3D8803%26epage%3D8813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony J.  Wilson</span>, <span class="hlFld-ContribAuthor ">Jeffrey K.  Kerns</span>, <span class="hlFld-ContribAuthor ">James F.  Callahan</span>, and <span class="hlFld-ContribAuthor ">Christopher J.  Moody</span>  . </span><span class="cited-content_cbyCitation_article-title">Keap Calm, and Carry on Covalently. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (19)
                                     , 7463-7476. <a href="https://doi.org/10.1021/jm400224q" title="DOI URL">https://doi.org/10.1021/jm400224q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400224q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400224q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKeap%252BCalm%25252C%252Band%252BCarry%252Bon%252BCovalently%26aulast%3DWilson%26aufirst%3DAnthony%2BJ.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D13022013%26date%3D25072013%26date%3D10102013%26date%3D09072013%26volume%3D56%26issue%3D19%26spage%3D7463%26epage%3D7476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaquan  Wu</span>, <span class="hlFld-ContribAuthor ">Francoise  Powell</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Larsen</span>, <span class="hlFld-ContribAuthor ">Zhongwu  Lai</span>, <span class="hlFld-ContribAuthor ">Kate F.  Byth</span>, <span class="hlFld-ContribAuthor ">Jon  Read</span>, <span class="hlFld-ContribAuthor ">Rong-Fang  Gu</span>, <span class="hlFld-ContribAuthor ">Mark  Roth</span>, <span class="hlFld-ContribAuthor ">Dorin  Toader</span>, <span class="hlFld-ContribAuthor ">Jamal Carlos  Saeh</span>, and <span class="hlFld-ContribAuthor ">Huawei  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Mechanism and In Vitro Pharmacology of TAK1 Inhibition by (5Z)-7-Oxozeaenol. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2013,</strong> <em>8 </em>
                                    (3)
                                     , 643-650. <a href="https://doi.org/10.1021/cb3005897" title="DOI URL">https://doi.org/10.1021/cb3005897</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb3005897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb3005897%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DMechanism%252Band%252BIn%252BVitro%252BPharmacology%252Bof%252BTAK1%252BInhibition%252Bby%252B%2525285Z%252529-7-Oxozeaenol%26aulast%3DWu%26aufirst%3DJiaquan%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D30102012%26date%3D28122012%26date%3D07012013%26date%3D15032013%26date%3D28122012%26volume%3D8%26issue%3D3%26spage%3D643%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ranjan  Banerjee</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Pace</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Brown</span>, and <span class="hlFld-ContribAuthor ">Eranthie  Weerapana</span>  . </span><span class="cited-content_cbyCitation_article-title">1,3,5-Triazine as a Modular Scaffold for Covalent Inhibitors with Streamlined Target Identification. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2013,</strong> <em>135 </em>
                                    (7)
                                     , 2497-2500. <a href="https://doi.org/10.1021/ja400427e" title="DOI URL">https://doi.org/10.1021/ja400427e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja400427e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja400427e%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3D1%25252C3%25252C5-Triazine%252Bas%252Ba%252BModular%252BScaffold%252Bfor%252BCovalent%252BInhibitors%252Bwith%252BStreamlined%252BTarget%252BIdentification%26aulast%3DBanerjee%26aufirst%3DRanjan%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D14012013%26date%3D08022013%26date%3D20022013%26date%3D04022013%26volume%3D135%26issue%3D7%26spage%3D2497%26epage%3D2500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas J.  Pace</span> and <span class="hlFld-ContribAuthor ">Eranthie  Weerapana</span>  . </span><span class="cited-content_cbyCitation_article-title">Diverse Functional Roles of Reactive Cysteines. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2013,</strong> <em>8 </em>
                                    (2)
                                     , 283-296. <a href="https://doi.org/10.1021/cb3005269" title="DOI URL">https://doi.org/10.1021/cb3005269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb3005269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb3005269%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDiverse%252BFunctional%252BRoles%252Bof%252BReactive%252BCysteines%26aulast%3DPace%26aufirst%3DNicholas%2BJ.%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D01102012%26date%3D19112012%26date%3D29112012%26date%3D15022013%26date%3D19112012%26volume%3D8%26issue%3D2%26spage%3D283%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frank E.  Kwarcinski</span>, <span class="hlFld-ContribAuthor ">Christel C.  Fox</span>, <span class="hlFld-ContribAuthor ">Michael E.  Steffey</span>, and <span class="hlFld-ContribAuthor ">Matthew B.  Soellner</span>  . </span><span class="cited-content_cbyCitation_article-title">Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2012,</strong> <em>7 </em>
                                    (11)
                                     , 1910-1917. <a href="https://doi.org/10.1021/cb300337u" title="DOI URL">https://doi.org/10.1021/cb300337u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb300337u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb300337u%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DIrreversible%252BInhibitors%252Bof%252Bc-Src%252BKinase%252BThat%252BTarget%252Ba%252BNonconserved%252BCysteine%26aulast%3DKwarcinski%26aufirst%3DFrank%2BE.%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D07072012%26date%3D28082012%26date%3D05092012%26date%3D16112012%26date%3D28082012%26volume%3D7%26issue%3D11%26spage%3D1910%26epage%3D1917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyunsoo  Kim</span>, <span class="hlFld-ContribAuthor ">Yoon Soo  Hwang</span>, <span class="hlFld-ContribAuthor ">Mingi  Kim</span>, <span class="hlFld-ContribAuthor ">Seung Bum  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the development of covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (7)
                                     , 1037-1045. <a href="https://doi.org/10.1039/D1MD00068C" title="DOI URL">https://doi.org/10.1039/D1MD00068C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00068C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00068C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdevelopment%252Bof%252Bcovalent%252Binhibitors%26aulast%3DKim%26aufirst%3DHyunsoo%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D7%26spage%3D1037%26epage%3D1045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Hu  Yue</span>, <span class="hlFld-ContribAuthor ">Ping  Sun</span>, <span class="hlFld-ContribAuthor ">Lei  Hua</span>, <span class="hlFld-ContribAuthor ">Shuli  Liang</span>, <span class="hlFld-ContribAuthor ">Yitao  Ou</span>, <span class="hlFld-ContribAuthor ">Dan  Wu</span>, <span class="hlFld-ContribAuthor ">Xinyi  Wu</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Ying  Hao</span>, <span class="hlFld-ContribAuthor ">Wenhui  Hu</span>, <span class="hlFld-ContribAuthor ">Zhongjin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>219 </em>, 113417. <a href="https://doi.org/10.1016/j.ejmech.2021.113417" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113417%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bchalcone%252Banalogues%252Bas%252Bnovel%252BNLRP3%252Binflammasome%252Binhibitors%252Bwith%252Bpotent%252Banti-inflammation%252Bactivities%26aulast%3DZhang%26aufirst%3DCheng%26date%3D2021%26volume%3D219%26spage%3D113417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaping  Cheng</span>, <span class="hlFld-ContribAuthor ">Jingyuan  Wu</span>, <span class="hlFld-ContribAuthor ">Ying  Han</span>, <span class="hlFld-ContribAuthor ">Jingyao  Xu</span>, <span class="hlFld-ContribAuthor ">Yifan  Da</span>, <span class="hlFld-ContribAuthor ">Qian  Zhao</span>, <span class="hlFld-ContribAuthor ">Guoying  Guo</span>, <span class="hlFld-ContribAuthor ">Yani  Zhou</span>, <span class="hlFld-ContribAuthor ">Yimin  Chen</span>, <span class="hlFld-ContribAuthor ">Jinghong  Liu</span>, <span class="hlFld-ContribAuthor ">Huayao  Chen</span>, <span class="hlFld-ContribAuthor ">Xianxing  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">A CDR-based approach to generate covalent inhibitory antibody for human rhinovirus protease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>42 </em>, 116219. <a href="https://doi.org/10.1016/j.bmc.2021.116219" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116219%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DA%252BCDR-based%252Bapproach%252Bto%252Bgenerate%252Bcovalent%252Binhibitory%252Bantibody%252Bfor%252Bhuman%252Brhinovirus%252Bprotease%26aulast%3DCheng%26aufirst%3DYaping%26date%3D2021%26volume%3D42%26spage%3D116219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Jing  Pang</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Yin-Ru  Li</span>, <span class="hlFld-ContribAuthor ">Guang-Xi  Yu</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Tian</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Cheng-Yun  Jin</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4250. <a href="https://doi.org/10.3390/molecules26144250" title="DOI URL">https://doi.org/10.3390/molecules26144250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144250%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDrug%252BDiscovery%252BTargeting%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Bas%252Ba%252BPromising%252BCancer%252BTherapy%26aulast%3DPang%26aufirst%3DXiao-Jing%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fanwang  Meng</span>, <span class="hlFld-ContribAuthor ">Zhongjie  Liang</span>, <span class="hlFld-ContribAuthor ">Kehao  Zhao</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Drug design targeting active posttranslational modification protein isoforms. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>41 </em>
                                    (3)
                                     , 1701-1750. <a href="https://doi.org/10.1002/med.21774" title="DOI URL">https://doi.org/10.1002/med.21774</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21774%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DDrug%252Bdesign%252Btargeting%252Bactive%252Bposttranslational%252Bmodification%252Bprotein%252Bisoforms%26aulast%3DMeng%26aufirst%3DFanwang%26date%3D2021%26date%3D2020%26volume%3D41%26issue%3D3%26spage%3D1701%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard R.  Furman</span>, <span class="hlFld-ContribAuthor ">John C.  Byrd</span>, <span class="hlFld-ContribAuthor ">Roger G.  Owen</span>, <span class="hlFld-ContribAuthor ">Susan M.  O’Brien</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Brown</span>, <span class="hlFld-ContribAuthor ">Peter  Hillmen</span>, <span class="hlFld-ContribAuthor ">Deborah M.  Stephens</span>, <span class="hlFld-ContribAuthor ">Nataliya  Chernyukhin</span>, <span class="hlFld-ContribAuthor ">Tamara  Lezhava</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Hamdy</span>, <span class="hlFld-ContribAuthor ">Raquel  Izumi</span>, <span class="hlFld-ContribAuthor ">Priti  Patel</span>, <span class="hlFld-ContribAuthor ">Marshall  Baek</span>, <span class="hlFld-ContribAuthor ">Beth  Christian</span>, <span class="hlFld-ContribAuthor ">Martin J. S.  Dyer</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Streetly</span>, <span class="hlFld-ContribAuthor ">Clare  Sun</span>, <span class="hlFld-ContribAuthor ">Simon  Rule</span>, <span class="hlFld-ContribAuthor ">Michael  Wang</span>, <span class="hlFld-ContribAuthor ">Paolo  Ghia</span>, <span class="hlFld-ContribAuthor ">Wojciech  Jurczak</span>, <span class="hlFld-ContribAuthor ">John M.  Pagel</span>, <span class="hlFld-ContribAuthor ">Jeff P.  Sharman</span>. </span><span class="cited-content_cbyCitation_article-title">Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1038/s41375-021-01252-y" title="DOI URL">https://doi.org/10.1038/s41375-021-01252-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41375-021-01252-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41375-021-01252-y%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DPooled%252Banalysis%252Bof%252Bsafety%252Bdata%252Bfrom%252Bclinical%252Btrials%252Bevaluating%252Bacalabrutinib%252Bmonotherapy%252Bin%252Bmature%252BB-cell%252Bmalignancies%26aulast%3DFurman%26aufirst%3DRichard%2BR.%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>. </span><span class="cited-content_cbyCitation_article-title">Multiple Sclerosis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-43. <a href="https://doi.org/10.1002/0471266949.bmc203.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc203.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc203.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc203.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DMultiple%252BSclerosis%26aulast%3DPitts%26aufirst%3DWilliam%2BJ.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D43%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kei  Takenaka</span>, <span class="hlFld-ContribAuthor ">Kensuke  Kaneko</span>, <span class="hlFld-ContribAuthor ">Nobuaki  Takahashi</span>, <span class="hlFld-ContribAuthor ">Shinichi  Nishimura</span>, <span class="hlFld-ContribAuthor ">Hideaki  Kakeya</span>. </span><span class="cited-content_cbyCitation_article-title">Retro-aza-Michael reaction of an o-aminophenol adduct in protic solvents inspired by natural products. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>35 </em>, 116059. <a href="https://doi.org/10.1016/j.bmc.2021.116059" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DRetro-aza-Michael%252Breaction%252Bof%252Ban%252Bo-aminophenol%252Badduct%252Bin%252Bprotic%252Bsolvents%252Binspired%252Bby%252Bnatural%252Bproducts%26aulast%3DTakenaka%26aufirst%3DKei%26date%3D2021%26volume%3D35%26spage%3D116059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (3)
                                     , 223-238. <a href="https://doi.org/10.1080/13543776.2021.1860210" title="DOI URL">https://doi.org/10.1080/13543776.2021.1860210</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1860210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1860210%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282014-present%252529%26aulast%3DSun%26aufirst%3DXin%26date%3D2021%26date%3D2020%26volume%3D31%26issue%3D3%26spage%3D223%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianbo  Sun</span>, <span class="hlFld-ContribAuthor ">Hui  Zhong</span>, <span class="hlFld-ContribAuthor ">Kun  Wang</span>, <span class="hlFld-ContribAuthor ">Na  Li</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>13 </em><a href="https://doi.org/10.1016/j.apsb.2021.02.023" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.02.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.02.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.02.023%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DGains%252Bfrom%252Bno%252Breal%252BPAINS%25253A%252BWhere%252B%2525E2%252580%252598Fair%252BTrial%252BStrategy%2525E2%252580%252599%252Bstands%252Bin%252Bthe%252Bdevelopment%252Bof%252Bmulti-target%252Bligands%26aulast%3DSun%26aufirst%3DJianbo%26date%3D2021%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling Covalent Protein-Ligand Interactions. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 174-189. <a href="https://doi.org/10.1016/B978-0-12-801238-3.11519-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-801238-3.11519-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-801238-3.11519-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-801238-3.11519-3%26sid%3Dliteratum%253Aachs%26atitle%3DModeling%252BCovalent%252BProtein-Ligand%252BInteractions%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26spage%3D174%26epage%3D189%26pub%3DElsevier%26atitle%3DSystems%252BMedicine%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingfeng  Liu</span>, <span class="hlFld-ContribAuthor ">Chengcheng  Kong</span>, <span class="hlFld-ContribAuthor ">Marco  Fumagalli</span>, <span class="hlFld-ContribAuthor ">Karin  Savková</span>, <span class="hlFld-ContribAuthor ">Yiwen  Xu</span>, <span class="hlFld-ContribAuthor ">Stanislav  Huszár</span>, <span class="hlFld-ContribAuthor ">José C.  Sammartino</span>, <span class="hlFld-ContribAuthor ">Dongguang  Fan</span>, <span class="hlFld-ContribAuthor ">Laurent R.  Chiarelli</span>, <span class="hlFld-ContribAuthor ">Katarína  Mikušová</span>, <span class="hlFld-ContribAuthor ">Zhaogang  Sun</span>, <span class="hlFld-ContribAuthor ">Chunhua  Qiao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112773. <a href="https://doi.org/10.1016/j.ejmech.2020.112773" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112773</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112773%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bcovalent%252Binhibitors%252Bof%252BDprE1%252Bas%252Bantitubercular%252Bagents%26aulast%3DLiu%26aufirst%3DLingfeng%26date%3D2020%26volume%3D208%26spage%3D112773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Bianco</span>, <span class="hlFld-ContribAuthor ">David S.  Goodsell</span>, <span class="hlFld-ContribAuthor ">Stefano  Forli</span>. </span><span class="cited-content_cbyCitation_article-title">Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2020,</strong> <em>41 </em>
                                    (12)
                                     , 1038-1049. <a href="https://doi.org/10.1016/j.tips.2020.10.005" title="DOI URL">https://doi.org/10.1016/j.tips.2020.10.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2020.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2020.10.005%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DSelective%252Band%252BEffective%25253A%252BCurrent%252BProgress%252Bin%252BComputational%252BStructure-Based%252BDrug%252BDiscovery%252Bof%252BTargeted%252BCovalent%252BInhibitors%26aulast%3DBianco%26aufirst%3DGiulia%26date%3D2020%26volume%3D41%26issue%3D12%26spage%3D1038%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Xiaojun Julia  Liang</span>, <span class="hlFld-ContribAuthor ">Martin  Schröder</span>, <span class="hlFld-ContribAuthor ">Stefan  Gerstenecker</span>, <span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (23)
                                     , 9269. <a href="https://doi.org/10.3390/ijms21239269" title="DOI URL">https://doi.org/10.3390/ijms21239269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21239269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21239269%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BClass%252Bof%252BCovalent%252BDual%252BInhibitors%252BTargeting%252Bthe%252BProtein%252BKinases%252BBMX%252Band%252BBTK%26aulast%3DForster%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D23%26spage%3D9269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sha-Sha  Cheng</span>, <span class="hlFld-ContribAuthor ">Guan-Jun  Yang</span>, <span class="hlFld-ContribAuthor ">Wanhe  Wang</span>, <span class="hlFld-ContribAuthor ">Chung-Hang  Leung</span>, <span class="hlFld-ContribAuthor ">Dik-Lung  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">The design and development of covalent protein-protein interaction inhibitors for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00850-0" title="DOI URL">https://doi.org/10.1186/s13045-020-00850-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00850-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00850-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DThe%252Bdesign%252Band%252Bdevelopment%252Bof%252Bcovalent%252Bprotein-protein%252Binteraction%252Binhibitors%252Bfor%252Bcancer%252Btreatment%26aulast%3DCheng%26aufirst%3DSha-Sha%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Szuyuan  Pu</span>, <span class="hlFld-ContribAuthor ">Stanford  Schor</span>, <span class="hlFld-ContribAuthor ">Marwah  Karim</span>, <span class="hlFld-ContribAuthor ">Sirle  Saul</span>, <span class="hlFld-ContribAuthor ">Makeda  Robinson</span>, <span class="hlFld-ContribAuthor ">Sathish  Kumar</span>, <span class="hlFld-ContribAuthor ">Laura I.  Prugar</span>, <span class="hlFld-ContribAuthor ">Danielle E.  Dorosky</span>, <span class="hlFld-ContribAuthor ">Jennifer  Brannan</span>, <span class="hlFld-ContribAuthor ">John M.  Dye</span>, <span class="hlFld-ContribAuthor ">Shirit  Einav</span>. </span><span class="cited-content_cbyCitation_article-title">BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2020,</strong> <em>184 </em>, 104966. <a href="https://doi.org/10.1016/j.antiviral.2020.104966" title="DOI URL">https://doi.org/10.1016/j.antiviral.2020.104966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2020.104966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2020.104966%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DBIKE%252Bregulates%252Bdengue%252Bvirus%252Binfection%252Band%252Bis%252Ba%252Bcellular%252Btarget%252Bfor%252Bbroad-spectrum%252Bantivirals%26aulast%3DPu%26aufirst%3DSzuyuan%26date%3D2020%26volume%3D184%26spage%3D104966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tom  van der Wel</span>, <span class="hlFld-ContribAuthor ">Riet  Hilhorst</span>, <span class="hlFld-ContribAuthor ">Hans  den Dulk</span>, <span class="hlFld-ContribAuthor ">Tim  van den Hooven</span>, <span class="hlFld-ContribAuthor ">Nienke M.  Prins</span>, <span class="hlFld-ContribAuthor ">Joost A. P. M.  Wijnakker</span>, <span class="hlFld-ContribAuthor ">Bogdan I.  Florea</span>, <span class="hlFld-ContribAuthor ">Eelke B.  Lenselink</span>, <span class="hlFld-ContribAuthor ">Gerard J. P.  van Westen</span>, <span class="hlFld-ContribAuthor ">Rob  Ruijtenbeek</span>, <span class="hlFld-ContribAuthor ">Herman S.  Overkleeft</span>, <span class="hlFld-ContribAuthor ">Allard  Kaptein</span>, <span class="hlFld-ContribAuthor ">Tjeerd  Barf</span>, <span class="hlFld-ContribAuthor ">Mario  van der Stelt</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-17027-5" title="DOI URL">https://doi.org/10.1038/s41467-020-17027-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-17027-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-17027-5%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DChemical%252Bgenetics%252Bstrategy%252Bto%252Bprofile%252Bkinase%252Btarget%252Bengagement%252Breveals%252Brole%252Bof%252BFES%252Bin%252Bneutrophil%252Bphagocytosis%26aulast%3Dvan%2Bder%2BWel%26aufirst%3DTom%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raji E  Joseph</span>, <span class="hlFld-ContribAuthor ">Neha  Amatya</span>, <span class="hlFld-ContribAuthor ">D Bruce  Fulton</span>, <span class="hlFld-ContribAuthor ">John R  Engen</span>, <span class="hlFld-ContribAuthor ">Thomas E  Wales</span>, <span class="hlFld-ContribAuthor ">Amy  Andreotti</span>. </span><span class="cited-content_cbyCitation_article-title">Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2020,</strong> <em>9 </em><a href="https://doi.org/10.7554/eLife.60470" title="DOI URL">https://doi.org/10.7554/eLife.60470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.60470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.60470%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DDifferential%252Bimpact%252Bof%252BBTK%252Bactive%252Bsite%252Binhibitors%252Bon%252Bthe%252Bconformational%252Bstate%252Bof%252Bfull-length%252BBTK%26aulast%3DJoseph%26aufirst%3DRaji%2BE%26date%3D2020%26date%3D2020%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chizuru  Miura</span>, <span class="hlFld-ContribAuthor ">Naoya  Shindo</span>, <span class="hlFld-ContribAuthor ">Kei  Okamoto</span>, <span class="hlFld-ContribAuthor ">Keiko  Kuwata</span>, <span class="hlFld-ContribAuthor ">Akio  Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2020,</strong> <em>68 </em>
                                    (11)
                                     , 1074-1081. <a href="https://doi.org/10.1248/cpb.c20-00547" title="DOI URL">https://doi.org/10.1248/cpb.c20-00547</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c20-00547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c20-00547%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DFragment-Based%252BDiscovery%252Bof%252BIrreversible%252BCovalent%252BInhibitors%252Bof%252BCysteine%252BProteases%252BUsing%252BChlorofluoroacetamide%252BLibrary%26aulast%3DMiura%26aufirst%3DChizuru%26date%3D2020%26volume%3D68%26issue%3D11%26spage%3D1074%26epage%3D1081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eun  Lee</span>, <span class="hlFld-ContribAuthor ">Hyewon  Cho</span>, <span class="hlFld-ContribAuthor ">Da Kyung  Lee</span>, <span class="hlFld-ContribAuthor ">JuHyun  Ha</span>, <span class="hlFld-ContribAuthor ">Byeong Jo  Choi</span>, <span class="hlFld-ContribAuthor ">Ji Hye  Jeong</span>, <span class="hlFld-ContribAuthor ">Jae-Ha  Ryu</span>, <span class="hlFld-ContribAuthor ">Jong Soon  Kang</span>, <span class="hlFld-ContribAuthor ">Raok  Jeon</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (21)
                                     , 8006. <a href="https://doi.org/10.3390/ijms21218006" title="DOI URL">https://doi.org/10.3390/ijms21218006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21218006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21218006%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDiscovery%252Bof%252B5-Phenoxy-2-aminopyridine%252BDerivatives%252Bas%252BPotent%252Band%252BSelective%252BIrreversible%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DLee%26aufirst%3DEun%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D21%26spage%3D8006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">João D.  Seixas</span>, <span class="hlFld-ContribAuthor ">Bárbara B.  Sousa</span>, <span class="hlFld-ContribAuthor ">Marta C.  Marques</span>, <span class="hlFld-ContribAuthor ">Ana  Guerreiro</span>, <span class="hlFld-ContribAuthor ">Rui  Traquete</span>, <span class="hlFld-ContribAuthor ">Tiago  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Inês S.  Albuquerque</span>, <span class="hlFld-ContribAuthor ">Marcos F. Q.  Sousa</span>, <span class="hlFld-ContribAuthor ">Ana R.  Lemos</span>, <span class="hlFld-ContribAuthor ">Pedro M. F.  Sousa</span>, <span class="hlFld-ContribAuthor ">Tiago M.  Bandeiras</span>, <span class="hlFld-ContribAuthor ">Di  Wu</span>, <span class="hlFld-ContribAuthor ">Shelby K.  Doyle</span>, <span class="hlFld-ContribAuthor ">Carol V.  Robinson</span>, <span class="hlFld-ContribAuthor ">Angela N.  Koehler</span>, <span class="hlFld-ContribAuthor ">Francisco  Corzana</span>, <span class="hlFld-ContribAuthor ">Pedro M.  Matias</span>, <span class="hlFld-ContribAuthor ">Gonçalo J. L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Chemical Biology</span><span> <strong>2020,</strong> <em>1 </em>
                                    (4)
                                     , 251-262. <a href="https://doi.org/10.1039/D0CB00033G" title="DOI URL">https://doi.org/10.1039/D0CB00033G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CB00033G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CB00033G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Chemical%2520Biology%26atitle%3DStructural%252Band%252Bbiophysical%252Binsights%252Binto%252Bthe%252Bmode%252Bof%252Bcovalent%252Bbinding%252Bof%252Brationally%252Bdesigned%252Bpotent%252BBMX%252Binhibitors%26aulast%3DSeixas%26aufirst%3DJo%25C3%25A3o%2BD.%26date%3D2020%26date%3D2020%26volume%3D1%26issue%3D4%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Feiyi  Yang</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (19)
                                     , 115669. <a href="https://doi.org/10.1016/j.bmc.2020.115669" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115669%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthiapyran-pyrimidine%252Bderivatives%252Bas%252Bpotential%252BEGFR%252Binhibitors%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D28%26issue%3D19%26spage%3D115669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaan  Shao</span>, <span class="hlFld-ContribAuthor ">Shuangrong  Liu</span>, <span class="hlFld-ContribAuthor ">Xingyu  Liu</span>, <span class="hlFld-ContribAuthor ">Youlu  Pan</span>, <span class="hlFld-ContribAuthor ">Wenteng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and SAR study of 2-aminopyrimidines with diverse Michael addition acceptors for chemically tuning the potency against EGFRL858R/T790M. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (19)
                                     , 115680. <a href="https://doi.org/10.1016/j.bmc.2020.115680" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115680%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252BSAR%252Bstudy%252Bof%252B2-aminopyrimidines%252Bwith%252Bdiverse%252BMichael%252Baddition%252Bacceptors%252Bfor%252Bchemically%252Btuning%252Bthe%252Bpotency%252Bagainst%252BEGFRL858R%25252FT790M%26aulast%3DShao%26aufirst%3DJiaan%26date%3D2020%26volume%3D28%26issue%3D19%26spage%3D115680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parth  Bhatia</span>, <span class="hlFld-ContribAuthor ">Vrinda  Sharma</span>, <span class="hlFld-ContribAuthor ">Ozair  Alam</span>, <span class="hlFld-ContribAuthor ">Ajay  Manaithiya</span>, <span class="hlFld-ContribAuthor ">Perwaiz  Alam</span>, <span class="hlFld-ContribAuthor ">Kahksha</span>, <span class="hlFld-ContribAuthor ">Md Tauquir  Alam</span>, <span class="hlFld-ContribAuthor ">Mohd  Imran</span>. </span><span class="cited-content_cbyCitation_article-title">Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112640. <a href="https://doi.org/10.1016/j.ejmech.2020.112640" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112640%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bquinazoline-based%252BEGFR%252Bkinase%252Binhibitors%25253A%252BA%252Breview%252Bfocussing%252Bon%252BSAR%252Band%252Bmolecular%252Bdocking%252Bstudies%252B%2525282015-2019%252529%26aulast%3DBhatia%26aufirst%3DParth%26date%3D2020%26volume%3D204%26spage%3D112640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huma  Naz</span>, <span class="hlFld-ContribAuthor ">Mohammad  Tarique</span>, <span class="hlFld-ContribAuthor ">Mohd  Suhail</span>, <span class="hlFld-ContribAuthor ">Hari  Shankar</span>, <span class="hlFld-ContribAuthor ">Naoshad  Muhammad</span>, <span class="hlFld-ContribAuthor ">Darksha  Usmani</span>, <span class="hlFld-ContribAuthor ">Mohammad  Ashraf</span>, <span class="hlFld-ContribAuthor ">Torki A.  Zughaibi</span>. </span><span class="cited-content_cbyCitation_article-title">Calcium-/Calmodulin-Dependent Protein Kinase IV (CAMKIV): A Multifunctional Enzyme and Its Role in Various Cancer: An Update. </span><span class="cited-content_cbyCitation_journal-name">Current Molecular Biology Reports</span><span> <strong>2020,</strong> <em>6 </em>
                                    (3)
                                     , 139-147. <a href="https://doi.org/10.1007/s40610-020-00138-9" title="DOI URL">https://doi.org/10.1007/s40610-020-00138-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40610-020-00138-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40610-020-00138-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Molecular%2520Biology%2520Reports%26atitle%3DCalcium-%25252FCalmodulin-Dependent%252BProtein%252BKinase%252BIV%252B%252528CAMKIV%252529%25253A%252BA%252BMultifunctional%252BEnzyme%252Band%252BIts%252BRole%252Bin%252BVarious%252BCancer%25253A%252BAn%252BUpdate%26aulast%3DNaz%26aufirst%3DHuma%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D3%26spage%3D139%26epage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent inhibitors: back on track?. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (15)
                                     , 1363-1368. <a href="https://doi.org/10.4155/fmc-2020-0118" title="DOI URL">https://doi.org/10.4155/fmc-2020-0118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0118%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Binhibitors%25253A%252Bback%252Bon%252Btrack%25253F%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26volume%3D12%26issue%3D15%26spage%3D1363%26epage%3D1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerjan  de Bruin</span>, <span class="hlFld-ContribAuthor ">Dennis  Demont</span>, <span class="hlFld-ContribAuthor ">Edwin  de Zwart</span>, <span class="hlFld-ContribAuthor ">Saskia  Verkaik</span>, <span class="hlFld-ContribAuthor ">Niels  Hoogenboom</span>, <span class="hlFld-ContribAuthor ">Bas  van de Kar</span>, <span class="hlFld-ContribAuthor ">Bart  van Lith</span>, <span class="hlFld-ContribAuthor ">Maaike  Emmelot- van Hoek</span>, <span class="hlFld-ContribAuthor ">Michael  Gulrajani</span>, <span class="hlFld-ContribAuthor ">Todd  Covey</span>, <span class="hlFld-ContribAuthor ">Allard  Kaptein</span>, <span class="hlFld-ContribAuthor ">Tjeerd  Barf</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of quinoline-based irreversible BTK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (14)
                                     , 127261. <a href="https://doi.org/10.1016/j.bmcl.2020.127261" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127261</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127261%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bquinoline-based%252Birreversible%252BBTK%252Binhibitors%26aulast%3Dde%2BBruin%26aufirst%3DGerjan%26date%3D2020%26volume%3D30%26issue%3D14%26spage%3D127261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica  Ceramella</span>, <span class="hlFld-ContribAuthor ">Domenico  Iacopetta</span>, <span class="hlFld-ContribAuthor ">Alexia  Barbarossa</span>, <span class="hlFld-ContribAuthor ">Anna  Caruso</span>, <span class="hlFld-ContribAuthor ">Fedora  Grande</span>, <span class="hlFld-ContribAuthor ">Maria Grazia  Bonomo</span>, <span class="hlFld-ContribAuthor ">Annaluisa  Mariconda</span>, <span class="hlFld-ContribAuthor ">Pasquale  Longo</span>, <span class="hlFld-ContribAuthor ">Saturnino  Carmela</span>, <span class="hlFld-ContribAuthor ">Maria Stefania  Sinicropi</span>. </span><span class="cited-content_cbyCitation_article-title">Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (6)
                                     , 444-465. <a href="https://doi.org/10.2174/1389557520666200117144701" title="DOI URL">https://doi.org/10.2174/1389557520666200117144701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557520666200117144701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557520666200117144701%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3DCarbazole%252BDerivatives%252Bas%252BKinase-Targeting%252BInhibitors%252Bfor%252BCancer%252BTreatment%26aulast%3DCeramella%26aufirst%3DJessica%26date%3D2020%26volume%3D20%26issue%3D6%26spage%3D444%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Yin</span>, <span class="hlFld-ContribAuthor ">Cheng-Juan  Chen</span>, <span class="hlFld-ContribAuthor ">Ru-Nan  Yu</span>, <span class="hlFld-ContribAuthor ">Lei  Shu</span>, <span class="hlFld-ContribAuthor ">Zhi-Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Tian-Tai  Zhang</span>, <span class="hlFld-ContribAuthor ">Da-Yong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103720. <a href="https://doi.org/10.1016/j.bioorg.2020.103720" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103720%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252B1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-6-amino%252Bderivatives%252Bas%252Bpotent%252Bselective%252BJanus%252Bkinase%252B3%252B%252528JAK3%252529%252Binhibitors.%252BEvaluation%252Bof%252Btheir%252Bimproved%252Beffect%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DYin%26aufirst%3DYuan%26date%3D2020%26volume%3D98%26spage%3D103720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xufeng  Huang</span>, <span class="hlFld-ContribAuthor ">Zhouling  Xie</span>, <span class="hlFld-ContribAuthor ">Chenzhong  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Developing polo-like kinase 1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 869-871. <a href="https://doi.org/10.4155/fmc-2020-0055" title="DOI URL">https://doi.org/10.4155/fmc-2020-0055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0055%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDeveloping%252Bpolo-like%252Bkinase%252B1%252Binhibitors%26aulast%3DHuang%26aufirst%3DXufeng%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D869%26epage%3D871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Deng</span>, <span class="hlFld-ContribAuthor ">Qian  Lei</span>, <span class="hlFld-ContribAuthor ">Yangping  Wu</span>, <span class="hlFld-ContribAuthor ">Yang  He</span>, <span class="hlFld-ContribAuthor ">Weimin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Activity-based protein profiling: Recent advances in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>191 </em>, 112151. <a href="https://doi.org/10.1016/j.ejmech.2020.112151" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112151%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DActivity-based%252Bprotein%252Bprofiling%25253A%252BRecent%252Badvances%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DDeng%26aufirst%3DHui%26date%3D2020%26volume%3D191%26spage%3D112151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naoya  Shindo</span>, <span class="hlFld-ContribAuthor ">Akio  Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">
                In Vivo
              
              Targeting of Endogenous Proteins with Reactive Small Molecules. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 281-307. <a href="https://doi.org/10.1002/9783527344406.ch10" title="DOI URL">https://doi.org/10.1002/9783527344406.ch10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527344406.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527344406.ch10%26sid%3Dliteratum%253Aachs%26atitle%3DIn%252BVivo%252BTargeting%252Bof%252BEndogenous%252BProteins%252Bwith%252BReactive%252BSmall%252BMolecules%26aulast%3DShindo%26aufirst%3DNaoya%26date%3D2020%26date%3D2019%26spage%3D281%26epage%3D307%26pub%3DWiley%26atitle%3DHandbook%252Bof%252BIn%252BVivo%252BChemistry%252Bin%252BMice%26aulast%3DTanaka%26aufirst%3DKatsunori%26date%3D2020%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueying  Wang</span>, <span class="hlFld-ContribAuthor ">Gang  Xue</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structure–activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111918. <a href="https://doi.org/10.1016/j.ejmech.2019.111918" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111918%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bof%252Bindolylindazoles%252Bas%252Bpotent%252Band%252Bselective%252Bcovalent%252Binhibitors%252Bof%252Binterleukin-2%252Binducible%252BT-cell%252Bkinase%252B%252528ITK%252529%26aulast%3DWang%26aufirst%3DXueying%26date%3D2020%26volume%3D187%26spage%3D111918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors: An Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 43-94. <a href="https://doi.org/10.1007/7355_2020_103" title="DOI URL">https://doi.org/10.1007/7355_2020_103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_103%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%25253A%252BAn%252BOverview%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D43%26epage%3D94%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lídia Moreira  Lima</span>, <span class="hlFld-ContribAuthor ">Maria Letícia  de Castro Barbosa</span>, <span class="hlFld-ContribAuthor ">Daniel Nascimento  do Amaral</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 155-201. <a href="https://doi.org/10.1007/7355_2020_95" title="DOI URL">https://doi.org/10.1007/7355_2020_95</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_95%26sid%3Dliteratum%253Aachs%26atitle%3DCase%252BStudy%252Bon%252BReceptor%252BTyrosine%252BKinases%252BEGFR%25252C%252BVEGFR%25252C%252Band%252BPDGFR%26aulast%3DLima%26aufirst%3DL%25C3%25ADdia%2BMoreira%26date%3D2020%26date%3D2020%26spage%3D155%26epage%3D201%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Donatella  Callegari</span>, <span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>. </span><span class="cited-content_cbyCitation_article-title">Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 307-337. <a href="https://doi.org/10.1007/978-1-0716-0282-9_19" title="DOI URL">https://doi.org/10.1007/978-1-0716-0282-9_19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-0716-0282-9_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-0716-0282-9_19%26sid%3Dliteratum%253Aachs%26atitle%3DDesign%252Band%252BSAR%252BAnalysis%252Bof%252BCovalent%252BInhibitors%252BDriven%252Bby%252BHybrid%252BQM%25252FMM%252BSimulations%26aulast%3DLodola%26aufirst%3DAlessio%26date%3D2020%26date%3D2020%26spage%3D307%26epage%3D337%26pub%3DSpringer%2520US%26atitle%3DQuantum%252BMechanics%252Bin%252BDrug%252BDiscovery%26aulast%3DHeifetz%26aufirst%3DAlexander%26date%3D2020%26volume%3D2114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rachel M.  Sammons</span>, <span class="hlFld-ContribAuthor ">Kevin N.  Dalby</span>. </span><span class="cited-content_cbyCitation_article-title">A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 109-139. <a href="https://doi.org/10.1007/978-3-030-48283-1_6" title="DOI URL">https://doi.org/10.1007/978-3-030-48283-1_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-48283-1_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-48283-1_6%26sid%3Dliteratum%253Aachs%26atitle%3DA%252BToolbox%252Bof%252BStructural%252BBiology%252Band%252BEnzyme%252BKinetics%252BReveals%252Bthe%252BCase%252Bfor%252BERK%252BDocking%252BSite%252BInhibition%26aulast%3DSammons%26aufirst%3DRachel%2BM.%26date%3D2020%26date%3D2020%26spage%3D109%26epage%3D139%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNext%252BGeneration%252BKinase%252BInhibitors%26aulast%3DShapiro%26aufirst%3DPaul%26date%3D2020%26volume%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Davies</span>, <span class="hlFld-ContribAuthor ">Sharon  Barrans</span>, <span class="hlFld-ContribAuthor ">Cathy  Burton</span>, <span class="hlFld-ContribAuthor ">Katy  Mercer</span>, <span class="hlFld-ContribAuthor ">Joshua  Caddy</span>, <span class="hlFld-ContribAuthor ">Fay  Chinnery</span>, <span class="hlFld-ContribAuthor ">Laura  Day</span>, <span class="hlFld-ContribAuthor ">Diana  Fernando</span>, <span class="hlFld-ContribAuthor ">Kirit  Ardeshna</span>, <span class="hlFld-ContribAuthor ">Graham  Collins</span>, <span class="hlFld-ContribAuthor ">John  Radford</span>, <span class="hlFld-ContribAuthor ">Simon  Rule</span>, <span class="hlFld-ContribAuthor ">Andrew  McMillan</span>, <span class="hlFld-ContribAuthor ">Peter  Johnson</span>, <span class="hlFld-ContribAuthor ">Gareth  Griffiths</span>. </span><span class="cited-content_cbyCitation_article-title">ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. </span><span class="cited-content_cbyCitation_journal-name">F1000Research</span><span> <strong>2020,</strong> <em>9 </em>, 941. <a href="https://doi.org/10.12688/f1000research.22318.1" title="DOI URL">https://doi.org/10.12688/f1000research.22318.1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12688/f1000research.22318.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12688%2Ff1000research.22318.1%26sid%3Dliteratum%253Aachs%26jtitle%3DF1000Research%26atitle%3DACCEPT%252B-%252Bcombining%252Bacalabrutinib%252Bwith%252Brituximab%25252C%252Bcyclophosphamide%25252C%252Bdoxorubicin%25252C%252Bvincristine%252Band%252Bprednisolone%252B%252528R-CHOP%252529%252Bfor%252BDiffuse%252BLarge%252BB-cell%252BLymphoma%252B%252528DLBCL%252529%25253A%252Bstudy%252Bprotocol%252Bfor%252Ba%252BPhase%252BIb%25252FII%252Bopen-label%252Bnon-randomised%252Bclinical%252Btrial%26aulast%3DDavies%26aufirst%3DAndrew%26date%3D2020%26date%3D2020%26volume%3D9%26spage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ram B.  Khattri</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Morris</span>, <span class="hlFld-ContribAuthor ">Stephanie M.  Bilinovich</span>, <span class="hlFld-ContribAuthor ">Erendra  Manandhar</span>, <span class="hlFld-ContribAuthor ">Kahlilah R.  Napper</span>, <span class="hlFld-ContribAuthor ">Jacob W.  Sweet</span>, <span class="hlFld-ContribAuthor ">David A.  Modarelli</span>, <span class="hlFld-ContribAuthor ">Thomas C.  Leeper</span>. </span><span class="cited-content_cbyCitation_article-title">Identifying Ortholog Selective Fragment Molecules for Bacterial Glutaredoxins by NMR and Affinity Enhancement by Modification with an Acrylamide Warhead. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (1)
                                     , 147. <a href="https://doi.org/10.3390/molecules25010147" title="DOI URL">https://doi.org/10.3390/molecules25010147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25010147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25010147%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIdentifying%252BOrtholog%252BSelective%252BFragment%252BMolecules%252Bfor%252BBacterial%252BGlutaredoxins%252Bby%252BNMR%252Band%252BAffinity%252BEnhancement%252Bby%252BModification%252Bwith%252Ban%252BAcrylamide%252BWarhead%26aulast%3DKhattri%26aufirst%3DRam%2BB.%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D1%26spage%3D147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaohua  Wang</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Dai</span>, <span class="hlFld-ContribAuthor ">Jijuan  Nai</span>, <span class="hlFld-ContribAuthor ">Liqiao  Zhu</span>, <span class="hlFld-ContribAuthor ">Huagang  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Solubility and Bioavailability Enhancement of Oridonin: A Review. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 332. <a href="https://doi.org/10.3390/molecules25020332" title="DOI URL">https://doi.org/10.3390/molecules25020332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25020332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25020332%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSolubility%252Band%252BBioavailability%252BEnhancement%252Bof%252BOridonin%25253A%252BA%252BReview%26aulast%3DZhang%26aufirst%3DYuanyuan%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzo  Rossi</span>, <span class="hlFld-ContribAuthor ">Maurizio  Ciofalo</span>. </span><span class="cited-content_cbyCitation_article-title">Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2019,</strong> <em>23 </em>
                                    (19)
                                     , 2016-2101. <a href="https://doi.org/10.2174/1385272823666191014154129" title="DOI URL">https://doi.org/10.2174/1385272823666191014154129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666191014154129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666191014154129%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DCurrent%252BAdvances%252Bin%252Bthe%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPharmacologically%252BRelevant%252B1%25252C2%25252C4%25252C5-Tetrasubstituted-1H-Imidazole%252BDerivatives%26aulast%3DRossi%26aufirst%3DRenzo%26date%3D2019%26volume%3D23%26issue%3D19%26spage%3D2016%26epage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunyuan  Huang</span>, <span class="hlFld-ContribAuthor ">Lin  Wei</span>, <span class="hlFld-ContribAuthor ">Xinya  Han</span>, <span class="hlFld-ContribAuthor ">Haifeng  Chen</span>, <span class="hlFld-ContribAuthor ">Yanliang  Ren</span>, <span class="hlFld-ContribAuthor ">Yanhong  Xu</span>, <span class="hlFld-ContribAuthor ">Rongrong  Song</span>, <span class="hlFld-ContribAuthor ">Li  Rao</span>, <span class="hlFld-ContribAuthor ">Chen  Su</span>, <span class="hlFld-ContribAuthor ">Chao  Peng</span>, <span class="hlFld-ContribAuthor ">Lingling  Feng</span>, <span class="hlFld-ContribAuthor ">Jian  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>184 </em>, 111749. <a href="https://doi.org/10.1016/j.ejmech.2019.111749" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111749%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Ballosteric%252Bsite%252Band%252Bcovalent%252Binhibitors%252Bof%252BFBPase%252Bwith%252Bpotent%252Bhypoglycemic%252Beffects%26aulast%3DHuang%26aufirst%3DYunyuan%26date%3D2019%26volume%3D184%26spage%3D111749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm3003203&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-14%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Fjm3003203%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=226&amp;pagesCount=3&amp;pageNumber=2" title="Load more citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load more citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0017.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. For conventional drugs, the pharmacodynamic effect is driven by the pharmacokinetics of the drug (left). For irreversible covalent drugs, the pharmacodynamic effect is driven by the turnover rate (de novo synthesis) of the protein target (right). The red hatched area is drug exposure not required for efficacy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0016.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. IC<sub>50</sub> determination depends on the ATP concentration and preincubation time for an irreversible kinase inhibitor (left), whereas an ATP competitive kinase inhibitor is only affected by ATP concentration (right). Data are from an unpublished kinase inhibitor study included for illustration purposes only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0018.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of lysine trapping kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0019.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic representation of available cysteines in or near the ATP binding pocket of kinases in the active conformation (based on the crystal structure of interleukin 2 tyrosine kinase, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SM2">1SM2</a>). The spheres indicate the locations of cysteines that are in principle accessible for covalent modification: group 1, glycine-rich- or P-loop (dark blue); group 2, the roof of the ATP binding pocket (pink); group 3, hinge region and front pocket (yellow); group 4, DFG-motif neighboring cysteine (light blue). Group 5 (in dark red) denotes the cluster of cysteines that resides on the activation loop. The gatekeeper group is shown in orange. Adapted by permission from Macmillan Publishers Ltd.: <i>Nature Reviews Cancer</i> (<a href="http://www.nature.com/nrc/index.html" class="extLink">http://www.nature.com/nrc/index.html</a>), Copyright 2009.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (Top) Chemical structure of FGFR inhibitor <b>4</b>. (Bottom) The human kinome and the group 1B cysteines. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (Left) Human kinome and the group 2B cysteines. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (Right) Chemical structures of group 2B inhibitor <b>5</b>–<b>8</b> and group 2C kinase inhibitor <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Human kinome and the group 3F kinases. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Reversible ATP competitive EGFR inhibitors gefitinib and erlotinib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Group 3F irreversible ErbB family kinase inhibitors <b>12</b>–<b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Group 3F irreversible ErbB family kinase inhibitors <b>19</b>–<b>21</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Irreversible pan-ErbB kinase inhibitors in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Crystal structure of EGFR T790M covalently bound to <b>26</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>.pdb; P-loop omitted for clearity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Chemical structures of group 3F irreversible Btk inhibitors <b>28</b>–<b>32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0010.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (Top-Left) Human kinome and the group 4 kinases. Adapted illustration reproduced with permission from AAAS (<contrib-group>Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</contrib-group>The protein kinase complement of the human genome.  <cite>Science</cite> <span class="NLM_year">2002</span>, <em>298</em>, 1912−1934) and courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (Top-Right) Chemical structures of selected irreversible group 4 kinase inhibitors <b>33</b>–<b>37</b>. (Bottom) Compound <b>35</b> bound in the active site of Erk2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E14">2E14</a>.pdb).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Irreversible group 5 kinase inhibitors <b>38</b>–<b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0012.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Transformation of imatinib into an irreversible c-KIT/PDGFR inhibitor <b>45</b> and JNK inhibitor <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0013.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Examples of chemical probes bases on irreversible protein kinase inhibitors. TAMRA = tetramethylrhodamine. NBD = nitrobenzoxadiazole. BODIPY = boron dipyrromethene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0014.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of the BODIPY-derived Btk chemical probe <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/medium/jm-2012-003203_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0015.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Pyrazolopyrimidine derivative <b>54</b> in covalent complex with c-Src T338C (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SVV">3SVV</a>.pdb; P-loop omitted for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3003203/production/images/large/jm-2012-003203_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3003203&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i26">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 111 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0ljJS9hEpM--Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljJS9hEpM--Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference componds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+componds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520componds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Huth, J .R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olejniczak, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cothron, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span> </span><span class="NLM_article-title">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja0455547" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=217-224&author=J+.R.+Huthauthor=R.+Mendozaauthor=E.+T.+Olejniczakauthor=R.+W.+Johnsonauthor=D.+A.+Cothronauthor=Y.+Liuauthor=C.+G.+Lernerauthor=J.+Chenauthor=P.+J.+Hajduk&title=ALARM+NMR%3A+a+rapid+and+robust+experimental+method+to+detect+reactive+false+positives+in+biochemical+screens"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span></div><div class="casAuthors">Huth, Jeffrey R.; Mendoza, Renaldo; Olejniczak, Edward T.; Johnson, Robert W.; Cothron, Darlene A.; Liu, Yaya; Lerner, Claude G.; Chen, Jun; Hajduk, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput screening (HTS) of large compd. collections typically results in numerous small mol. hits that must be carefully evaluated to identify valid drug leads.  Although several filtering mechanisms and other tools exist that can assist the chemist in this process, it is often the case that costly synthetic resources are expended in pursuing false positives.  We report here a rapid and reliable NMR-based method for identifying reactive false positives including those that oxidize or alkylate a protein target.  Importantly, the reactive species need not be the parent compd., as both reactive impurities and breakdown products can be detected.  The assay is called ALARM NMR (a La assay to detect reactive mols. by NMR) and is based on monitoring DTT-dependent 13C chem. shift changes of the human La antigen in the presence of a test compd. or mixt.  Extensive validation has been performed to demonstrate the reliability and utility of using ALARM NMR to assess thiol reactivity.  This included comparing ALARM NMR to a glutathione-based fluorescence assay, as well as testing a collection of more than 3500 compds. contg. HTS hits from 23 drug targets.  The data show that current in silico filtering tools fail to identify more than half of the compds. that can act via reactive mechanisms.  Significantly, we show how ALARM NMR data has been crit. in identifying reactive compds. that would otherwise have been prioritized for lead optimization.  In addn., a new filtering tool has been developed on the basis of the ALARM NMR data that can augment current in silico programs for identifying nuisance compds. and improving the process of hit triage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolKou1lGZ8tbVg90H21EOLACvtfcHk0liyEmdwUQWNWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF&md5=466332d4bdcddf6bc8a630aacbbb32ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fja0455547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0455547%26sid%3Dliteratum%253Aachs%26aulast%3DHuth%26aufirst%3DJ%2B.R.%26aulast%3DMendoza%26aufirst%3DR.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DJohnson%26aufirst%3DR.%2BW.%26aulast%3DCothron%26aufirst%3DD.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLerner%26aufirst%3DC.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DALARM%2520NMR%253A%2520a%2520rapid%2520and%2520robust%2520experimental%2520method%2520to%2520detect%2520reactive%2520false%2520positives%2520in%2520biochemical%2520screens%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D217%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug–target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug%E2%80%93target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug%25E2%2580%2593target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Residence time of receptor–ligand complexes and its effect on biological function</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5481</span><span class="NLM_x">–</span> <span class="NLM_lpage">5492</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi8002023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5481-5492&author=P.+J.+Tumminoauthor=R.+A.+Copeland&title=Residence+time+of+receptor%E2%80%93ligand+complexes+and+its+effect+on+biological+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fbi8002023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi8002023%26sid%3Dliteratum%253Aachs%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DResidence%2520time%2520of%2520receptor%25E2%2580%2593ligand%2520complexes%2520and%2520its%2520effect%2520on%2520biological%2520function%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D5481%26epage%3D5492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Smith, A. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, K. N.</span><span> </span><span class="NLM_article-title">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800498e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=225-233&author=A.+J.+T.+Smithauthor=X.+Zhangauthor=A.+G.+Leachauthor=K.+N.+Houk&title=Beyond+picomolar+affinities%3A+quantitative+aspects+of+noncovalent+and+covalent+binding+of+drugs+to+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins</span></div><div class="casAuthors">Smith, Adam J. T.; Zhang, Xiyun; Leach, Andrew G.; Houk, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review of 104 refs. summarized quant. aspects of noncovalent and covalent binding of drugs to proteins with subtopics including (1) introduction; (2) factors involved in ligand-recepto binding; (3) distribution of exptl. binding consts.; (3) covalent interactions with transition states as the origins of enzyme proficiency; (4) potential quant. advantages of covalent enzyme inhibitors and colent drugs; (5) selected examples of covalent inhibitors and drugs; (6) prospects for the design of covalent drugs; (7) conclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAhUbRxt1fu7Vg90H21EOLACvtfcHk0lgwgQmqxlJwvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1OltLw%253D&md5=529d4181046100b5e3c37a8fef571218</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm800498e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800498e%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DBeyond%2520picomolar%2520affinities%253A%2520quantitative%2520aspects%2520of%2520noncovalent%2520and%2520covalent%2520binding%2520of%2520drugs%2520to%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D225%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lewandowicz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyler, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furneaux, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, V. L.</span><span> </span><span class="NLM_article-title">Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31465</span><span class="NLM_x">–</span> <span class="NLM_lpage">31468</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31465-31468&author=A.+Lewandowiczauthor=P.+C.+Tylerauthor=G.+B.+Evansauthor=R.+H.+Furneauxauthor=V.+L.+Schramm&title=Achieving+the+ultimate+physiological+goal+in+transition+state+analogue+inhibitors+for+purine+nucleoside+phosphorylase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewandowicz%26aufirst%3DA.%26aulast%3DTyler%26aufirst%3DP.%2BC.%26aulast%3DEvans%26aufirst%3DG.%2BB.%26aulast%3DFurneaux%26aufirst%3DR.%2BH.%26aulast%3DSchramm%26aufirst%3DV.%2BL.%26atitle%3DAchieving%2520the%2520ultimate%2520physiological%2520goal%2520in%2520transition%2520state%2520analogue%2520inhibitors%2520for%2520purine%2520nucleoside%2520phosphorylase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31465%26epage%3D31468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Park, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boobis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldring, C. E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenna, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laverty, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naisbitt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll-Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Managing the challenge of chemically reactive metabolites in drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+P.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+challenge+of+chemically+reactive+metabolites+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0lgwgQmqxlJwvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520challenge%2520of%2520chemically%2520reactive%2520metabolites%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D292%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, J. S.</span><span> </span><span class="NLM_article-title">Applying mechanisms of chemical toxicity to predict drug safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">344</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx600260a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslahsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=344-369&author=F.+P.+Guengerichauthor=J.+S.+MacDonald&title=Applying+mechanisms+of+chemical+toxicity+to+predict+drug+safety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Applying Mechanisms of Chemical Toxicity to Predict Drug Safety</span></div><div class="casAuthors">Guengerich, F. Peter; MacDonald, James S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-369</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Toxicol. can no longer be used only as a science that reacts to problems but must be more proactive in predicting potential human safety issues with new drug candidates.  Success in this area must be based on an understanding of the mechanisms of toxicity.  This review summarizes and extends some of the concepts of an American Chem. Society ProSpectives meeting on the title subject held in June 2006.  One important area is the discernment of the exact nature of the most common problems in drug toxicity.  Knowledge of chem. structure alerts and relevant biol. pathways are important.  Biol. activation to reactive products and off-target pharmacol. are considered to be major contexts of drug toxicity, although defining exactly what the contributions are is not trivial.  Some newer approaches to screening for both have been developed.  A goal in predictive toxicol. is the use of in vitro methods and database development to make predictions concerning potential modes of toxicity and to stratify drug candidates for further development.  Such predictions are desirable for several economic and other reasons but are certainly not routine yet.  However, progress has been made using several approaches.  Some examples of the application of studies of wide-scale biol. responses are now available, with incorporation into development paradigms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxyWz1mKS0h7Vg90H21EOLACvtfcHk0ljQ7fyF4BLglw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslahsrk%253D&md5=d1ef7299d11c39d0ff3b031779915e54</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Ftx600260a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx600260a%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26aulast%3DMacDonald%26aufirst%3DJ.%2BS.%26atitle%3DApplying%2520mechanisms%2520of%2520chemical%2520toxicity%2520to%2520predict%2520drug%2520safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D344%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Nakayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takakusa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, O.</span><span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span> <span class="citation_source-journal">Drug. Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1970</span><span class="NLM_x">–</span> <span class="NLM_lpage">1977</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0ljQ7fyF4BLglw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug.%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Erve, J. C. L.</span><span> </span><span class="NLM_article-title">Chemical toxicology: reactive intermediate and their role in pharmacology and toxicology</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">923</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1517%2F17425255.2.6.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17125409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=923-946&author=J.+C.+L.+Erve&title=Chemical+toxicology%3A+reactive+intermediate+and+their+role+in+pharmacology+and+toxicology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology</span></div><div class="casAuthors">Erve, John C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">923-946</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Reactive intermediates formed during the metab. of drugs have been investigated extensively over the past decades.  Today, interest in reactive intermediates in drug discovery is focused on minimizing bioactivation in hopes of reducing the risk of causing so-called idiosyncratic toxicity.  These efforts are justified based on the hapten hypothesis', namely, that on binding to protein, reactive intermediates may elicit an immune response to the modified protein, leading to a cascade of events that ultimately manifests as a toxic outcome.  However, the pharmacol. action of certain drugs depends on reactive intermediates that modify crit. amino acid residues of proteins, typically enzymes, thereby altering their activity.  Thus, the notion that reactive intermediates are inherently dangerous is unjustified.  When a reactive intermediate is necessary for the desired pharmacol. effect of a drug, the selectivity it displays towards the target protein is crucial, as off-target binding may produce unwanted toxicities.  On the other hand, reactive intermediates may play no role in toxicity.  This review provides a balanced perspective, primarily focusing on the proposed role of reactive intermediates in drug toxicity, while also highlighting examples in which they are involved in causing the desired pharmacol.  It is hoped that this knowledge can help scientists involved in drug discovery and development in their challenging task of producing safe and effective drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBIFLSUGUWN7Vg90H21EOLACvtfcHk0ljQ7fyF4BLglw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1eks7nK&md5=320b9ade5e38e5d21b92a4e2781e9e62</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.6.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.6.923%26sid%3Dliteratum%253Aachs%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26atitle%3DChemical%2520toxicology%253A%2520reactive%2520intermediate%2520and%2520their%2520role%2520in%2520pharmacology%2520and%2520toxicology%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26spage%3D923%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uetrecht, J.</span><span> </span><span class="NLM_article-title">Involvement of the immune system in idiosyncratic drug reactions</span> <span class="citation_source-journal">Drug. Metab. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2133%2Fdmpk.DMPK-10-RV-085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21084762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ortb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2011&pages=47-59&author=X.+Zhangauthor=F.+Liuauthor=X.+Chenauthor=X.+Zhuauthor=J.+Uetrecht&title=Involvement+of+the+immune+system+in+idiosyncratic+drug+reactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the immune system in idiosyncratic drug reactions</span></div><div class="casAuthors">Zhang, Xiaochu; Liu, Feng; Chen, Xin; Zhu, Xu; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-59</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A review.  There is strong evidence that most idiosyncratic drug reactions (IDRs) are immune-mediated and are caused by reactive metabolites of a drug rather than by the drug itself.  Several hypotheses have been proposed by which a drug could induce an immune response.  The major hypotheses are the hapten hypothesis and the danger hypothesis; however, the characteristics and spectrum of IDRs are different with different drugs, and this likely reflects mechanistic differences; therefore, no one hypothesis is likely to explain all IDRs.  Some IDRs appear to involve epigenetic effects, direct activation of antigen-presenting cells, or disturbing the normal balance of the immune system.  It has been suggested that many cases of idiosyncratic liver injury are not immune-mediated, and other mechanisms such as mitochondrial injury may be involved.  It is essential that any hypothesis be consistent with the clin. characteristics of the IDR.  Although the characteristics of most idiosyncratic liver injury do not suggest that mitochondria are the major target, it is quite possible that milder mitochondrial injury could stimulate an immune-mediated reaction.  The observation that IDRs can vary widely among different drugs and different patients is most easily explained by an immune mechanism in which the target of the immune response is different.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXisRIJF7wu7Vg90H21EOLACvtfcHk0lgRv5BjmbfWYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ortb4%253D&md5=9e5e4d5ec4ad38b14d58e10e8e739835</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.DMPK-10-RV-085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.DMPK-10-RV-085%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DInvolvement%2520of%2520the%2520immune%2520system%2520in%2520idiosyncratic%2520drug%2520reactions%26jtitle%3DDrug.%2520Metab.%2520Pharmacokinet.%26date%3D2011%26volume%3D26%26spage%3D47%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Garuti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Non-ATP competitive protein kinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2804</span><span class="NLM_x">–</span> <span class="NLM_lpage">2821</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F092986710791859333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20586715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2804-2821&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Non-ATP+competitive+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Non-ATP competitive protein kinase inhibitors</span></div><div class="casAuthors">Garuti, L.; Roberti, M.; Bottegoni, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2804-2821</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Protein kinases represent an attractive target in oncol. drug discovery.  Most of kinase inhibitors are ATP-competitive and are called type I inhibitors.  The ATP-binding pocket is highly conserved among members of the kinase family and it is difficult to find selective agents.  Moreover, the ATP-competitive inhibitors must compete with high intracellular ATP levels leading to a discrepancy between IC50s measured by biochem. vs. cellular assays.  The non-ATP competitive inhibitors, called type II and type III inhibitors, offer the possibility to overcome these problems.  These inhibitors act by inducing a conformational shift in the target enzyme such that the kinase is no longer able to function.  In the DFG-out form, the phenylalanine side chain moves to a new position.  This movement creates a hydrophobic pocket available for occupation by the inhibitor.  Some common features are present in these inhibitors.  They contain a heterocyclic system that forms one or two hydrogen bonds with the kinase hinge residue.  They also contain a hydrophobic moiety that occupies the pocket formed by the shift of phenylalanine from the DFG motif.  Moreover, all the inhibitors bear a hydrogen bond donor-acceptor pair, usually urea or amide, that links the hinge-binding portion to the hydrophobic moiety and interacts with the allosteric site.  Examples of non ATP-competitive inhibitors are available for various kinases.  In this review small mols. capable of inducing the DFG-out conformation are reported, esp. focusing on structural feature, SAR and biol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXB1pXUfqNQLVg90H21EOLACvtfcHk0lgRv5BjmbfWYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFaju7bF&md5=6211d4dba33e8863d5781dfbaaa0fbfc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F092986710791859333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791859333%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DNon-ATP%2520competitive%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2804%26epage%3D2821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Qin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhondi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossetta, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palani, A.</span><span> </span><span class="NLM_article-title">Discovery of a potent dihydrooxadiazole series of non-ATP competitive MK2 (MAPKAPK2) inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml200238g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=100-105&author=J.+Qinauthor=P.+Dhondiauthor=X.+Huangauthor=R.+Aslanianauthor=J.+Fossettaauthor=F.+Tianauthor=D.+Lundellauthor=A.+Palani&title=Discovery+of+a+potent+dihydrooxadiazole+series+of+non-ATP+competitive+MK2+%28MAPKAPK2%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fml200238g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200238g%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DDhondi%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DAslanian%26aufirst%3DR.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DF.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DPalani%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520dihydrooxadiazole%2520series%2520of%2520non-ATP%2520competitive%2520MK2%2520%2528MAPKAPK2%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D100%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0lgUw0RwPeXF4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluge, A. F.</span><span> </span><span class="NLM_article-title">Targeted covalent drugs of the kinase family</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.cbpa.2010.06.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20609616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=475-480&author=J.+Singhauthor=R.+D.+Petterauthor=A.+F.+Kluge&title=Targeted+covalent+drugs+of+the+kinase+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent drugs of the kinase family</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Kluge, Arthur F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-480</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In the past decade tremendous progress has been made toward a new class of therapeutics termed 'targeted covalent drugs', in which structure-based approaches are employed to create small mols. that inactivate their protein target through targeted covalent attachment to a specific cysteine.  In the kinase field, this approach is demonstrating promise in overcoming the potency, selectivity, and efficacy challenges currently faced by reversible kinase inhibitors, with several advancing into late stage clin. testing.  This design paradigm has been successfully applied to making drug candidates for epidermal growth factor receptor (EGFR), Her2, and Bruton's tyrosine kinase (Btk).  Here we review recent pre-clin. and clin. advances with targeted covalent kinase inhibitors, and the potential for broader application of the approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQb40Eok-vbVg90H21EOLACvtfcHk0lgUw0RwPeXF4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqtr8%253D&md5=ee3b8b9e0c6ec317f975a426cf08428f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2010.06.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2010.06.168%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BD.%26aulast%3DKluge%26aufirst%3DA.%2BF.%26atitle%3DTargeted%2520covalent%2520drugs%2520of%2520the%2520kinase%2520family%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D14%26spage%3D475%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Krippendorf, B.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisinga, W.</span><span> </span><span class="NLM_article-title">Mechanism-based inhibition: deriving <i>K</i><sub>i</sub> and <i>k</i><sub>inact</sub> directly from time-dependent IC<sub>50</sub> values</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19675314" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-923&author=B.-F.+Krippendorfauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+Huisinga&title=Mechanism-based+inhibition%3A+deriving+Ki+and+kinact+directly+from+time-dependent+IC50+values"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorf%26aufirst%3DB.-F.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%26atitle%3DMechanism-based%2520inhibition%253A%2520deriving%2520Ki%2520and%2520kinact%2520directly%2520from%2520time-dependent%2520IC50%2520values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Garuti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2981</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F092986711796391705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21651479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2981-2994&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Irreversible+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible protein kinase inhibitors</span></div><div class="casAuthors">Garuti, L.; Roberti, M.; Bottegoni, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2981-2994</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting cancer with small mol. irreversible inhibitors of kinases represents an emerging challenge in drug discovery.  Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket.  The most common mechanism is the Michael reaction, that refers to the addn. of a nucleophile, such as cysteine, to an α,β-unsatd. carbonyl.  The nucleophile reacts at the electrophilic β-position to form an adduct; as a result the inhibitor irreversibly blocks binding of ATP to the kinase, rendering the kinase inactive.  Different cysteine-reactive groups have been evaluated, an acrylamide or a substituted acrylamide moiety are the Michael acceptors of choice.  There are some advantages for the irreversible kinase inhibition.  These compds. are highly selective because they target a specific cysteine and only a limited no. of kinases has a cysteine at the corresponding position.  Another advantage is that covalent bond formation can overcome competition with the high endogenous concn. of ATP.  A further motivation for designing irreversible inhibitors is their longer duration of action respect to conventional inhibitors.  In fact, once bound to enzyme, these compds. do not readily dissoc. and the inhibition continues even after the inhibitor leaves the circulation.  Moreover, these inhibitors have the potential to overcome and prevent the emergence of acquired resistance conferred by mutations.  In this review examples of irreversible inhibitors are reported, focusing on chem. structures, SAR and biol. activities.  The great potential of these compds. could open new and promising perspectives for a broader application of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkLFECsvPg2LVg90H21EOLACvtfcHk0lgUw0RwPeXF4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D&md5=8c732cb9de810f9fac6484c245e41867</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F092986711796391705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391705%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2981%26epage%3D2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Carrera, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandrov, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span> </span><span class="NLM_article-title">The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">442</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.90.2.442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=8421674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADyaK3sXns1Srsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=442-446&author=A.+C.+Carreraauthor=K.+Alexandrovauthor=T.+M.+Roberts&title=The+conserved+lysine+of+the+catalytic+domain+of+protein+kinases+is+actively+involved+in+the+phosphotransfer+reaction+and+not+required+for+anchoring+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP</span></div><div class="casAuthors">Carrera, Ana C.; Alexandrov, Kirill; Roberts, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">442-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The study of the various protein kinases reveals that, despite their considerably diversity, they have evolved from a common origin.  Eleven conserved subdomains have been described that encompass the catalytic core of these enzymes.  One of these conserved regions, subdomain II, contains an invariant lysine residue present in all known protein kinase catalytic domains.  Two facts have suggested that this conserved lysine of subdomain II is essential for binding ATP: (i) several investigators have demonstrated that this residue is phys. proximal to the ATP mol., and (ii) conservative substitutions at this site render the kinase inactive.  However, these results are also consistent with a functional role of the conserved lysine of subdomain II in orienting or facilitating the transfer of phosphpate.  To study in more detail the role of subdomain II, mutants of the protein-tyrosine kinase pp56lck were generated that have single amino acid substitutions within the area surrounding the conserved residue Lys-273 in subdomain II.  When compared with wild-type pp56lck, these mutants displayed profound redns. in their phosphotransfer efficiencies and small differences in their affinities for ATP.  Further, the substitution of arginine for Lys-273 resulted in a mutant protein unable to transfer the γ-phosphate of ATP but able to bind 8-azido-ATP with an efficiency similar to that of wild-type pp56lck.  These results suggest that the region including Lys-273 of subdomain II is involved in the enzymic process of phosphate transfer, rather than in anchoring ATP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobhyjaBAT6A7Vg90H21EOLACvtfcHk0lhfZ_vexyyAqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXns1Srsg%253D%253D&md5=ce9443a738a784493a3258d13210968a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.2.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.2.442%26sid%3Dliteratum%253Aachs%26aulast%3DCarrera%26aufirst%3DA.%2BC.%26aulast%3DAlexandrov%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26atitle%3DThe%2520conserved%2520lysine%2520of%2520the%2520catalytic%2520domain%2520of%2520protein%2520kinases%2520is%2520actively%2520involved%2520in%2520the%2520phosphotransfer%2520reaction%2520and%2520not%2520required%2520for%2520anchoring%2520ATP%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D442%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Buhrow, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staros, J. V.</span><span> </span><span class="NLM_article-title">Affinity labeling of the protein kinase associated with the epidermal growth factor receptor in membrane vesicles from A431 cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">4019</span><span class="NLM_x">–</span> <span class="NLM_lpage">4020</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=4019-4020&author=S.+A.+Buhrowauthor=S.+Cohenauthor=J.+V.+Staros&title=Affinity+labeling+of+the+protein+kinase+associated+with+the+epidermal+growth+factor+receptor+in+membrane+vesicles+from+A431+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuhrow%26aufirst%3DS.%2BA.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DStaros%26aufirst%3DJ.%2BV.%26atitle%3DAffinity%2520labeling%2520of%2520the%2520protein%2520kinase%2520associated%2520with%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520membrane%2520vesicles%2520from%2520A431%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D4019%26epage%3D4020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Scoggins, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summerfield, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staros, J. V.</span><span> </span><span class="NLM_article-title">5′-(<i>p</i>-Fluorosulfonylbenzoyl)-2′(or 3′)-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: Interaction with the kinase active site of the receptor for epidermal growth factor</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">9197</span><span class="NLM_x">–</span> <span class="NLM_lpage">9203</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi952909d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1996&pages=9197-9203&author=R.+M.+Scogginsauthor=A.+E.+Summerfieldauthor=R.+A.+Steinauthor=C.+A.+Guyerauthor=J.+V.+Staros&title=5%E2%80%B2-%28p-Fluorosulfonylbenzoyl%29-2%E2%80%B2%28or+3%E2%80%B2%29-%28methylanthraniloyl%29adenosine%2C+fluorescent+affinity+labels+for+adenine+nucleotide+binding+sites%3A+Interaction+with+the+kinase+active+site+of+the+receptor+for+epidermal+growth+factor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1021%2Fbi952909d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi952909d%26sid%3Dliteratum%253Aachs%26aulast%3DScoggins%26aufirst%3DR.%2BM.%26aulast%3DSummerfield%26aufirst%3DA.%2BE.%26aulast%3DStein%26aufirst%3DR.%2BA.%26aulast%3DGuyer%26aufirst%3DC.%2BA.%26aulast%3DStaros%26aufirst%3DJ.%2BV.%26atitle%3D5%25E2%2580%25B2-%2528p-Fluorosulfonylbenzoyl%2529-2%25E2%2580%25B2%2528or%25203%25E2%2580%25B2%2529-%2528methylanthraniloyl%2529adenosine%252C%2520fluorescent%2520affinity%2520labels%2520for%2520adenine%2520nucleotide%2520binding%2520sites%253A%2520Interaction%2520with%2520the%2520kinase%2520active%2520site%2520of%2520the%2520receptor%2520for%2520epidermal%2520growth%2520factor%26jtitle%3DBiochemistry%26date%3D1996%26volume%3D35%26spage%3D9197%26epage%3D9203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Fox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzgibbon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao, H.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brummel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M. S.-S.</span><span> </span><span class="NLM_article-title">Kinetic mechanism and ATP-binding site reactivity of p38γ MAP kinase</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">461</span><span class="NLM_x">, </span> <span class="NLM_fpage">323</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=461&publication_year=1999&pages=323-328&author=T.+Foxauthor=M.+J.+Fitzgibbonauthor=M.+A.+Flemingauthor=H.-M.+Hsiaoauthor=C.+L.+Brummelauthor=M.+S.-S.+Su&title=Kinetic+mechanism+and+ATP-binding+site+reactivity+of+p38%CE%B3+MAP+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DT.%26aulast%3DFitzgibbon%26aufirst%3DM.%2BJ.%26aulast%3DFleming%26aufirst%3DM.%2BA.%26aulast%3DHsiao%26aufirst%3DH.-M.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DSu%26aufirst%3DM.%2BS.-S.%26atitle%3DKinetic%2520mechanism%2520and%2520ATP-binding%2520site%2520reactivity%2520of%2520p38%25CE%25B3%2520MAP%2520kinase%26jtitle%3DFEBS%2520Lett.%26date%3D1999%26volume%3D461%26spage%3D323%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Vereb, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gergely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulkan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heilmeyer, L. M. G.</span><span> </span><span class="NLM_article-title">The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5′-<i>p</i>-fluorosulfonylbenzoyladenosine</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">259</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2FS1357-2725%2801%2900006-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=11311856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD3MXislGgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2001&pages=249-259&author=G.+Verebauthor=A.+Ballaauthor=P.+Gergelyauthor=M.+P.+Wymannauthor=H.+Gulkanauthor=S.+Suerauthor=L.+M.+G.+Heilmeyer&title=The+ATP-binding+site+of+brain+phosphatidylinositol+4-kinase+PI4K230+as+revealed+by+5%E2%80%B2-p-fluorosulfonylbenzoyladenosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5'-p-fluorosulfonylbenzoyladenosine</span></div><div class="casAuthors">Vereb, G.; Balla, A.; Gergely, P.; Wymann, M. P.; Gulkan, H.; Suer, S.; Heilmeyer, L. M. G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-259</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The ATP-binding site of purified bovine brain phosphatidylinositol 4-kinase 230 (PI4K230) was studied by its reaction with 5'-p-fluorosulfonylbenzoyladenosine (FSBA), an ATP-like alkylating reagent.  Four hundred to eight hundred micromolar FSBA inactivated PI4K230 specifically with apparently first-order kinetics and resulted in 50% loss of enzyme activity in 36-130 min.  The specificity of the reaction with FSBA was demonstrated by the lack of inactivation with 5'-p-fluorosulfonylbenzoyl chloride and by protection with ATP and ATP analogs against inactivation.  Most ATP analogs competed with FSBA inactivation in order of their increasing hydrophobicity, parallel to their inhibitory potency in activity measurements.  The specific binding of FSBA to PI4K230 was demonstrated also by Western-blot expts.  These results suggest that FSBA-reactive group(s) involved in the enzyme activity are located near to the ATP-binding site in a hydrophobic region of native PI4K230.  Expts. with site-directed mutagenesis indicate that the conserved Lys-1792 plays an essential role in the enzyme activity and serves as one target of affinity labeling by FSBA.  Prevention of both Lys-1792-directed and Lys-1792-independent binding of FSBA by Cibacron Blue 3GA suggest that these sites are located spatially close to each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjba_qOmUngbVg90H21EOLACvtfcHk0lj_QFjJs-d0fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXislGgsbo%253D&md5=3de0c6c1ab29228d9a6d25a9f4bd8a2d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2801%2900006-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252801%252900006-1%26sid%3Dliteratum%253Aachs%26aulast%3DVereb%26aufirst%3DG.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DGulkan%26aufirst%3DH.%26aulast%3DSuer%26aufirst%3DS.%26aulast%3DHeilmeyer%26aufirst%3DL.%2BM.%2BG.%26atitle%3DThe%2520ATP-binding%2520site%2520of%2520brain%2520phosphatidylinositol%25204-kinase%2520PI4K230%2520as%2520revealed%2520by%25205%25E2%2580%25B2-p-fluorosulfonylbenzoyladenosine%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2001%26volume%3D33%26spage%3D249%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culberson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallicchio, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kett, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quigley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waxmann, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zartman, C. B.</span><span> </span><span class="NLM_article-title">Biochemical and structural characterization of a novel class of inhibitors of the type 1 insuline-like growth factor and insulin receptor kinases</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">9430</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0500628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=9430-9440&author=I.+M.+Bellauthor=S.+M.+Stirdivantauthor=J.+Ahernauthor=C.+Culbersonauthor=P.+L.+Darkeauthor=C.+J.+Dinsmoreauthor=R.+A.+Drakasauthor=S.+N.+Gallicchioauthor=S.+L.+Grahamauthor=D.+C.+Heimbrookauthor=D.+L.+Hallauthor=J.+Huaauthor=N.+R.+Kettauthor=A.+S.+Kimauthor=M.+Kornienkoauthor=L.+C.+Kuoauthor=S.+K.+Munshiauthor=A.+G.+Quigleyauthor=J.+C.+Reidauthor=B.+W.+Trotterauthor=L.+H.+Waxmannauthor=T.+M.+Williamsauthor=C.+B.+Zartman&title=Biochemical+and+structural+characterization+of+a+novel+class+of+inhibitors+of+the+type+1+insuline-like+growth+factor+and+insulin+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fbi0500628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0500628%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DAhern%26aufirst%3DJ.%26aulast%3DCulberson%26aufirst%3DC.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DKett%26aufirst%3DN.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DKuo%26aufirst%3DL.%2BC.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26aulast%3DWaxmann%26aufirst%3DL.%2BH.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DZartman%26aufirst%3DC.%2BB.%26atitle%3DBiochemical%2520and%2520structural%2520characterization%2520of%2520a%2520novel%2520class%2520of%2520inhibitors%2520of%2520the%2520type%25201%2520insuline-like%2520growth%2520factor%2520and%2520insulin%2520receptor%2520kinases%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D9430%26epage%3D9440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Powis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonjouklian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berggren, M. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallegos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashendel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalkow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grindey, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlahos, C. J.</span><span> </span><span class="NLM_article-title">Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2419</span><span class="NLM_x">–</span> <span class="NLM_lpage">2423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=2419-2423&author=G.+Powisauthor=R.+Bonjouklianauthor=M.+M+Berggrenauthor=A.+Gallegosauthor=R.+Abrahamauthor=C.+Ashendelauthor=L.+Zalkowauthor=W.+F.+Matterauthor=J.+Dodgeauthor=G.+Grindeyauthor=C.+J.+Vlahos&title=Wortmannin%2C+a+potent+and+selective+inhibitor+of+phosphatidylinositol-3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPowis%26aufirst%3DG.%26aulast%3DBonjouklian%26aufirst%3DR.%26aulast%3DBerggren%26aufirst%3DM.%2BM%26aulast%3DGallegos%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DR.%26aulast%3DAshendel%26aufirst%3DC.%26aulast%3DZalkow%26aufirst%3DL.%26aulast%3DMatter%26aufirst%3DW.%2BF.%26aulast%3DDodge%26aufirst%3DJ.%26aulast%3DGrindey%26aufirst%3DG.%26aulast%3DVlahos%26aufirst%3DC.%2BJ.%26atitle%3DWortmannin%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520phosphatidylinositol-3-kinase%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D2419%26epage%3D2423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulgarelli-Leva, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvelebil, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirola, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van-haesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panayotou, G.</span><span> </span><span class="NLM_article-title">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">–</span> <span class="NLM_lpage">1733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1128%2FMCB.16.4.1722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=8657148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=1722-1733&author=M.+P.+Wymannauthor=G.+Bulgarelli-Levaauthor=M.+J.+Zvelebilauthor=M.+L.+Pirolaauthor=B.+Van-haesebroeckauthor=M.+D.+Waterfieldauthor=G.+Panayotou&title=Wortmannin+inactivates+phosphoinositide+3-kinase+by+covalent+modification+of+Lys-802%2C+a+residue+involved+in+the+phosphate+transfer+reaction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction</span></div><div class="casAuthors">Wymann, Matthias P.; Bulgarelli-Leva, Ginette; Zvelebil, Marketa J.; Pirola, Luciano; Vanhaesebroeck, Bart; Waterfield, Michael D.; Panayotou, George</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1722-33</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Wortmannin at nanomolar concns. is a potent and specific inhibitor of phosphoinositide (PI) 3-kinase and has been used extensively to demonstrate the role of this enzyme in diverse signal transduction processes.  At higher concns., wortmannin inhibits the ataxia telangiectasia gene (ATM)-related DNA dependent protein kinase (DNA-PKcs).  The authors report here the identification of the site of interaction of wortmannin in the catalytic subunit of PI3-kinase, p110α.  At physiol. pH (6.5 to 8) wortmannin reacted specifically with p110α.  Phosphatidylinositol-4,5-diphosphate, ATP, and ATP analogs [adenine and 5'-(4-fluorosulfonylbenzoyl)adenine] competed effectively with wortmannin, while substances contg. nucleophilic amino acid side chain functions had no effect at the same concns.  This suggests that the wortmannin target site is localized in proximity to the substrate-binding site and that residues involved in wortmannin binding have an increased nucleophilicity because of their protein environment.  Proteolytic fragments of wortmannin-treated, recombinant P110α were mapped with anti-wortmannin and anti-p110α peptide antibodies, thus limiting the target site within a 10-kDa fragment, colocalizing with the ATP-binding site.  Site-directed mutagenesis of all candidate residues within this region showed that only the conservative Lys-802-59-Arg mutation abolished wortmannin binding.  Inhibition of PI 3-kinase occurs, therefore, by the formation of an enamine following the attack of Lys-802 on the furan ring (at C-20) of wortmannin.  The Lys-802-t9-Arg mutant was also unable to bind FSBA and was catalytically inactive in lipid and protein kinase assays, indicating a crucial role for Lys-802 in the phosphotransfer reaction.  In contrast, an Arg-916-to-Pro mutation abolished the catalytic activity whereas covalent wortmannin binding remained intact.  The results provide the basis for the design of novel and specific inhibitors of an enzyme family, including PI kinases and ATM-related genes, that play a central role in many physiol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoobMQ6HMdUcbVg90H21EOLACvtfcHk0liQiEgqQX5FNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVags7s%253D&md5=54ebe365b4ad8260555c8b962e03d28b</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.4.1722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.4.1722%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DBulgarelli-Leva%26aufirst%3DG.%26aulast%3DZvelebil%26aufirst%3DM.%2BJ.%26aulast%3DPirola%26aufirst%3DM.%2BL.%26aulast%3DVan-haesebroeck%26aufirst%3DB.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DPanayotou%26aufirst%3DG.%26atitle%3DWortmannin%2520inactivates%2520phosphoinositide%25203-kinase%2520by%2520covalent%2520modification%2520of%2520Lys-802%252C%2520a%2520residue%2520involved%2520in%2520the%2520phosphate%2520transfer%2520reaction%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D1722%26epage%3D1733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Norman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutherford, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worzalla, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vlahos, C. J.</span><span> </span><span class="NLM_article-title">Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1106</span><span class="NLM_x">–</span> <span class="NLM_lpage">1111</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm950619p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADyaK28XpsFKhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1106-1111&author=B.+H.+Normanauthor=C.+Shihauthor=J.+E.+Tothauthor=J.+E.+Rayauthor=J.+A.+Dodgeauthor=D.+W.+Johnsonauthor=P.+G.+Rutherfordauthor=R.+M.+Schultzauthor=J.+F.+Worzallaauthor=C.+J.+Vlahos&title=Studies+on+the+mechanism+of+phosphatidylinositol+3-kinase+inhibition+by+wortmannin+and+related+analogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the Mechanism of Phosphatidylinositol 3-Kinase Inhibition by Wortmannin and Related Analogs</span></div><div class="casAuthors">Norman, Bryan H.; Shih, Chuan; Toth, John E.; Ray, James E.; Dodge, Jeffrey A.; Johnson, Doug W.; Rutherford, Pamela G.; Schultz, Richard M.; Worzalla, John F.; Vlahos, Chris J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1106-11</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Wortmannin, a fungal metabolite, was identified as a potent inhibitor (IC50 = 4.2 nM) of phosphatidylinositol 3-kinase (PI 3-kinase).  Due to the importance of PI 3-kinase in several intracellular signaling pathways, structure-activity studies on wortmannin analogs were performed in an effort to understand the structural requirements necessary for PI 3-kinase inhibition.  Since wortmannin is an irreversible inhibitor of PI 3-kinase, it was postulated that covalent attachment at the electrophilic C-21 site was a possible mode of action for PI 3-kinase inhibition.  The authors have prepd. various wortmannin analogs which address the possibility of this mechanism.  Of particular interest are compds. which affect the C-21 position of wortmannin either sterically or electronically.  Our results support the conclusion that nucleophilic addn. by the kinase onto the C-21 position of wortmannin is required for inhibition of PI 3-kinase by wortmannin analogs.  Addnl., we have prepd. several D-ring analogs of wortmannin, and their activities are reported herein.  The authors conclude that the wortmannin D ring is an important recognition site since modifications have such a dramatic effect on inhibitor potency.  Finally, the identification of 17β-hydroxywortmannin represents the first reported subnanomolar inhibitor of PI 3-kinase.  These studies, along with in vivo antitumor expts., suggest that the mechanism of PI 3-kinase inhibition correlates to the assocd. toxicity obsd. with wortmannin-based inhibitors of PI 3-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiKiIYaSVQJrVg90H21EOLACvtfcHk0liQiEgqQX5FNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XpsFKhsQ%253D%253D&md5=62f71b396d36de4fe03a63ee624753c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm950619p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950619p%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DB.%2BH.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DJ.%2BE.%26aulast%3DRay%26aufirst%3DJ.%2BE.%26aulast%3DDodge%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DD.%2BW.%26aulast%3DRutherford%26aufirst%3DP.%2BG.%26aulast%3DSchultz%26aufirst%3DR.%2BM.%26aulast%3DWorzalla%26aufirst%3DJ.%2BF.%26aulast%3DVlahos%26aufirst%3DC.%2BJ.%26atitle%3DStudies%2520on%2520the%2520mechanism%2520of%2520phosphatidylinositol%25203-kinase%2520inhibition%2520by%2520wortmannin%2520and%2520related%2520analogs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D1106%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Walker, E. H</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wymann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R.</span><span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporin</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporin%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreder, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferris, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, J. S.</span><span> </span><span class="NLM_article-title">Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian Polo-like kinase</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2004.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15664519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=99-107&author=Y.+Liuauthor=K.+R.+Shrederauthor=W.+Gaiauthor=S.+Corralauthor=D.+K.+Ferrisauthor=J.+S.+Rosenblum&title=Wortmannin%2C+a+widely+used+phosphoinositide+3-kinase+inhibitor%2C+also+potently+inhibits+mammalian+Polo-like+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Wortmannin, a Widely Used Phosphoinositide 3-Kinase Inhibitor, also Potently Inhibits Mammalian Polo-like Kinase</span></div><div class="casAuthors">Liu, Yongsheng; Shreder, Kevin R.; Gai, Wenzhi; Corral, Sergio; Ferris, Douglas K.; Rosenblum, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-107</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polo-like kinases (PLKs) play crit. roles throughout mitosis.  Here, we report that wortmannin, which was previously thought to be a highly selective inhibitor of phosphoinositide (PI) 3-kinases, is a potent inhibitor of mammalian PLK1.  Observation of the wortmannin-PLK1 interaction was enabled by a tetramethylrhodamine-wortmannin conjugate (AX7503) that permits rapid detection of PLK1 activity and expression in complex proteomes.  Importantly, we show that wortmannin inhibits PLK1 activity in an in vitro kinase assay with an IC50 of 24 nM and when incubated with intact cells.  Taken together, our results indicate that, at the concns. of wortmannin commonly used to inhibit PI 3-kinases, PLK1 is also significantly inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo0cYBstR6BbVg90H21EOLACvtfcHk0lhD_zBckOgk1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlKmuw%253D%253D&md5=8aaad2a6d961730e547db70be1dc0c32</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26aulast%3DGai%26aufirst%3DW.%26aulast%3DCorral%26aufirst%3DS.%26aulast%3DFerris%26aufirst%3DD.%2BK.%26aulast%3DRosenblum%26aufirst%3DJ.%2BS.%26atitle%3DWortmannin%252C%2520a%2520widely%2520used%2520phosphoinositide%25203-kinase%2520inhibitor%252C%2520also%2520potently%2520inhibits%2520mammalian%2520Polo-like%2520kinase%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D99%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblum, J. S.</span><span> </span><span class="NLM_article-title">Polo-like kinases inhibited by wortmannin</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">2505</span><span class="NLM_x">–</span> <span class="NLM_lpage">2511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=2505-2511&author=Y.+Liuauthor=N.+Jiangauthor=J.+Wuauthor=W.+Daiauthor=J.+S.+Rosenblum&title=Polo-like+kinases+inhibited+by+wortmannin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DRosenblum%26aufirst%3DJ.%2BS.%26atitle%3DPolo-like%2520kinases%2520inhibited%2520by%2520wortmannin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D2505%26epage%3D2511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Barr, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugochukwu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, O. N. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippakopoulos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfano, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savitsky, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess-Brown, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.cell.2008.11.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19167335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=352-363&author=A.+J.+Barrauthor=E.+Ugochukwuauthor=W.+H.+Leeauthor=O.+N.+F.+Kingauthor=P.+Filippakopoulosauthor=I.+Alfanoauthor=P.+Savitskyauthor=N.+A.+Burgess-Brownauthor=S.+M%C3%BCllerauthor=S.+Knapp&title=Large-scale+structural+analysis+of+the+classical+human+protein+tyrosine+phosphatome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale structural analysis of the classical human protein tyrosine phosphatome</span></div><div class="casAuthors">Barr, Alastair J.; Ugochukwu, Emilie; Lee, Wen Hwa; King, Oliver N. F.; Filippakopoulos, Panagis; Alfano, Ivan; Savitsky, Pavel; Burgess-Brown, Nicola A.; Muller, Susanne; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">352-363</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases (PTPs) play a crit. role in regulating cellular functions by selectively dephosphorylating their substrates.  Here we present 22 human PTP crystal structures that, together with prior structural knowledge, enable a comprehensive anal. of the classical PTP family.  Despite their largely conserved fold, surface properties of PTPs are strikingly diverse.  A potential secondary substrate-binding pocket is frequently found in phosphatases, and this has implications for both substrate recognition and development of selective inhibitors.  Structural comparison identified four diverse catalytic loop (WPD) conformations and suggested a mechanism for loop closure.  Enzymic assays revealed vast differences in PTP catalytic activity and identified PTPD1, PTPD2, and HDPTP as catalytically inert protein phosphatases.  We propose a "head-to-toe" dimerization model for RPTPγ/ζ that is distinct from the "inhibitory wedge" model and that provides a mol. basis for inhibitory regulation.  This phosphatome resource gives an expanded insight into intrafamily PTP diversity, catalytic activity, substrate recognition, and autoregulatory self-assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0kaabM4U0LLVg90H21EOLACvtfcHk0lhD_zBckOgk1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Kiu7o%253D&md5=f47994736342cc0490609596d66fd03e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.11.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.11.038%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DA.%2BJ.%26aulast%3DUgochukwu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DW.%2BH.%26aulast%3DKing%26aufirst%3DO.%2BN.%2BF.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DAlfano%26aufirst%3DI.%26aulast%3DSavitsky%26aufirst%3DP.%26aulast%3DBurgess-Brown%26aufirst%3DN.%2BA.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DLarge-scale%2520structural%2520analysis%2520of%2520the%2520classical%2520human%2520protein%2520tyrosine%2520phosphatome%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D352%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Roberts, R.</span><span> </span><span class="NLM_article-title">Lysosomal cysteine proteases: structure, function and inhibition of cathepsins</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1358%2Fdnp.2005.18.10.949485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=16491162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt1KrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=605-614&author=R.+Roberts&title=Lysosomal+cysteine+proteases%3A+structure%2C+function+and+inhibition+of+cathepsins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal cysteine proteases: Structure, function and inhibition of cathepsins</span></div><div class="casAuthors">Roberts, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">605-614</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Lysosomal cysteine proteases, a subgroup of the cathepsin family, are crit. for normal cellular functions such as general protein turnover, antigen processing, and bone remodeling.  In the past decade, the no. of identified human cathepsins has more than doubled and their known role in several pathologies has expanded rapidly.  An increased understanding of the structure and mechanism of this class of enzymes has brought on new fervor in the design of small-mol. inhibitors with the hope of producing specific, therapeutic drugs for diseases such as arthritis, allergy, multiple sclerosis, atherosclerosis, Alzheimer's disease, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMyLfopyr_tLVg90H21EOLACvtfcHk0lhD_zBckOgk1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt1KrtrY%253D&md5=bb28891faef6af18373b82ad41407e2a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2005.18.10.949485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2005.18.10.949485%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DR.%26atitle%3DLysosomal%2520cysteine%2520proteases%253A%2520structure%252C%2520function%2520and%2520inhibition%2520of%2520cathepsins%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2005%26volume%3D18%26spage%3D605%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kortemme, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, T. E.</span><span> </span><span class="NLM_article-title">Ionisation of cysteine residues at the termini of model alpha-helical peptides. Relevance to unusual thiol p<i>K</i><sub>a</sub> values in proteins of the thioredoxin family</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">253</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">812</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1995&pages=799-812&author=T.+Kortemmeauthor=T.+E.+Creighton&title=Ionisation+of+cysteine+residues+at+the+termini+of+model+alpha-helical+peptides.+Relevance+to+unusual+thiol+pKa+values+in+proteins+of+the+thioredoxin+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DCreighton%26aufirst%3DT.%2BE.%26atitle%3DIonisation%2520of%2520cysteine%2520residues%2520at%2520the%2520termini%2520of%2520model%2520alpha-helical%2520peptides.%2520Relevance%2520to%2520unusual%2520thiol%2520pKa%2520values%2520in%2520proteins%2520of%2520the%2520thioredoxin%2520family%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D253%26spage%3D799%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Paulsen, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K. S.</span><span> </span><span class="NLM_article-title">Orchestrating redox signaling networks through regulatory cysteine switches</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=47-62&author=C.+E.+Paulsenauthor=K.+S.+Carroll&title=Orchestrating+redox+signaling+networks+through+regulatory+cysteine+switches"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DC.%2BE.%26aulast%3DCarroll%26aufirst%3DK.%2BS.%26atitle%3DOrchestrating%2520redox%2520signaling%2520networks%2520through%2520regulatory%2520cysteine%2520switches%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26spage%3D47%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Paulsen, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K. S.</span><span> </span><span class="NLM_article-title">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio.736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=57-64&author=C.+E.+Paulsenauthor=T.+H.+Truongauthor=F.+J.+Garciaauthor=A.+Homannauthor=V.+Guptaauthor=S.+E.+Leonardauthor=K.+S.+Carroll&title=Peroxide-dependent+sulfenylation+of+the+EGFR+catalytic+site+enhances+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity</span></div><div class="casAuthors">Paulsen, Candice E.; Truong, Thu H.; Garcia, Francisco J.; Homann, Arne; Gupta, Vinayak; Leonard, Stephen E.; Carroll, Kate S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein sulfenylation is a post-translational modification of emerging importance in higher eukaryotes.  However, investigation of its diverse roles remains challenging, particularly within a native cellular environment.  Herein we report the development and application of DYn-2, a new chemoselective probe for detecting sulfenylated proteins in human cells.  These studies show that epidermal growth factor receptor (EGFR)-mediated signaling results in H2O2 prodn. and oxidn. of downstream proteins.  In addn., we demonstrate that DYn-2 has the ability to detect differences in sulfenylation rates within the cell, which are assocd. with differences in target protein localization.  We also show that the direct modification of epidermal growth factor receptor by H2O2 at a crit. active site cysteine (Cys797) enhances its tyrosine kinase activity.  Collectively, our findings reveal sulfenylation as a global signaling mechanism that is akin to phosphorylation and has regulatory implications for other receptor tyrosine kinases and irreversible inhibitors that target oxidant-sensitive cysteines in proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp30snMrGIfzLVg90H21EOLACvtfcHk0lhrAJkaWFAfhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Sku77E&md5=44011c82266cf6a47922b1ba1038cc30</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.736%26sid%3Dliteratum%253Aachs%26aulast%3DPaulsen%26aufirst%3DC.%2BE.%26aulast%3DTruong%26aufirst%3DT.%2BH.%26aulast%3DGarcia%26aufirst%3DF.%2BJ.%26aulast%3DHomann%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLeonard%26aufirst%3DS.%2BE.%26aulast%3DCarroll%26aufirst%3DK.%2BS.%26atitle%3DPeroxide-dependent%2520sulfenylation%2520of%2520the%2520EGFR%2520catalytic%2520site%2520enhances%2520kinase%2520activity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D57%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Leonberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, Y.-C.</span><span> </span><span class="NLM_article-title">The functional role of cysteine residues for c-Abl kinase activity</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2007&pages=207-212&author=A.+K.+Leonbergauthor=Y.-C.+Chai&title=The+functional+role+of+cysteine+residues+for+c-Abl+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeonberg%26aufirst%3DA.%2BK.%26aulast%3DChai%26aufirst%3DY.-C.%26atitle%3DThe%2520functional%2520role%2520of%2520cysteine%2520residues%2520for%2520c-Abl%2520kinase%2520activity%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2007%26volume%3D304%26spage%3D207%26epage%3D212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Satoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipton, S. A.</span><span> </span><span class="NLM_article-title">Redox regulation of neuronal survival mediated by electrophilic compounds</span> <span class="citation_source-journal">Trends Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2006&pages=37-45&author=T.+Satohauthor=S.+A.+Lipton&title=Redox+regulation+of+neuronal+survival+mediated+by+electrophilic+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DLipton%26aufirst%3DS.%2BA.%26atitle%3DRedox%2520regulation%2520of%2520neuronal%2520survival%2520mediated%2520by%2520electrophilic%2520compounds%26jtitle%3DTrends%2520Neurosci.%26date%3D2006%26volume%3D30%26spage%3D37%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lhrAJkaWFAfhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformatinally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformatinally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformatinally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. A.</span><span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+A.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lhjadEJHkFeSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BA.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Powers, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeskey, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellstein, A.</span><span> </span><span class="NLM_article-title">Fibroblast growth factors, their receptors and signaling</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2000&pages=165-197&author=C.+J.+Powersauthor=S.+W.+McLeskeyauthor=A.+Wellstein&title=Fibroblast+growth+factors%2C+their+receptors+and+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DC.%2BJ.%26aulast%3DMcLeskey%26aufirst%3DS.%2BW.%26aulast%3DWellstein%26aufirst%3DA.%26atitle%3DFibroblast%2520growth%2520factors%252C%2520their%2520receptors%2520and%2520signaling%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2000%26volume%3D7%26spage%3D165%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0lhjadEJHkFeSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0lhjadEJHkFeSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frödin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Fr%C3%B6dinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0lj-QmjefFPgaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFr%25C3%25B6din%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Malakhova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tereshko, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z.</span><span> </span><span class="NLM_article-title">Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnsmb1347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18084304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=112-113&author=M.+Malakhovaauthor=V.+Tereshkoauthor=S.-Y.+Leeauthor=K.+Yaoauthor=Y.-Y.+Choauthor=A.+Bodeauthor=Z.+Dong&title=Structural+basis+for+activation+of+the+autoinhibitory+C-terminal+kinase+domain+of+p90+RSK2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2</span></div><div class="casAuthors">Malakhova, Margarita; Tereshko, Valentina; Lee, Sung-Young; Yao, Ke; Cho, Yong-Yeon; Bode, Ann; Dong, Zigang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-113</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The x-ray structure at 2.0-Å resoln. of the p90 ribosomal S6 kinase 2 C-terminal kinase domain revealed a C-terminal autoinhibitory αL-helix that was embedded in the kinase scaffold and dets. the inactive kinase conformation.  We suggest a mechanism of activation through displacement of the αL-helix and rearrangement of the conserved residue Glu500, as well as the reorganization of the T-loop into the active conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOwN4HkRh6CbVg90H21EOLACvtfcHk0lj-QmjefFPgaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWgtA%253D%253D&md5=cf16ccfd40d8e3f605ddb0f740fa9578</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1347%26sid%3Dliteratum%253Aachs%26aulast%3DMalakhova%26aufirst%3DM.%26aulast%3DTereshko%26aufirst%3DV.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DYao%26aufirst%3DK.%26aulast%3DCho%26aufirst%3DY.-Y.%26aulast%3DBode%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DStructural%2520basis%2520for%2520activation%2520of%2520the%2520autoinhibitory%2520C-terminal%2520kinase%2520domain%2520of%2520p90%2520RSK2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D112%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Henise, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4133</span><span class="NLM_x">–</span> <span class="NLM_lpage">4146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0lj-QmjefFPgaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Cross, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Templeton, D. J.</span><span> </span><span class="NLM_article-title">Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">675</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2004&pages=675-683&author=J.+V.+Crossauthor=D.+J.+Templeton&title=Oxidative+stress+inhibits+MEKK1+by+site-specific+glutathionylation+in+the+ATP-binding+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DJ.%2BV.%26aulast%3DTempleton%26aufirst%3DD.%2BJ.%26atitle%3DOxidative%2520stress%2520inhibits%2520MEKK1%2520by%2520site-specific%2520glutathionylation%2520in%2520the%2520ATP-binding%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2004%26volume%3D381%26spage%3D675%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Cross, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foss, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rady, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Templeton, D. J.</span><span> </span><span class="NLM_article-title">The isothiocyanate class of bioactive nutrients covalently inhibit the MEKK1 protein kinase</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=183&author=J.+V.+Crossauthor=F.+W.+Fossauthor=J.+M.+Radyauthor=T.+L.+Macdonaldauthor=D.+J.+Templeton&title=The+isothiocyanate+class+of+bioactive+nutrients+covalently+inhibit+the+MEKK1+protein+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DJ.%2BV.%26aulast%3DFoss%26aufirst%3DF.%2BW.%26aulast%3DRady%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DTempleton%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520isothiocyanate%2520class%2520of%2520bioactive%2520nutrients%2520covalently%2520inhibit%2520the%2520MEKK1%2520protein%2520kinase%26jtitle%3DBMC%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaoud, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laroche, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalby, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerwin, S. M.</span><span> </span><span class="NLM_article-title">Synthesis and biological evalution of p38α kinase-targeting dialkynylimidazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6293</span><span class="NLM_x">–</span> <span class="NLM_lpage">6297</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6293-6297&author=J.+Liauthor=T.+S.+Kaoudauthor=C.+Larocheauthor=K.+N.+Dalbyauthor=S.+M.+Kerwin&title=Synthesis+and+biological+evalution+of+p38%CE%B1+kinase-targeting+dialkynylimidazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKaoud%26aufirst%3DT.%2BS.%26aulast%3DLaroche%26aufirst%3DC.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26aulast%3DKerwin%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520biological%2520evalution%2520of%2520p38%25CE%25B1%2520kinase-targeting%2520dialkynylimidazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6293%26epage%3D6297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Fitzgerald, C. E.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=764-769&author=C.+E.+Fitzgerald&title=Structural+basis+for+p38alpha+MAP+kinase+quinazolinone+and+pyridol-pyrimidine+inhibitor+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DC.%2BE.%26atitle%3DStructural%2520basis%2520for%2520p38alpha%2520MAP%2520kinase%2520quinazolinone%2520and%2520pyridol-pyrimidine%2520inhibitor%2520specificity%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D764%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris., M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=1-11&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+Kris.author=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris.%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance on non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+J%C3%A4nneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+on+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lgNtYD9WSq6WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520on%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liVXPhBlsy8Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haske, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span> </span><span class="NLM_article-title">Structure-based design of a potent, selective and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1130</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960380s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1130-1135&author=J.+Singhauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=T.+Haskeauthor=A.+Whittyauthor=D.+J.+McNamara&title=Structure-based+design+of+a+potent%2C+selective+and+irreversible+inhibitor+of+the+catalytic+domain+of+the+erbB+receptor+subfamily+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm960380s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960380s%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DHaske%26aufirst%3DT.%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26atitle%3DStructure-based%2520design%2520of%2520a%2520potent%252C%2520selective%2520and%2520irreversible%2520inhibitor%2520of%2520the%2520catalytic%2520domain%2520of%2520the%2520erbB%2520receptor%2520subfamily%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1130%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosin kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+T.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosin+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%2BT.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosin%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnick, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by <i>N</i>-[4-[3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,875)</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1999&pages=917-925&author=C.+M.+Discafaniauthor=M.+L.+Carrollauthor=M.+B.+Floydauthor=I%2C+J.+Hollanderauthor=Z.+Husainauthor=B.+D.+Johnsonauthor=D.+Kitchenauthor=M.+K.+Mayauthor=M.+S.+Maloauthor=A.+A.+Minnickauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=A.+Wissnerauthor=L.+M.+Greenberger&title=Irreversible+inhibition+of+epidermal+growth+factor+receptor+tyrosine+kinase+with+in+vivo+activity+by+N-%5B4-%5B3-bromophenyl%29amino%5D-6-quinazolinyl%5D-2-butynamide+%28CL-387%2C875%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DCarroll%26aufirst%3DM.%2BL.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DHollander%26aufirst%3DI%252C%2BJ.%26aulast%3DHusain%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DKitchen%26aufirst%3DD.%26aulast%3DMay%26aufirst%3DM.%2BK.%26aulast%3DMalo%26aufirst%3DM.%2BS.%26aulast%3DMinnick%26aufirst%3DA.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DIrreversible%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520activity%2520by%2520N-%255B4-%255B3-bromophenyl%2529amino%255D-6-quinazolinyl%255D-2-butynamide%2520%2528CL-387%252C875%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1999%26volume%3D57%26spage%3D917%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">The development of HKI-272 and related compounds for the treatment of cancer</span> <span class="citation_source-journal">Arch. Pharm. Chem. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1002%2Fardp.200800009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18493974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=465-477&author=A.+Wissnerauthor=T.+S.+Mansour&title=The+development+of+HKI-272+and+related+compounds+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The development of HKI-272 and related compounds for the treatment of cancer</span></div><div class="casAuthors">Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-477</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of HKI-272 and EKB-569 for the treatment of cancer is described.  These compds. function as irreversible inhibitors of some members of the ErbB family of receptor tyrosine kinases.  In particular, they target epidermal growth factor receptor (EGFR, also known as ErbB-1) and human epidermal growth factor receptor-2 (HER2, also known as ErbB-2).  Both, HKI-272 and EKB-569 are 4-anilino-3-cyano quinoline derivs. that contain a 4-(dimethylamino)crotonamide Michael-acceptor group at the 6-position.  These compds. inhibit the function of the target enzymes by forming a covalent interaction with a conserved cysteine residue located in the kinase domains of these proteins.  The potential advantages of using irreversible inhibitors for this purpose are discussed.  We summarize the recent findings concerning some somatic mutations in EGFR and their relevance with respect to the irreversible inhibitors.  In particular, we highlight the findings that these irreversible inhibitors retain activity against tumors that have acquired a resistance to the reversible binding inhibitors gefitinib and erlotinib.  The promising interim clin. trial results for HKI-272 and EKB-569 in treating colon, lung, and breast cancers are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSokM42ZhprVg90H21EOLACvtfcHk0lgjJHLeISKiCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E&md5=2e46d99ca74e297e6a7e860634bf096d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800009%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DThe%2520development%2520of%2520HKI-272%2520and%2520related%2520compounds%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DArch.%2520Pharm.%2520Chem.%2520Life%2520Sci.%26date%3D2008%26volume%3D341%26spage%3D465%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Monica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronin, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2038</span><span class="NLM_x">–</span> <span class="NLM_lpage">2050</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901558p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2038-2050&author=C.+Carmiauthor=A.+Cavazzoniauthor=S.+Vezzosiauthor=F.+Bordiauthor=F.+Vacondioauthor=C.+Silvaauthor=S.+Rivaraauthor=A.+Lodolaauthor=R.+R.+Alfieriauthor=S.+La+Monicaauthor=M.+Galettiauthor=A.+Ardizzoniauthor=P.+G.+Petroninauthor=M.+Mor&title=Novel+irreversible+epidermal+growth+factor+receptor+inhibitors+by+chemical+modulation+of+the+cysteine-trap+portion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901558p%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DVezzosi%26aufirst%3DS.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronin%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DNovel%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520chemical%2520modulation%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2038%26epage%3D2050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byron Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brignola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasheard, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caferro, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reno, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">6-Ethynylthieno[3,2-<i>d</i>]- and 6-ethynylthieno[2,3-<i>d</i>]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2772</span><span class="NLM_x">–</span> <span class="NLM_lpage">2778</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2772-2778&author=E.+R.+Woodauthor=L.+M.+Shewchukauthor=B.+Byron+Ellisauthor=P.+Brignolaauthor=R.+L.+Brasheardauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=H.+D.+Dicksonauthor=K.+H.+Donaldsonauthor=M.+Gaulauthor=R.+J.+Griffinauthor=A.+M.+Hassellauthor=B.+Keithauthor=R.+Mullinauthor=K.+G.+Petrovauthor=M.+J.+Renoauthor=D.+W.+Rusnakauthor=S.+M.+Tadepalliauthor=J.+C.+Ulrichauthor=C.+D.+Wagnerauthor=D.+E.+Vanderwallauthor=A.+G.+Watersonauthor=J.+D.+Williamsauthor=W.+L.+Whiteauthor=D.+E.+Uehling&title=6-Ethynylthieno%5B3%2C2-d%5D-+and+6-ethynylthieno%5B2%2C3-d%5Dpyrimidin-4-anilines+as+tunable+covalent+modifiers+of+ErbB+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DByron%2BEllis%26aufirst%3DB.%26aulast%3DBrignola%26aufirst%3DP.%26aulast%3DBrasheard%26aufirst%3DR.%2BL.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DMullin%26aufirst%3DR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DReno%26aufirst%3DM.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTadepalli%26aufirst%3DS.%2BM.%26aulast%3DUlrich%26aufirst%3DJ.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BD.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BL.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3D6-Ethynylthieno%255B3%252C2-d%255D-%2520and%25206-ethynylthieno%255B2%252C3-d%255Dpyrimidin-4-anilines%2520as%2520tunable%2520covalent%2520modifiers%2520of%2520ErbB%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2772%26epage%3D2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Brigdes, A. J.</span><span> </span><span class="NLM_article-title">Chemical inhibitors of protein kinases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">2541</span><span class="NLM_x">–</span> <span class="NLM_lpage">2571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2000&pages=2541-2571&author=A.+J.+Brigdes&title=Chemical+inhibitors+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrigdes%26aufirst%3DA.%2BJ.%26atitle%3DChemical%2520inhibitors%2520of%2520protein%2520kinases%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D101%26spage%3D2541%26epage%3D2571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Ban, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabeyama, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span> </span><span class="NLM_article-title">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4415</span><span class="NLM_x">–</span> <span class="NLM_lpage">4427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1039%2Fb909504g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19830290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4415-4427&author=H.+S.+Banauthor=T.+Usuiauthor=W.+Nabeyamaauthor=H.+Moritaauthor=K.+Fukuzawaauthor=H.+Nakamura&title=Discovery+of+boron-conjugated+4-anilinoquinazoline+as+a+prolonged+inhibitor+of+EGFR+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span></div><div class="casAuthors">Ban, Hyun Seung; Usui, Taikou; Nabeyama, Wataru; Morita, Hidetoshi; Fukuzawa, Kaori; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4415-4427</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Boron-conjugated 4-anilinoquinazolines were designed and synthesized as inhibitors of EGFR tyrosine kinase with possible covalent bond interactions between the boron atom and the nucleophilic groups of the EGFR kinase domain.  Among the compds. synthesized, compds. I and II (X = CH:CH, 1,4-phenylene) reduced the EGF-mediated phosphorylation of EGFR tyrosine kinase and its downstream kinases including ERK and Akt in A431 cells.  The cell growth was inhibited by these compds. through arrest of G1 cell cycle, which induced apoptosis.  A time-dependent in vitro preincubation assay demonstrated the irreversible inhibition of compd. II [X = 1,4-phenylene; (III)] against EGFR tyrosine kinase.  Quantum mech. docking simulation revealed that the boronic acid moiety of compd. III formed a covalent B-O bond with Asp800 in addn. to hydrogen bonds with Asp800 and Cys797, which may cause the prolonged inhibition of compd. III toward EGFR tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_ARjWKN7LLVg90H21EOLACvtfcHk0ljffZRFVOOipA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN&md5=b61ee61865bdff8e4706485b1f030554</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2Fb909504g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb909504g%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DH.%2BS.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DNabeyama%26aufirst%3DW.%26aulast%3DMorita%26aufirst%3DH.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520boron-conjugated%25204-anilinoquinazoline%2520as%2520a%2520prolonged%2520inhibitor%2520of%2520EGFR%2520tyrosine%2520kinase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D4415%26epage%3D4427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1019</span><span class="NLM_x">–</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F138955711797247725" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21861809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1019-1030&author=C.+Carmiauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Cavazzoniauthor=R.+R.+Alfieriauthor=A.+Ardizzoniauthor=P.+G.+Petroniniauthor=M.+Mor&title=Epidermal+growth+factor+receptor+irreversible+inhibitors%3A+chemical+exploration+of+the+cysteine-trap+portion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion</span></div><div class="casAuthors">Carmi, C.; Lodola, A.; Rivara, S.; Vacondio, F.; Cavazzoni, A.; Alfieri, R. R.; Ardizzoni, A.; Petronini, P. G.; Mor, M.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1019-1030</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Covalent EGFR irreversible inhibitors showed promising potential for the treatment of gefitinib-resistant tumors and for imaging purposes.  They contain a cysteine-reactive portion forming a covalent bond with the protein.  Irreversible kinase inhibitors have been advanced to clin. studies, mostly characterized by an acrylamide or butynamide warhead.  However, the clin. usefulness of these compds. has been hampered by resistances, toxicity and pharmacokinetic problems.  Investigation on the structure-activity and structure-reactivity relationships may provide useful information for compds. with improved selectivity and pharmacokinetic properties.  This review focuses on the exploration of the cysteine-trap portions able to irreversibly inhibit EGFR and other erbB receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupbZjLNpfFrVg90H21EOLACvtfcHk0lha3V70aMguOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1OnsL3O&md5=d531960c09e4676366b3611c3187533d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2174%2F138955711797247725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955711797247725%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520irreversible%2520inhibitors%253A%2520chemical%2520exploration%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D1019%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.’</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.%E2%80%99+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+a+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%25E2%2580%2599%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D52%26spage%3D6880%26epage%3D6888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Fast-forwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=J.-S.+Pengauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.+K.+Chittimallaauthor=J.-S.+Songauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fast-forwarding+hit+to+lead%3A+Aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification</span></div><div class="casAuthors">Coumar, Mohane Selvaraj; Chu, Chang-Ying; Lin, Cheng-Wei; Shiao, Hui-Yi; Ho, Yun-Lung; Reddy, Randheer; Lin, Wen-Hsing; Chen, Chun-Hwa; Peng, Yi-Hui; Leou, Jiun-Shyang; Lien, Tzu-Wen; Huang, Chin-Ting; Fang, Ming-Yu; Wu, Szu-Huei; Wu, Jian-Sung; Chittimalla, Santhosh Kumar; Song, Jen-Shin; Hsu, John T.-A.; Wu, Su-Ying; Liao, Chun-Chen; Chao, Yu-Sheng; Hsieh, Hsing-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4980-4988</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Furanopyrimidines such as I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] are prepd. as Aurora A kinase and epidermal growth factor receptor (EGFR) inhibitors by prepn. of a combinatorial library of approx. 350 furanopyridines and optimization of the inhibitors found from the library.  The initial hit compd. I (R = HOCH2CH2; R1 = Ph) was modified to better fit the back pocket to produce the potent Aurora A kinase inhibitor I (R = 4-PhNHCONHC6H4; R1 = Ph) with submicromolar antiproliferative activity in the HCT-116 human colon cancer cell line.  On the basis of docking studies with EGFR hit I [R = (S)-HOCH2CHPh; R1 = Ph], introduction of an acrylamide Michael acceptor group led to I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4], which inhibited both the wild and mutant EGFR kinases and also showed antiproliferative activity in the gefitinib-resistant HCC827 human lung cancer cells.  The X-ray cocrystal structures of I (R = HOCH2CH2, 4-PhNHCONHC6H4; R1 = Ph) bound to Aurora A kinase and the crystal structure of I [R = (S)-HOCH2CHPh; R1 = 3-(H2C:CCONH)C6H4] bound to EGFR confirmed their hypothesized binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCOPMtJ1xilrVg90H21EOLACvtfcHk0lha3V70aMguOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhs7s%253D&md5=8064e99d8d31603c7186b5fa33e019a6</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFast-forwarding%2520hit%2520to%2520lead%253A%2520Aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Wu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno[2,3-<i>d</i>]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.-H.+Wuauthor=M.+S.+Coumarauthor=C.-Y.+Chuauthor=W.-H.+Linauthor=Y.-R.+Chenauthor=C.-T.+Chenauthor=H.-Y.+Shiaoauthor=S.+Rafiauthor=S.-Y.+Wangauthor=H.+Hsuauthor=C.-H.+Chenauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=T.-W.+Lienauthor=M.-Y.+Fangauthor=K.-C.+Yehauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=S.-H.+Hsiehauthor=J.+T.-A.+Hsuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+the+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DY.-R.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DYeh%26aufirst%3DK.-C.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHsieh%26aufirst%3DS.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520the%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit68"><span>Clinical Trials. <a href="http://clinicaltrials.gov/" class="extLink">http://clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials.+http%3A%2F%2Fclinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simar, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simarauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.-H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0lj6T6VlYDG3Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimar%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.-H.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%9Cgatekeeper%E2%80%9D+mutation+in+EGFR+mediates+resistance+to+low+concentrations+of+an+irreversible+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0liRtk-ZdPP_Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutation%2520in%2520EGFR%2520mediates%2520resistance%2520to%2520low%2520concentrations%2520of%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Ocana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amir, E.</span><span> </span><span class="NLM_article-title">Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.ctrv.2009.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19733440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=685-691&author=A.+Ocanaauthor=E.+Amir&title=Irreversible+pan-ErbB+tyrosine+kinase+inhibitors+and+breast+cancer%3A+current+status+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions</span></div><div class="casAuthors">Ocana, Alberto; Amir, Eitan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers.  Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients.  Despite overexpressing HER2, some patients do not respond to these targeted treatments or progress after a short period of time.  Irreversible tyrosine kinase inhibitors have been developed to bypass several pathways that could be involved in this resistance.  In vitro, these agents have been shown to be more potent and to prolong target inhibition.  Clin. development of these agents is ongoing and early results are promising.  This review will describe the biol. rationale that justifies the development of these agents in breast cancer focusing on the current status and future directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov4KYTpGeBILVg90H21EOLACvtfcHk0liRtk-ZdPP_Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGlsb3E&md5=d7b5b04a11ec7dd6f187eb77e2df046f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2009.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2009.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DOcana%26aufirst%3DA.%26aulast%3DAmir%26aufirst%3DE.%26atitle%3DIrreversible%2520pan-ErbB%2520tyrosine%2520kinase%2520inhibitors%2520and%2520breast%2520cancer%253A%2520current%2520status%2520and%2520future%2520directions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D685%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Eskens, F. A. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mom, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planting, A. S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gietema, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amelsberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doorn, L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van.; Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vries, E. G. E.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fsj.bjc.6604108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18026190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2008&pages=80-85&author=F.+A.+L.+M.+Eskensauthor=C.+H.+Momauthor=A.+S.+T.+Plantingauthor=J.+A.+Gietemaauthor=A.+Amelsbergauthor=H.+Huismanauthor=L+Doornauthor=H.+van.%3B+Burgerauthor=P.+Stopferauthor=J.+Verweijauthor=E.+G.+E.+de+Vries&title=A+phase+I+dose+escalation+study+of+BIBW+2992%2C+an+irreversible+dual+inhibitor+of+epidermal+growth+factor+receptor+1+%28EGFR%29+and+2+%28HER2%29+tyrosine+kinase+in+a+2-week+on%2C+2-week+off+schedule+in+patients+with+advanced+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Eskens, F. A. L. M.; Mom, C. H.; Planting, A. S. T.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clin. activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992.  An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was explored.  Thirty-eight patients were enrolled.  Dose levels were 10, 20, 30, 45, 70, 85, and 100 mg.  At 100 mg dose-limiting toxicity (DLT) (common toxicity criteria grade 3 skin rash and grade 3 diarrhea despite treatment with loperamide) occurred in two patients.  In the next-lower dose of 70 mg, DLT (grade 3 fatigue and ALAT elevation) occurred in one of six patients.  An intermediate dose level of 85 mg was studied.  Here DLT occurred in two patients (grade 3 diarrhea despite treatment and grade 2 diarrhea lasting more than 7 days despite treatment).  An addnl. 12 patients were treated at 70 mg.  BIBW 2992 PK after single and multiple doses revealed moderately fast absorption, and no deviation from dose proportionality.  Pharmacodynamics anal. in skin biopsies did not show significant changes in EGFR-assocd. biomarkers.  However, a significant inhibitory effect on the proliferation index of epidermal keratinocytes was obsd.  No partial or complete responses were obsd., stable disease lasting more than four cycles was seen in seven patients.  The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD.  British Journal of Cancer (2008) 98, 80-85. doi:10.1038/sj.bjc.6604108 www.bjcancer.com Published online 20 Nov. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQZL8pTnjAwrVg90H21EOLACvtfcHk0liYTng4gf8l7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisF2qtg%253D%253D&md5=96a0be31145bf1691640109d69ff5dc0</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6604108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6604108%26sid%3Dliteratum%253Aachs%26aulast%3DEskens%26aufirst%3DF.%2BA.%2BL.%2BM.%26aulast%3DMom%26aufirst%3DC.%2BH.%26aulast%3DPlanting%26aufirst%3DA.%2BS.%2BT.%26aulast%3DGietema%26aufirst%3DJ.%2BA.%26aulast%3DAmelsberg%26aufirst%3DA.%26aulast%3DHuisman%26aufirst%3DH.%26aulast%3DDoorn%26aufirst%3DL%26aulast%3Dvan.%253B%2BBurger%26aufirst%3DH.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%2BE.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBW%25202992%252C%2520an%2520irreversible%2520dual%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%25201%2520%2528EGFR%2529%2520and%25202%2520%2528HER2%2529%2520tyrosine%2520kinase%2520in%2520a%25202-week%2520on%252C%25202-week%2520off%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2008%26volume%3D98%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.-M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0li2EyPGo8Pqtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Want, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wantauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWant%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nat. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Lacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DLacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNat.%2520Lett.%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0li0yRS8VbRKkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Walter, A. O.; Tjin, R.; Haringsma, H.; Lin, K. K.; Dubrovskiy, A.; Lee, K.; St. Martin, T.; Karp, R.; Zhu, Z.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W. F.; Singh, J.; Raponi, M.; Allen, A.</span><span> </span><span class="NLM_article-title">CO-1886, an Orally Available, Mutant-Selective Inhibitor of the Epidermal Growth Factor Receptor (EGFR), Causes Tumor Skrinkage in Non-Small Cell Lung Cancer (NSCLC) with T790M Resistance Mutations</span>. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, November 12–16,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+O.+Walter&author=R.+Tjin&author=H.+Haringsma&author=K.+K.+Lin&author=A.+Dubrovskiy&author=K.+Lee&author=T.+St.+Martin&author=R.+Karp&author=Z.+Zhu&author=D.+Niu&author=M.+Nacht&author=R.+C.+Petter&author=W.+F.+Westlin&author=J.+Singh&author=M.+Raponi&author=A.+Allen&title=CO-1886%2C+an+Orally+Available%2C+Mutant-Selective+Inhibitor+of+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29%2C+Causes+Tumor+Skrinkage+in+Non-Small+Cell+Lung+Cancer+%28NSCLC%29+with+T790M+Resistance+Mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26atitle%3DCO-1886%252C%2520an%2520Orally%2520Available%252C%2520Mutant-Selective%2520Inhibitor%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%252C%2520Causes%2520Tumor%2520Skrinkage%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520with%2520T790M%2520Resistance%2520Mutations%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lg0-oGmQVyP6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.</span><span> </span><span class="NLM_article-title">The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study</span>. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Advani&author=J.+Sharman&author=S.+Smith&author=T.+Boyd&author=B.+Grant&author=K.+Kolibaba&author=R.+Furman&author=J.+Buggy&author=D.+Loury&author=E.+Hedrick&author=R.+Izumi&author=A.+Hamdy&author=N.+Fowler&title=The+Btk+Inhibitor+PCI-32765+Is+Highly+Active+and+Well+Tolerated+in+Patients+with+Relapsed%2FRefractory+B+Cell+Malignancies%3A+Final+Results+from+a+Phase+I+Study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%26atitle%3DThe%2520Btk%2520Inhibitor%2520PCI-32765%2520Is%2520Highly%2520Active%2520and%2520Well%2520Tolerated%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B%2520Cell%2520Malignancies%253A%2520Final%2520Results%2520from%2520a%2520Phase%2520I%2520Study%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Moriarty, K. J.; Konteatis, Z.; Moffett, K.; Lee, Y.; Chao, W.</span> Int. Pat. Appl. WO 2010/126960 A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Moriarty%2C+K.+J.%3B+Konteatis%2C+Z.%3B+Moffett%2C+K.%3B+Lee%2C+Y.%3B+Chao%2C+W.+Int.+Pat.+Appl.+WO+2010%2F126960+A1%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DK.%2BJ.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Labenski, M.; Chaturvendi, P.; Evans, E.; Mazdiyasni, H.; Sheets, M.; Aslanian, S.; Niu, D.; Nacht, M.; Singh, J.; Westlin, W.</span><span> </span><span class="NLM_article-title">In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton’s Tyrosine Kinase</span>. Presented at the 17th North America Regional Meeting of International Society for the Study of Xenobiotics, Atlanta, GA, October 16–20,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>Poster P211.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Labenski&author=P.+Chaturvendi&author=E.+Evans&author=H.+Mazdiyasni&author=M.+Sheets&author=S.+Aslanian&author=D.+Niu&author=M.+Nacht&author=J.+Singh&author=W.+Westlin&title=In+Vitro+Reactivity+Assessment+of+Covalent+Drugs+Targeting+Bruton%E2%80%99s+Tyrosine+Kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DLabenski%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Reactivity%2520Assessment%2520of%2520Covalent%2520Drugs%2520Targeting%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Petter, R.</span><span> </span><span class="NLM_article-title">Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk</span>. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Petter%2C+R.+Targeted+Covalent+Kinase+Inhibitors%3A+AVL+292+as+a+Potent%2C+Irreversible+and+Selective+Inhibitor+of+Btk.+Presented+at+the+5th+Anglo-Swedish+Medicinal+Chemistry+Symposium+%28ASMC%29%2C+%C3%85re%2C+Sweden%2C+March+20%E2%80%9323%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPetter%26aufirst%3DR.%26atitle%3DTargeted%2520Covalent%2520Kinase%2520Inhibitors%253A%2520AVL%2520292%2520as%2520a%2520Potent%252C%2520Irreversible%2520and%2520Selective%2520Inhibitor%2520of%2520Btk%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Evans, E.; Tester, R.; Aslanian, S.; Mazdiyasni, H.; Ponader, S.; Tesar, B.; Chaturvedi, P.; Nacht, M.; Stiede, K.; Witowski, S.; Lounsbury, H.; Silver, B.; Burger, J.; Brown, J. R.; Mahadevan, D.; Sharman, J.; Harb, W.; Petter, R.; Singh, J.; Westlin, W.</span><span> </span><span class="NLM_article-title">Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies</span>. Presented at the ASH Annual Meeting, San Diego, CA, December 10–13,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=E.+Evans&author=R.+Tester&author=S.+Aslanian&author=H.+Mazdiyasni&author=S.+Ponader&author=B.+Tesar&author=P.+Chaturvedi&author=M.+Nacht&author=K.+Stiede&author=S.+Witowski&author=H.+Lounsbury&author=B.+Silver&author=J.+Burger&author=J.+R.+Brown&author=D.+Mahadevan&author=J.+Sharman&author=W.+Harb&author=R.+Petter&author=J.+Singh&author=W.+Westlin&title=Clinical+Development+of+AVL-292%3A+A+Potent%2C+Selective+Covalent+Btk+Inhibitor+for+the+Treatment+of+B+Cell+Malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DClinical%2520Development%2520of%2520AVL-292%253A%2520A%2520Potent%252C%2520Selective%2520Covalent%2520Btk%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520B%2520Cell%2520Malignancies%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Kim, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.-H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+Soutterauthor=N.+Caspersauthor=S.+Hanauthor=R.+Kurumbailauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingalls, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nittoli, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annable, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loganzo, F.</span><span> </span><span class="NLM_article-title">2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7560</span><span class="NLM_x">–</span> <span class="NLM_lpage">7581</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050559f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7560-7581&author=A.+Wissnerauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=H.+Fraserauthor=C.+Ingallsauthor=T.+Nittoliauthor=R.+G.+Dushinauthor=C.+Discafaniauthor=R.+Nilakantanauthor=J.+Mariniauthor=M.+Raviauthor=K.+Cheungauthor=X.+Tanauthor=S.+Mustoauthor=T.+Annableauthor=M.+M.+Siegelauthor=F.+Loganzo&title=2-%28Quinazolin-4-ylamino%29-%5B1%2C4%5Dbenzoquinones+as+covalent-binding%2C+irreversible+inhibitors+of+the+kinase+domain+of+vascular+endothelial+growth+factor+receptor-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm050559f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050559f%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DFraser%26aufirst%3DH.%26aulast%3DIngalls%26aufirst%3DC.%26aulast%3DNittoli%26aufirst%3DT.%26aulast%3DDushin%26aufirst%3DR.%2BG.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DMarini%26aufirst%3DJ.%26aulast%3DRavi%26aufirst%3DM.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DMusto%26aufirst%3DS.%26aulast%3DAnnable%26aufirst%3DT.%26aulast%3DSiegel%26aufirst%3DM.%2BM.%26aulast%3DLoganzo%26aufirst%3DF.%26atitle%3D2-%2528Quinazolin-4-ylamino%2529-%255B1%252C4%255Dbenzoquinones%2520as%2520covalent-binding%252C%2520irreversible%2520inhibitors%2520of%2520the%2520kinase%2520domain%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7560%26epage%3D7581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Schirmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">4234</span><span class="NLM_x">–</span> <span class="NLM_lpage">4239</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1073%2Fpnas.0600445103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=16537514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=4234-4239&author=A.+Schirmerauthor=J.+Kennedyauthor=S.+Murliauthor=R.+Reidauthor=D.+V.+Santi&title=Targeted+covalent+inactivation+of+protein+kinases+by+resorcylic+acid+lactone+polyketides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span></div><div class="casAuthors">Schirmer, Andreas; Kennedy, Jonathan; Murli, Sumati; Reid, Ralph; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4234-4239</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Resorcylic acid lactones contg. a cis-enone are susceptible to Michael addn. reactions and are potent inhibitors of several protein kinases.  A structural-bioinformatics anal. identified a conserved Cys residue in the ATP-binding site of the kinases reported to be inhibited by cis-enone resorcylic acid lactones but absent in those that are not.  Mining of the kinome database revealed that a subset of some 46 kinases contained this Cys residue.  Screening a panel of 124 kinases with the resorcylic acid lactone hypothemycin showed that 18 of 19 targets contg. the conserved Cys were inhibited.  Kinetic analyses showed time-dependent inhibition, a hallmark of covalent inactivation, and biochem. studies of the interaction of extracellular signal-regulated kinase (ERK)2 with hypothemycin confirmed covalent adduct formation.  Resorcylic acid lactones are unique among kinase inhibitors in that they target mitogen-activated protein (MAP) kinase pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downstream ERK substrates.  Cell lines dependent on the activation of Tyr kinase mitogen receptor targets of the resorcylic acid lactones were unusually sensitive toward hypothemycin and showed the expected inhibition of kinase phosphorylation due to inhibition of the mitogen receptors and/or MEK1/2 and ERK1/2.  Among cells without mitogen receptor targets, those harboring an ERK pathway-activating B-RAF V600E mutation were selectively and potently inhibited by hypothemycin.  Hypothemycin also prevented stimulated activation of the p38 cascade through inhibition of the Cys-contg. targets MEK3/6 and TGF-β-activated kinase 1 and of the JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase) cascade through inhibition of MEK4/7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraww22qbwEYLVg90H21EOLACvtfcHk0lgrGtBqkcZcfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D&md5=6a4be819f2c2a5a601e5c9cb75faf433</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0600445103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0600445103%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmer%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DJ.%26aulast%3DMurli%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DTargeted%2520covalent%2520inactivation%2520of%2520protein%2520kinases%2520by%2520resorcylic%2520acid%2520lactone%2520polyketides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D4234%26epage%3D4239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Rastelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Molecular modeling and crystal structure of ERK2-hypothemycin complexes</span> <span class="citation_source-journal">J. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2008&pages=18-23&author=G.+Rastelliauthor=R.+Rosenfeldauthor=R.+Reidauthor=D.+V.+Santi&title=Molecular+modeling+and+crystal+structure+of+ERK2-hypothemycin+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRastelli%26aufirst%3DG.%26aulast%3DRosenfeld%26aufirst%3DR.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DMolecular%2520modeling%2520and%2520crystal%2520structure%2520of%2520ERK2-hypothemycin%2520complexes%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2008%26volume%3D164%26spage%3D18%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Ohori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kioshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span> </span><span class="NLM_article-title">Role of a cysteine residue in the active site of ERK and the MAPKK family</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">633</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2007&pages=633-637&author=M.+Ohoriauthor=T.+Kioshitaauthor=S.+Yoshimuraauthor=M.+Warizayaauthor=H.+Nakajimaauthor=H.+Miyake&title=Role+of+a+cysteine+residue+in+the+active+site+of+ERK+and+the+MAPKK+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhori%26aufirst%3DM.%26aulast%3DKioshita%26aufirst%3DT.%26aulast%3DYoshimura%26aufirst%3DS.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DH.%26aulast%3DMiyake%26aufirst%3DH.%26atitle%3DRole%2520of%2520a%2520cysteine%2520residue%2520in%2520the%2520active%2520site%2520of%2520ERK%2520and%2520the%2520MAPKK%2520family%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D353%26spage%3D633%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Goto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muramoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obaishi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirota, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusovsky, F.</span><span> </span><span class="NLM_article-title">E6201 [(3<i>S</i>,4<i>R</i>,5<i>Z</i>,8<i>S</i>,9<i>S</i>,11<i>E</i>)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1<i>H</i>-2-benzoxacyclotetradecine-1,7(8<i>H</i>)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1124%2Fjpet.109.156554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=19684251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=485-495&author=M.+Gotoauthor=J.+Chowauthor=K.+Muramotoauthor=K.-I.+Chibaauthor=S.+Yamamotoauthor=M.+Fujitaauthor=H.+Obaishiauthor=K.+Taiauthor=Y.+Mizuiauthor=I.+Tanakaauthor=D.+Youngauthor=H.+Yangauthor=Y.+J.+Wangauthor=H.+Shirotaauthor=F.+Gusovsky&title=E6201+%5B%283S%2C4R%2C5Z%2C8S%2C9S%2C11E%29-14-%28ethylamino%29-8%2C9%2C16-trihydroxy-3%2C4-dimethyl-3%2C4%2C9%2C19-tetrahydro-1H-2-benzoxacyclotetradecine-1%2C7%288H%29-dione%5D%2C+a+novel+kinase+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase+%28MEK%29-1+and+MEK+kinase-1%3A+in+vitro+characterization+of+its+anti-inflammatory+and+antihyperproliferative+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities</span></div><div class="casAuthors">Goto, Masaki; Chow, Jesse; Muramoto, Kenzo; Chiba, Ken-ichi; Yamamoto, Satoshi; Fujita, Masanori; Obaishi, Hiroshi; Tai, Kenji; Mizui, Yoshiharu; Tanaka, Isao; Young, Donna; Yang, Hua; Wang, Yuan J.; Shirota, Hiroshi; Gusovsky, Fabian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">485-495</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The goal of this study is to identify a novel inhibitor with anti-inflammatory and antiproliferative properties for the treatment of psoriasis.  Compd. f152A1 [(3S,5Z,8S,11E)-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-tetrahydro- 1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione] was identified as the main active metabolite with strong inhibitory activity against tumor necrosis factor-α (TNFα) transcription in a fraction originated from the fermn. broth of the fungus Curvularia verruculosa.  Although active in cell-based assays, f152A1 was unstable in plasma and liver microsome prepns., thus limiting its pharmaceutical utilization.  To improve the metabolic properties of f152A1, a medicinal chem. program was undertaken, resulting in the generation of over 400 analogs of f152A1.  Eventually, E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione] was identified as a promising analog in this series.  In the present study, we characterized the in vitro activities of E6201 and discovered that the compd. inhibits lipopolysaccharide-activated TNFα reporter activity in THP-1-33 cells with an IC50 value of 50 nM and selectively inhibits mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1 in cell-free biochem. assays.  In addn., E6201 showed inhibitory activity in several other cell-based systems:(1) phosphorylation of c-jun N-terminal kinase and p38 MAPKs; (2) nuclear factor-κB and activated protein-1 activation in various cell types; (3) interleukin (IL)-2 prodn. from human lymphocytes; (4) hyperproliferation of human keratinocytes; (5) IL-8 prodn. from human keratinocytes; and (6) proinflammatory cytokine prodn. from human peripheral blood mononuclear cells.  Based on the data presented here, E6201 may be beneficial for treatment of inflammatory and hyperproliferative diseases such as psoriasis through its anti-inflammatory activities on immune cells and antihyperproliferative activities on keratinocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxBdDTs96tNbVg90H21EOLACvtfcHk0lhVZzMc42DcXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu7zO&md5=6d7f61889a8d50c2a073f8921c441814</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.156554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.156554%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DChow%26aufirst%3DJ.%26aulast%3DMuramoto%26aufirst%3DK.%26aulast%3DChiba%26aufirst%3DK.-I.%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DObaishi%26aufirst%3DH.%26aulast%3DTai%26aufirst%3DK.%26aulast%3DMizui%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DI.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DShirota%26aufirst%3DH.%26aulast%3DGusovsky%26aufirst%3DF.%26atitle%3DE6201%2520%255B%25283S%252C4R%252C5Z%252C8S%252C9S%252C11E%2529-14-%2528ethylamino%2529-8%252C9%252C16-trihydroxy-3%252C4-dimethyl-3%252C4%252C9%252C19-tetrahydro-1H-2-benzoxacyclotetradecine-1%252C7%25288H%2529-dione%255D%252C%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase%2520%2528MEK%2529-1%2520and%2520MEK%2520kinase-1%253A%2520in%2520vitro%2520characterization%2520of%2520its%2520anti-inflammatory%2520and%2520antihyperproliferative%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D485%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Muramoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, K.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuboi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omae, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusovsky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirota, H.</span><span> </span><span class="NLM_article-title">E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1124%2Fjpet.110.168583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20627998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2010&pages=23-31&author=K.+Muramotoauthor=M.+Gotoauthor=Y.+Inoueauthor=N.+Ishiiauthor=K.-I.+Chibaauthor=Y.+Kuboiauthor=T.+Omaeauthor=Y.+J.+Wangauthor=F.+Gusovskyauthor=H.+Shirota&title=E6201%2C+a+novel+kinase+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase-1+and+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase+kinase-1%3A+in+vivo+effects+on+cutaneous+inflammatory+responses+by+topical+administration"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration</span></div><div class="casAuthors">Muramoto, Kenzo; Goto, Masaki; Inoue, Yoko; Ishii, Naoto; Chiba, Ken-ichi; Kuboi, Yoshikazu; Omae, Takao; Wang, Yuan J.; Gusovsky, Fabian; Shirota, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-31</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,10-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione)] is a novel anti-inflammatory agent that has potent inhibitory effects on the prodn. of proinflammatory cytokines from leukocytes and antiproliferative activity on keratinocytes.  To characterize the in vivo pharmacol. activity of E6201, topically administered E6201 was evaluated in several different animal models of dermatitis.  E6201 formulated as an ointment or cream showed dose-dependent inhibition of croton oil-induced acute edema formation and neutrophil infiltration into mouse skin.  In addn., E6201 cream inhibited the 1-fluoro-2,4-dinitrobenzene-induced contact hypersensitivity reaction mediated by T cells in mice.  In this model, E6201 cream also suppressed the migration of neutrophils and lymphocytes into the inflammatory site.  Pretreatment with E6201 cream attenuated phorbol-12 myristate 13-acetate-induced ornithine decarboxylase activity, a marker of proliferation in epidermis.  Furthermore, E6201 ointment showed inhibitory effects on both mezerein-induced and interleukin (IL)-23-induced epidermal hyperplasia.  E6201 also suppressed T cell receptor-stimulated IL-17 prodn. from human T cells.  These results indicate that topically administered E6201 may be a useful agent for the prevention and treatment of cutaneous inflammatory and hyperproliferative diseases such as psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WAaqpkhIvrVg90H21EOLACvtfcHk0lhVZzMc42DcXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Gisr3M&md5=f951a66efba352d172abdc333b650de5</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.168583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.168583%26sid%3Dliteratum%253Aachs%26aulast%3DMuramoto%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DChiba%26aufirst%3DK.-I.%26aulast%3DKuboi%26aufirst%3DY.%26aulast%3DOmae%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DGusovsky%26aufirst%3DF.%26aulast%3DShirota%26aufirst%3DH.%26atitle%3DE6201%252C%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase-1%2520and%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase%2520kinase-1%253A%2520in%2520vivo%2520effects%2520on%2520cutaneous%2520inflammatory%2520responses%2520by%2520topical%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D335%26spage%3D23%26epage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jogireddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koripelly, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">In vivo efficacy of natural product-inspired irreversible kinase inhibitors</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1002%2Fcbic.201000205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=20623569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVyqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1692-1699&author=S.+Barluengaauthor=R.+Jogireddyauthor=G.+K.+Koripellyauthor=N.+Winssinger&title=In+vivo+efficacy+of+natural+product-inspired+irreversible+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">In Vivo Efficacy of Natural Product-Inspired Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Barluenga, Sofia; Jogireddy, Rajamalleswaramma; Koripelly, Girish K.; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1692-1699</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hypothemycin and related resorcylic acid lactones (RAL) bearing a cis-enone moiety have emerged as an alternative pharmacophore to heterocyclic motifs for kinase inhibition, and are endowed with a unique selectivity filter based on the irreversible reaction with a subset of the kinome bearing a suitably positioned cysteine residue.  Two prototypical examples of "edited" RAL were evaluated for antitumoral, antimetastatic and antiangiogenic efficacy in an orthotopic murine renal cell carcinoma (RENCA) model.  Both compds. (3 and 5) are good inhibitors of VEGFRs in vitro, and inhibited tumor growth in vivo with comparable efficacy to sunitinib, an FDA-approved VEGFRs inhibitor.  Compd. 3 promoted lung metastasis to a similar extent as sunitinib, while compd. 5 strongly inhibited lung metastasis.  This study attests to the potential of irreversible kinase inhibitors and mol. editing of natural pharmacophores and provides encouraging results to a clin. significant problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNKnAGz2gxurVg90H21EOLACvtfcHk0lhVZzMc42DcXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVyqu7c%253D&md5=cbe2869e3c669a89f3d5ac7f7a2c5479</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000205%26sid%3Dliteratum%253Aachs%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DJogireddy%26aufirst%3DR.%26aulast%3DKoripelly%26aufirst%3DG.%2BK.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DIn%2520vivo%2520efficacy%2520of%2520natural%2520product-inspired%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D1692%26epage%3D1699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><div class="note"><p class="first last">Reviewed in the following: </p></div><span class="NLM_contrib-group">Gaestel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bothe, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asadullah, K.</span><span> </span><span class="NLM_article-title">Protein kinases as small molecule inhibitor targets in inflammation</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2214</span><span class="NLM_x">–</span> <span class="NLM_lpage">2234</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.2174%2F092986707781696636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17896971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=2214-2234&author=M.+Gaestelauthor=A.+Mengelauthor=U.+Botheauthor=K.+Asadullah&title=Protein+kinases+as+small+molecule+inhibitor+targets+in+inflammation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinases as small molecule inhibitor targets in inflammation</span></div><div class="casAuthors">Gaestel, M.; Mengel, A.; Bothe, U.; Asadullah, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2214-2234</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The human kinome describes a major group of intracellular signaling mols.  In the last few years, many mols. in the group have become targets for therapeutic interventions.  Due to the conserved reaction mechanism of catalysis, protein kinases seem well "drugable" by small mol. wt. inhibitors, thus opening the chance to novel oral bioavailable drug development.  A large no. of small mol. wt. inhibitors for protein kinases have already been introduced into research and these mols. are extensively analyzed in regard to their efficiency, potency and selectivity.  Here we summarize the use of small mol. protein kinase inhibitors relevant for acute and chronic inflammation based on their essential role in cellular signaling mechanisms in immune cells such as macrophages, lymphocytes and granulocytes.  We describe the progress made to develop inhibitors against Toll-like receptor assocd. kinases (IRAKs), against the MAPK kinase kinases Cot/Tpl-2 and TAK1, against Inhibitor-κB kinases (IKKs), against MAPK kinases (MEKs, MKKs), against MAPKs (ERK2, p38, JNKs) and against their downstream kinases MNK1 and MK2/3.  This overview should help to keep up with the fast developing field and the continuously growing no. of protein kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtC245E_OSPbVg90H21EOLACvtfcHk0lhQwVXWxCvPSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKqtrvK&md5=ef5cdd7f122e37d8bf8bf0f22db131a9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2174%2F092986707781696636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707781696636%26sid%3Dliteratum%253Aachs%26aulast%3DGaestel%26aufirst%3DM.%26aulast%3DMengel%26aufirst%3DA.%26aulast%3DBothe%26aufirst%3DU.%26aulast%3DAsadullah%26aufirst%3DK.%26atitle%3DProtein%2520kinases%2520as%2520small%2520molecule%2520inhibitor%2520targets%2520in%2520inflammation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D2214%26epage%3D2234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Perez, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wandosell, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelpi, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span> </span><span class="NLM_article-title">Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6914</span><span class="NLM_x">–</span> <span class="NLM_lpage">6925</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=6914-6925&author=D.+I.+Perezauthor=S.+Condeauthor=C.+Perezauthor=C.+Gilauthor=D.+Simonauthor=F.+Wandosellauthor=F.+J.+Morenoauthor=J.+L.+Gelpiauthor=F.+J.+Luqueauthor=A.+Martinez&title=Thienylhalomethylketones%3A+irreversible+glycogen+synthase+kinase+3+inhibitors+as+useful+pharmacological+tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DConde%26aufirst%3DS.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DD.%26aulast%3DWandosell%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DF.%2BJ.%26aulast%3DGelpi%26aufirst%3DJ.%2BL.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DThienylhalomethylketones%253A%2520irreversible%2520glycogen%2520synthase%2520kinase%25203%2520inhibitors%2520as%2520useful%2520pharmacological%2520tools%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D6914%26epage%3D6925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Rossi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M. G.</span><span> </span><span class="NLM_article-title">Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkB kinase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">403</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2000&pages=103-108&author=A.+Rossiauthor=P.+Kapahiauthor=G.+Natoliauthor=T.+Takahashiauthor=Y.+Chenauthor=M.+Karinauthor=M.+G.+Santoro&title=Anti-inflammatory+cyclopentenone+prostaglandins+are+direct+inhibitors+of+IkB+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DA.%26aulast%3DKapahi%26aufirst%3DP.%26aulast%3DNatoli%26aufirst%3DG.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%2BG.%26atitle%3DAnti-inflammatory%2520cyclopentenone%2520prostaglandins%2520are%2520direct%2520inhibitors%2520of%2520IkB%2520kinase%26jtitle%3DNature%26date%3D2000%26volume%3D403%26spage%3D103%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Straus, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengchanthalangsy, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, C. K.</span><span> </span><span class="NLM_article-title">15-Deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> inhibits multiple steps in the NF-κB signaling pathway</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">4844</span><span class="NLM_x">–</span> <span class="NLM_lpage">4849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=4844-4849&author=D.+S.+Strausauthor=G.+Pascualauthor=M.+Liauthor=J.+S.+Welchauthor=M.+Ricoteauthor=C.-H.+Hsiangauthor=L.+L.+Sengchanthalangsyauthor=G.+Ghoshauthor=C.+K.+Glass&title=15-Deoxy-%CE%9412%2C14-prostaglandin+J2+inhibits+multiple+steps+in+the+NF-%CE%BAB+signaling+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStraus%26aufirst%3DD.%2BS.%26aulast%3DPascual%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWelch%26aufirst%3DJ.%2BS.%26aulast%3DRicote%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DC.-H.%26aulast%3DSengchanthalangsy%26aufirst%3DL.%2BL.%26aulast%3DGhosh%26aufirst%3DG.%26aulast%3DGlass%26aufirst%3DC.%2BK.%26atitle%3D15-Deoxy-%25CE%259412%252C14-prostaglandin%2520J2%2520inhibits%2520multiple%2520steps%2520in%2520the%2520NF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D4844%26epage%3D4849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Ji, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozak, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span> </span><span class="NLM_article-title">IκB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">18223</span><span class="NLM_x">–</span> <span class="NLM_lpage">18228</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=18223-18228&author=C.+Jiauthor=K.+R.+Kozakauthor=L.+J.+Marnett&title=I%CE%BAB+kinase%2C+a+molecular+target+for+inhibition+by+4-hydroxy-2-nonenal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DC.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26atitle%3DI%25CE%25BAB%2520kinase%252C%2520a%2520molecular%2520target%2520for%2520inhibition%2520by%25204-hydroxy-2-nonenal%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D18223%26epage%3D18228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Kim, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span> </span><span class="NLM_article-title">Artemisolide is a typical inhibitor of IκB kinase β targeting cysteine-179 residue and down-regulates NF-κB-dependent TNF-α expression in LPS-activated macrophages</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2007&pages=593-598&author=B.+H.+Kimauthor=J.-Y.+Leeauthor=J.+H.+Seoauthor=H.+Y.+Leeauthor=S.+Y.+Ryuauthor=B.+W.+Ahnauthor=C.-K.+Leeauthor=B.+Y.+Hwangauthor=S.-B.+Hanauthor=Y.+Kim&title=Artemisolide+is+a+typical+inhibitor+of+I%CE%BAB+kinase+%CE%B2+targeting+cysteine-179+residue+and+down-regulates+NF-%CE%BAB-dependent+TNF-%CE%B1+expression+in+LPS-activated+macrophages"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DB.%2BH.%26aulast%3DLee%26aufirst%3DJ.-Y.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DRyu%26aufirst%3DS.%2BY.%26aulast%3DAhn%26aufirst%3DB.%2BW.%26aulast%3DLee%26aufirst%3DC.-K.%26aulast%3DHwang%26aufirst%3DB.%2BY.%26aulast%3DHan%26aufirst%3DS.-B.%26aulast%3DKim%26aufirst%3DY.%26atitle%3DArtemisolide%2520is%2520a%2520typical%2520inhibitor%2520of%2520I%25CE%25BAB%2520kinase%2520%25CE%25B2%2520targeting%2520cysteine-179%2520residue%2520and%2520down-regulates%2520NF-%25CE%25BAB-dependent%2520TNF-%25CE%25B1%2520expression%2520in%2520LPS-activated%2520macrophages%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D361%26spage%3D593%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Wagner, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullally, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, F. A.</span><span> </span><span class="NLM_article-title">Reactive lipid species from cyclooxygenase-2 inactivate tumor suppressor LKB1/STK11</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">2598</span><span class="NLM_x">–</span> <span class="NLM_lpage">2604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=2598-2604&author=T.+M.+Wagnerauthor=J.+E.+Mullallyauthor=F.+A.+Fitzpatrick&title=Reactive+lipid+species+from+cyclooxygenase-2+inactivate+tumor+suppressor+LKB1%2FSTK11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DT.%2BM.%26aulast%3DMullally%26aufirst%3DJ.%2BE.%26aulast%3DFitzpatrick%26aufirst%3DF.%2BA.%26atitle%3DReactive%2520lipid%2520species%2520from%2520cyclooxygenase-2%2520inactivate%2520tumor%2520suppressor%2520LKB1%252FSTK11%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D2598%26epage%3D2604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Toral-Barza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salaski, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, W.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernan, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span> </span><span class="NLM_article-title">Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1158%2F1535-7163.MCT-07-0211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17989320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWkt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3028-3038&author=L.+Toral-Barzaauthor=W.-G.+Zhangauthor=X.+Huangauthor=L.+A.+McDonaldauthor=E.+J.+Salaskiauthor=L.+R.+Barbieriauthor=W.-D.+Dingauthor=G.+Krishnamurthyauthor=Y.+B.+Huauthor=J.+Lucasauthor=V.+S.+Bernanauthor=P.+Caiauthor=J.+I.+Levinauthor=T.+S.+Mansourauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=K.+Yu&title=Discovery+of+lactoquinomycin+and+related+pyranonaphthoquinones+as+potent+and+allosteric+inhibitors+of+AKT%2FPKB%3A+mechanistic+involvement+of+AKT+catalytic+activation+loop+cysteines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines</span></div><div class="casAuthors">Toral-Barza, Lourdes; Zhang, Wei-Guo; Huang, Xinyi; McDonald, Leonard A.; Salaski, Edward J.; Barbieri, Laurel R.; Ding, Wei-Dong; Krishnamurthy, Girija; Hu, Yong Bo; Lucas, Judy; Bernan, Valerie S.; Cai, Ping; Levin, Jeremy I.; Mansour, Tarek S.; Gibbons, James J.; Abraham, Robert T.; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine kinase AKT/PKB plays a crit. role in cancer and represents a rational target for therapy.  Although efforts in targeting AKT pathway have accelerated in recent years, relatively few small mol. inhibitors of AKT have been reported.  The development of selective AKT inhibitors is further challenged by the extensive conservation of the ATP-binding sites of the AGC kinase family.  In this report, we have conducted a high-throughput screen for inhibitors of activated AKT1.  We have identified lactoquinomycin as a potent inhibitor of AKT kinases (AKT1 IC50, 0.149±0.045 μmol/L).  Biochem. studies implicated a novel irreversible interaction of the inhibitor and AKT involving a crit. cysteine residue(s).  To examine the role of conserved cysteines in the activation loop (T-loop), we studied mutant AKT1 harboring C296A, C310A, and C296A/C310A.  Whereas the ATP-pocket inhibitor, staurosporine, indiscriminately targeted the wild-type and all three mutant-enzymes, the inhibition by lactoquinomycin was drastically diminished in the single mutants C296A and C310A, and completely abolished in the double mutant C296A/C310A.  These data strongly implicate the binding of lactoquinomycin to the T-loop cysteines as crit. for abrogation of catalysis, and define an unprecedented mechanism of AKT inhibition by a small mol.  Lactoquinomycin inhibited cellular AKT substrate phosphorylation induced by growth factor, loss of PTEN, and myristoylated AKT.  The inhibition was substantially attenuated by coexpression of C296A/C310A.  Moreover, lactoquinomycin reduced cellular mammalian target of rapamycin signaling and cap-dependent mRNA translation initiation.  Our results highlight T-loop targeting as a new strategy for the generation of selective AKT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55q72vlKjqrVg90H21EOLACvtfcHk0lh3zb3FDc64RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWkt7fI&md5=160c96c8a11ec01c0c919c4c8361c27a</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0211%26sid%3Dliteratum%253Aachs%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.-G.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DMcDonald%26aufirst%3DL.%2BA.%26aulast%3DSalaski%26aufirst%3DE.%2BJ.%26aulast%3DBarbieri%26aufirst%3DL.%2BR.%26aulast%3DDing%26aufirst%3DW.-D.%26aulast%3DKrishnamurthy%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DY.%2BB.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DBernan%26aufirst%3DV.%2BS.%26aulast%3DCai%26aufirst%3DP.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520lactoquinomycin%2520and%2520related%2520pyranonaphthoquinones%2520as%2520potent%2520and%2520allosteric%2520inhibitors%2520of%2520AKT%252FPKB%253A%2520mechanistic%2520involvement%2520of%2520AKT%2520catalytic%2520activation%2520loop%2520cysteines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3028%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inesta-Vaquera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niepel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoGrasso, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorger, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective covalent inhibitors of JNK</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.chembiol.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=22284361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=140-154&author=T.+Zhangauthor=F.+Inesta-Vaqueraauthor=M.+Niepelauthor=J.+Zhangauthor=S.+B.+Ficarroauthor=T.+Machleidtauthor=T.+Xieauthor=J.+A+Martoauthor=N.+Kimauthor=T.+Simauthor=J.+D.+Laughlinauthor=H.+Parkauthor=P.+V.+LoGrassoauthor=M.+Patricelliauthor=T.+K.+Nomanbhoyauthor=P.+K.+Sorgerauthor=D.+R.+Alessiauthor=N.+S.+Gray&title=Discovery+of+potent+and+selective+covalent+inhibitors+of+JNK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Covalent Inhibitors of JNK</span></div><div class="casAuthors">Zhang, Tinghu; Inesta-Vaquera, Francisco; Niepel, Mario; Zhang, Jianming; Ficarro, Scott B.; Machleidt, Thomas; Xie, Ting; Marto, Jarrod A.; Kim, Nam Doo; Sim, Taebo; Laughlin, John D.; Park, Hajeung; LoGrasso, Philip V.; Patricelli, Matt; Nomanbhoy, Tyzoon K.; Sorger, Peter K.; Alessi, Dario R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-154</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response.  Here, we report the discovery of irreversible inhibitors of JNK1/2/3.  We describe two JNK3 cocrystal structures at 2.60 and 2.97 Å resoln. that show the compds. form covalent bonds with a conserved cysteine residue.  JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue.  Extensive biochem., cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compd. will be broadly useful as a pharmacol. probe of JNK-dependent signal transduction.  Potential lead compds. have also been identified for kinases, including IRAK1, PIK3C3, PIP4K2C, and PIP5K3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXs0FY7FSmt7Vg90H21EOLACvtfcHk0lh3zb3FDc64RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D&md5=f7d9647fb2be162c637b1d31a778ceb4</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DInesta-Vaquera%26aufirst%3DF.%26aulast%3DNiepel%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DLaughlin%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520covalent%2520inhibitors%2520of%2520JNK%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D140%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Cravatt, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">Activity-based protein profiling: from enzyme chemistry to proteomic chemistry</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1146%2Fannurev.biochem.75.101304.124125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=18366325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1ekur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=383-414&author=B.+F.+Cravattauthor=A.+T.+Wrightauthor=J.+W.+Kozarich&title=Activity-based+protein+profiling%3A+from+enzyme+chemistry+to+proteomic+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-based protein profiling: From enzyme chemistry to proteomic chemistry</span></div><div class="casAuthors">Cravatt, Benjamin F.; Wright, Aaron T.; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">383-414</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Genome sequencing projects have provided researchers with a complete inventory of the predicted proteins produced by eukaryotic and prokaryotic organisms.  Assignment of functions to these proteins represents one of the principal challenges for the field of proteomics.  Activity-based protein profiling (ABPP) has emerged as a powerful chem. proteomic strategy to characterize enzyme function directly in native biol. systems on a global scale.  Here, the authors review the basic technol. of ABPP, the enzyme classes addressable by this method, and the biol. discoveries attributable to its application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFnUWDsqzOLVg90H21EOLACvtfcHk0lh3zb3FDc64RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1ekur0%253D&md5=2f2c471169d2473f7024eeb41d4eaecd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.75.101304.124125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.75.101304.124125%26sid%3Dliteratum%253Aachs%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DWright%26aufirst%3DA.%2BT.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DActivity-based%2520protein%2520profiling%253A%2520from%2520enzyme%2520chemistry%2520to%2520proteomic%2520chemistry%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2008%26volume%3D77%26spage%3D383%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Q. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. V.</span><span> </span><span class="NLM_article-title">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17334377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=229-238&author=J.+A.+Blairauthor=D.+Rauhauthor=C.+Kungauthor=C.-H.+Yunauthor=Q.+W.+Fanauthor=H.+Rodeauthor=C.+Zhangauthor=M.+J.+Eckauthor=W.+A.+Weissauthor=K.+V.+Shokat&title=Structure-guided+development+of+affinity+probes+for+tyrosine+kinases+using+chemical+genetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span></div><div class="casAuthors">Blair, Jimmy A.; Rauh, Daniel; Kung, Charles; Yun, Cai-Hong; Fan, Qi-Wen; Rode, Haridas; Zhang, Chao; Eck, Michael J.; Weiss, William A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-mol. inhibitors.  The authors report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue.  Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Cocrystal structures of two irreversible quinazoline inhibitors (I, II) bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Based on these structures, the authors developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe (III) to report the fraction of kinase necessary for cellular signaling, and the authors used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0KmYAm-skrVg90H21EOLACvtfcHk0ljKclbLMeZWeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D&md5=ce4d24a8d65d7080645bf382cd65dbca</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnchembio866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio866%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DFan%26aufirst%3DQ.%2BW.%26aulast%3DRode%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BV.%26atitle%3DStructure-guided%2520development%2520of%2520affinity%2520probes%2520for%2520tyrosine%2520kinases%2520using%2520chemical%2520genetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadjivassiliou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">A clickable inhibitor reveals context-dependent autoactivation of p90 RSK</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">160</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1038%2Fnchembio859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17259979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=156-160&author=M.+S.+Cohenauthor=H.+Hadjivassiliouauthor=J.+Taunton&title=A+clickable+inhibitor+reveals+context-dependent+autoactivation+of+p90+RSK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">A clickable inhibitor reveals context-dependent autoactivation of p90 RSK</span></div><div class="casAuthors">Cohen, Michael S.; Hadjivassiliou, Haralambos; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">156-160</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P90 ribosomal protein S6 kinases (RSKs) integrate upstream signals through two catalytic domains.  Autophosphorylation of Ser386 by the regulatory C-terminal kinase domain (CTD) is thought to be essential for activation of the N-terminal kinase domain (NTD), which phosphorylates multiple downstream targets.  We recently reported fmk, an irreversible inhibitor of the CTD of RSK1 and RSK2.  Here we describe fmk-pa, a propargylamine variant that has improved cellular potency and a 'clickable' tag for assessing the extent and selectivity of covalent RSK modification.  Copper-catalyzed conjugation of an azidoalkyl reporter (the click reaction) revealed that fmk-pa achieves selective and saturable modification of endogenous RSK1 and RSK2 in mammalian cells.  Satg. concns. of fmk-pa inhibited Ser386 phosphorylation and downstream signaling in response to phorbol ester stimulation, but had no effect on RSK activation by lipopolysaccharide.  RSK autoactivation by the CTD is therefore context dependent, which suggests that NTD and CTD inhibitors should have distinct physiol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVn6uut4m1lbVg90H21EOLACvtfcHk0ljKclbLMeZWeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWgsL4%253D&md5=68f7da1c274678e884ea71d1078b092c</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fnchembio859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio859%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DHadjivassiliou%26aufirst%3DH.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DA%2520clickable%2520inhibitor%2520reveals%2520context-dependent%2520autoactivation%2520of%2520p90%2520RSK%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D156%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Yuan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Josephson, L.</span><span> </span><span class="NLM_article-title">Synthesis and activity of C11-modified wortmannin probes for PI3 kinase</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/doi/10.1021/bc049714f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Kit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=669-675&author=H.+Yuanauthor=J.+Luoauthor=S.+Fieldauthor=R.+Weisslederauthor=L.+Cantleyauthor=L.+Josephson&title=Synthesis+and+activity+of+C11-modified+wortmannin+probes+for+PI3+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Activity of C11-Modified Wortmannin Probes for PI3 Kinase</span></div><div class="casAuthors">Yuan, Hushan; Luo, Ji; Field, Seth; Weissleder, Ralph; Cantley, Lewis; Josephson, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">669-675</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The key role played by PI3 kinase in cancer, hormone action, and a host of other biol. functions suggests that specific inhibitors whose disposition could be ascertained in vivo would be useful in biol. research or, potentially, for imaging PI3K in a clin. setting.  Wortmannin (Wm, 1) is an inhibitor of PI3 kinase with high specificity for this enzyme.  We synthesized three modified Wm probes, a biotinylated Wm (7a), a 4-hydroxy-3-iodophenylated Wm, which was obtained both unlabeled (7b) and labeled with 125I (8), and a fluoresceinated Wm (7c), through modification at C-11, and evaluated their inhibitive activity as inhibitors of PI3 kinase.  Biotinylated (7a) and 4-hydroxy-3-iodophenylated Wm's (7b) had IC50s for PI3K of 6.11 and 11.02 nM, resp., compared to an IC50 for Wm of 1.63 nM.  Fluoresceinated Wm (7c) lost considerably more activity than the other derivs., with an IC50 of 64.9 nM.  The 125I labeled 4-hydroxy-3-iodophenylated Wm (8) could be detected after reaction with an immunoppt. of PI3 kinase.  The activity of these reporter Wm's is discussed in relationship to earlier findings on the pharmacol. activity of Wm derivs. and the ability of inhibitors to fit into the ATP pocket of PI3 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXkEj722oMLVg90H21EOLACvtfcHk0ljKclbLMeZWeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Kit7o%253D&md5=faa35d07c25d7ea709f3557a15db49dc</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fbc049714f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc049714f%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DField%26aufirst%3DS.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DCantley%26aufirst%3DL.%26aulast%3DJosephson%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520activity%2520of%2520C11-modified%2520wortmannin%2520probes%2520for%2520PI3%2520kinase%26jtitle%3DBioconjugate%2520Chem.%26date%3D2005%26volume%3D16%26spage%3D669%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Yee, M.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fas, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stohlmeyer, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wandless, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cimprich, K. A.</span><span> </span><span class="NLM_article-title">A cell-permeable, activity-based probe for protein and lipid kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">29053</span><span class="NLM_x">–</span> <span class="NLM_lpage">29059</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=29053-29059&author=M.-C.+Yeeauthor=S.+C.+Fasauthor=M.+M.+Stohlmeyerauthor=T.+J.+Wandlessauthor=K.+A.+Cimprich&title=A+cell-permeable%2C+activity-based+probe+for+protein+and+lipid+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYee%26aufirst%3DM.-C.%26aulast%3DFas%26aufirst%3DS.%2BC.%26aulast%3DStohlmeyer%26aufirst%3DM.%2BM.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26atitle%3DA%2520cell-permeable%252C%2520activity-based%2520probe%2520for%2520protein%2520and%2520lipid%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D29053%26epage%3D29059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betancort, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gai, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samii, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szardenings, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreder, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">Design and synthesis of AX4697, a bisindolylmaleimide exo-affinity probe that labels protein kinase C alpha and beta</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5955</span><span class="NLM_x">–</span> <span class="NLM_lpage">5958</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5955-5958&author=Y.+Liuauthor=J.+Wuauthor=H.+Weissigauthor=J.+M.+Betancortauthor=W.+Z.+Gaiauthor=P.+S.+Leventhalauthor=M.+P.+Patricelliauthor=B.+Samiiauthor=A.+K.+Szardeningsauthor=K.+R.+Shrederauthor=J.+W.+Kozarich&title=Design+and+synthesis+of+AX4697%2C+a+bisindolylmaleimide+exo-affinity+probe+that+labels+protein+kinase+C+alpha+and+beta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DBetancort%26aufirst%3DJ.%2BM.%26aulast%3DGai%26aufirst%3DW.%2BZ.%26aulast%3DLeventhal%26aufirst%3DP.%2BS.%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DSamii%26aufirst%3DB.%26aulast%3DSzardenings%26aufirst%3DA.%2BK.%26aulast%3DShreder%26aufirst%3DK.%2BR.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520AX4697%252C%2520a%2520bisindolylmaleimide%2520exo-affinity%2520probe%2520that%2520labels%2520protein%2520kinase%2520C%2520alpha%2520and%2520beta%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5955%26epage%3D5958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Koch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauf, S.</span><span> </span><span class="NLM_article-title">A chemical genetic approach for covalent inhibition of analogue-sensitive aurora kinase</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb200465c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=723-731&author=A.+Kochauthor=H.+R.+Rodeauthor=A.+Richtersauthor=D.+Rauhauthor=S.+Hauf&title=A+chemical+genetic+approach+for+covalent+inhibition+of+analogue-sensitive+aurora+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fcb200465c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb200465c%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DRode%26aufirst%3DH.%2BR.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DHauf%26aufirst%3DS.%26atitle%3DA%2520chemical%2520genetic%2520approach%2520for%2520covalent%2520inhibition%2520of%2520analogue-sensitive%2520aurora%2520kinase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D723%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Garske, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortesi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Chemical genetic strategy for targeting protein kinases based on covalent complementarity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">15046</span><span class="NLM_x">–</span> <span class="NLM_lpage">15062</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=15046-15062&author=A.+L.+Garskeauthor=U.+Petersauthor=A.+T.+Cortesiauthor=J.+L.+Perezauthor=K.+M.+Shokat&title=Chemical+genetic+strategy+for+targeting+protein+kinases+based+on+covalent+complementarity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarske%26aufirst%3DA.%2BL.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DCortesi%26aufirst%3DA.%2BT.%26aulast%3DPerez%26aufirst%3DJ.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DChemical%2520genetic%2520strategy%2520for%2520targeting%2520protein%2520kinases%2520based%2520on%2520covalent%2520complementarity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D15046%26epage%3D15062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grütter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterlo, van, W. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">–</span> <span class="NLM_lpage">2566</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2557-2566&author=S.+Kl%C3%BCterauthor=J.+R.+Simardauthor=H.+R.+Rodeauthor=C.+Gr%C3%BCtterauthor=V.+Pawarauthor=H.+A.+Raaijmakersauthor=T.+A.+Barfauthor=M.+Rabillerauthor=W.+A.+L.+Otterlo%2C+vanauthor=D.+Rauh&title=Characterization+of+irreversible+kinase+inhibitors+by+directly+detecting+covalent+bond+formation%3A+a+tool+for+dissecting+kinase+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRode%26aufirst%3DH.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DRaaijmakers%26aufirst%3DH.%2BA.%26aulast%3DBarf%26aufirst%3DT.%2BA.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DOtterlo%252C%2Bvan%26aufirst%3DW.%2BA.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520irreversible%2520kinase%2520inhibitors%2520by%2520directly%2520detecting%2520covalent%2520bond%2520formation%253A%2520a%2520tool%2520for%2520dissecting%2520kinase%2520drug%2520resistance%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D2557%26epage%3D2566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Oballa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truchon, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayly, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauret, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crane, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berthelette, C.</span><span> </span><span class="NLM_article-title">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">998</span><span class="NLM_x">–</span> <span class="NLM_lpage">1002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm3003203&amp;key=10.1016%2Fj.bmcl.2006.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm3003203&amp;key=17157022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm3003203&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=998-1002&author=R.+M.+Oballaauthor=J.+F.+Truchonauthor=C.+I.+Baylyauthor=N.+Chauretauthor=S.+Dayauthor=S.+Craneauthor=C.+Berthelette&title=A+generally+applicable+method+for+assessing+the+electrophilicity+and+reactivity+of+diverse+nitrile-containing+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds</span></div><div class="casAuthors">Oballa, Renata M.; Truchon, Jean-Francois; Bayly, Christopher I.; Chauret, Nathalie; Day, Stephen; Crane, Sheldon; Berthelette, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">998-1002</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Nitrile-based inhibitors of cathepsin K have been known for some time and mechanism-of-action studies have demonstrated that cysteinyl proteases interact with nitriles in a reversible fashion.  Three main classes of nitrile-contg. inhibitors have been published in the cathepsin K field: (i) cyanamides, (ii) arom. nitriles, and (iii) aminoacetonitriles.  A computational approach was used to calc. the theor. reactivities of diverse nitriles and this was found to correlate with their extent of reactivity with free cysteine.  Moreover, there is a tentative link between high reactivity with cysteine and the potential to lead to irreversible covalent binding to proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSFCCd4sSYvbVg90H21EOLACvtfcHk0liMq0pucOUdYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12qtr4%253D&md5=b8fff00bdd6a746753f8f244d25b0cc8</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DChauret%26aufirst%3DN.%26aulast%3DDay%26aufirst%3DS.%26aulast%3DCrane%26aufirst%3DS.%26aulast%3DBerthelette%26aufirst%3DC.%26atitle%3DA%2520generally%2520applicable%2520method%2520for%2520assessing%2520the%2520electrophilicity%2520and%2520reactivity%2520of%2520diverse%2520nitrile-containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D998%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SM2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1SM2','PDB','1SM2'); return false;">PDB: 1SM2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E14" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2E14','PDB','2E14'); return false;">PDB: 2E14</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SVV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SVV','PDB','3SVV'); return false;">PDB: 3SVV</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm3003203&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-14%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Fjm3003203%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm3003203" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679930e5393132cd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
